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IV - Abstract 
Clostridium difficile is a major problem as the aetiological agent of antibiotic 
associated diarrhoea. The mechanism by which the bacterium colonises the gut is 
poorly understood, but undoubtedly involves a myriad of components present on 
the bacterial surface. The aims of this study were to further define roles for 
selected surface proteins using a knockout approach, to evaluate the feasibility of 
surface protein based immunotherapeutics and to obtain structural information 
using X-ray crystallography. Mutants of cell wall-binding domain (PFam04122) 
containing proteins CD1036, CD2735, CD2784, Cwp66, CD2791, Cwp84, CD2795 
and the flagella cap (FliD) were created. Mutants were characterised with regard to 
growth, sporulation, toxin production, adhesion in vitro, and, for the Cwp84 
mutant, using the in vivo hamster model. The surface-located cysteine protease, 
Cwp84, was found to play a key role in maturation of the C. difficile S-layer, yet the 
Cwp84 mutant still caused disease with a similar pathology to the wildtype. Culture 
supernatant levels of toxin A were increased in CD2735, Cwp66, CD2791, CD2795 
and particularly in Cwp84 and FliD 24 hr cultures, while CD2735, Cwp66, CD2791, 
CD2795 mutants also showed reduced adherence to Caco-2 cells compared to the 
wild-type. Passively administered immunotherapy, generated to low pH surface 
protein extracts of the C. difficile R20291 strain, did not protect hamsters from 
challenge with the cognate strain. Structural studies were undertaken on the 
surface proteins CD2791, Cwp66 and CD2767. Crystallisation conditions were 
identified for a recombinant N-terminal domain of CD2767 and an X-ray data set 
collected to 2 Å, although the structure was not solved by molecular replacement. 
Together these results further our knowledge of C. difficile surface proteins, 
although further work is required to identify which surface proteins play key roles 
in vivo during infection.  
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1 General Introduction 
Clostridium difficile is a Gram-positive, spore-forming rod-shaped bacterium, first 
identified in 1935 (Hall & O'Toole 1935) but is thought to have evolved within the 
last 1.1 - 85 million years (He et al. 2010). C. difficile can be cultured from the stool 
of 2-3% of healthy adults and up to two thirds of healthy newborns and infants 
(Viscidi et al. 1981; Larson et al. 1982; Sunenshine & McDonald 2006). C. difficile 
infection (CDI) is primarily associated with the administration of antibiotics, most 
famously clindamycin (Bartlett et al. 1977), but particularly broad spectrum 
penicillins, third generation cephalosporins and fluoroquinolones (Bartlett 2006). 
CDI symptoms range from mild self-limiting diarrhoea without appreciable lesions 
through colitis, pseudomembranous colitis (PMC) and finally, if left untreated, CDI 
culminates with colonic perforation, toxic megacolon, prolonged ileus, ascites and 
death (Kelly & LaMont 1998). CDI has a mortality rate typically between 6-30% 
(Bartlett 2002). Metronidazole or vancomycin (identified originally to treat S. 
aureus colitis (Bartlett 2008a)) are, in that order, the usual treatment regimens. 
However, between 10-40% of patients relapse (McFarland 2008), thus patients not 
only require repeated rounds of treatment, but often suffer repeated rounds of 
symptoms. 
 
The unique environment found in healthcare settings (large cohorts of patients, 
wide antibiotic use, age of inhabitants and a transient ‘population’) provides a 
discrete ‘ecosystem’ where C. difficile (primarily spores) persist and can be rapidly 
transmitted amongst individuals. Increased stay in this environment is but one of a 
number of risk factors for CDI. These include, age, gender, use of proton pump 
inhibitors or immunosuppressant’s and underlying disease e.g. inflammatory bowel 
disease (Vaishnavi 2009).  
 
The numbers of patients suffering from CDI have increased over the past decade 
(increases in reporting and diagnosis aside) (Figure 1.1). In the United States, CDI is 
responsible for more deaths than all other intestinal infections combined (Redelings 
et al. 2007) causing considerable economic cost (Ghantoji et al. 2010). 
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The increase in incidence and mortality was particularly marked by an epidemic in 
2003-2004 in Quebec, Canada (Pepin et al. 2005). This outbreak was characterised 
by CDI that was more severe, more refractory to therapy and subject to high rates 
of relapse (Bartlett 2006).  
 
Upon investigation of isolates, it appeared most patients were infected with one 
particular, previously uncommon, fluoroquinolone resistant strain, C. difficile 
BI/NAP1/027 toxinotype III (restriction-endonuclease analysis [REA] group BI, 
pulsed-field gel electrophoresis [PFGE] type NAP1 [North American PFGE type 1] 
and polymerase chain reaction (PCR) ribotype 027]) (Pepin et al. 2005; MacCannell 
et al. 2006) 
 
The 027 ribotype has since been isolated worldwide and now represents the most 
frequently isolated C. difficile ribotype in the UK (Brazier et al. 2008; Freeman et al. 
2010; Gerding 2010). Based on this ability i.e. rapid spread, and particularly its 
association with more served disease, there remains concern about whether any 
other strain(s) e.g. ribotype 078 (Burns et al. 2010c) can cause another epidemic. 
 
In the UK, deaths from C. difficile appear to be decreasing (Figure 1.1). Reasons 
behind this are likely to be increased awareness of CDI and increased diagnosis and 
treatment; however the effect of hospital cleaning and antibiotic stewardship 
should not be underestimated (Vonberg et al. 2008).  
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Figure 1.1 Numbers of deaths in the UK where C. difficile was the underlying cause of 
death. Source: Office for National Statistics (ONS) data. 
1.1 Pathogenesis  
C. difficile is primarily acquired via spores from a range of surfaces, the skin of 
healthcare workers or from aerosolized spores from symptomatic patients 
(McFarland 2002; Bobulsky et al. 2008; Best et al. 2010). Following traversal of the 
stomach, putative spore receptors come in contact with bile acid derivatives 
(cholate and chenodeoxycholate) and begin the germination process: a process 
absolutely requiring SleC a spore cortex-lytic enzyme (Burns et al. 2010b; Ramirez 
et al. 2010; Sorg & Sonenshein 2010).  
 
The constituents of the spore have been determined proteomically and upon 
comparision with other Clostridial spore there appears to be a set of 28 proteins 
unique to C. difficile including a collagen-like glycoprotein and BclA (CD0332), two 
surface layer proteins (CD2791 and CD2793 [SlpA]), putatively involved in in spore 
attachment or spore-host interactions (Lawley et al. 2009b). Interestingly, C. difficile 
spores appear covered in spines/hair like projections (Kumar, V. & Roberts, A.K., 
unpublished data) putatively involved in adhering to host cells, as demonstrated 
using field emission scanning electron microscopes (FESEM) (Panessa-Warren et al. 
2007). 
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The proteolytic load and transit time of the small intestine generally prevents C. 
difficile colonisation. Therefore, in humans, the slow moving large intestine is the 
most common site of CDI infection (Keel & Songer 2006). 
 
Administration of broad spectrum antibiotics, altered gastrointestinal function e.g. 
inflammatory bowel disease or immunodeficiency, removes competitive inhibition 
of C. difficile; however C. difficile outgrowth only occurs when the causative 
antibiotic goes below the MIC of C. difficile (Freeman et al. 2007). 
 
C. difficile vegetative cell adhesion and colonisation mechanisms are still relatively 
unknown. To date only a limited number of putative adhesins have been identified, 
including the S-layer, flagella and other specific proteins (Deneve et al. 2009b). 
Bacterial adherence is arguably the first step in pathogenesis, assisting in the 
efficient delivery of toxins to the cell, thereupon putatively increasing adherence. 
For example the C. difficile actin-ADP-ribosylating (binary) toxin putatively causes 
protrusions that may aid bacterial adhesion (Schwan et al. 2009). 
 
The primary virulence factors of C. difficile are its toxins, TcdA (tcdA), TcdB (tcdB) 
(herein referred to as toxin A and B) and a binary toxin (made up of two, CdtA and B 
subunits). Both toxin A (308 kDa) and toxin B (269 kDa) are cytotoxic and encoded 
on the 19.6 kbp pathogenicity locus (PaLoc) (Hammond & Johnson 1995). The PaLoc 
also encodes three other genes tcdR (previously named tcdD (Rupnik et al. 2005)), 
tcdE and tcdC. TcdR is an alternative RNA polymerase sigma factor that positively 
regulates toxin gene transcription and its own transcription. TcdC is a negative 
regulator (Dupuy et al. 2008) and TcdE is a putative holin, which may aid release of 
C. difficile toxins to the extracellular environment (Tan et al. 2001) 
 
Both toxins A and B have four major domains: the glucosyltransferase N-terminal 
domain, translocation (delivery) and cysteine protease automaturation domains 
and a C-terminal receptor binding domain (Pruitt et al. 2010). Toxin A and B enter 
the cell through receptor-mediated endocytosis and require an acidified endosome 
for translocation. Following internalisation, toxin A and B inactivate small GTP-
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binding proteins, which include Rho, Rac, and Cdc42, through monoglucosylation of 
a single threonine (Thr37 for RhoA) within the effector-binding loop and coordinate 
a divalent cation, critical to binding GTP, thus locking them in an inactive 
confirmation (Voth & Ballard 2005). Since Rho, Rac, and Cdc42 are involved in signal 
transduction associated with apoptosis and the maintenance and regulation of the 
cell actin cytoskeleton, loss of this regulation at the cellular level results in shrinking 
and rounding of cells via retraction of neurite-like fibres and finally, cell death 
(Poxton et al. 2001; Voth & Ballard 2005). Cordially, this cytoskeletal perturbation 
and loss of cell polarity results in breakdown of tight junctions, resulting in 
increased paracellular permeability of mucosal surfaces. The gut mucosa damage 
and toxin induced inflammation results in CDI aetiology (Ng et al. 2010).  
 
The binary toxin (actin-specific ADP-ribosyltransferase) consists of two subunits, 
CDTa- the enzymatic component and CDTb- the binding component. The structure 
of CDTa has been determined (Sundriyal et al. 2009). The role of the binary toxin in 
pathogenesis is not clearly understood as ‘hypervirulent’ 027 strains produce the 
binary toxin (Cartman et al. 2010), however strains which do not express the binary 
toxin still cause disease e.g. 630 and VPI10463 (Rupnik et al. 2003). Conversely a 
pathogenic A-B- binary toxin-positive strain of C. difficile strain has been reported 
(Elliott et al. 2009) contradicting data that A-B- binary toxin-positive strains, while 
being enterotoxic, do not cause disease in hamsters (Geric et al. 2006).  
 
Current understanding, given the lack of natural A+B- isolates, is that toxin B is 
required for virulence (Lyras et al. 2009). However, a C. difficile 630 (low toxin 
producer) A+B- knockout demonstrates virulence in hamsters, although 
colonisation to death figures appear more protracted compared to A+B+ or A-B+ 
strains (Kuehne et al. 2010). 
 
As demonstrated using mice, CDI results in a so called supershedder state where 
spores are, unsurprisingly, transmitted into and contaminate the environment 
(Lawley et al. 2009a). Studies have suggested epidemic strains show increased toxin 
or prolonged production and robust sporulation, however these virulence factors 
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have been found to vary amongst BI/NAP1/027 isolates, and differ little from other 
non-epidemic strains (Akerlund et al. 2008; Burns et al. 2010a; Merrigan et al. 
2010). 
1.2 Bacterial surface proteins 
Adherence and subsequent colonisation represents a key milestone in infection as 
without adhesion, bacteria will simply be excreted. C. difficile endogenous in 
asymptomatic carriers are, for example, already utilising the tools of adherence but 
have, as yet, not caused CDI.  
 
Bacterial adherence requires the participation of two factors: a receptor or a ligand 
and an adhesin. Adhesins are typically found on the bacterial surface and can 
interact in a complementary and/or specific manner with their receptor or 
substrate. 
 
The surface of Gram-Positive bacteria contains a plethora of proteins attached to 
the cell envelope in a variety of different ways (Desvaux et al. 2006) (Figure 1.2).  
 
These include: 
 Membrane proteins- associated with the phospholipid bi-layer 
 Lipoproteins- containing lipid covalently linked to an N-terminal cysteine 
residue (Hutchings et al. 2009) 
 LPXTG containing proteins –covalently linked to the peptidoglycan by 
sortases (Marraffini et al. 2006) 
 Other putatively non-covalently attached surface proteins - which include 
domains putatively attaching/associating them to peptidoglycan e.g. LysM 
Motif (Buist et al. 2008), S-layer homology (SLH) domain, Cell Wall Binding 
Domain Type 2 (CWBD2) (PFam 04122) 
 Motility associated proteins - flagella and pili (Jarrell & McBride 2008; Kline 
et al. 2010)  
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Figure 1.2 Schematic representations of the different types of surface proteins found in 
Gram-positive bacteria. Figure taken from Desvaux et al. (2006). 
 
Interestingly, the Clostridial and Bacilli peptidoglycan is suggested to be thinner 
than other Gram positive species e.g. Corynebacterium, Mycobacterium, or 
Propionibacterium, and has been found to thin beneath the S-layer during lag and 
initial exponential growth phases. By stationary phase, Clostridia and Bacilli cultures 
can be virtually Gram negative (Beveridge 1990). 
1.2.1 S-layers 
The first and largest (in terms of cell coverage) of these surface proteins in C. 
difficile is that of the paracrystalline S-layer. S-layers are two-dimensional 
(glyco)protein lattices formed by the entropy driven aggregation of monomer 
subunits (Sara & Sleytr 2000). Despite the apparent local entropy decrease upon 
forming a regular array, the net entropy of the system is increased due to the 
release of water molecules from a hydration shell formed on the surface of the 
hydrophobic domains of the S-layer monomeric units (Teixeira et al. 2010). S-layers 
are found in a variety of pathogenic bacteria including Bacillus anthracis (the 
causative agent of Anthrax), Campylobacter sp., Aeromonas salmonicida and many 
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Archaea (Sara & Sleytr 2000). Maintenance of the S-layer over the entire bacterial 
surface requires significant energy investment, for example at a generation time of 
20 minutes, approximately 500 S-layer subunits per second are needed to 
completely cover the bacterial cell (Sleytr & Messner 1983; Messner & Sleytr 1992). 
S-layers therefore provide a vital function to the bacterial cell for such an 
investment to be worthwhile. Engelhardt (2007) proposes S-layers provide basic 
primary ‘survival’ functions such as mechanical, osmotic and thermal stability while 
also providing functions such as protection against the immune system, adhesion 
and nutrient acquisition. Some S-layers contain Surface-Layer Homology (SLH) 
domains which are proposed to attach the S-layer subunits to the cell surface 
(Lupas 1996), although the method of actual attachment varies among species and 
may involve secondary cell wall polymers (SCWPs) (Mesnage et al. 2000; Schaffer & 
Messner 2005).  
1.2.2 C. difficile S-layer structural identification and 
characterisation 
The C. difficile S-layer was initially characterised by a group at Tokushima University 
School of Medicine, Japan. Analysis of autolysed cell walls revealed a regularly 
arranged rhombic array possessing sides of 8.1 nm and an interior angle of 88 
degrees visible on the cell surface. SDS-PAGE analysis of cells treated with 4 M 
guanidine hydrochloride or 6 M urea revealed two main proteins of approximately 
45 kDa (high molecular weight S-layer protein, HMW SLP) and 32 kDa (low 
molecular weight S-layer protein, LMW SLP) that varied in size amongst strains. Cell 
wall extracts were also able to form flattened or rod-like paracrystalline sheet-like 
fragments in vitro, a feature that appeared to require divalent cations specifically 
Ca2+ or Zn2+. Resistance of the 35 kDa protein to trypsin degradation lead to the 
suggestion that, together with the 45 kDa proteins, the array formed by these two 
proteins played a role in protection against physicochemical agents including 
proteolytic enzymes. Cerquetti et al. (2000), using freeze etching of whole bacterial 
cells, demonstrated the presence of a square ordered lattice on the outermost 
surface and, using autolysed cell wall and urea extracted SLPs, an inner hexagonal 
lattice innermost with spacing of ~10 nm.  
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Moreover, antibodies to the either the LMW or HMW SLP, or C. difficile cells which 
had been subjected to treatment with urea or guanidine hydrochloride had 
significantly decreased adhesion in vitro, suggesting the S-layer played a key role in 
adhesion (Takumi et al. 1987; Takeoka et al. 1991; Takumi et al. 1991; Takumi et al. 
1992). This was later supported by Karjalainen et al. (2001) who also found that 
antiserum to the LMW SLP inhibited adhesion of C. difficile to Caco-2 cells.  
 
Other groups suggested that the size variability of the S-layer bands (also 
extractable with EDTA) formed a typing system (Wexler et al. 1984; Delmee et al. 
1986; Delmee et al. 1990; McCoubrey & Poxton 2001). The typing of bacterial 
strains based on their S-layer (although the gene rather than the surface extracts) is 
still suggested today (McCoubrey & Poxton 2001; Karjalainen et al. 2002; Kato et al. 
2005; Kato et al. 2009). 
 
In 2001, as a result of searching the unfinished C. difficile 630 genome (completed 
in 2006 (Sebaihia et al. 2006)), it was found that the HMW and LMW SLPs were 
encoded on one gene (slpA) and post-translationally cleaved to their respective 
SLPs, a feature unique to C. difficile. The HMW SLP was found to contain repeat 
regions with homology to N-acetylmuramoyl-L-alanine amidase CwlB of Bacillus 
subtilis and demonstrated this activity in zymogram assay. The amidase domain was 
found in 28 other proteins at either the N- or C- terminus with a ‘functional’ domain 
at the opposite end, some of which have been found to be expressed during normal 
growth (Calabi et al. 2001; Karjalainen et al. 2001). The cell wall binding 2 domain 
(Pfam 04122) (CWBD) is thought to bind the overall protein to the cell surface, non-
covalently, analogous to the S-layer Homology Domain (SLH (Lupas et al. 1994)) 
found in many species paracrystalline S-layers (Engelhardt & Peters 1998). The 
PFam 04122 domain appears not to be restricted to C. difficile, as 20 proteins 
containing the PFam 04122 are found in Finegoldia magna (formerly 
Peptostreptococcus magnus) (Goto et al. 2008) and many other bacterial species.  
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Patients appear to raise antibodies to both the HMW and LMW SLP during CDI 
(Pantosti et al. 1989; Cerquetti et al. 1992; Drudy et al. 2004; Pechine et al. 2005a; 
Wright et al. 2008). Responses to the HMW SLP are conserved across strains, while 
responses to the LMW SLP are only similar within a serogroup (Cerquetti et al. 
2000; Calabi et al. 2001; Karjalainen et al. 2002). This variability is reflected 
genetically as, other than a conserved cleavage site between the two SLPs, the 
HMW portion of slpA has been found to be more conserved than the LMW (Eidhin 
et al. 2006).  
 
Proteomic analysis of a range of different surface protein extraction techniques by 
Wright et al (2005), confirmed suggestions by Wexler et al. (1984) that in addition 
to the S-layer a large number of other proteins are extractable from the cell 
surface, including a number of the slpA paralogs. Removal efficiency of the HMW vs 
LMW SLP also differed, confirming the hypothesis that the LMW SLP was 
outermost, while the HMW SLP was intimately associated with the underlying cell 
wall.  
 
Various studies had suggested that either one or both of the S-layer subunits were 
glycosylated (Mauri et al. 1999; Cerquetti et al. 2000; Calabi et al. 2001). However, 
a study by Qazi et al. (2009) utilised a range of methods to determine that the 
observed molecular masses matched the predicted masses of the LMW and HMW 
SLPs in a range of C. difficile strains, suggesting no glycosylation or posttranslational 
modifications other than cleavage of SlpA into the LMW and HMW SLP. 
 
In 2009, a crystal structure of a fragment of the LMW SLP to 2.4 Å (PDB 3CVZ) was 
reported, together with data further characterising the interactions between the 
HMW and LMW SLP (Fagan et al. 2009). The crystal structure of the LMW SLP 
fragment revealed a two domain structure (Figure 1.3A), domain 2 (pink) displays a 
novel protein fold not yet classified (which is surface-most) while domain 1 (yellow) 
adopts a two-layer sandwich architecture.  
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By mixing recombinant HMW and LMW SLPs in an equimolar ratio, it was 
demonstrated that, similar to low pH extracted SLPs (Calabi et al. 2001); they form 
a single species (termed the H/L complex) in native PAGE. Small angle X-ray 
scattering (SAXS) in solution, using recombinant SLP subunits and extracted SLPs, 
revealed that the H/L complex was made up of an elongated heterodimeric 
molecule with approximate dimensions of 240 Å x 105 Å x 75 Å, with an estimated 
MW of 81 kDa, where the HMW and LMW interact ‘end-to-end’ (via a contact area 
of c. 450 Å²) presenting the LMW externally (Figure 1.3B). However, when low pH 
extracted SLPs were run on size exclusion chromatography (SEC) a single peak was 
observed corresponding to 320 kDa, thought to be caused by the elongated shape 
of the H/L complex. It was also demonstrated that the C-terminal 62 residues (260–
321) of the LMW SLP were absolutely required to form the H/L complex, confirming 
the existence of a conserved cleavage site and SLP subunit interaction domain 
(Calabi & Fairweather 2002; Eidhin et al. 2006). Together the data suggests that the 
formation of the each H/L complex does not require co-factors and does not 
preclude that divalent cations or a currently unknown co-factor or cell wall 
component may be involved in S-layer array assembly, i.e. assembly of multiple H/L 
complexes or the non-covalent interaction with the cell wall. 
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Figure 1.3 Proposed structures of the C. difficile S-layer. (A) Crystal structure of the N-
terminal fragment of the LMW SLP (LMW1-262) Domain 1 – Yellow, Domain 2 – Pink (B) 
Proposed orientation of the S-layer of C. difficile, combined LMW/HMW SAXS structure 
with overlaid LMW fragment crystal structure (Blue) (Note the crystal structure lacks the C-
terminal region (residues 245–274 and 304–321) of the LMW SLP essential for LMW/HMW 
interaction for H/L complex formation. (A) Prepared using PyMOL (www.pymol.org) 
(B) Adapted from Fagan et al. (2009).
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1.2.3 Role of the C. difficile S-layer and its proteins in infection 
C. difficile cells, from which the S-layer had been removed by urea or GnHCl, 
scarcely adhered to human HeLa cells. Furthermore, adhesion could be inhibited by 
~50% using FAb2 fragments of anti-LMW or anti-HMW SLP IgG, however when used 
together they inhibited adhesion by 84% (Takumi 1991). Together these results 
suggested that the S-layer (and other removable surface proteins) play a key role in 
adhesion of C. difficile. 
 
Recombinant HMW SLP and low pH extracted SLPs bound to gastrointestinal 
tissues, collagen I, thrombospondin and weakly to vitronectin, suggesting S-layer 
adhesion is ECM based, mediated by the HMW SLP (Calabi et al. 2002). Moreover, 
C. difficile SLPs appear to induce cytokines in monocytes and dendritic cells, 
suggesting that SLPs are able to affect inflammatory and regulatory cytokine 
production (Ausiello et al. 2006). 
 
Together these results suggest that the C. difficile S-layer provides not only 
physiochemical stability to the cell but also mediates bacterial cell adhesion. It 
appears that an incorrectly matured S-layer i.e. no longer cleaved into the 
HMW/LMW SLPs by Cwp84, does not affect the ability of C. difficile to cause 
infection in the hamster model (Kirby et al. 2009), bringing into question the role of 
the S-layer in pathogenesis. Indeed, Calabi et al., (2002) suggests that a slpA mutant 
would confirm the role of the S-layer in pathogenesis, although to date this mutant 
has proved elusive. 
 
S-layer mutants of Campylobacter fetus subsp. Fetus (created by multiple passage 
(Tummuru & Blaser 1992)) were avirulent in a mouse model (Blaser & Pei 1993) and 
did not colonise or cause abortions in pregnant ewes when administered 
subcutaneously (Grogono-Thomas et al. 2000). BslA mutants of B. anthracis Ames 
(constructed by allelic exchange) were largely avirulent in subcutaneously 
challenged guinea pigs, despite toxin secretion remaining unchanged (Kern & 
Schneewind 2009). Furthermore, an S-layer (A-layer) mutant of Aeromonas 
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salmonicida was obtainable after growth of cultures at an increased temperature 
(Ishiguro et al. 1981) and were found to be more sensitive to bactericidal activity of 
serum (Munn et al. 1982) and avirulent in animal studies (Kay & Trust 1991). These 
studies therefore suggest that if a C. difficile SlpA mutant was created, it is likely to 
be less virulent than the WT. 
 
Proteins on the cell surface of C. difficile putatively change in response to 
environmental stimuli e.g. heat shock thereby increasing adherence to cell lines 
(Eveillard et al. 1993; Karjalainen et al. 1994; Waligora et al. 1999). The C. difficile 
response to heat shock led to the characterisation of the 66 kDa cell surface slpA 
paralog Cwp66 (Waligora et al. 2001) (discussed further in Chapter 5).  
 
Furthermore, the 160 kDa phase variable surface protein CwpV is, similar to SlpA, 
post-translationally cleaved into two interacting subunits, a 40 kDa (cell wall 
anchoring) and a 120 kDa (surface exposed) subunit. Mutants in which CwpV is 
permanently ‘on’, have altered colony phenotypes and increased bacterial 
aggregation, although the exact role of CwpV is yet unknown (Emerson et al. 2009b; 
Reynolds et al. 2010). 
 
The presence of antibodies in patient sera to these and other ‘minor’ surface 
components suggests firstly, that they are expressed on the bacterial surface during 
human CDI and secondly, that proteins, other than SlpA, containing CWBD (PFam 
PF04122) repeats, are likely to play key roles in C. difficile in vivo physiology and/or 
pathogenesis such as cell signaling, matrix degradation and adherence and 
therefore warrant further study (Drudy et al. 2004; Pechine et al. 2005a; Wright et 
al. 2008). 
 
1.3 Aims 
The aim of the research in this thesis was to understand more about the role of the 
surface proteins in C. difficile, in particular the roles of the S-layer and its 28 
paralogs containing the PFam04122 motif. 
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The work is divided into three main parts: 
 Use of a novel gene knockout system for Clostridia, the ClosTron, to obtain 
mutants and characterise any obtained phenotype(s). 
 Establish whether passively administered systemic (circulating) antibodies to 
selected surface proteins on the bacterium itself can prevent CDI in an 
animal model. 
 Acquire structural data on selected surface layer proteins (SLPs) to gain 
further insights into their roles in CDI pathogenesis. 
 
The findings presented in this thesis have revealed that certain surface proteins of 
C. difficile play key roles in S-layer biogenesis, adhesion in vitro and may alter 
expression of known virulence factors. The identified surface proteins therefore 
mark a step forward in CDI research but one that is far from complete. Research 
into the use of surface proteins to prevent CDI suggests that surface proteins 
although important, may not be as important as the C. difficile toxins or not 
targetable for CDI intervention via circulating antibodies.  
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2 General Methods 
2.1 General Molecular biology methods  
2.1.1 DNA sequencing 
Sequencing was performed by Cogenics™ using the ABI 3730xl DNA Analyzer 
platform (Applied Biosystems). 
2.1.2 PCR Primer synthesis 
Primers were synthesised by Eurofins MWG Operon (Ebersberg, Germany) by 
automated Oligo-2000 and ultra parallel HTS synthesisers with phosphoramidite 
chemistry. 
2.1.3 Gene synthesis 
Synthetic genes were synthesised by GENEART (Regensburg, Germany) using E. coli 
expression optimisation ‘GeneOptimizer® technology (given differences in codon 
bias between E. coli and C. difficile) where necessary or by DNA2.0 (California, USA). 
Synthetic genes were either cloned into a standard vector backbone or 
chosen/provided vector, for further details see chapter specific methods. 
2.1.4 Agarose gel electrophoresis  
Agarose gel electrophoresis was performed unless otherwise stated with 1% 
(wt/vol.) agarose in tris-acetate-EDTA buffer (TAE) plus ethidium bromide (Fluka) or 
SYBR Safe Stain (Invitrogen), or via primed E-Gel® Pre-cast 0.8% agarose gel(s) on a 
E-Gel® iBase™ Power System (Invitrogen) as per manufacturer’s instructions. 
2.1.5 Polymerase Chain Reaction (PCR) 
PCR was performed using either illustra PuReTaq Ready-To-Go™ PCR Beads (GE 
Healthcare) as per manufacturer’s instructions, FailSafe Premix E (EPICENTRE 
Biotechnologies) with Expand High FidelityPLUS polymerase (Roche) or Platinum Taq 
(Invitrogen) in a Bio-Rad DNA Engine (PTC-200) Peltier Thermal Cycler. For colony 
PCR 2.5 µl of selected colony(s) suspension (in 10 µl molecular biology water) was 
used as template DNA either directly (E.coli) or after microwaving for 2 min (C. 
difficile only). Cycling temperatures for primer pairs are mentioned where 
necessary. 
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2.1.6 Digestion of DNA 
DNA (PCR product(s), plasmid(s) or otherwise) was digested using either standard 
New England Biolabs (NEB) restriction enzymes or FastDigest® restriction enzymes 
(Fermentas) as described by the manufacturers. Individual restriction enzyme(s) 
used in digestion reactions are mentioned where necessary. 
2.1.7 Ligation of DNA 
DNA was ligated using the Rapid DNA Ligation Kit (Fermentas) or T4 ligase with T4 
ligase buffer (NEB), used as described by the respective manufacturers. 
2.1.8  Purification of plasmid DNA  
Plasmid purification “miniprep” was undertaken using the QIAprep Spin Miniprep 
Kit (Qiagen) as described by the manufacturer. Eluted DNA was either used directly 
or frozen at -20 °C.  
2.1.9  Purification of PCR product(s) 
PCR products were purified using the QIAquick PCR Purification Kit (Qiagen) as 
described by the manufacturer. Eluted DNA was either used directly or frozen at -
20 °C. 
2.1.10 Gel extraction of DNA 
DNA band(s) were excised from an agarose gel after electrophoresis and purified 
using the QIAquick gel extraction kit (Qiagen) using protocols provided by the 
manufacturer. Eluted DNA was either used directly or frozen at -20 °C. 
2.1.11 Small scale genomic DNA extraction 
Genomic DNA (gDNA) was extracted using the DNeasy Blood and Tissue Kit (Qiagen) 
via enzymatic lysis using protocols provided by the manufacturer. Eluted gDNA was 
either used directly or frozen at -20 °C. 
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2.1.12 RNA extraction 
2.1.12.1 Small scale Total RNA extraction 
C. difficile was re-streaked on FAA plate(s) and incubated for 24 hr at 37 °C. An 
appropriate culture volume was inoculated with a streak of colonies and grown 
overnight at 37 °C. Total RNA was extracted from the C. difficile culture using 
RNeasy mini kit (Qiagen) with enzymatic lysis and proteinase K digestion as per 
manufacturer’s instructions. Total RNA was treated with Turbo DNAse™ (Ambion) 
as per Section 2.1.12.2. 
2.1.12.2 Large scale Total RNA extraction 
C. difficile was re-streaked on FAA plate(s) and incubated for 24 hr at 37 °C. An 
appropriate starter culture volume was inoculated with a streak of colonies and 
grown overnight at 37 °C. This culture was used to inoculate a final vessel which 
was then grown until the desired endpoint (24 hr - stationary phase (Chapter 5 
Section 5.2.2.1)). At the appropriate endpoint RNAprotect (Qiagen) was added to 
the culture and incubated at room temperature for 5 min as per manufacturer’s 
instructions. The cells were then pelleted and resuspended in 1.2 ml TRIzol 
(Invitrogen) and transferred to a Lysing Matrix B (MPBio) ribolyser tube. Samples 
were ribolysed at 6.5 m/sec for 45 sec then transferred to a tube containing 240 µl 
chloroform. The tube(s) were vigorously shaken for 15 sec then centrifuged at 
12000-15000 g for 10 min. The aqueous phase was removed and added to 600 µl 
chloroform and the process repeated. The aqueous phase was washed a further 
time with 600 µl chloroform before transferring to 600 µl isopropanol plus 0.3 M 
sodium acetate (final concentration) before storing at -80 °C to aid precipitation. 
The RNA was pelleted at 12000-15000 g for 10 min then washed with 500 µl 70% 
ethanol then centrifuged as before. The supernatant was removed and the pellet 
allowed to air dry, before resuspension in 800 µl RNase Free water. To remove DNA 
contamination RNA was split into two 400 µl aliquots and treated with 20 units 
TURBO™ DNase (2 x 10 units 30 min apart) for 1 hr. DNase was inactivated by 
addition of 30 mM EDTA followed by heating to 75 °C for 10 min. Following DNAse 
treatment 600 µl isopropanol plus 0.3 M sodium acetate (final concentration) were 
added, mixed and precipitation allowed to proceed at -80 °C for 24 hr. The RNA was 
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pelleted at 12000-15000 g for 10 min then washed with 500 µl 70% ethanol then 
centrifuged as before. The supernatant was removed and the pellet allowed to air 
dry, before resuspension in 200 µl RNase Free water followed by measurement on a 
Nanodrop 1000. To check for DNA contamination PCR was undertaken with 1 µl 
RNA sample using gene specific primers. If DNA was present, RNA sample was 
diluted to 800 µl and DNAse treated as before. The process was repeated until 
residual DNA contamination was not detectable by PCR. The RNA was purified with 
RNeasy MinElute Cleanup kit to remove contaminating protein and buffer 
constituents and eluted with 80 µl RNase free water, followed by measurement by 
Nanodrop 1000. To remove residual buffer constituents from spin column 
purification, RNA was precipitated with 3.5 M lithium chloride precipitation solution 
(final concentration) (Ambion) before re-suspension in RNase free water to 
≥200 ng/µl. RNA was then aliquotted and stored at -80 °C.  
2.2 ClosTron Gene Knockout system 
The ClosTron gene knock-out system developed by Heap et al. (Heap et al. 2007) 
was for used for insertional inactivation of the chosen gene(s). Intron integration 
sites within the chosen genes were identified and intron re-targeting IBS, EBS1d and 
EBS2. PCR primers were designed using the algorithms available on the TargeTron 
Design Site (http://www.sigmaaldrich.com) or the implementation of the Peruka 
(Perutka et al. 2004) algorithm available at 
(http://www.clostron.com/clostron1.php).  
 
The 353 bp region containing the IBS, EBS1d and EBS2 sequences responsible for 
intron specificity was either: re-targeted by ‘splicing-by-overlap extension’ (SOEing) 
PCR using the primers designed above in conjunction with the EBS universal primer 
(CGAAATTAGAAACTTGCGTTCAGTAAAC) which, after gel purification, was cloned 
into pMTL007C-E2 via HindIII and BsrGI sites and sequenced in situ with primers 
CspFdx-F1 (GATGTAGATAGGATAATAGAATCCATAGAAAATATAGG) and pMTL007-R1 
(AGGGTATCCCCAGTTAGTGTTAAGTCTTGG). Alternatively, the 353 bp region was 
synthetically synthesised based on in silico mutation of an intron (re)targeting 
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region template (Figure 2.1) using primers designed by the relevant intron 
retargeting site.  
 
 
 
Figure 2.1 The intron re-targeting region from pMTL007. The 
unique HindIII and BsrGI restriction sites are shown in white. 
 
The derivative pMTL007 plasmid construct(s) were transformed, via 
electroporation, into the conjugative donor E. coli CA434 and then transferred, via 
conjugation, into C. difficile 630ΔErm (Purdy et al. 2002). 
 
Successful transconjugants and subsequent integrants were selected for by 
streaking onto C. difficile selective media (E&O Labs) with the addition of 
thiamphenicol (15 µg/ml) and then on sBHI agar containing erythromycin (5 µg/ml), 
respectively. Confirmation of knockout was performed using PCR with primers 
flanking the intron insertion site (gene specific primers mentioned in chapter 
specific methods) and using the Erm-RAM primers 
(ErmRAM_F ACGCGTTATATTGATAAAAATAATAATAGTGGG and ErmRAM_R 
ACGCGTGCGACTCATAGAATTATTTCCTCCCG). Erythromycin mutants were both re-
streaked onto sBHI agar containing erythromycin (5 µg/ml) and spread onto FAA 
plus 5% horse blood (Oxoid) for safekeeping. 
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2.3 Protein expression 
2.3.1 ‘Harvesting’ of bacterial cultures 
Bacterial cultures were centrifuged at 3488 g for 20 min (culture volume <250 ml) 
or 4652 g for 40 min (culture volume >250 ml) unless otherwise stated. 
2.3.2  Small scale expression trials 
An appropriate E. coli host was transformed with an expression vector containing a 
gene of choice and grown overnight at 37 °C on L-agar plus appropriate antibiotic. 
One colony was inoculated into 2 ml L-broth plus appropriate antibiotic plus 0.5% 
glucose and grown until OD600 ~0.6. Cultures were then cooled to 30 or 16 °C then 
induced with 1 mM IPTG and grown for a further 4 hr or 16 hr respectively, before 
harvest. Soluble/insoluble expression analysis was performed by resuspending the 
pellet in Cellytic B reagent™ (Sigma) plus Benzonaze™ and incubating for 5 min at 
room temperature. Cell suspension was then centrifuged at ≥10,000 g for 5 min to 
pellet insoluble material. The soluble fraction (supernatant) was mixed with 4x LDS 
sample buffer, while insoluble material was resuspended in 1x LDS loading buffer, 
ready for SDS-PAGE. 
2.3.3 Large scale expression 
Large scale expression was similar to small scale expression (Section 2.3.2) except 
after plating, a 50 ml starter culture of terrific broth (TB) with appropriate antibiotic 
plus 0.5% glucose was inoculated and grown overnight at 30 °C with shaking. The 
starter culture was then inoculated into 950 ml of the aforementioned 
supplemented TB media and grown until OD600 ~0.6. Cultures were then cooled to 
30 or 16 °C then induced with 1 mM IPTG and grown for a further 4 hr or 16 hr 
respectively before harvest. Cell pellets were either used directly or frozen at -
20 °C. 
2.3.3.1 Protein extraction/Cell lysis 
Bacterial cells from large scale expression were thawed on ice and resuspended in 
chromatography binding/wash buffer. Cells were then sonicated for 6 x 30 sec (with 
30 sec cooling) before centrifugation at 47,860 g (20,000 rpm Sorval SS-24 rotor) to 
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remove cell debris. The soluble fraction was decanted and retained on ice until 
processing, insoluble fraction was used for refolding if necessary. 
 
2.4  Protein Purification 
2.4.1 Affinity Chromatography 
2.4.1.1 Glutathione sepharose affinity purification 
GST tagged proteins were purified using a GSTrap™ column (GE Healthcare) 
Binding/Wash buffer – 1 x PBS (±10 mM DTT) pH 7.3  
Elution buffer - 50 mM tris-HCl, 10-50 mM reduced glutathione (±10 mM DTT) 
pH 8.0 
Alterations to the above buffers, along with flow rates, gradients and fraction sizes 
are mentioned where necessary. 
2.4.1.2 Purification of IgG by affinity purification 
IgG fraction of animal serum was purified using either HiTrap™ Protein A HP (guinea 
pig serum) or Protein G (sheep serum)  
Binding/Wash buffer – 20 mM sodium phosphate pH 7.0 
Elution buffers - 0.2 M sodium citrate pH 3.0 (Protein A) or 0.1 M glycine pH 2.7 
(Protein G) 
Neutralisation buffer - 1 M tris pH 9.0 
2.4.1.3 Immobilised metal-ion affinity chromatography (IMAC) 
Native IMAC was performed on an ÄKTA Design FPLC (GE Healthcare) using either:  
 
HiTrap™ chelating HP column (GE healthcare) charged with 0.1 M nickel sulphate or 
0.1 M cobalt sulphate (Sigma) or pre-charged HisTrap™ column 
Binding/Wash buffer- 50 mM tris, 0.5 M NaCl, 20 mM imidazole pH 8.0 
Elution buffer- 50 mM tris, 0.5 M NaCl, 0.5 M imidazole pH 8.0 
 
Or using BD TALON™ (Clontech) resin (recharged where necessary with 0.1 M 
cobalt chloride) 
Binding/Wash buffer- 50 mM sodium phosphate, 300 mM NaCl pH 7.0 
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Elution buffer- 50 mM sodium phosphate, 300 mM NaCl, 150 mM imidazole pH 7.0. 
 
 Alterations to the above buffers, along with flow rates, gradients and fraction sizes 
are mentioned where necessary. 
2.4.2  Ion-exchange chromatography (IEX) 
Anion Exchange Chromatography was performed primarily using Q-
sepharose™ fastflow (FF) (GE healthcare). Where MonoQ beads were used, for 
higher resolution, buffers remained the same. 
Binding/Wash buffer – 50 mM tris pH 8.0 
Elution buffer 50 mM tris, 1 M NaCl pH 8.0 
Cation Exchange Chromatography was performed primarily using S-
sepharose™ FF  
Binding/Wash buffer – 50 mM sodium acetate pH 6.0 
Elution buffer - 50 mM sodium acetate, 1 M NaCl, pH 6.0 
 
Alterations to the above buffers, along with flow rates, gradients and fraction sizes 
are mentioned where necessary. 
2.4.3  Hydrophobic Interaction Chromatography (HIC) 
HIC scouting experiments were performed using 1 ml HiTrap™ HIC selection kit (GE 
healthcare). Large scale HIC was undertaken using 5 ml HiTrap phenyl HP (GE 
Healthcare) columns. 
Trial buffers were: 
Binding/Wash buffer – 50 mM sodium phosphate, 1 M ammonium sulphate pH 7.0 
Elution buffer- 50 mM sodium phosphate pH 7.0 
 
Alterations to the above buffers, along with flow rates, gradients and fraction sizes 
are mentioned where necessary. 
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2.5 Protein analysis 
2.5.1 Sodium dodecyl sulphate- Polyacrylamide Gel Electrophoresis 
(SDS-PAGE) 
Denaturing SDS-PAGE was carried out using NuPAGE® Novex® bis-tris 12well or 
10well 1.0 mm pre-cast gels (Invitrogen), NuPAGE LDS 4X LDS sample buffer 
(Invitrogen) and either stained with SimplyBlue™ Safe Stain (Invitrogen) or with 
Pierce Silver Stain Kit II (Pierce, Thermo) as per manufacturer’s instructions. 
2.5.2 Blue Native Polyacrylamide Gel Electrophoresis (BN PAGE) 
Blue Native PAGE was performed using the NativePAGE™ bis-tris gel system 
(Invitrogen) as per manufacturer’s instructions. Samples were prepared with 
NativePAGE™ sample buffer (4X) and ran on either NativePAGE™ Novex® 3-12% or 
4-16% bis-tris 1.0 mm pre-cast gel(s), using 200 ml light blue cathode buffer 
(containing 0.002% Coomassie G-250) (1 ml NativePAGE™ cathode additive (20X) 
plus 10 ml NativePAGE™ running buffer (20X)) together with 1X NativePAGE™ 
anode buffer. 
2.5.3  Western blotting 
SDS-PAGE gel(s) were transferred onto nitrocellulose or PVDF membrane(s) using 
the XCell SureLock® Mini-Cell and XCell II™ Blot Module Kit with NuPAGE® Transfer 
Buffer. Membranes were blocked with 5% w/v non-fat dried milk (Fluka) in water or 
PBS plus 0.1% Tween 20 (PBS/T) (blocking buffer). Incubation with primary antibody 
(at appropriate dilution in blocking buffer) was for 1 hr followed by 3 washes in 
PBS/T. If necessary, a further incubation with secondary antibody again for 1 hr was 
followed by 3 washes in PBS/T prior to chemiluminescent detection/development 
using ECL™ western blotting detection reagents (Amersham and/or Pierce). 
Common antibodies and dilutions used in western blot: 
Mouse monoclonal T7•Tag® HRP Conjugate (Novagen) - 1:5000 
Mouse Monoclonal Anti-PolyHistidine (His6) −Peroxidase (Sigma) – 1:7000 
2.5.4  Mass spectrometric identification of proteins 
These analyses were conducted at the Centre for Proteomic Research, University of 
Southampton. Excised protein bands were subjected to in situ trypsin digestion 
using previously described methods (Shevchenko et al. 1996). The resulting 
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peptides were separated by nano-reverse phase liquid chromatography, using a 
Dionex C18 PepMap, 3 µm, 100 Å (150 mm x 75 µm, i.d.) column, and 
electrosprayed into a quadrupole time-of-flight tandem mass spectrometer. All 
data were acquired using a Q-tof Global Ultima (Waters Ltd) fitted with a 
nanoLockSpray™ source. A survey scan was acquired from m/z 375 to 1800 with the 
switching criteria for MS to MS/MS including ion intensity and charge state. The 
collision energy used to perform MS/MS was varied according to the mass and 
charge state of the eluting peptide. All MS/MS spectra were automatically 
processed using MASCOT distiller (Matrix Science) and subsequently searched 
against a FASTA formatted listing of protein sequences predicted from the C. 
difficile 630 genome sequences using the search algorithm MASCOT ver2.2. The 
following parameters were used: parent mass tolerance was 150 ppm, fragment 
mass tolerance 0.25 Da, carbamidomethylation was set as a fixed modification, the 
oxidation of methionine as a variable modification and a maximum of one missed 
cleavage was allowed. The significance threshold for search results was set at p < 
0.05 which indicates identity or extensive homology. 
 
2.6  Clostridium difficile strains and growth conditions 
The C. difficile strains used throughout this thesis are summarised in Table 2.1. 
Liquid cultures were grown in pre-reduced supplemented brain-heart infusion 
broth (sBHI) (per litre of broth – 37 g brain heart infusion (Oxoid), 5 g yeast extract 
(Oxoid) 1 ml resazurin (1.0 mg/ml) 0.5 g L-cysteine HCl, 10 ml haemin solution, 1 ml 
vitamin K1 solution) at 37 °C in an atmosphere of 10% H2, 10% CO2 and 80% N2 in a 
Don Whitley MG1000 anaerobic workstation. 
Plate cultures, unless otherwise stated, were grown on pre-reduced Fastidious 
Anaerobe Agar (FAA) plus 5% horse blood (Oxoid) and incubated anaerobically as 
above. 
2.7 Other general methods 
2.7.1 Toxin A or B ELISA 
Affinity purified sheep anti-toxoid A and B IgG was biotinylated using EZ-Link® Sulfo-
NHS-Biotin reagents (Pierce) as per manufacturer’s instructions. Prior to and after 
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biotinylation IgG was dialysed against 50 mM HEPES, 0.15 M NaCl pH 7.4 overnight 
at 4 °C. Unbiotinylated sheep anti-toxoid A and B IgG was coated onto a Maxisorb 
plate at 5 µg/ml in PBS and incubated for 1 hr or overnight at 4 °C. Plates were 
washed three times with PBS plus 0.1% Tween 20 (Sigma) (PBS/T) followed by 
application of PBS/T plus 5% foetal calf serum (blocking buffer) and incubated for 
1 hr. Plates were washed a further three times before the application of 
appropriate samples and toxin A and B standards (diluted to 1000 ng/ml) and 
incubated for 1 hr. Plates were washed a further three times before application of 
either biotinylated sheep anti-toxoid A (1 µg/ml) or B IgG (10 µg/ml) and incubated 
for 1 hr. Plates were washed as before then streptavidin-HRP conjugate (GE 
Healthcare) (1:1000, in blocking buffer) applied and incubated for 10 min followed 
by a final three washes. Detection was undertaken with the addition of a TMB 
substrate and TMB stop solution (BioFX), then read at 450 nm using a Tecan™ 
Sunrise microtitre plate reader. Toxin concentrations were estimated using a 
sigmoidal four-parameter logistic standard curve.  
 
C. difficile culture supernatants for toxin A or B ELISA were obtained by removing 
bacterial cells from C. difficile culture by centrifugation, then dialysing the culture 
supernatant for 24 hr into 50 mM HEPES 0.15 M NaCl pH 7.4, using 12 kDa MWCO 
dialysis tubing before storage at -80 °C if not used directly. 
2.7.2 Surface protein extraction 
Surface protein extraction was essentially as described by (Cerquetti et al. 2000; 
Calabi et al. 2001) using low pH glycine extraction. Briefly, the harvested cell pellets 
were washed once with 10 mM HEPES containing 100 mM NaCl pH 7.4, re-
suspended in 0.2 M glycine pH 2.2 and incubated for 30 min at 22 °C. Cells were 
then removed by centrifugation and the supernatant neutralised with 2 M tris-HCl 
pH 9.0. Extracted SLPs were dialysed into 50 mM HEPES containing 0.15 M NaCl 
pH 7.4 and stored at -80 °C if not used directly. 
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Table 2.1 C. difficile strains used in this thesis 
Referred to in 
this text 
Ribotype Toxinotype Toxin production Source ARL Cardiff 
Reference 
ATCC Reference 
R20291 027 III A+B+ Stoke Mandeville 
Hospital 
R20291 13366 
VPI10463 001 0 A+B+ Human abdominal 
wound isolate 
 43255 
ARL001 001 0 A+B+ ARL R8652 11209 
630ΔErm 630 0 A+B+ A gift from N. Minton 
(Nottingham 
University) as 
generated in Hussain 
et al. (2005)  
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CHAPTER 3 
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3 CHAPTER 3 – Cwp84 
3.1 Introduction 
3.1.1.1 Proteases in infection 
Clostridia exist primarily as apparently harmless saprophytes and are normally 
found in anaerobic environments high in fermentable organic compounds including 
soils, aquatic sediments and the intestinal tracts of animals. Being saprophytic, 
Clostridia produce a wide variety of cellular and extracellular enzymes to degrade 
nutrients and large biological molecules e.g. proteins, lipids, collagen, cellulose. This 
action normally contributes to the natural cycles in the environment, however upon 
an infection (usually opportunistic) these factors play a role in invasion and 
pathology (Allen et al. 2003; Todar 2008). 
 
Directly or indirectly proteases therefore play key roles during the colonisation 
process as adhesins, as part of nutrient acquisition or in the processing of bacterial 
proteins necessary for growth and ensuring continued proliferation (Maeda 1996; 
Potempa & Pike 2005). For example, the pathogenesis of C. difficile is primarily due 
its toxins (TcdA and TcdB), both of which are automatured via cysteine protease 
activity, a mechanism shared by Vibrio cholerae toxins (Sheahan et al. 2007; 
Giesemann et al. 2008) highlighting how, through the action of maturing these 
toxins, cysteine proteases promote infection indirectly.  
3.1.1.2 Cysteine proteases 
Cysteine proteases are so called as the sulphydryl group of a cysteine residue acts 
as a nucleophile allowing hydrolysis of the peptide bond. The nucleophilic cysteine 
thiol acts with a histidine forming a catalytic dyad. Orientation of the imidazole ring 
of the active histidine and formation of an 'oxyanion hole’ is believed to be assisted 
by a glutamine preceding the cysteine and an asparagine following the catalytic 
histidine respectively. The inclusion of either of these additional residues therefore 
leads to the active site residues also being described as a catalytic triad, although 
only the Cysteine and Histidine participate catalysis (Otto & Schirmeister 1997; 
Rawlings et al. 2010). The structure of papain (PDB: 9PAP) demonstrates a globular 
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protein with two interacting domains, with substrates bound in the cleft of the 
domains into the 'oxyanion hole’ (Drenth et al. 1968) (Figure 3.1.1). 
 
 
 
Figure 3.1.1 Cysteine proteases and their active sites. (A) Cysteine protease papain and 
highlight of nucleophilic cysteine thiol and active histidine. (B) The cleavage of the peptide 
carbonyl group by the cysteine and histidine. Taken from Berg et al. (2002) 
 
Like many proteins the tertiary structure is more conserved than the primary 
sequence, hence cysteine proteases can be divided into clans and further sub-
divided into families on the basis of the architecture of their catalytic dyad or triad 
and on their origin e.g. C1 papain, C3 and 4 viral (Rawlings & Barrett 1993; Barrett & 
Rawlings 2001). 
 
Cysteine proteases, like other proteases, are involved in pathogenesis in a variety of 
ways, for example papain-like, type III secreted, cysteine proteases of Yersinia that 
arrest the cell cycle (Yao et al. 2009), the degradation of complement by Prevotella 
intermedia (Potempa et al. 2009) or surface-associated proteolytic degradation of 
IgA in Entamoeba histolytica (Garcia-Nieto et al. 2008). 
 
3.1.1.3 Discovery and characterisation of a surface located cysteine 
protease in C. difficile. 
A putative surface located thiol protease was first discovered by Seddon & Borriello 
(1992). The cell surface associated protease exhibited trypsin-like substrate 
specificity but was inhibited by thiol protease inhibitors, with an optimum pH of 7.5 
and temperature of 37 °C. Seddon & Borriello (1992) therefore suggested that the 
C. difficile thiol protease was more like clostripain (C11 family cysteine protease), 
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which cleaves the carboxy peptide bond of arginine, than trypsin (which cleaves the 
carboxyl side of the lysine or arginine). They also found there was no correlation 
between virulence and protease production, suggesting that the protease was not 
related to virulence. 
 
Following the examination of a 37 kbp DNA fragment flanking slpA (gene of main S-
layer) in the genome of C. difficile 630, Karjalainen et al. (2001) and Calabi et al. 
(2001) found 17 open reading frames (ORFs) in the same genetic locus as slpA, with 
a further 11 suggest to exist elsewhere in the C. difficile genome. Eleven of which 
encoded a domain present at either the N- or C-terminus with homology to the N-
terminal cell wall-anchoring domain of the CwlB autolysin of B. subtilis (Kuroda & 
Sekiguchi 1991). Subsequently, 28 genes encoding an N- or C-terminal cell wall 
binding domain (CWBD (PFam04122)) have been found (Sebaihia et al. 2006). 
However, only two genes contain a conserved peptidase C1 (papain) family domain 
at the N-terminus (and three CWBDs at the C-terminus) (Figure 3.1.2), cwp84 
(cd2787) found in the 37 kbp putative surface protein cluster and named from the 
putatively 84 kDa protein the gene encodes (Savariau-Lacomme et al. 2003), and 
cd1751, less attractively named from the C. difficile 630 genome gene numbering 
system, found a large distance away from slpA the C. difficile genome.  
 
 
 
803 aa (87,280Da predicted) 
Signal peptide ............................1-32  
Peptidase_C1A...........................104-322    
3x CWBD ....................................507-595, 604-697, 702-793 
Active residues (Q110, C116, H262, N294) 
 
Figure 3.1.2 Domain structure of Cwp84. Sig – signal peptide, Peptidase_C1 - C1A (papain) 
peptidase family, CWBD – cell wall binding domain (Pfam04122). Flags denote Cwp84 
active residues C116 and H262. Putative domain location(s) obtained from C. difficile 630 
genome annotations, available at ncbi.nlm.nih.gov. [Note: domain structure of CD1751 is 
similar to Cwp84] 
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To understand more about cwp84, expression and analysis of the cwp84 gene was 
undertaken. Savariau-Lacomme et al. (2003) found the cwp84 gene is highly 
conserved and appears to be transcribed as a monocistronic message particularly 
prominent at early exponential growth, while amino acid sequence analysis 
suggested the conserved active site residues of C116, H262 and N287. Initial 
proteolytic assays using recombinant Cwp84 did not confirm specific substrates, nor 
did typical cysteine protease inhibitors inhibit the recombinant Cwp84 produced. 
Interestingly, free GST-Cwp84 N-term fragments found during expression of the 
whole cwp84 ORF (including signal peptide) in E. coli lead to the suggestion that 
Cwp84 may auto-cleave (auto-mature), a mechanism found in other cysteine 
proteases e.g. papain (Vernet et al. 1995). Savariau-Lacomme et al. (2003) also 
found no correlation between expression of cwp84 and virulence which, taken with 
the above data, led to the suggestion that Cwp84 was key in the physiology of C. 
difficile possibly in cleavage of other cell surface-associated proteins e.g. SlpA. 
 
By expressing only the cysteine protease domain (343 aa total) (less signal peptide) 
tagged to GST, Janoir et al. (2004) found that the proteolytic activity on gelatine and 
BAPNA (N-α-Benzoyl-DL-arginine 4-nitroanilide hydrochloride, a chromogenic 
trypsin substrate) was inhibited by cysteine and serine protease inhibitors. The 
refolded recombinant Cwp84 displayed a molecular weight of 45 kDa on SDS-PAGE 
and proved to have a weaker activity than trypsin but higher than papain. The 
proteolytic activity appeared to decrease quickly, suggesting enzyme instability. A 
significant finding by Janoir et al. (2004) was that CDI patient serum contained 
antibodies to the cysteine protease domain of Cwp84. This highlights how an 
immune response is generated to Cwp84 but also how Cwp84 must be accessible to 
the immune system to generate the immune response i.e. it is surface located. 
Cwp84’s surface-based location and immunogenicity was confirmed by both 
Pechine et al. (2005a) who found only 2 out of 17 patients tested did not have 
antibodies to Cwp84 and Wright et al. (2008) who found antibodies to Cwp84 in 
patient serum by proteomic analysis of reacting surface proteins. 
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Full length recombinant His6 tagged Cwp84 (rCwp84) displayed an inhibition profile 
similar to that seen previously, with typically 10% activity remaining after serine 
and cysteine protease inhibitor treatment, except when 100 µM E64 was used 
which fully inhibits Cwp84. rCwp84 appeared to be automatured upon exposure to 
DTT, presenting as a final ‘mature’ 61 kDa species (mCwp84). However, both 
‘immature’ (rCwp84) and ‘mature’ (mCwp84) displayed proteolytic activity. In 
support of a host tissue and infection dissemination hypothesis, Cwp84 was found 
to degrade fibronectin, laminin, and vitronectin but not type IV collagen. Moreover, 
as found in Seddon & Borriello (1992) the pH optimum was pH 7.5 (Janoir et al. 
2007).  
3.1.1.4 Localisation of Cwp84 
Use of mCwp84 to generate antiserum led to the identification of Cwp84 in various 
cell fractions of C. difficile. Cwp84 was found as a 90 kDa pre-proprotein (including 
signal peptide) in the cytoplasm, an 82 kDa protein in the membrane and cell wall 
fractions and finally as a putatively glycosylated 85 kDa version in low pH glycine 
surface protein extracts. A small amount of 61 kDa protein was also found in the 
glycine extract (Janoir et al. 2007).  
 
Proteomic analysis of cell wall and low pH surface extracts only identified Cwp84 as 
a small fragment in the lysozyme cell wall extract indicating that either Cwp84 is an 
easily degraded or labile protein, or that it is not found in glycine extracts under the 
conditions tested (Wright et al. 2005). 
3.1.1.5 Understanding the role of Cwp84 in C. difficile  
From gene expression studies it appears that certain surface located genes e.g. 
cd2791, slpA, cwp66, and especially cwp84, are upregulated during environmental 
stress e.g. high osmolarity, iron depletion or when C. difficile is exposed to sub-MIC 
levels of antibiotics (Deneve et al. 2008; Emerson et al. 2008; Deneve et al. 2009a). 
In response to fluoroquinolones, the amounts of Cwp84 found on the cell surface 
did not correlate perfectly with the increased expression of cwp84, suggesting that 
Cwp84 may also be secreted (potentially similar to the supernatant based 
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proteolytic activity originally eluded to by Seddon & Borriello (1992)) (Deneve et al. 
2009a). 
 
The hypothesised role(s) of Cwp84 in vivo are therefore; an infection dissemination 
hypothesis, based upon the ability of recombinant Cwp84 to degrade ECM proteins 
and potential being secreted or Cwp84 playing a key role in the bacterium’s 
physiological response particularly to stress e.g. environmental or chemical 
(antibiotics) from expression data.  
 
Presented here and reported in Kirby et al. (2009), the ClosTron gene knockout 
system was used to further understand the role of Cwp84. Knockout of Cwp84 
results in a bacterial phenotype in which only immature, single chain SlpA is 
presented at the cell surface. Furthermore, Cwp84 appears not to be an essential 
virulence factor and bacteria expressing immature SlpA are able to cause disease. 
Recently, it has also been shown that by inhibition of surface protease activity and 
use of activity based probes, that it is Cwp84 that mediates SlpA maturation in vivo. 
Dual expression also demonstrated Cwp84 cleavage of SlpA at a defined cleavage 
site (Dang et al. 2010). 
 
Taken together these data provide convincing evidence that Cwp84 plays a key role 
in S-layer maturation. Corroborating earlier reports, Cwp84 and the lack thereof is 
not directly correlated with virulence; however a connection between its ability to 
be up or down-regulated and virulence is not precluded.  
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3.2 Chapter 3 Specific Methods 
3.2.1 Cloning and expression of recombinant Cwp84 
3.2.1.1 Genetic methods 
3.2.1.1.1 Synthetic synthesis of C. difficile 027 (R20291) strain cwp84 gene 
The C. difficile 630 cwp84 gene sequence was BLAST searched against the Sanger 
Institute’s C. difficile strain R20291 (Stoke Mandeville, UK) assembly (March, 2008). 
The resulting match was reverse transcribed and translated in silico. The resulting 
amino acid sequence, flanked by BamHI, two C-term Stop codons and XhoI 
restriction sites was submitted to GENEART (Regensburg, Germany) for optimised 
gene synthesis and direct insertion into pET28(a) using the same two restriction 
sites. The resulting cwp84 gene is herein referred to as cwp84(g).  
3.2.1.1.2 Primers used to clone and mutate cwp84 
The primers given in Table 3.2.1 were used to clone or mutate cwp84 from gDNA of 
C. difficile 630ΔErm or cwp84(g) directly in pET28a. Resulting PCR products were 
purified as described in General Methods 2.1.9, then digested (where necessary) 
with appropriate restriction enzymes (Fast Digest, Fermentas) (Section 2.1.6). The 
resulting cloned cwp84 gene(s) are herein referred to as cwp84([derived strain]) 
e.g. cwp84(630) 
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Table 3.2.1 Primers used to clone or mutate rCwp84 and rCwp8433-497. 
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3.2.1.1.3 Insertion of cwp84 into a range of expression vectors 
In order to assess the expression and solubility of recombinant Cwp84, a number of 
expression vectors were assessed (Table 3.2.2).  
 
Table 3.2.2 Expression vectors used in this chapter 
Vector 
Name 
Supplier Antibiotic 
Resistance 
Tag 5’ 
Restriction 
site 
3’ 
Restriction 
site 
pET28a Novagen kan N-term 
His6 
 
N-term 
His6.T7 
NheI   
 
BamHI 
EcoRI  
 
XhoI 
pET24b Novagen kan N-term T7 
C-term His6 
BamHI XhoI 
pET43.1a Novagen amp N-term 
NusA.His6.S 
tag 
BamHI XhoI 
pET41a Novagen kan N-term 
GST.His6.S 
tag 
BamHI XhoI 
pET41b Novagen kan N-term 
GST.His6.S 
tag 
C-term His6 
BamHI XhoI 
pGEX-6P-1 GE 
Lifescience 
amp N-term 
GST 
BamHI XhoI 
pTAC-MAT2 Sigma amp C-term His6 HindIII EcoRI 
 
3.2.1.2 Expression of recombinant Cwp84 variants 
3.2.1.2.1 Expression hosts 
In order to assess the expression and solubility of recombinant Cwp84, a number of 
E. coli expression hosts were tried (Table 3.2.3) 
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Table 3.2.3 E. coli expression hosts used in this chapter 
Name Supplier Notes 
BL21 Novagen General purpose expression 
host 
BL21 (DE3)  Novagen General purpose expression 
host. Expression of SUMO 
fusion. 
BL21 (DE3) Star Invitrogen General purpose expression 
host with reduced mRNA 
degradation. For expression of 
T7 driven promoters 
Origami 2 (DE3) Novagen Thioredoxin reductase (trxB) 
and glutathione reductase (gor) 
mutants for increased 
cytplasmic disulphide bond 
formation 
Overexpress C41 &C43 (DE3) Lucigen BL21(DE3) derivatives 
empirically selected for toxic 
gene expression 
T7 Express lysY/Iq (High 
Efficiency) 
NEB Tighter control of expression 
and less susceptibility to lysis 
during induction 
 
3.2.1.2.2 General expression protocol for full length pET constructs 
Constructs were transformed into the expression strain via heat shock and spread 
onto L-agar containing the appropriate antibiotic then incubated overnight at 37 °C. 
Due to plasmid or DE3 lysogen loss, the plating method of induction was used. Two 
bacterial lawns were required per litre of culture thus two colonies were 
resuspended in 2 x 100 µl PBS then re-spread onto L-agar and incubated as before. 
1 litre of L-broth plus the appropriate antibiotic supplemented with 0.5% w/v D-
glucose was inoculated by scraping off and re-suspending the 2 plates of bacterial 
lawn. Cultures were grown at 30 °C until OD600 ~0.6. Cultures were then cooled to 
30 °C then induced with 1 mM IPTG for 1hour or cooled to 16 °C then induced 
overnight. Cells were then harvested and frozen at -20 °C 
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3.2.1.2.3 General expression protocol for other constructs 
All other construct expression was performed as detailed in General Methods (small 
scale- section 2.3.2 or large scale- section 2.3.3) 
3.2.1.3 Purification of recombinant Cwp84 
3.2.1.3.1 Purification of soluble His6 or MAT tagged rCwp84 
His6 or MAT tagged material was purified in native IMAC as described in General 
Methods (Section 2.4.1.3).  
3.2.1.3.2 Purification and refolding of insoluble His tagged rCwp84 
Isolation of insoluble material was based on the inclusion body isolation procotol 
found in the Pierce Protein Refolding Kit (Thermo). Frozen cell pellets were thawed 
and resuspended in lysis/wash solution containing 50 mM tris, 2% triton X-100, 
5 mM DTT, 500 mM NaCl pH 8.0 and sonicated for 6x30 sec on ice. Cell debris and 
insoluble material was recovered by centrifugation at 38,770 g (18,000 rpm Sorval 
SS-34 rotor) for 20 min. The pellet was directly resuspended in ice cold 50 mM tris, 
7 M guanidine hydrochloride (GnHCl) pH 8.0 and left overnight at 4 °C with stirring 
to solubise. After solubisation the suspension was centrifuged for 30 min at 
47,860 g at 4 °C, the supernatant was then filtered with a 0.2 µm filter and returned 
to ice ready for denaturing IMAC. 
 
Denaturing IMAC was undertaken on a 1 ml HisTrap™ column with 50 mM tris, 6 M 
GnHCl, 20 mM imidazole, pH 8.0 (binding/wash buffer) and as above but with 0.5 M 
Immidazole in the elution buffer. Fractions were analysed by SDS-PAGE by first 
removing GnHCl using Pierce SDS-PAGE Sample Prep Kit (Pierce) as per 
manufacturer’s instructions, followed by silver staining and western blot where 
necessary. 
 
Fractions of denaturing IMAC purified His.T7.Cwp84 were refolded as outlined in 
the Pierce Protein Refolding Kit (Thermo), using the low protein concentration 
protocol. Refolding was allowed to proceed overnight at 4 °C. Assessment of 
refolding on protein was performed by SDS-PAGE. 
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3.2.1.3.3 Purification of (pGEX) GST tagged rCwp84 
GST tagged protein was purified using a glutathione column as described in General 
Methods (Section 2.4.1.1). 
3.2.1.3.4 Purification of SUMO tagged rCwp8433-497 
Expression was performed as described in general expression protocol (Section 
2.3.3) using E. coli BL21 (DE3). His6.SUMO tagged proteins were first purified by 
IMAC (Section 2.4.1.3) then dialysed into SUMO protease cleavage buffer (50 mM 
tris-HCl, 150 mM NaCl pH 8.0, 0.2% igepal, 1 mM DTT). A second round of IMAC was 
performed using 50 mM tris-HCl, 150 mM NaCl pH 8.0 as binding/wash buffer, to 
ensure any uncleaved material and/or contaminants bound, with cleaved untagged 
protein not binding. To remove residual detergent from cleavage buffer, the flow 
through was dialysed into IEX (Q pH 8.0) start buffer and purification undertaken as 
per General Methods (Section 2.4.2).  
3.2.1.4 In vitro transcription and translation (IVT) of recombinant 
Cwp84 and small scale batch purification of Cwp84 
In vitro transcription and translation (IVT) was undertaken using EasyXpress Protein 
Synthesis Kit (Qiagen) as per manufacturer’s instructions, using plasmid miniprep as 
template DNA. Expression analysis was performed using 1 µl of the IVT reaction in 
SDS-PAGE, while the remainder (49 µl) was used in native, small scale, batch 
purification with BD TALON (Clontech) IMAC resin as per the manufacturers 
protocol “Appendix B”. Briefly, 100 µl resin slurry was first equilibrated with 2 
washes in binding/wash buffer followed by re-suspension and incubation with IVT 
reaction for 10 min at room temperature. Unbound material was removed with a 
further 2 washes with binding/wash buffer. Bound material was then eluted, twice, 
by resuspending resin in elution buffer. Fractions were analysed by SDS-PAGE and 
western blot with appropriate antibodies. 
3.2.1.5 Treatment of purified rCwp84 with DTT 
Insoluble refolded rCwp84 was incubated overnight with 5 mM DTT at 4 °C. Soluble 
material eluted from IMAC was either incubated with 5 mM DTT at room 
temperature or at 37 °C for 4 hr.  
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3.2.1.6 Treatment of purified rCwp84 with thrombin 
Purified protein from pET28a constructs was incubated with thrombin as per small 
scale optimisation protocol with Thrombin, Restriction grade (Novagen).  
3.2.2 Knockout of cwp84 
3.2.2.1 Genetic methods 
3.2.2.1.1 Knockout of Cwp84 – ClosTron system 
The ClosTron gene knock-out system was used for insertional inactivation of cwp84 
using protocols outlined in General Methods (Section 2.2). Retargeting primers 
were designed by the TargeTron site (Sigma) (Table 3.2.4). Retargeting for insertion 
site 347|348a was performed by SOE PCR, while other sites retargeting 353 bp 
region was synthetically synthesised.  
 
Flanking primers used to confirm successful integration into cwp84 were (Cwp84_F 
TGAGCTAGCGCAGAAAACCATAAAACTCTAGATG & Cwp84_R 
ATACTCTTTTAGGAAAATAGGAATTCAC)(Janoir et al. 2007).  
3.2.2.1.2 Genomic DNA extraction 
Small scale genomic DNA extraction was performed as per General Method’s 
(Section 2.1.11). 
3.2.2.1.3 Analysis of the CD1751 gene 
Full length cd1751 was amplified by PCR using primers in Chapter 5 Table 5.2.2. 
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Table 3.2.4 IBS, IBD1d and EBS primers for retargeting ClosTron Ll.ltrB intron 
Gene 
insertion 
location IBS IBS1d EBS2 
cwp84 68|69a AAAAAAGCTTATAA
TTATCCTTAGGTATC
GTTGACGTGCGCCC
AGATAGGGTG 
CAGATTGTACAAATG
TGGTGATAACAGAT
AAGTCGTTGACACTA
ACTTACCTTTCTTTGT 
TGAACGCAAGTTTCT
AATTTCGATTATACCT
CGATAGAGGAAAGT
GTCT 
cwp84 347|348a AAAAAAGCTTATAA
TTATCCTTAGAAAA
CGACCAGGTGCGCC
CAGATAGGGTG 
CAGATTGTACAAATG
TGGTGATAACAGAT
AAGTCGACCAGCAT
AACTTACCTTTCTTTG
T 
TGAACGCAAGTTTCT
AATTTCGATTTTTTCT
CGATAGAGGAAAGT
GTCT 
cwp84 677|678a AAAAAAGCTTATAA
TTATCCTTATATTGC
ATTATAGTGCGCCC
AGATAGGGTG 
CAGATTGTACAAATG
TGGTGATAACAGAT
AAGTCATTATAGCTA
ACTTACCTTTCTTTGT 
TGAACGCAAGTTTCT
AATTTCGGTTCAATAT
CGATAGAGGAAAGT
GTCT 
cwp84 2054|2055a AAAAAAGCTTATAA
TTATCCTTAGTAGC
CGTACCAGTGCGCC
CAGATAGGGTG 
CAGATTGTACAAATG
TGGTGATAACAGAT
AAGTCGTACCACCTA
ACTTACCTTTCTTTGT 
TGAACGCAAGTTTCT
AATTTCGATTGCTACT
CGATAGAGGAAAGT
GTCT 
tcdA 
(Toxin 
A) 
979|980a AAAAAAGCTTATAA
TTATCCTTATATCAC
AGTTTTGTGCGCCC
AGATAGGGTG 
CAGATTGTACAAATG
TGGTGATAACAGAT
AAGTCAGTTTTCTTA
ACTTACCTTTCTTTGT 
TGAACGCAAGTTTCT
AATTTCGGTTTGATAT
CGATAGAGGAAAGT
GTCT 
 
3.2.2.1.4 Analysis of cwp84 mRNA 
Total RNA was extracted as per General Methods 2.1.12.1 from stationary phase 
(24 hr) C. difficile 630ΔErm and CDΔCwp84347. To isolate mRNA and remove residual 
genomic DNA contamination, the total RNA was treated with mRNA-ONLY™ 
Prokaryotic mRNA Isolation Kit (Epicentre Biotech) then TURBO DNA- free ™ Kit 
(Ambion). Reverse transcription PCR (RT-PCR), using primers amplifying cwp84 
either pre-intron insertion site (cwp84PreIntron_F CCTGTCTCAGCAGAAAACCA & 
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cwp84PreIntron_R GACCAA GATCCATTGGGTTG) or flanking the intron insertion site 
(cwp84-899-2334_F TCTCCTGAAGTAGCTTGTCC & cwp84-899-2334_R 
CCTGTCTCAGCAGAAAACC), was performed using SuperScript III One-Step RT-PCR 
system with Platinum® Taq DNA (Invitrogen).  
3.2.2.2 Characterisation of cwp84 knockout mutants 
3.2.2.2.1 Growth rate determination  
Crude spore suspension (30 µl) (produced as detailed in 3.2.2.2.2) was spread onto 
pre-reduced FAA plate(s) and incubated at 37 °C for 3 days in anaerobic conditions. 
sBHI broth (80 ml) was inoculated with 1 streak of colonies and incubated overnight 
as above. sBHI (80 ml) was inoculated with the resulting overnight culture, such 
that the OD600 ~0.1. The culture was then stirred and 1 ml samples removed at 
hourly intervals (including time 0) and OD600 measured. OD600 vs time was plotted 
and the linear (slope/gradient/exponential) part of the curve was analysed where 
appropriate. 
3.2.2.2.2 Preparation of C. difficile spores 
A portion of 48 hr C. difficile culture (300 µl) was spread onto FAA plates and 
incubated for 10 days. After incubation the bacterial lawn was scraped off and 
transferred to 15 ml of sterile DMEM and centrifuged for 20 min at 872 g. The 
resulting pellet was washed twice by resuspension into 12 ml DMEM followed by 
centrifugation and then resuspended into DMEM and heat shocked 62 °C for 
40 min. The resulting crude spore suspension was aliquoted and stored at -80 °C. 
Samples (200 µl) were used to obtain viable counts after heat shocking. 
3.2.2.2.3 Toxin A and B ELISA 
Sandwich ELISA to toxins A and B was performed as detailed in General Methods 
Section 2.7.1. 
3.2.2.2.4 Production of anti-Cwp84 peptides and antiserum production 
The cwp84 gene (C. difficile 630) was entered into MIF Bioinformatics epitope 
prediction program (September 2008). The following predicted antigenic peptides 
were synthesised and conjugated to keyhole limpet hemocyanin (KLH) by Peptide 
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Protein Research Ltd (Hampshire, UK) (numbers refer to Cwp84 amino acid 
position): 
124   (C)TLEAYLKL    131 
258   (C)APLNHAVAIV   267 
513   (C)YETAVKVSQ   521 
Three guinea pigs, one for each peptide, were injected with 800 µg peptide diluted 
in PBS and emulsified with Titremax™ adjuvant prior to injection into 2 sites 
subcutaneously. Boosts of 400 µg were administered at 21 and 42 days later. 
Animals were bled at 6 weeks and serum collected. Antibodies were purified from 
serum using a HiTrap Protein A column (General Methods section 2.4.1.2). Western 
blots were performed against low pH glycine extracts and cell wall extracts 
(Jonquieres et al. 1999; Wright et al. 2005) using guinea pig anti-Cwp84 peptide IgG 
at the following concentrations: 1:100, 1000, 5000, 7000, 1:10,000. Anti-guinea pig 
HRP (Sigma) was used at a 1:2000 dilution in blocking buffer. The following blocking 
reagents were tested, 5% milk, 3% BSA, protein-free blocking reagent (Pierce). 
3.2.2.2.5 Cleavage of CDΔCwp84 SLPs with trypsin and other proteases 
CDΔCwp84 SLPs, or CDΔCwp84 culture supernatant, was mixed with 1, 5 or 
10 µg/ml trypsin (in 50 mM HEPES, 0.15 M NaCl pH 7.4) and incubated at room 
temperature. Samples were removed at time intervals and the reaction stopped by 
addition of trypsin inhibitor (final concentration 5 times that trypsin concentration). 
Samples were then analysed by SDS-PAGE. 
 
CDΔCwp84 SLPs were also incubated with pre-activated clostripain (5 µg/ml) 
chymotrypsin (5 µg/ml), papain (1 or 5 µg/ml) and cathepsin B (50 µg/ml) and 
incubated at either room temperature or 37 °C. Samples were removed at time 
intervals and the reaction stopped by mixing with 4 x LDS loading buffer and 
heating at 95 °C for 5 min. 
3.2.2.2.6 CDΔCwp84 grown in trypsin 
CDΔCwp84 was grown in sBHI with addition of 0.1, 10 or 100 µg/ml trypsin for 
24 hr. Cells were then harvested and washed once in 10 mM HEPES, 0.15 M NaCl 
pH 7.4 containing 500 µg/ml trypsin inhibitor. SLPs were then extracted, as 
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aforementioned (General Methods section 2.7.2), but using 0.2 M glycine pH 2.2 
containing 100 µg/ml trypsin inhibitor.  
3.2.2.2.7 Animal Model for Clostridium difficile Infection 
Syrian hamsters (80-100 g) were housed (2 per cage) in isolator cages fitted with air 
filters on lids to minimise contamination between groups. Groups of 14 hamsters 
were divided into a ‘Test’ subgroup of 10 and ‘Control’ subgroup of 4 animals. All 14 
hamsters were weighed and administered clindamycin (2 mg in 0.2 ml sterile H2O) 
by the orogastric route on Day 0. On Day 2, hamsters in the ‘Test’ subgroup were 
challenged with 200 colony forming units of C. difficile spores in 0.2 ml DMEM, 
given orogastically. Control subgroup animals received just DMEM. All animals were 
weighed daily and monitored 6 times/day for 12 days for disease symptoms which 
included: diarrhoea, weight loss, lethargy and tender abdomen (Sambol et al. 2001; 
Babcock et al. 2006). Hamsters were scored on a 0-3 scale for disease symptoms 
and animals in advanced stages of disease or become immobile were euthanized. 
Faecal samples of euthanized animals were taken by colectomy and C. difficile 
isolated/cultured using alcohol shock method (HPA 2008) and plated onto C. 
difficile selective medium (E&O Labs) and grown for up to 7 days. 
3.2.2.2.8 Microscopy of CDΔCwp84 mutant 
Transmission electron microscopy (TEM) and Cryo-Scanning Electron Microscopy 
(Cryo-SEM) of whole cells was performed by Dr. H. Tolley (Health Protection 
Agency). Atomic force microscopy was performed by Dr. J. Mitchells at the 
Microscopy and Analysis Suite (MAS), University of Bath. 
3.2.2.2.8.1 Transmission electron microscopy (TEM) – Whole cells 
Cultures of WT and CDΔcwp84 were grown for 24 hr before harvesting and washing 
in PBS. Pellets were then resuspended with formalin and incubated for 16 hr before 
brief sonication. C. difficile cell suspension (2-3 µl) was applied to carbon film 
coated copper grids and incubated for 30 sec; surplus was removed with moist filter 
paper. Grids were stained with 2-3 µl 2% methylamine tungstate (pH 6.5) for 1-10 
seconds before surplus removal as aforementioned. Grids were allowed to air dry 
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before examination on a Philips CM100 operating at 80kV (LaB6 (lanthanum 
hexaboride crystal) filament). 
3.2.2.2.8.2 Embedded sectioning TEM – Whole cells 
WT and CDΔcwp84 24 hr culture was harvested by centrifugation then resuspended 
in 2% glutaraldehyde buffered with 150 mM Sorensen’s buffer pH 7.4 for 2 hr at 
22 °C. Cells were pelleted by centrifugation then secondary fixed by re-suspension 
in osmium tetroxide for 3 hr at 4˚C. Cells were pelleted and gently re-suspended in 
molten 2% agarose, allowed to cool then cut in to 1 mm3 cubes. Cubes were 
dehydrated through an ethanol gradient (30, 50, 70, 90, 100% for 10, 10, 20, 30 and 
2 x 30 min respectively) followed by two incubations in 100% propylene oxide for 
2 x 10 min. Cubes were then transferred to a 50:50 mixture of propylene 
oxide:Araldite™ CY212 resin mixture and incubated for first 2 hr, then overnight in 
fresh Araldite™ CY212 resin only at 22 °C. The cubes were transferred to embedding 
capsules and covered with fresh Araldite™ CY212 resin and incubated for 24 hr at 
22 °C, followed by incubation at 60 °C for 72 hr to polymerise resin. Ultrathin 70 nm 
sections were prepared on a Reichert Ultracut E Ultramicrotome and transferred on 
to 400 mesh copper grids, followed by double staining with uranyl acetate then by 
lead citrate. Grids were carbon coated and examined using a Philips CM100 TEM as 
above. 
3.2.2.2.8.3 Cryo-Scanning electron microscopy (Cryo-SEM) 
C. difficile was spread onto FAA and grown for 24 hr (WT only) and 48 hr (WT and 
CDΔcwp84) in anaerobic conditions. Bacterial colonies were carefully scraped from 
the plate and applied to a rivet. A second rivet was placed on top of the meniscus of 
bacterial culture. The rivet-bacteria-rivet assembly was snap frozen in liquid 
nitrogen slush, placed in a specimen holder (under liquid nitrogen) and transferred 
(frozen) into the Gatan Alto 2500 cryo-preparation unit. The top rivet was snapped 
off at a temperature of -184˚C. The specimen holder was warmed up to -95˚C and 
held at this temperature for 2 minutes to allow for sublimation of water from the 
fracture plane and then cooled down to below -140˚C prior to sputter coating with 
gold for 120 seconds (approximately 10 nm thickness of gold). The prepared 
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specimen was then transferred into the Philips XL30 FEG for SEM. All temperatures 
are those indicated on the Gatan Alto 2500 control pad and are not absolute values. 
3.2.2.2.8.4 Atomic Force Microscopy (AFM) 
3.2.2.2.8.4.1  Sample preparation 
The native S-layer from C. difficile was extracted from 24 hr cultures of WT and 
CDΔCwp84347 using low pH extraction (see General Methods 2.7.2) or using 50 mM 
tris 8 M urea pH 8.0 and incubating for 40 min at 22 °C, followed by centrifugation 
and 0.2 µm filtering. Samples were stored until processing at 4 °C.  
3.2.2.2.8.4.2 Atomic Force Microscopy 
Samples were dialysed for 12 hr using 1 kDa MWCO dialysis tubing against 15 mM 
PIPES pH 6.76 with 50 mM calcium chloride. The following surfaces were then 
immersed in the S-layer solution for 16 hr: graphite (positive surface charge - 
hydrophobic), ozone modified graphite (negative surface charge - hydrophilic) or 
freshly cleaved mica (negative surface charge – hydrophilic). Samples were 
removed from S-layer solution and washed with 10 mM potassium orthophosphate 
adjusted tris buffer pH 7.8 (with additional 50 mM calcium chloride for CDΔCwp84 
S-layer imaging).  
 
Atomic force spectroscopy was performed with a Nanoscope IIIa AFM (Brooker, 
Santa Barbara, USA) equipped with a J scanner (80 μm) and an oxide sharpened 
Si3N4 stylus on cantilevers with a spring constant of approximately 0.05 N/m (MSNL 
probes, Brooker, UK) with a radius of curvature ≤5 nm. Topographs were recorded 
in tapping mode (WT S-layer) or contact mode (CDΔCwp84 S-layer) at an 
approximate stylus loading force of 100 pN and a line frequency of typically 1Hz. 
AFM was performed at 22 °C in orthophosphate adjusted tris buffer pH 7.8 (with 
additional 50 mM calcium chloride for CDΔCwp84 S-layer imaging) using the fluid 
cell. AFM images of S-layers were basically processed by using the open-source 
Gwyddion AFM image processing tool (www.gwyddion.net). 
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3.3 Results 
3.3.1 Production of C. difficile cwp84 Knockout mutants. 
Using the Sigma TargeTron algorithm, a total of 28 potential intron insertion sites 
were found in the cwp84 gene. Out of the 28 the following sites were chosen 
(numbers represent base pairs from the start codon) (Table 3.3.1). 
 
Table 3.3.1 Selected cwp84 gene knockout target sites chosen from TargeTron algorithm  
Insertion 
location       
Gene 5`exon -intron-exon Gene 3’     Score        E-value  Functional 
insertion 
region 
2054|2055a     TCTAAATTTGATGATAAAGTAGCTGTAC
CA - intron - CCAATTATATAAGAC      
8.73         0.063 
 
Cell wall 
binding repeat 
domain 
677|678a       CCTGATGTCACTGAACCATATTGCATTA
TA - intron - GCATTTTTTACAGTT      
7.54         0.153 
 
Cysteine 
protease 
domain* 
347|348a       TCTAAAGTTGACATACCTGAAAAAGAC
CAG - intron - CATGTATTAAGACTT     
7.30         0.183 
 
Cysteine 
protease 
domain* 
68|69a         TGGTTTTCTGCTGAGACAGGTATTGTTG
AC - intron - ACTATTAAAAAGCAA      
6.93         0.242 
 
Signal Peptide 
*Active site residues for Cwp84 are predicted to be at Gln-110 (328 bp), Cys-116 (346 bp), His-
262 (784 bp), Asn-287 (859 bp) (Savariau-Lacomme et al. 2003).  
 
Initially, insertion site 347|348a was chosen for investigation. However, a further 
three KO sites were selected to verify the outcome of the initial knockout and to 
determine whether the insertion location affected knockout outcome. The (353 bp) 
intron retargeting region for cwp84 insertion sites 68|69a, 677|678a, 2054|2055a 
were produced by de novo gene synthesis, whereas 347|348a was retargeted by 
site SOE PCR.  
 
Confirmation of cwp84 knockout, i.e. intron integration, was performed by PCR 
using primers flanking cwp84 (Figure 3.3.1 A). Confirmatory PCR of the Erm-RAM 
region also confirmed the Erm resistant phenotype was due to self-splicing of the 
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group I intron within the group II intron rather than a spontaneous erythromycin 
mutant (Figure 3.3.1 B).  
 
RT-PCR of CDΔCwp84347 mRNA using primers flanking the intron insertion site 
showed expression of the full length transcript in stationary phase cells from wild 
type C. difficile 630ΔErm and a complete absence of a similar size product from 
CDΔCwp84347 (Figure 3.3.1 C(i)). However, primers amplifying cwp84 mRNA pre-
intron insertion site e.g. <345 bp, gave bands in both WT and CDΔCwp84347. As 
expected primers amplifying cwp84 post-intron insertion site, e.g. >348 bp, only 
gave a product for WT transcript, demonstrating truncation of the CDΔCwp84347 
cwp84 transcript (Figure 3.3.1 C(ii)). It follows therefore, that the transcript of 
CDΔCwp842054 contains coding information for the cysteine protease domain and 
one of the three CWB domains. 
 
 
Figure 3.3.1 Genetic Characterisation of Cwp84 Mutant. (A) Confirmation of intron 
integration in cwp84 gene by PCR. Lane 1, 4.3 kbp product from CDΔCwp84347. Lane 2, 2.4 
kbp product from C. difficile 630ΔErm. (B) Demonstration of Erythromycin 
Retrotransposition-Activated Marker (Erm-RAM) self-splicing, an event strictly coupled to 
group II intron integration. Lane 1, 900 bp product from CDΔCwp84347. Lane 2, 1300 bp 
product from native pMTL007-EC2 shuttle vector. (C) Reverse transcription PCR (RT-PCR) of 
cwp84 mRNA (C(i)) flanking intron integration site in stationary phase cultures. (C(ii)) Pre-
intron insertion site. Lane 1, C. difficile 630ΔErm; Lane 2 CDΔCwp84347.  
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3.3.2 Assessment of other genes potentially affected by intron 
insertion 
To confirm that any phenotypic effects observed were a direct result of cwp84 KO 
and not due to intron promiscuity, analysis of other potentially affected genes was 
undertaken.  
 
Analysis of the cd1751 gene was undertaken since this shows significant identity 
(70.4%) to the cwp84 gene and encodes another putative C. difficile surface-
associated cysteine protease in C. difficile 630. The cd1751 gene is also highly 
conserved with 99.0% identity between 630 (ribotype 012) and R20291 (ribotype 
027). RT-PCR of WT and CDΔcwp84347 KO mRNA using primers flanking cd1751 does 
not give a product, suggesting cd1751 is not expressed in stationary phase. PCR 
analysis of cd1751 in all cwp84 KO mutants showed this gene to be unmodified by 
the gene knockout procedure. Furthermore, erythromycin resistant (indicating 
possible intron integration) but cwp84 KO negative mutants were checked for 
integration into cd1751. All screened cwp84 KO negative clones had WT (2.4 kbp) 
cd1751 indicating either insertion elsewhere in the genome or were spontaneous 
erythromycin mutant(s).  
 
Due to the observed effects on SlpA maturation, slpA was sequenced from 
CDΔCwp84 mutants to ensure that the resultant phenotype was due to cwp84 KO 
rather than mutations, introduced either accidentally or in slpA as a result of C. 
difficile survival mechanisms, which caused the observed changes in SlpA 
processing. No mutations were found suggesting that the effect on cleavage was a 
result of cwp84 KO and specific to cwp84 inactivation. Intron insertion into slpA was 
also assessed by PCR, no insertion was found in slpA in all created cwp84 mutants 
(Table 3.31). Intron insertion into the 26 other CWBD containing protein genes 
were not assessed.  
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3.3.3 Morphology and growth characteristics of cwp84 KO mutants 
3.3.3.1 Morphological  
Cwp84 KO mutants grown on solid medium showed significantly different colony 
morphology compared to wildtype C. difficile 630ΔErm. While the latter showed a 
characteristic irregular, translucent appearance, CDΔCwp84 formed more regular 
circular colonies which were creamy white in appearance (Figure 3.3.2). 
 
 
Figure 3.3.2 Difference in colony morphology of wildtype C. difficile 630ΔErm 
and CDΔCwp84347 grown on FAA plus 5% horse blood.  
 
Gram stain of CDΔCwp84 cells from solid phase 24 hr and 48 hr cultures appeared 
indistinguishable from the wildtype C. difficile 630ΔErm, however 48 hr CDΔCwp84 
cultures appeared largely as pink ‘Gram negative’ cell debris. 
3.3.3.2 Growth 
In liquid culture CDΔCwp84 grew slower than wildtype C. difficile 630ΔErm (Table 
1.3.2) and at higher culture ODs CDΔCwp84 appeared to be unable to maintain a 
prolonged stationary phase and proceeded rapidly into death phase (Figure 3.3.3). 
CDΔCwp84 post death phase cultures maintain a culture OD600 ~0.4, a value 
reached and maintained by the WT after 48 hr post inoculation. 
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Figure 3.3.3 Decline in culture OD600 of CDΔCwp84347 over time. An entire plate 
culture (24hr) was scraped off and re-suspended into culture media (time 0) 
and OD600 measured at hourly intervals during growth. Note: plate cultures 
were used to inoculate, to prevent dilution of any potential growth altering 
substance found within liquid starter cultures. 
 
In line with the decrease in culture OD during growth of CDΔCwp84, is an increase 
in culture viscosity and propensity of the culture to aggregate and form stringy 
precipitates, particularly on the walls of a stirred culture vessel. 
 
Growth rates of a tcdA (Toxin A) knockout were similar to the WT (Table 3.3.2) 
suggesting slower growth was due to cwp84 KO and not a general consequence of 
the knockout process. 
3.3.3.3 Sporulation 
Cwp84 mutants retained their ability to sporulate, albeit at reduced efficiency 
compared to the wildtype. The level of sporulation, estimated from viable counts 
before and after heat shock treatment was determined to be 0.64 ± 0.03% (64.19 
±0.14% Log cfu) for 18 day cultures of CDΔCwp84347 compared to 7.18 ± 3.45% 
(78.41 ±6.11% log cfu) for wildtype C. difficile 630ΔErm.  
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Table 3.3.2 Growth rates of C. difficile mutants 
C. difficile Strain Growth Rate (OD600 h
-1)          %WT 
C. difficile 630ΔErm        0.29 ± 0.011                      100% 
CDΔCwp84347        0.12 ± 0.007                        42% 
CDΔToxinA980        0.26 ± 0.018                        90% 
C. difficile 630ΔErm + trypsin*         0.30 ± 0.002                       103% 
    CDΔCwp84347 + trypsin (μg/ml) 
                                              0 
                                          1 
                                          3 
                                        10 
                                      100 
        
       0.12 ± 0.002                        42% 
       0.13 ± 0.008                        43% 
       0.16 ± 0.003                        55% 
       0.17 ± 0.003                        58% 
       0.21 ± 0.018                        71% 
Growth rates were measured on the linear portion of the growth curve (n=3) 
*Trypsin added to growth medium at100 μg/ml 
3.3.3.4 Toxin production of cwp84 mutants 
Toxins A and B are produced when cultures reach stationary phase (usually after 
15 hr, 24 hr for C. difficile 630 (Merrigan et al. 2010)) and when cultures are 
stressed, typically though nutrition depletion. The ability of CDΔcwp84347 to 
produce toxin was assessed by ELISA and compared to toxin production of the wild-
type under similar growth conditions.  
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Figure 3.3.4 Toxin A ELISA of culture supernatant fluids from CDΔCwp84347 and wildtype C. difficile 630ΔErm grown in sBHI. (A) CDΔCwp84347, 
taken at hourly intervals (culture inoculated from solid phase media). (B) Wildtype C. difficile 630ΔErm over 3 days at 6 and 18 hr intervals. 
Limit of Quantification: 5 ng/ml. 
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Culture supernatant fluids of CDΔCwp84347 contained approximately 50 ng/ml 
toxin A after 7 hr (Figure 3.3.4 A) and after 24 hr contained ~ 860 ng/ml toxin A, 
whereas no quantifiable toxin A was found in the culture supernatant of C. difficile 
630ΔErm until after 24 hr (Figure 3.3.4 B). Culture supernatants from 24 hr growth 
of a tcdR(D) mutant did not contain any toxin, whereas 24 hr culture supernatant 
from a Spo0A mutant contained approximately 260 ng/ml toxin A (Chapter 5 
Section 5.3.3.2). The culture supernatant of other surface protein mutants also 
demonstrated higher toxin A levels compared to the WT after 24 hr, particularly a 
FliD (flagella cap) KO (Chapter 5 Section 5.3.3.2). This data suggests that higher 
culture supernatant toxin A levels are not specific to CDΔCwp84347 and may be 
associated with changes in toxin gene expression and/or a decrease in cellular 
integrity i.e. intracellular toxin is leaking out more easily.  
3.3.3.5 Anecdotal results 
Analysis of the culture supernatant from CDΔCwp84 grown in incompletely reduced 
media showed a large number of protein species (other than those normally visible 
without concentration) suggesting a large degree of cell lysis. Furthermore, 
CDΔCwp84 stored in poorly sealed anaerobic jars were not viable. In contrast, WT 
growth was unaffected by either incompletely reduced media or microaerobic 
environments. These two anecdotal results suggest that the Cwp84 mutants appear 
to be more sensitive to oxygen levels than the WT.  
 
C. difficile is known to produce a characteristic smell, primarily due to production of 
volatile organic compounds (VOCs) including p-cresol (Dawson et al. 2008). The 
smell of the cwp84 mutant is very much stronger and sharper on the nose. 
Examination of the pattern of VOCs on gas-liquid chromatography may elucidate 
individual components or fermentation pathways creating this unique smell, 
particularly those differing from the WT. 
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3.3.4 Analysis of surface layer proteins of cwp84 mutants 
Previous studies have demonstrated that a large number of the SLPs of C. difficile 
can be conveniently extracted by several methods including low pH (Calabi et al. 
2001; Wright et al. 2005). 
 
SDS-PAGE of SLPs extracted from wildtype C. difficile 630ΔErm by this method 
showed a characteristic band pattern in which the two principal SLPs, derived from 
the post translational cleavage of the single precursor, SlpA, appeared as bands of 
approximately 39 kDa and 48 kDa corresponding to the LMW SLP and HMW SLP, 
respectively (Figure 3.3.5A).  
 
In contrast, these bands were absent in SLP extracts of CDΔcwp84 in which a new 
prominent band of approximately 84 kDa was evident by SDS-PAGE analysis. This 
band was subject to proteomic analysis (GeLC-MS/MS) using in-gel tryptic digestion. 
Mascot individual ion scores of >47 for 13 individual peptides positively identified 
the 84 kDa band as the SlpA precursor protein (predicted molecular mass of 76 
kDa). N-terminal sequence analysis of the SlpA precursor protein band gave the 
amino acid sequence ATTGT which is identical to that of the N-terminus of mature 
LMW SLP and demonstrated that the signal sequence has been removed from the 
precursor protein. These data show that in the CDΔCwp84 mutant, maturation of 
the SlpA precursor protein is incomplete, in that following removal of the signal 
peptide, cleavage into the HMW and LMW SLPs fails to occur.  
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Figure 3.3.5 Comparision of C. difficile 630ΔErm and CDΔCwp84 surface protein extracts. (A) Analysis of extracted SLPs from wildtype C. difficile 630ΔErm, 
CDΔCwp84347, CDΔCwp84677 and CDΔCwp842054. Lanes 5 and 6, 24 hr culture supernatant fluids from C. difficile 630ΔErm (Cul sup WT), CDΔCwp84347 (Cul 
sup ΔCwp84), respectively. (B) Analysis of extracted SLPs by silver stained SDS-PAGE from wildtype C. difficile 630ΔErm and CDΔCwp84347. (C) Native PAGE 
(BN PAGE) analysis of extracted SLPs wildtype C. difficile 630ΔErm and CDΔCwp84347 (concentrations normalised). 
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 Another characteristic of CDΔCwp84 is that the SlpA precursor protein was evident 
in the culture supernatant of 24 hr cultures (Figure 3.3.5A), unlike wildtype C. 
difficile 630ΔErm where there was no evidence of any SLPs being released under 
similar growth conditions. Brisk agitation of the CDΔCwp84 and WT cultures did not 
appear to increase the concentration of SlpA in the culture medium nor release any 
SLPs from the WT, suggesting the loss of SlpA is not a consequence of physical 
sheering. 
 
Blue native PAGE analysis reveals that while SlpA of CDΔCwp84347 is not matured 
into its component SLPs, it can also form a 320 kDa species similar to WT SLPs 
(Figure 3.3.5C), as originally demonstrated by size exclusion chromatography (Fagan 
et al. 2009).  
3.3.4.1 Identification of other surface proteins in cwp84 KO SLPs 
The cwpV gene (cd0514) encodes a predicted surface protein of 167 kDa. Recently, 
it has been shown by analysis of surface protein extracts that CwpV is processed 
into two fragments: a 40 kDa N-terminal cell wall binding fragment and a 120 kDa 
C-terminal fragment (Emerson et al. 2009b). Silver stained SDS-PAGE of SLPs 
extracted from wildtype C. difficile 630ΔErm and CDΔCwp84347 both showed the 
presence of a band of approximately 115 kDa (Fig 3.3.5B). Proteomic analysis of the 
115 kDa band from CDΔCwp84347 identified this band as the 120 kDa C-terminal 
fragment of CwpV. These data suggest that the maturation of CwpV is not affected 
by knockout of cwp84. Moreover, a protein of equivalent size (115 kDa) is found in 
the culture supernatant of CDΔCwp84, putatively indicating that CwpV is also lost 
from the cell surface similar to immature SlpA.  
 
Silver stained SLP extracts from both WT and CDΔCwp84347 demonstrate how, other 
than the loss of the main S-layer bands, the SLP extracts appear similar. Bands at 
84, 66, 58, 45 and 36 kDa are present in both extracts. The presence of an 84 kDa 
band (identified as SlpA in CDΔCwp84347 SLPs) in WT SLPs (and in R20291, VPI10463 
and ARL001 SLPs, Chapter 4 Section 4.3.1) may suggest that the SLP extraction may 
have also removed immature SlpA, presumably that which has yet to be cleaved.  
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Due to its prominence in CDΔCwp84 SLPs (Figure 3.3.5A), the 36 kDa band was 
subjected to N-terminal sequence analysis and gave the amino acid sequence 
MRVNT. BLAST searching this sequence against the C. difficile 630 proteome, 
assuming no post-translational modifications, matches the first 5 amino acids of FliC 
the flagella core/subunit protein. 
 
Freeze thaw cycles of CDΔCwp84347 SLPs result in the appearance of a 45 kDa band 
(Figure 3.3.5B) while other bands remain unchanged, suggesting the 45 kDa band 
resulted from degradation of immature SlpA. No protease contamination or auto-
processing/maturity ability was found (Section 3.3.6.3) confirming the likely 
sensitivity of SlpA to freeze-thaw cycles. 
3.3.5 Identification of Cwp84 at the cell surface. 
It is suggested that Cwp84 can be found in cytoplasmic (90 kDa), membrane, cell 
wall associated (82 kDa) and surface (low pH) fractions (primarily 85 kDa), as 
determined by immunoblotting with mCwp84 antibodies (Janoir et al. 2007). To 
confirm the loss of Cwp84 from the cell surface of CDΔcwp84347, two methods were 
used. 
 
A proteomic approach was assessed, whereby GeLC-MS/MS was used to identify 
proteins found between a 62-100 kDa region in 1D SDS-PAGE of WT and cwp84 KO 
SLPs. Mass spectrometric analysis did not reveal the presence of Cwp84 in WT (or a 
lack of in CDΔCwp84347) SLPs between 62-100 kDa. A variety of metabolic proteins 
were identified in WT SLPs present together with CwpV, CD2791 and CD2784, 
peptidases PepV and PepD. Analysis of the CDΔCwp84347 SLPs region resulted in 5 
identified proteins – CwpV, PepV, SlpA, CD2791 and CD2784, no metabolic 
associated proteins were found (Table 3.3.3). Reasons for the lack of metabolic 
protein ‘contamination’ in the 62-100 kDa region CDΔCwp84347 SLPs are unknown. 
 
To identify Cwp84 by immunoblotting, antibodies to synthetic peptides to predicted 
epitopes of Cwp84; covering the cysteine protease domain (104-322 aa) (T124-L131 
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and A258-V267 aka CP1 and CP2), and the first CWB domain (507-595 aa) (Y513-
Q521 aka CWB-1), were produced in guinea pigs.  
 
Unfortunately, immunoblotting WT SLPs or cell wall extracts (by method of 
Jonquières et al. (1999)) with the guinea pig serum or purified IgG for each of the 
peptides or combined, did not detect any unique bands (or a lack of in CDΔcwp84347 
SLPs). Optimisation of antibody concentrations, blocking material or 
chemiluminescent reagents did not change the result. Blots using the CWB-1 
epitope serum/antibodies did detect some specific bands, however these were 
likely to be CWB repeat (PFam04122) containing proteins or fragments. Confidence 
in the obtained results was undermined by strong cross reactions with molecular 
weight markers for all antiserum. 
 
Cwp84 was therefore not found in between 62-100 kDa in low pH SLPs using a 
proteomic approach or by immunoblotting SLPs or other protein extracts of C. 
difficile with antiserum raised to peptides of predicted epitopes of Cwp84. 
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Table 3.3.3 Proteins identified by GeLC-MS/MS between a 62-100 kDa region excised 
from a 1D SDS-PAGE gel of WT and cwp84 KO low pH SLPs.  
 
WT KO 
WT1 
 gi|126698095|ref|YP_001086992.1|- 
CD0514 (cwpV) 
 gi|126700400|ref|YP_001089297.1|- 
CD2784 (Cwp6) 
 3-hydroxybutyryl-CoA dehydrogenase 
(organic acid metabolism) 
 Rubredoxin oxidoreductase (iron 
binding protein) 
 Enolase (phosphopyruvate 
dehydratase) 
 Acetyl-CoA acetyltransferase 
KO1 
 gi|126698095|ref|YP_001086992.1|- 
CD0514 (cwpV) 
 gi|126700719|ref|YP_001089616.1|- 
PepV (CD3102) Peptidase 
 
WT2 
 gi|126700400|ref|YP_001089297.1|- 
CD2784 (Cwp6) 
 Acetyl-CoA acetyltransferase 
 gi|126697752|ref|YP_001086649.1|- 
NAD-specific glutamate dehydrogenase 
 Electron transfer flavoprotein alpha and 
beta subunits  
 Rubredoxin oxidoreductase (iron 
binding protein) 
KO2 
 gi|126700409|ref|YP_001089306.1|   - 
SlpA 
 
 
 
WT3 
 gi|126700400|ref|YP_001089297.1|- 
CD2784 (Cwp6) 
 Acetyl-CoA acetyltransferase 
 Rubredoxin oxidoreductase (iron 
binding protein) 
 gi|126700719|ref|YP_001089616.1|- 
PepV (CD3102) Peptidase 
 gi|126700078|ref|YP_001088975.1|   - 
DnaK (CD2461) - Molecular chaperone 
 
KO3 
 gi|126700409|ref|YP_001089306.1|   - 
SlpA 
 
WT4 
 gi|126700407|ref|YP_001089304.1| - 
CD2791 (Cwp2) 
 gi|126700400|ref|YP_001089297.1|- 
CD2784 (Cwp6) 
 gi|126700078|ref|YP_001088975.1|   - 
DnaK (CD2461) - Molecular chaperone 
 gi|126698287|ref|YP_001087184.1| - 
PepD (CD0708) - putative aminoacyl-
histidine dipeptidase 
 
KO 4 
 gi|126700407|ref|YP_001089304.1| - 
CD2791 (Cwp2) 
 gi|126700409|ref|YP_001089306.1|   - 
SlpA 
 gi|126700400|ref|YP_001089297.1|- 
CD2784 (Cwp6) 
 
The 62-100 kDa region was divided into four sub-regions (WT1-4 or KO1-4, decreasing in 
MW) prior to analysis. Proteins in Blue are CWBD containing proteins. 
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3.3.6 Effect of proteases on SlpA in vitro and effect on Cwp84 
mutants 
3.3.6.1 Effect of trypsin treatment on the SlpA precursor in vitro  
Previous studies have suggested that SlpA is matured into its component HMW and 
LMW parts by cleavage at the Ser345-Ala346 bond within the sequence: ETKSANDT 
(Eidhin et al. 2006). Since there is a lysine residue close to the natural cleavage site 
of the SlpA precursor, the ability of trypsin to generate analogs of the LMW and 
HMW SLPs was assessed. 
 
Treatment of CDΔCwp84 SLPs with a low concentration of trypsin (1 μg/ml) resulted 
in the disappearance of the 84 kDa (SlpA) band and concomitant appearance of two 
bands of similar size to the HMW and LMW SLP bands from wildtype C. difficile 
630ΔErm (Figure 3.3.6A).  
 
GeLC-MS/MS analysis identified the 39 and 48 kDa bands as the LMW and HMW 
SLPs, respectively. In addition, N-terminal sequencing of the 48 kDa (HMW) band 
gave the sequence SANDT, consistent with both predicted native maturation site 
and the expected trypsin cleavage site. N-terminal sequencing of the 39 kDa (LMW) 
band gave the sequence ATTGT, consistent with the predicted N-terminus of the 
LMW SLP. Similar results were obtained when higher trypsin concentrations (5 and 
10 μg/ml) were used.  
 
The LMW SLP appeared relatively resistant to trypsin digestion, while the HMW SLP 
appeared to be slowly degraded (Figure 3.3.6A). Assessment of the culture 
supernatant ‘shed SlpA’ from CDΔCwp84 also demonstrated the same cleavage by 
trypsin to give bands migrating at identical mobility to the WT S-layer bands.  
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Figure 3.3.6 Effect of trypsin on the SLPs of CDΔCwp84. (A) Cleavage of SLP extracts from CDΔcwp84347 with 1 µg/ml trypsin (DPCC-treated, bovine 
pancreas; Sigma T1005) in 50 mM HEPES pH 7.4 containing 0.15 M NaCl at 22oC for various times. (B) Extracted SLPs from 24 hr cultures of CDΔcwp84347 
grown in sBHI supplemented with 0, 1, 10 and 100 µg/ml trypsin. Prior to low pH extraction of SLPs, cultures were washed 10 mM HEPES containing 
100 mM NaCl pH 7.4 and 0.5 mg/ml trypsin inhibitor and then extracted in 0.2 M glycine pH 2.2 buffer containing 0.1 mg/ml trypsin inhibitor.  
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The 120 kDa band (CwpV) appeared to also be resistant to trypsin cleavage, while 
other components of the SLP extract tended to be degraded to completion (Figure 
3.3.6). 
 
Using trypsin inhibitor rather than heat inactivation, CDΔcwp84 SLPs incubated with 
1 µg/ml trypsin appear to be cleaved into a multitude of fragments between 49-
62 kDa. A WT-like 38 kDa LMW SLP band appears first, followed by a WT-like HMW 
SLP, then the degradation of other 49-62 kDa fragments (Figure 3.3.7).  
3.3.6.2 Effect of trypsin on growth and SLPs of Cwp84 KO mutants 
As the extracted SlpA precursor protein in CDΔCwp84347 SLPs is rapidly cleaved in 
solution by trypsin, the ability of trypsin to cleave SlpA displayed on the surface of 
the bacterium was also assessed. 
 
CDΔCwp84347 was grown in medium supplemented with various concentrations of 
trypsin followed by washing with media containing trypsin inhibitor. Figure 3.3.6B 
shows SLPs extracted from cells treated in this manner compared to the SLP 
extracts from the untreated wildtype and CDΔCwp84347 cultures. N-terminal 
sequences (SANDT and ATTGT) of the prominent bands which appeared as a result 
of trypsin treatment confirmed their identity as the HMW and LMW SLPs, 
respectively. The data shows that >50% of the SlpA precursor protein is cleaved on 
cells grown in the presence of the highest trypsin concentration used. Compared to 
trypsin treatment of the extracted SlpA, the HMW SLP appeared more resistant to 
trypsin degradation which may reflect its proposed orientation within the S-layer, in 
which the HMW SLP is the lesser exposed of the two subunits.   
 
Addition of trypsin to the CDΔCwp84347 growth medium significantly increased its 
growth rate in a dose dependent manner (Table 3.3.2) consistent with the cleavage 
of SlpA (Figure 3.3.6 B). The presence of trypsin in the growth medium also 
eliminated the propensity of CDΔCwp84 to aggregate; furthermore immature SlpA 
was not found in the culture supernatant in trypsin supplemented media. 
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Figure 3.3.7 Termination of trypsin mediated cleavage of CDΔcwp84347 SLPs with trypsin inhibitor. Analysis of trypsin cleavage of 
SLP extracts from CDΔcwp84347 with 1 µg/ml trypsin in 50 mM HEPES pH 7.4 containing 0.15 M NaCl at 22
oC for various times. 
Reaction stopped by addition of 0.5 mg/ml trypsin inhibitor. 
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3.3.6.3 Effect of other proteases on the SlpA precursor 
To test the hypothesis that SlpA is cleaved by Cwp84, investigations were made as 
to whether other members of the cysteine protease C1A family, to which Cwp84 
putatively belongs, could cleave the SlpA precursor in vitro to give WT-like SLPs 
(Figure 3.3.8). 
 
Treatment of CDΔCwp84 SLPs with a low concentration of papain (1 μg/ml) 
appeared to partially cleave SlpA giving bands at 57, 50, 48 and 38 kDa, while 
incubation with a higher concentration (10 µg/ml) appeared to digest SlpA leaving a 
48 kDa band above highly fragmented lower MW species. 
 
Treatment of CDΔCwp84 SLPs with cathepsin B required a relatively high (50 µg/ml) 
concentration before cleavage of SlpA was seen. Cathepsin B cleaved CDΔCwp84 
SLPs into a highly fragmented band pattern between 84-47 kDa, with the original 
lower MW SLP extract bands (<38 kDa) remaining unaffected.  
 
Two other digestive enzymes were also assessed for their ability to cleave SlpA. 
Chymotrypsin, at 5 µg/ml, appeared to partially digest CDΔCwp84 SLPs to give a 
band at 45 kDa, slightly lower than the WT HMW SLP (48 kDa), with a co-
appearance of a 29 kDa band. The 74 kDa total of these two 45 and 29 kDa bands, 
although less than the observed 84 kDa for SlpA, correlates well with the predicted 
molecular weight of SlpA of 74 kDa, suggesting they are derived from the cleavage 
of SlpA rather than other SLP components. The ability of elastase to cleave the 
Ser345-Ala346 bond within SlpA was also assessed. Like trypsin, elastase appeared 
to cleave SlpA in CDΔCwp84 SLPs into two bands at 39 and 45 kDa, rather than 39 
and 48 kDa for WT SLPs. 
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Figure 3.3.8 Effect of proteases on SlpA in CDΔcwp84347 SLPs. Extracts incubated with: Papain (Sigma 76220) at 1 and 10 µg/ml in 50 mM HEPES plus 
0.15 M NaCl pH 7.4 at 22 °C, after 4 hr and 30 min respectively. Cathepsin B (Sigma C0150) at 50 µg/ml in 50 mM HEPES plus 0.15 M NaCl pH 6.0 at 40 °C, 
after 5 hr. Chymotrypsin (Sigma C3142) at 5 µg/ml in 50 mM HEPES plus 0.15 M NaCl pH 7.4 at 22 °C, after 4 hr. Elastase (Sigma E0258) at 5 µg/ml in 
50 mM HEPES plus 0.15 M NaCl pH 7.4 with 50 µg/ml trypsin inhibitor at 22 °C, after 2 hr. Clostripain (Sigma C0888) at 5 µg/ml in 50 mM HEPES 
10 mM CaCl2 2.5 mM DTT pH 7.6 at 22 °C (pre-activated for 3 hr), after 30 min and 2 hr. Lines across figure represent reference MW to HMW and LMW 
SLP bands.  
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The surface located thiol protease, eluded to by Seddon & Borriello (1992), was 
suggested to have trypsin-like characteristics, but an inhibition profile more akin 
with C11 family cysteine protease clostripain from C. histolyticum. Incubation of 
CDΔCwp84 SLPs with 10 µg/ml clostripain initially gave two bands at 47 and 51 kDa 
after 30 min, 40 and 47 kDa bands after 120 min.  
 
It is interesting to note that 120 kDa fragment of CwpV was not cleaved by trypsin, 
cathepsin B, chymotrypsin, clostripain or elastase but was degraded by papain at 
10 µg/ml.  
 
To ensure that SlpA was not being cleaved by SLP extract protease contamination 
or via auto-maturation, CDΔCwp84 SLPs were incubated for 24 hr in the absence or 
presence of DTT. No change in band pattern was observed, suggesting CDΔCwp84 
SLPs contained no protease contamination, any contained proteases did not further 
alter the band pattern or SlpA does not auto-mature. 
3.3.7 Ability of CDΔCwp84347 to cause infection 
To assess the capacity of CDΔCwp84 to cause CDI, the hamster model was used as it 
is the most widely recognized model currently available. This disease model 
parallels most of the recognized characteristics of the human disease and hamsters 
can readily be made susceptible to CDI by treatment with a broad spectrum 
antibiotic such as clindamycin. After administration of clindamycin, test groups 
were challenged 48 hr later by the orogastric administration of 2 x 102 spores 
produced from either CDΔCwp84347 or wildtype C. difficile 630ΔErm. 
 
Three experiments were conducted in the following manner; two experiments with 
animals challenged with CDΔCwp84347 or wildtype C. difficile 630ΔErm and one with 
animals experiment challenged with just CDΔCwp84347. In total 50 observations 
were made, 20 animals were challenged with the WT strain and 30 with the mutant 
strain. 
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A first experiment of 20 hamsters (2 test groups of 10) was challenged with 
wildtype C. difficile 630ΔErm or CDΔCwp84347. In both test groups 90% succumbed 
to severe disease within 6 days post challenge. However, the difference in median 
survival time of 2.5 days for C. difficile 630ΔErm and 1day for CDΔCwp84347 (mean 
survival time 3.6 and 2.4 days respectively) suggested slightly increased virulence of 
the CDΔCwp84347 mutant (Figure 3.3.9 A). 
 
To confirm this, a second experiment was performed but with only CDΔCwp84347 
challenged animals (1 test group of 10). Only 60% of challenged animals succumbed 
to severe disease within 6 days post challenge (Figure 3.3.9 B). The Kaplan-Meier 
survival curves appear more protracted and did not show the rapid onset of disease 
as previously observed, also reflected by an increase in the median survival time of 
5.5 days. However, of the 60% that did succumb to disease, the median survival 
time was to 3 days, more consistent with the first experiment. 
 
A final experiment was therefore performed to determine if the differences 
between the two experiments were consistent. 
 
20 hamsters (2 test groups of 10) were again challenged with wildtype C. difficile 
630ΔErm or CDΔCwp84347 (2 control groups of 4 animals were unchallenged). 100% 
of the CDΔCwp84347 and 80% of wildtype C. difficile 630ΔErm challenged animals 
succumbed to severe disease within 6 days post challenge. The difference in 
median survival time of 2.5 days for CDΔCwp84347 and 4 days for C. difficile 
630ΔErm confounds the possible increase in virulence of the CDΔCwp84347 strain 
(Figure 3.3.9 C). 
 
Unfortunately, due to technical issues two control animals also succumbed to 
symptoms of CDI, with one death. While faeces from challenge test groups isolated 
the respective challenge strain, the C. difficile strain(s) isolated from infected 
control animal(s) had a wildtype cwp84 gene. It is unknown whether this strain(s) 
originated from other challenged C. difficile 630ΔErm animals or whether another 
C. difficile strain was brought in to the experimental environment. 
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Overall, of 30 hamsters (3 test groups of 10) challenged with CDΔCwp84347, 83.3% 
succumbed to severe disease within 6 days post challenge compared to 85% 
challenged with C. difficile 630ΔErm (20 hamsters, 2 test groups of 10). Both strains 
displayed typical symptoms of CDI (diarrhoea, weight loss, lethargy). Figure 3.3.9D 
shows combined survival plots for this data which were analysed with a log rank 
test to assess the relative hazard of succumbing to disease. The difference in 
median survival time (with 95% confidence intervals) of 2 days for CDΔCwp84347 
and 4 days for C. difficile 630ΔErm was found not to be statistically different (p-
value of 0.218, Log-rank test).  
 
Comparison of the median survival times between the two C. difficile 630ΔErm and 
CDΔCwp84347 experiments reveals that on average, CDΔCwp84347 challenged 
animals die 1.5 days before WT challenged animals. Since only mutant-challenged 
animals were in Experiment 2, this might confound the relationship between 
challenge strain type and survivorship. When animals in experiment 2 are excluded, 
the hazard of dying for animals challenged with the WT strain is significantly lower 
(p=0.008, Log-rank test) than for mutant-challenged animals. 
 
Faecal samples were removed from euthanised animals by colectomy and C. difficile 
isolated and analysed. PCR of the cwp84 gene demonstrated that all C. difficile 
isolates from the CDΔcwp84347 test groups contained the expected intron (4.3 kbp 
product) while all isolates from the wildtype group gave a 2.4 kbp product 
consistent with the wildtype gene (as described in Figure 3.3.1A). The data 
demonstrates that the CDΔCwp84347 mutant is capable of causing CDI in the 
hamster model at a similar rate of onset as the wildtype strain. 
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Figure 3.3.9 Virulence of C. difficile 630ΔErm and CDΔCwp84347 in hamsters. (A) 2 test 
groups of 10 animals, challenged with CDΔCwp84347 or C. difficile 630ΔErm. (B) 1 test group 
of 10 animals challenged with only CDΔCwp84347. (C) 2 test groups of 10 animals, 
challenged with CDΔCwp84347 or C. difficile 630ΔErm. (D) Combined Kaplan-Meier plots, for 
CDΔCwp84347 the data represent 3 test groups of 10 animals and for C. difficile 630ΔErm, 2 
test groups of 10 animals. Data shows time from challenge to severe disease/death in the 
hamster model for CDI. 
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3.3.8 Recombinant Cwp84 
3.3.8.1 Cloning, expression, purification of rCwp84 and cleavage of 
SlpA. 
Knockout of the cwp84 gene results in the presentation of immature, i.e. uncleaved 
SlpA at the cell surface. The hypothesis stands that Cwp84 performs this maturation 
role and thus cleavage of SlpA may be demonstrable in vitro, i.e. with recombinant 
Cwp84. Recently, cleavage of a GST tagged SlpA fragment by rCwp84 has been 
demonstrated in E. coli, an action prevented by mutation of Cwp84’s predicted 
active cysteine (C116A) (Dang et al. 2010).  
 
To establish if rCwp84 could cleave SlpA in vitro, similar to the action of trypsin i.e. 
on extracted CDΔCwp84 SLPs, a number of recombinant Cwp84 variants were 
expressed, purified and their cleavage assessed. Table 3.3.4 summarises the Cwp84 
variants produced, expression strains tried and the purified forms of full length 
(rCwp84) and cysteine protease domain (rCwp8433-497).  
 
Recombinant Cwp84 expression and purification has been described previously 
(Janoir et al. 2007) therefore the route for obtaining rCwp84 in this chapter 
mirrored this approach. Briefly, Janoir et al. (2007) expressed purified His6-tagged 
full length Cwp84 (rCwp84) which upon incubation with DTT auto-matured to a 
61 kDa (mCwp84) active species.  
3.3.8.1.1 Initial problems 
Initial efforts to express full length rCwp84 were hampered by loss of the DE3 
prophage, particularly in liquid culture, and toxicity (from basal expression and 
upon induction). The use of only freshly transformed cells and the plating method 
of culture inoculation (Suter-Crazzolara & Unsicker 1995) allowed limited 
expression of pET constructs, as did use of E. coli K-12 derivative strains e.g. 
HMS174 (DE3) and Origami2 (DE3). Constructs which were either not under T7 
polymerase control e.g. tac promoter, or which encoded only the cysteine protease 
domain of Cwp84 (rCwp8433-497) were not so problematic. However, toxicity 
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putatively from expressing an active cysteine protease remained a problem, leading 
to lower cell yield and low recombinant protein yield. 
 
Codon optimisation of the cwp84 gene, for expression in E. coli, did not appear to 
alter construct stability/tolerance, as both natively cloned and synthetically 
synthesised (E. coli optimised) cwp84 gene(s) behaved in a similar fashion. 
However, necessary mutations and modifications e.g. removal or stop codon(s) and 
changes in reading frame/restriction sites, were made to the optimised version of 
cwp84, as it was considered the most likely to give good expression. 
3.3.8.2 Expression of full length rCwp84 
3.3.8.2.1.1 E. coli expressed His-tagged rCwp84 
Full length His6 tagged variants of rCwp84 (cloned from C. difficile 630ΔErm or E. 
coli optimised) appeared to be expressed as an 84 kDa insoluble form at higher 
induction temperatures (30 and 37 °C) (as determined by western blot with anti-
His6 due to low expression levels). Changing media type or addition of media 
supplements (commercial or empirical) did not change expression levels. 
 
When the induction temperature was reduced to 16 °C, 58 kDa (soluble) and 84 kDa 
(insoluble) bands reacted with anti-His6 antibodies. 
 
IMAC purification of soluble material expressed from the E. coli optimised construct 
yielded a doublet at 60, 58 kDa with a 10 kDa lower band, regardless of His6 tag 
position. Material expressed from natively cloned cwp84 (His6.rCwp84) eluted 
impurely. However, western blotting suggested full length (84 kDa) rCwp84 was 
being expressed from T7.rCwp84.His6 or natively cloned (His6.rCwp84) constructs. 
The His6 tags were removable from all N-terminally tagged versions with thrombin. 
However, incubation of all IMAC eluted soluble His6 tag variants (pre or post 
thrombin treatment) with 5 mM DTT to assess self-maturation, did not affect band 
pattern on SDS-PAGE (Figure 3.3.10). 
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Table 3.3.4 Expression and soluble/insoluble analysis of recombinant Cwp84. 
cwp84 variant source vector N-term C-term Expression strain soluble insoluble soluble insoluble
Full length 630 pET28a His BL21 (DE3) Star none 84 58 84
T7 Express lysY/Iq none 84 58 84
IVT 84 84 n/a n/a
geneart pET28a His.T7 BL21 (DE3) Star none 84 58 84
Origami 2 (DE3) 58 84 58 84
T7 Express lysY/Iq none 84 58 84
HMS174 (DE3) 58 84 ND ND
IVT 84 84 n/a n/a
pET24b T7 His BL21 (DE3) Star none 84 58 84
pET43.1a NusA.His.S tag BL21 (DE3) Star 62 multiple <130 as 30°C as 30°C
pET41a GST.His.S tag BL21 (DE3) Star multiple <40 multiple <130 as 30°C as 30°C
pET41b GST.His.S tag His BL21 (DE3) Star multiple <40 multiple <130 as 30°C as 30°C
pGEX-6P-1 GST BL21 (DE3) Star 84 84 84 84
pGEX-6P-1 GST BL21 84 84 84 84
Cwp8433-497 630 pET28a His BL21 (DE3) Star 45 45 45 45
630 pET28a His IVT 52 & 45 52 & 45 n/a n/a
geneart pET SUMO His.SUMO BL21 none 65 65 65
geneart pTAC-MAT2 MAT BL21 (DE3) Star 52
Mut 52Mut ND ND
Tag(s) Expression 30°C (kDa) Expression at 16°C (kDa)
 
ND Not determined, n/a not applicable, Mut mutated version only (see Section 3.3.8.3.1.2
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Figure 3.3.10 Analysis of soluble fractions of native IMAC purified His6-tagged rCwp84 variants expressed at 16 °C (A) His6.T7.rCwp84 elution 
chromatographs and associated eluted fractions, dialysed into PBS. (B) T7.rCwp84.His6 chromatograph and associated eluted fractions & western blot with 
anti-T7 tag, fractions dialysed into 50 mM HEPES plus 0.15 M NaCl pH 7.4 (C) Natively cloned cwp84 His6.rCwp84 (630) chromatograph and associated 
eluted fractions, western blot with anti-His6, fractions dialysed into PBS. After dialysis fractions were incubated with 5 mM DTT (in tris pH 8.0) for 4 hr. 
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Due to the truncation seen, inclusion body isolation and purification was assessed. 
Inclusion body isolation and denaturing IMAC of the His6.T7.rCwp84 insoluble 
material eluted as a biphasic peak, which when analysed by SDS-PAGE gave three 
bands at 84, 76 and 66 kDa for both peaks (although peak overlap was pronounced) 
(Figure 3.3.11). Refolding of fractions from both of the His6.T7.Cwp84 ‘peaks’ by 
rapid dilution into a range of refolding buffers did not appear to alter the band 
pattern on SDS-PAGE. Furthermore, incubation with 5 mM DTT did not affect the 
band pattern (Figure 3.3.11). Remarkably, 84 kDa insoluble C-terminal His6 -tagged 
rCwp84 did not appear to bind to an IMAC column in denaturing conditions. 
 
Figure 3.3.11 Inclusion body purification of rCwp84. (A) Denaturing 
IMAC chromatograph showing ‘biphasic’ eluted peak of His.T7.rCwp84. 
(B) (i) His.T7.rCwp84 denaturing IMAC eluted material. (ii) Immunoblot 
of IMAC eluted material with anti-His antibodies. (iii) His.T7.rCwp84 
from (ii) after rapid dilution refolding. (iv) His.T7.rCwp84 from (iii) after 
16 hr incubation with 2 mM DTT at 4 °C. Images representative of all 
refolding conditions and species eluted in IMAC.  
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3.3.8.2.1.2 Other fusion partners 
In order to increase the expression of soluble rCwp84 and aid purification, a 
number of fusion tags were assessed, however none of the assessed fusion 
partners under either the T7 promoter (pET vectors with NusA or GST tags) or the 
tac promoter (pGEX-6P-1) produced satisfactory rCwp84. GST.rCwp84 (from a pGEX 
construct) appeared to be expressed as soluble and insoluble bands at 84 kDa, 
rather than the expected 119 kDa (84 kDa Cwp84 +35 kDa GST). The soluble 84 kDa 
did not show binding to glutathione resin and flowed through (suggesting GST tag 
occlusion) moreover incubation with PreScission protease for 4 hr did not cleave 
the GST tag from GST.Cwp84, again suggesting occlusion of the GST moiety. If 
however, GST.rCwp84 ran faster on SDS-PAGE (84kDa) than it should (93 kDa), then 
may resemble the His6 tagged rCwp84 expression, i.e. a truncated 58 kDa rCwp84 
species + 35 kDa GST tag. 
3.3.8.2.1.3 In vitro transcription and translation (IVT) of His tagged rCwp84 (full length) 
Expression of full length rCwp84 did not appear to be well tolerated in E. coli, 
potentially due to the expression an ‘active’ cysteine protease or misfolding and 
aggregation due to the CWBD interactions, particularly upon purification. To 
possibly overcome these problems, in vitro transcription and translation (IVT) of 
His6 tagged rCwp84 constructs was assessed.  
 
N-terminal His6 tagged constructs appeared to express an anti-His6 reacting 84 kDa 
protein in both total and soluble portions which purified using an IMAC 
micropurification procedure, although as a minor species (Figure 3.3.12). Incubation 
of the eluted material with DTT did not affect protein bands, pre- or post- His6 tag 
removal with thrombin.  
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Figure 3.3.12 IVT purification of His.rCwp84 (630). Lanes 1-6, 
TALON IMAC micro-purification scheme from a 48 µl IVT reaction. 
Lane 7 & 8, Western blot on eluted material with anti-His6. 
 
In summary, only a 58 kDa soluble protein putatively rCwp84 could be purified from 
the full length gene expressed in E. coli. When expressed in vitro, a small amount of 
84 kDa rCwp84 could be purified. 
3.3.8.3 Expression of rCwp8433-497 Cysteine Protease domain 
The PFam 04122 cell wall binding domain (CWBD) is suggested to play a role in 
anchoring to, forming an array on (as assumed by the HMW SLP) or integrating with 
the cell surface. Recombinant expression of proteins containing these CWB repeats 
then are likely to retain this characteristic, thus during protein expression and 
purification, the protein of interest either aggregates with itself or other E. coli 
proteins possibly causing misfolding, and creates difficulties obtaining pure protein. 
 
Therefore, defining and expressing the ‘functional’ part of the protein (without 
CWBD) is still likely to be valid and give important information about the business 
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end without interference from CWBD interactions. There is some precedent for this 
approach in the expression of SlpA where the LMW was soluble whereas the HMW 
(which consists of 3 x CWBDs) required refolding (Fagan et al. 2009). 
 
Expression of just the cysteine protease domain (residues 33-497 (464 aa), 
predicted MW approx 52 kDa) was therefore assessed.  
3.3.8.3.1.1 E. coli expression of rCwp8433-497 using N-terminal His-tag  
As there appeared to be little difference between E. coli optimised and natively 
(C. difficile 630ΔErm) cloned constructs, rCwp8433-497 was expressed with only an N-
terminal His6 tag cloned from C. difficile 630ΔErm. The construct expressed as 
fragmented anti-His6 reacting species at 52, 45, 42, 37, 28, 26 and 19 kDa. However, 
the anti-His6 reacting species did not bind during IMAC purification. 
 
Purification using IEX, as a first step, did not purify the main 45 kDa band away from 
contaminants, but appeared to increase the propensity to form 84 and 90 kDa 
species (Figure 3.3.13A). IEX purification at pH 6.5 (Q-sepharose) gave fractions 
which contained the same 45 kDa and 84 kDa species as pH 8.0, although slightly 
purer. This material when incubated with 5 mM DTT, resulted in the formation of a 
doublet at 42 and 45 kDa, other bands were unaffected (Figure 3.3.13B).  
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Figure 3.3.13 IEX purification of His.rCwp8433-497. (A) Q sepharose (pH 8.0) 
purification fractions and western blot with anti-His. (B) Q sepharose (pH 6.5) 
purification fractions, including fraction E6 prior and post incubation with 
5 mM DTT for 4 hr at 37 °C 
 
3.3.8.3.1.2 E. coli expression of rCwp8433-497 using C-terminal metal affinity tag  
When rCwp8433-497, with E. coli optimisation, was expressed with a C-terminal metal 
affinity tag (MAT) (HNHRHKH), as N-terminal tags may be removed during 
(auto)maturation, (rCwp8433-497.MAT) a prominent 45 kDa protein (52 kDa 
predicted) was seen in the soluble (IMAC load) fraction but did not appear to bind 
in IMAC. 
 
However, a rCwp8433-497.MAT (S85G and T167I) mutant, obtained through errors 
during PCR amplification (identified by sequencing), expressed well and was easily 
purified as a full length 52 kDa protein (Figure 3.3.14). The 52 kDa S85G and T167I 
mutant rCwp8433-497.MAT appeared to be unaffected by DTT i.e. could not 
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automature, but upon incubation with 5 µg/ml trypsin collapsed to a 46-49 kDa 
doublet i.e. being artificially matured by trypsin (similar to the effect of trypsin on 
rCwp84 (Janoir et al. 2007)). This data suggests that the mutation of S85G and 
T167I in rCwp8433-497.MAT alters the protein structure such that it exposes the C-
terminal MAT tag to allow binding to the IMAC resin and prevents automaturation, 
suggesting a requirement for correct structure for automaturation.  
 
 
 
Figure 3.3.14 Purification of a C-terminal MAT tagged S85G & T167I rCwp8433-
497 mutant. IMAC purification and fractions E3 & E4 after incubation with 
5 µg/ml trypsin or 2 mM DTT for 4 hr at room temperature. 
 
 
The putative in vivo maturation of rCwp8433-497 during expression in E. coli is 
highlighted by expression with an N-terminal His6.SUMO tag. Western blotting 
IMAC fractions from His.SUMO.rCwp8433-497 purification with anti-His6 mainly 
detected two 23 and 25 kDa species, which would correspond to a His6.SUMO tag 
(13 kDa) plus an N-terminal fragment of rCwp8433-497, while full length 
His.SUMO.rCwp8433-497 (65 kDa) and a 45 kDa species react much weaker (Figure 
3.3.15 A). 
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Figure 3.3.15 SUMO tagged rCwp8433-497 purification and cleavage. (A) IMAC eluted fractions and western blot with anti-his. (B) Post dialysis of 
fraction 4 into SUMO protease cleavage buffer (50 mM tris-HCl, pH 8.0, 0.2% Igepal, 1 mM DTT) and incubation with 10 units SUMO protease 
at 30 °C samples taken at 1 hr and 4 hr.  
  
96 
 
The 23/25 kDa His6.SUMO.rCwp8433-497 fragment band is lost upon incubation with 
SUMO protease further confounding its identity. As expected, full length 
His6.SUMO.rCwp8433-497 (65 kDa) is cleaved leaving 52 kDa (rCwp8433-497) and free 
13 kDa His6.SUMO (running at approximately 17 kDa on SDS-PAGE) (Figure 3.3.15 
B). The apparent collapse of the IMAC eluted bands between 47-42 kDa 
(Figure 3.3.15 A Lane 4) into a band at 49 kDa after dialysis into the SUMO protease 
cleavage buffer (50 mM tris-HCl, pH 8.0, 0.2% igepal, 1 mM DTT) may also suggest 
automaturation under reducing conditions.  
 
Taken together this data suggests ‘maturation’ of rCwp84 can occur in the 
cytoplasm of E. coli either through E. coli proteases or self-maturation. This 
maturation does not appear to be complete as multiple rCwp8433-497 species are 
present.  
3.3.8.3.2 In vitro transcription and translation of rCwp8433-497 
Anti-His6 western blots of IVT expressed His6.rCwp8433-497 detect a 52 kDa (un-
truncated) and a 42 kDa (presumably C-terminally truncated) species (Figure 
3.3.16). The presence of full length His6.rCwp8433-497 in the IVT micro-purification 
elution fraction(s) suggests that, as found with IVT of full length rCwp84 (where full 
length 84 kDa found), material expressed using IVT has a decreased, but not 
completely abolished, tendency to automature or to be cleaved by proteases 
present either the IVT E. coli extract or in E. coli during ‘normal’ expression. 
 
  
97 
 
Figure 3.3.16 IVT purification of His.rCwp8433-497. Lanes 1-6, 
TALON IMAC micro-purification scheme from a 48 µl IVT reaction. 
Lane 7 & 8, Western blot on eluted material with Anti-His6. L- 
Load, FT- Flow Through, W1 & 2- Wash, E1 &2 - Elution. 
 
3.3.8.4 Cleavage of SlpA with rCwp84 
As aforementioned, the hypothesis stands that Cwp84 plays a role in S-layer (SlpA) 
maturation and thus the cleavage of SlpA may be demonstrable in vitro. 
Recombinant Cwp84 was therefore assessed for its ability to cleave SlpA in vitro as 
to date only the action of trypsin appears to cleave SlpA into bands resembling the 
WT HMW and LMW SLPs.  
 
Obtaining recombinant Cwp84 of a sufficient purity restricted the variants of 
rCwp84 available for assessment. Table 3.3.5 summaries the rCwp84 forms 
assessed for their ability to cleave SlpA in CDΔCwp84 SLPs.  
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Table 3.3.5 Cleavage of CDΔCwp84 SLPs by recombinant Cwp84 
Version 
 
MW 
Pre-
reduced 
Reducing 
conditions 
Cleavage 
occurs 
Effect on 
SlpA/SLPs 
Inhibited 
by E64 
concentration of 
rCwp84 (approx) 
Time 
period 
His.T7.rCwp84 (Insoluble) E. coli 84,76,66 + - y 58 & 49 kDa n/d 0.2 µg (200 ng) 5 hr 
His.T7.rCwp84 E. coli 58 + - y 55,53+32 n/d 4 µg o/n 
  E. coli 
 
- + n - n/a 10 µg/ml (0.2 µg) 5 hr 
  E. coli   - + y 55,53+32 + 100 µg/ml (2 µg) 5 hr 
T7.rCwp84.His E. coli 58 + - y 55,53+32 n/d 1.5 µg o/n 
His.rCwp84 E. coli 84Δ - +/- n - n/a -   
His.rCwp84 IVT 84Δ - - y 53 + E1 o/n++ 
  
  
- + n* 36 - E1 o/n 
His.rCwp84 
 
84Δ +/- - n* 36 n/d E2 o/n 
(His.)rCwp84 
 
84Δ n/d n/d n - n/d E2 o/n 
His.T7.rCwp84 IVT 84Δ - - n* 36 n/d E1 o/n 
His.rCwp8433-497  IVT 52,42
Δ - +/- n* 36 - E1 o/n 
All other rCwp84 species were either not pure enough or did not stick to column and therefore flow-through fractions were not considered pure enough 
* the 38 kDa band disappears and a new 36 kDa band appears, unknown as to whether it is specific cleavage of SlpA 
  Δ blottable species with anti-his 
        ++ reaction could occur faster than o/n (16 hr) 
       E (1 or 2) – Represent first or second washes of resin with elution buffer during micro-scale purification of IVT produced rCwp84 types (see section 3.2.1.4). 
Protein concentration of the E1 or E2 fractions was not determined due to small volumes. 
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None of the recombinant Cwp84 variants assessed appeared to cleave SlpA in 
CDΔCwp84347 SLPs into the 39 kDa and 48 kDa WT-like S-layer bands, as seen for 
trypsin, in vitro (Figure 3.3.17). 
 
Full length refolded rCwp84 appeared to cleave SlpA into 58 and 49 kDa species 
(Figure 3.3.17 (i)), a result similar to cleavage of SlpA by low concentrations of 
papain (Figure 3.3.8). Full length soluble (58 kDa) and full length (cloned from 
C. difficile 630) IVT expressed rCwp84 cleaved SlpA in CDΔCwp84 SLPs into a 55,53 
kDa doublet and a 32 kDa ‘remainder’(Figure 3.3.17 (ii-v)). The demonstrated 
cleavage was inhibited by 100 µM E64, suggesting it was cysteine protease 
dependant.  
 
In summary, a variety of recombinant Cwp84 variants were produced however 
none have shown cleavage of SlpA into WT-like HMW and LMW S-layer bands, as 
seen with trypsin. These data suggest that factors, or lack thereof, have prevented 
rCwp84 from cleaving SlpA in vitro to form WT like SLPs. 
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Figure 3.3.17 Cleavage of SlpA in CDΔcwp84 SLPs by rCwp84. Lanes 1 and 2 CDΔCwp84 & WT C. 
difficile 630ΔErm SLPs respectively. (i) Refolded (R) His.T7.rCwp84 cleavage of SlpA. 10 µl (~0.2 µg) 
refolded His.T7.rCwp84 (refolded by rapid dilution into 55 mM tris, 21 mM NaCl, 0.88 mM KCl pH 8.2 
for 24 hr then incubated with 2 mM DTT for 24 hr) mixed with 10 µl (~3.45 µg) CDΔCwp84347 SLP 
incubated at 37 °C for 5 hr. Cleavage in other refolding buffers was equal to or less than cleavage of 
SlpA in the above buffer system (ii) 16 hr incubation at 37 °C of 20 µl (6.9 µg) CDΔCwp84347 SLPs with 
20 µl (~4 µg) His.T7.rCwp84 in PBS pre-incubated with at 37 °C with 5 mM DTT for 4 hr. (iii) 2 µg 
His.T7.rCwp84 in PBS incubated with 20 µl (6.9 µg) CDΔCwp84347 SLPs for 5 hr with addition of 5 mM 
DTT at 37 °C ± 100 µM E64. (iv) 16 hr incubation at 22 °C of 18 µl (6.2 µg) CDΔCwp84347 SLP with 2 µl 
(1.5 µg) T7.rCwp84.His in 50 mM HEPES 0.15 M NaCl pH 7.4 pre-incubated for 4 hr at 37 °C with 
2 mM DTT. (v) 16 hr incubation at 37 °C of 18 µl (6.2 µg) CDΔCwp84347 SLPs with 2 µl IVT 
micropurified (elution 1) His.rCwp84 (630) in 50 mM sodium phosphate 0.3 M NaCl 150 mM 
imidazole ± 100 µM E64. CDΔCwp84347 SLP extract in 50 mM HEPES 0.15 M NaCl pH 7.4. 
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3.3.9 Microscopy of Cwp84 mutant S-layer 
Previous studies have demonstrated that the S-layer of C. difficile forms a regular 
array on the cell surface (Takumi et al. 1992; Cerquetti et al. 2000). By freeze 
etching whole cells and negative straining extracted SLPs, Cerquetti et al. (2000) 
suggested the presence of a dual layered S-layer; with a square ordered lattice on 
the outermost surface, with lattice spacing of ~10 nm, and a hexagonal lattice 
innermost. As KO of cwp84 prevents S-layer maturation, a range of microscopy 
techniques were used to determine what effect the presentation of immature SlpA 
had on the cell surface, in particular if immature SlpA presented on the cell surface 
was able to form a regular array. 
3.3.9.1 Cryo-SEM 
Using low temperature-scanning electron microscopy (Cryo-SEM or LT-SEM), a 
method tending to replace freeze fracture replica techniques, no differences could 
be observed between the morphology of WT and CDΔCwp84 cells from solid phase 
bacterial culture (Figure 3.3.18). Examination of cells at low magnification revealed 
that CDΔCwp84347 cells were surrounded by high levels of extracellular debris not 
present in 24 or 48 hr WT cells. Solid phase cultures were used to minimise physical 
stress and manipulation, e.g. centrifugation, as CDΔCwp84 is known to be sensitive 
to such treatments. Due to the slow growth of CDΔCwp84347 only 48 hr cultures 
were used, although given the lack of stationary phase after 24 hr (Section 3.3.3.2), 
a similar outcome with cryo-SEM is likely. As no regularly ordered lattices were 
observed with either strain, other methods were pursued. 
3.3.9.2 TEM 
3.3.9.2.1 Whole cells 
Examination of negatively stained partially lysed CDΔcwp84 cells by transmission 
electron microscopy (TEM) revealed an apparently regular parallel array on the cell 
surface, a portion of which had flapped over, yet retained this array 
(Figure 3.3.19 A). The array demonstrates an average lattice spacing of 7.5 nm 
(Figure 3.3.19 B). 
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TEM of whole C. difficile 630 ΔErm cells did not result in any discernable S-layer 
arrays only heavily stained cells (Figure 3.3.20).  
3.3.9.2.2 Embedded sectioning 
Embedded sectioning of C. difficile was first used by Kawata et al. (1984) to 
demonstrate the presence of the S-layer as two superimposed layers on the cell 
surface. Therefore to examine structures other than those directly on the bacterial 
surface, 24 hr cultures of both WT and CDΔcwp84347 were embedded, sections 
taken then analysed by TEM (Figure 3.3.21). 
 
Using this technique, it is demonstrated that C. difficile 630ΔErm possesses a cell 
envelope composed of six layers (Figure 3.3.21 A). The cell membrane innermost 
(layer 1) is followed by a light thin ~1.5 nm layer (layer 2), a ~2.5nm darker layer 
(layer 3) then a very lightly stained ~2 nm layer (layer 4). Following these is the 
densely stained (approx 15-30 nm thick) peptidoglycan (layer 5). On the outermost 
surface, and presumed to be the S-layer, are two layers: a lightly stained ~4 nm 
(HMW SLP) and a ~7 nm densely stained thick compact outer layer (LMW SLP) 
(layers 6(a) and (b) respectively). Comparision of CDΔcwp84347 cells (Figure 3.3.21 
B) with C. difficile 630ΔErm cells, reveals that layer 3 appears as a large ~6 nm 
densely stained layer, whereas this layer is only ~1 nm thick in the WT (Figure 
3.3.21 A). The ill-defined appearance of the latter outermost layer (layer 6b), is 
consistent with the presentation of immature SlpA on the cell surface, which is 
possibly unable to form a properly locked S-layer array.  
 
These results suggest that SlpA presented on the cell surface of CDΔcwp84347 may 
lack the ability to form a regular packed lattice structure; moreover that 
CDΔcwp84347 produces a significantly thicker, previously unidentified inner layer 
compared to the WT under similar growth conditions.  
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Figure 3.3.18 Cryo-SEM of C. difficile solid phase cells. (A) 24 hr C. difficile 630ΔErm cells at (i) low & (ii) high magnification (B) 48 hr CDΔCwp84347 at (i) low 
& (ii) high magnification. Solid phase 48 hr CDΔCwp84347 was used due to slow growth of the mutant compared to 24 hr C. difficile 630ΔErm.  
KEY: 1 - Smooth outer layer, 2 - Perforated layer, 3 – Cell contents/cytoplasm. 
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Figure 3.3.19 Demonstration of a regular array on CDΔcwp84 by TEM. (A) Negatively stained lightly sonicated CDΔcwp84 cell from 24 hr culture, revealing a 
regular parallel array (B) zoom in (A). 
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Figure 3.3.20 TEM examination of negatively stained, lightly sonicated, C. 
difficile 630ΔErm cells from 24 hr culture. 
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Figure 3.3.21 Embedded sections through C. difficile 630ΔErm and CDΔcwp84347. (A) 
wildtype C. difficile 630ΔErm and (B) CDΔcwp84347. Image (i) acquired image, image (ii) 
electronically zoomed image of the area highlighted in image (i). Images are representative 
multiple grid examinations. Layer 1 - cell membrane, Layers 2-4- unknown, Layer 5 - 
peptidoglycan, Layer 6- S-layer (a) HMW SLP (b) LMW SLP.  
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3.3.9.3 AFM 
Atomic force microscopy (AFM) is a powerful tool for visualising physical and 
chemical nanomaterials in their native environment. AFM is capable of imaging 
protein surfaces to nanometre level and S-layer arrays fall within this magnitude. 
AFM has been successfully used to map the surface of many bacterial S-layers 
including those which have been removed from the cell surface (Scheuring et al. 
2002; Gyorvary et al. 2003; Dupres et al. 2009). AFM was therefore employed to 
help determine if immature SlpA in CDΔCwp84 SLPs affected S-layer array packing 
in vitro compared to the WT. 
 
 
Figure 3.3.22 SDS-PAGE analysis of urea or low pH glycine extracted SLPs, 
from 24 hr cultures of C. difficile 630ΔErm or CDΔCwp84347 used in atomic 
force microscopy. 
 
Tapping mode AFM of WT 8 M urea SLPs (SDS-PAGE Figure 3.3.22), revealed that 
using a negatively charged (hydrophilic) surface (ozone modified graphite or 
particularly mica) the SLP extract formed a non-structured polycrystalline surface 
with raised plaque regions at low resolution (Figure 3.3.23 A). Upon closer 
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inspection of the plaques formed on mica, it was apparent that they exhibited a 
regular array (Figure 3.3.23 B). The array was interrupted by pores approximately 
30-40 nm across. Examination of a 250 nm plaque region demonstrated that the 
array was made up of hexagonally packed units (Figure 3.3.23 C). The hexagonal 
arrays had a central core with a centre spacing of 100 nm, with approximately 
100 nm spacing between each row of hexagonal units (Figure 3.3.25 A).  
 
AFM imaging of the Cwp84 KO 8 M urea SLPs (SDS-PAGE Figure 3.3.22) 
required a similar substrate i.e. positivity charged (hydrophilic) surface but, 
also required the presence of calcium in the imaging buffer and could only be 
recorded using contact mode. Topographs of Cwp84 KO 8 M urea SLPs 
displayed a similar pattern of plaque formation, although plaques were not 
well formed (Figure 3.3.24 A). Closer inspection of a number of 
regions/plaques did not reveal any regular arrays (Figure 3.3.24 B). However, 
one 500 nm region clearly demonstrated a squarely arranged array (Figure 
3.3.24 C). The tetragonal array in this region was characterised by a centre 
spacing of approximately 50 nm in both x and y dimensions, with a secondary 
array running alongside the main vertical planes, with a distance of 11-15 nm 
between it and the main array (Figure 3.3.25 B).  
 
The AFM did not make contact with any surface when low pH SLP extracts were 
used, presumably because an array was not formed. This may have been due to 
impurities in the low pH SLP extract (despite a cleaner appearance in SDS-PAGE 
(Figure 3.3.22), a lack of component(s) present in 8 M urea extracts required for 
array formation or that other physical buffer/substrate conditions prevented array 
formation.  
 
This data suggests that proteins in CDΔCwp84 8 M urea SLPs appear different in 
vitro, when examined using AFM, than the WT C. difficile 630ΔErm 8 M urea SLPs. 
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Figure 3.3.23 Tapping mode AFM topographs of C. difficile 630ΔErm 8 M urea extracted 
SLPs. (A) 40 µm scan region (Z-axis: 221 - 243 nm). (B) 500 nm scan of plaques seen in (A) 
(Z-axis: 0 - 23.9 nm). (C) 250 nm scan of (B) (Z-axis: 10 - 21.2 nm). (D) Fast Fourier transform 
(FFT) of (B). Imaging buffer 10 mM potassium orthophosphate adjusted tris buffer pH 7.8  
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Figure 3.3.24 Contact mode AFM topographs of C. difficile ΔCwp84 8 M urea extracted 
SLPs. (A) 830 nm scan region (Z-axis: -3.5 – 9.6 nm). (B) 256 nm scan (Z-axis: -3.0 – 4.4 nm). 
(C) 500 nm scan (Z-axis: 0.0 – 20.0 nm). (D) Fast Fourier transform (FFT) of (C). Imaging 
buffer 10 mM potassium orthophosphate adjusted tris buffer pH 7.8 with additional 50 mM 
calcium chloride. 
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Figure 3.3.25 Diagrammatic interpretation of C. difficile 8 M urea AFM topographs. (A) 
Representation of hexagonal array seen in Figure 3.3.23(C). (B) Representation of 
tetragonal array seen in Figure 3.3.24(C). 
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3.3.10 Molecular modelling of the Cwp84 cysteine protease 
domain (Cwp8433-497) 
To understand more about structural aspects of Cwp84, tertiary structure 
prediction was undertaken with the N-terminal cysteine protease domain (residues 
33-497 of Cwp84).  
 
BLASTP (blast.ncbi.nlm.nih.gov) suggests approximately 44% of Cwp8433-497 is 
similar, by sequence coverage, to other known cysteine proteases in the PDB. The 
highest hits are to human cathepsin S (2FYE and 2G6D, 30% identity each) and 
human cathepsin L (3OF8 and 3H89, 28% identity each). 
 
Tertiary structure prediction by homology modelling is consistent with BLASTP 
results, as SWISSMODEL (Arnold et al. 2006) suggests residues 91 to 319 of 
Cwp8433-497 have 21.4% identity with porcine cathepsin H, while CPHmodels 
(Nielsen et al. 2010) suggests 30.6% identity with human cathepsin S (2FYE). 
Superposition and active site comparison suggests the active site residues of Cwp84 
are C116 and H262 (with Q110 and N261 assisting in orientation).  
 
Fold homology structure prediction supports homology modelling, as the Phyre 
server (Kelley & Sternberg 2009) suggests fold identity with procathepsin B (3PBH) 
& procathepsin L (1CS8), HHPred (Soding et al. 2005) suggests identity with 3BPH 
and also procathepsin S (2C0Y)). Comparision of active site residues of the 
templates with the Cwp84 models also suggests C116 and H262 as the catalytic 
dyad (with Q110 and N261 assisting in orientation) (Figure 3.3.26).  
 
HHPred and Phyre models are based on full length pro-enzymes i.e. still retaining 
the inhibitory pro-region. Analysis of the putative maximum pro-region (H33-N109) 
of Cwp8433-497 models highlights how, consistent with other zymogens, the pro-
region comes from above the active site cleft, through the ‘oxyanion’ hole and over 
one face of the enzyme into the bottom between the two domains (Cygler & Mort 
1997) (Figure 3.3.26). Moreover, removal of a pro-region up to Q110, five residues 
from the active Cys116, would result in a ~12 kDa loss including the signal peptide 
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(~8 kDa without) in Cwp84. This highlights how a loss of 23 kDa, as suggested during 
maturation by Janoir et al. (2007), may be from other regions of the protein or is an 
artefact of recombinant production. Moreover, N287 (as proposed by Savariau-
Lacomme et al. (2003)) does not appear to be close enough to interact with His262 
in all models, suggesting either N262 performs this role, or a non-predicted fold 
brings N287 into play.  
 
  
1
1
4
 
 
Figure 3.3.26 Tertiary structure prediction models of Cwp8433-497 from Hidden Markov Model (HMM)-HMM comparison, by HHPred (Soding et al. 2005). 
Cwp8433-497 modelled on (A) Procathepsin B (3PBH) (B) Procathepsin S (2C0Y). Active cysteine and histidine residues displayed in red, maximum proregion 
displayed in blue. Alignments modelled with MODELLER (Eswar et al. 2007) and prepared using PyMOL (www.pymol.org)
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3.4 Discussion 
It is only comparatively recently that it has become possible to generate stable, 
targeted gene knock-outs of C. difficile (Heap et al. 2007). Combined with 
proteomics and in vivo models for CDI, such techniques provide powerful tools with 
which to study disease pathogenesis. In this chapter, cwp84 a gene encoding a 
putative surface protein Cwp84, has been knocked-out and it demonstrated that 
this cysteine protease plays a key role in the maturation of the surface protein 
layer. 
3.4.1 Stringency of and genetic factors affecting KO outcome 
While the KO of cwp84 at multiple sites provides confidence that the phenotype 
observed was a result of the KO of cwp84 and not promiscuous insertion. It is 
possible that the intron consistently inserted into not only cwp84 but another gene 
which caused the resulting phenotype.  
 
CD1751, a putatively surface located C1A family cysteine protease is theoretically a 
gene into which promiscuous insertion could occur. However, none of the insertion 
sites chosen for cwp84 appear in cd1751 and no screened clones had intron 
insertion into cd1751. The lack of a cd1751 transcript and data by Dang et al. (2010) 
strongly suggests CD1751 does not play any significant role in pathogenesis. 
Inactivation of cd1751, for example using the ClosTron technology, may also 
confirm this. 
 
Given that the CWBD is found in multiple copies in multiple surface proteins, intron 
insertion sites within CWBD(s) e.g. Cwp84 2054|2055a, could putatively insert into 
other CWBD(s). While CWBD identity is relatively low (~50%), if intron insertion 
sequences are sufficiently similar ‘promiscuous’ insertion is possible, insofar as any 
highly homologous sequence is a candidate for promiscuous insertion.  
 
Group II introns integrate via a reverse transcription mechanism termed 
retrohoming, however a retrotransposition mechanism which occurs independently 
of the endonuclease function of the IEP, dependent on host recombinase functions, 
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has been found (Edgell et al. 2000) highlighting the possibility of intron mobility 
within CDΔCwp84. Complementation together with Southern blotting could be 
used to determine if, firstly returning the inactivated gene (cwp84) returns wild-
type phenotypes and secondly confirmation that the intron has not entered at 
multiple sites in the target organisms genome. Studies using these analyses have 
been published (Heap et al. 2007; Emerson et al. 2009b) and it is feasible that until 
these analyses are completed, multiple copies of the ClosTron group II intron are 
present in CDΔCwp84 (or other mutants presented in this thesis). Surface inhibition 
of Cwp84 by Dang et al. (2010) also obtained an immature SlpA phenotype 
suggesting that the cwp84 KO phenotype demonstrated in this chapter was due to 
lack of Cwp84 activity. 
3.4.1.1 Genetic considerations of Cwp84 mediated cleavage of SlpA. 
It is suggested that the ClosTron creates either a potentially active truncated 
product when an insertion site is at a distal location or a fore-shortened protein, 
still potentially retaining activity, when inserted at a proximal site (Heap et al. 
2009a). Of the four sites chosen in cwp84, three (68|69a, 347|348a and 677|678a) 
were chosen such that any fore-shortened protein would be unlikely to retain any 
functional activity. Insertion site 2054|2055a, which would result in a fully 
translated N-terminal cysteine protease domain, still resulted in the same immature 
SlpA phenotype. This suggests that either the KO process (at any site, in any gene) 
alters the mRNA structure such that it is not translated, or that inactivation of the 
first CWBD of Cwp84 results in an inability to mature SlpA, suggesting that Cwp84 
requires all the CWBDs for SlpA cleavage. The prominent species found on the cell 
surface is full length Cwp84 (85 kDa) (Janoir et al. 2007) and full length Cwp84 was 
found to cleave an SlpA fragment in E. coli (Dang et al. 2010).  
 
3.4.2 Morphology and growth characteristics of cwp84 KO mutants 
3.4.2.1 Morphological 
All observations regarding changes in C. difficile colony morphology should be 
treated with caution due to the pleomorphic nature of C. difficile colonies, 
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specifically as the white and circular colony morphology of CDΔcwp84 has been 
observed in other C. difficile strains (Siani et al. (Reynolds et al. 2010; 2010)). 
Furthermore, C. difficile cwpV mutants exhibit a small and round colony 
morphology which can be only to the characteristic C. difficile colony morphology 
by complementation (Reynolds et al. 2010) Changes in colony morphology as a 
result of knockout of surface associated genes have been found in other species, for 
example S-layer (Rothfuss et al. 2006) and peptidoglycan hydrolase mutants 
(Camiade et al. 2010). Microscopic examination of CDΔcwp84 clearly shows WT cell 
morphology suggesting that a division septum is able to be formed (and cleaved). In 
CDΔcwp84, increased inter-cell adherence may inhibit movement across solid 
medium resulting in cell clumping rather than the typical spreading C. difficile 
colony morphology. Together with Cryo SEM of CDΔcwp84 data, this suggests the 
accumulation of extracellular material is likely to change both the refractive index 
of the colony (making colonies white rather than grey) and impede motility across 
the medium (causing round rather than spread colonies).  
 
CDΔCwp84 grew more slowly and had a tendency to clump and form string-like 
precipitates, suggesting an increased degree of inter-cell adherence. In 
Corynebacterium ammoniagenes, a RamA (putative S-layer and cell wall 
biosynthesis regulator) knockout had increased cell surface hydrophobicity, leading 
to the formation of aggregated cell masses in liquid media (Lee et al. 2010b). 
Knockout of the majority of the Thermus thermophilus HB8 S-layer also lead to slow 
growth in liquid broth and a tendency to aggregate (Lasa et al. 1992). 
 
A significant finding is the presence of immature SlpA in the growth medium during 
culture of CDΔCwp84. This suggests a weakened attachment via the cell wall-
binding motifs, since the mature HMW SLP (or LMW SLP) was absent from the 
medium of wildtype C. difficile 630ΔErm. Immature SlpA presented on the surface 
of CDΔCwp84 is therefore unlikely to be able form a properly ‘locked’ lattice 
structure and, as a result, may be lost from the cell surface.  
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S-layer release into the culture supernatant has been described and may be 
connected with S-layer regulation through packing density (Breitwieser et al. 1992). 
Knockout of cwp84 may therefore directly or indirectly de-regulate slpA (or SlpA), 
via a surface based feedback system. Sleytr & Glauert (1976) suggest that in 
Clostridium thermohydrosulfuricum and C. thermosaccharolyticum, during cell 
separation, a ‘surplus’ of S-layer subunits appears at the site of division thereby 
ensuring that the newly formed cell poles remain completely covered by the S-layer 
throughout the separation process. Excess (immature) S-layer presented on the cell 
surface of CDΔCwp84, beyond the normal ‘surplus’ required, could therefore be 
free to shed into the medium. Moreover, an S-layer transcriptional control 
(slrA::kat) mutant of T. thermophilus HB, like CDΔCwp84, grew slower and appeared 
to have trouble maintaining stationary phase (Bahl et al. 1997), highlighting how a 
loss of S-layer control results in slower growth. 
3.4.2.2 Growth Rate  
The knockout of cwp84 leads to a reduction in cell integrity, primarily from having 
an altered S-layer. The observed slower growth of CDΔCwp84 is likely to be a result 
of an inability of the cell to maintain key physical characteristics normally upheld by 
an intact S-layer (Engelhardt 2007), i.e. cells are easily lysed. The in vitro action of 
trypsin on CDΔCwp84 SLPs, together with the observed increase in growth rate 
when trypsin supplemented culture media is used, suggests that trypsin is 
artificially maturing immature SlpA on the cell surface (or that which is shed into 
the culture medium) which is able to self-assemble and return some integrity to the 
cell. Therefore, trypsin causes the growth rate of CDΔCwp84 to appear to increase 
as lysis is being decreased.  
 
It is also tempting to speculate that the increased inter-cell adherence in 
CDΔCwp84 may turn on quorum sensing systems that cause a range of effects 
including slower growth. Indeed there may indeed be a specific molecule or protein 
produced, or leached, from CDΔCwp84 which affects the bacterial cells in culture.  
 
  
119 
Other surface protein knockouts (See Chapter 5) also display slower growth rates 
(flagella cap (FliD) (p=0.053), Cwp66 (p=0.046) and CD2784 (p=0.027)), suggesting 
that other proteins are key in maintaining cell integrity or highlight a mechanism to 
decrease growth upon significant surface change. 
3.4.2.3 Sporulation 
Lawley et al. (2009b) found low levels of SlpA in the spore coat of C. difficile 630 
spores. It follows that CDΔCwp84 spores are likely to be affected by the presence of 
immature SlpA polypeptide. However, CDΔCwp84 is able to a) sporulate, albeit at a 
reduced efficiency b) make viable, infectious spores. This suggests that for spore 
integrity it is not essential that SlpA be cleaved into HMW/LMW SLP or that, the 
domain(s) required for correct spore assembly are correctly folded. Decreased cell 
integrity is likely to lower sporulation efficiency, whereby spore formation creates 
stress on an already delicate cell resulting in cell lysis.  
3.4.3 Analysis of surface layer proteins of cwp84 mutants 
Extraction of the surface proteins of CDΔCwp84 primarily revealed the lack of SlpA 
maturation. However, a large number of other surface proteins are similar between 
the WT and Cwp84 KO indicating that these proteins are potentially unaffected by 
both cwp84 KO and the resulting presentation of immature SlpA.  
 
CwpV, a surface-associated protein which is also cleaved into two fragments 
(Emerson et al. 2009b) was found matured, as normal, in the SLPs of CDΔCwp84 
suggesting a different/additional processing mechanism for this surface protein. A 
band of similar size is found in the culture supernatant of CDΔCwp84, suggesting 
CwpV is also lost to the culture supernatant, possibly as a result of an association 
with SlpA or that CwpV’s regulatory control is altered resulting in excess CwpV and 
subsequent release into the medium.  
3.4.4 Identification of Cwp84 at the cell surface 
Proteomic analyses in this study and in a previous study by Wright et al. (2005) 
have not identified Cwp84 (aka Paralog 4 in Wright et al. (2005)) in glycine extracts 
of C. difficile 630(ΔErm in this study). However, Janoir et al. (2007) using antibodies 
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raised against matured rCwp84, and Dang et al. (2010) using pull down assay of ABP 
labelled Cwp84, have both found Cwp84 in glycine extracts.  
 
The inability to identify Cwp84 in glycine extracts in this study could be due to the 
variability of batch cultures and the culture growth conditions. The Cwp84 may be 
highly unstable in the extraction conditions. The non-identification of Cwp84 in 
glycine extracts could, however, be due to limitations with a mass spectrometry 
approach to protein identification in complex mixtures (Baldwin 2004).  
 
Antisera raised against peptides to predicted epitopes were unsuccessful at finding 
Cwp84 in glycine or lysozyme extracts. The primary reason for this is assumed to be 
the insolubility of the lyophilised peptides (conjugated to KLH). PBS ± 10% DMSO ± 
sonication did not appear to completely dissolve the conjugated peptides. 
Therefore, the amounts of soluble peptide immunised may have been far lower 
than expected, and the resulting concentrations of Cwp84 peptide specific 
antibodies may have been low. However, there is a possibility that usable 
antibodies were generated and the negative immunoblots were valid, as there may 
have not been any Cwp84 present in the glycine or lysozyme cell wall fraction(s). 
This may be due to the culture conditions, genuinely actual low (undetectable) 
amounts of Cwp84 or due to protein fragility/instability during the extraction 
procedure.  
 
As recombinant Cwp84 (full length-truncated or N-terminal domain only) became 
available, this should have been used for antiserum generation, comparable to the 
method used by Janoir et al. (2007). Alternatively, a transcriptomic approach (RNA-
seq) may have identified full length cwp84 mRNA and its subsequent truncation in 
CDΔCwp84. Given Cwp84’s key role in S-layer maturation there should be a ready 
supply of its message for RNA-seq, despite its putative short half-life to ensure 
Cwp84 is tightly controlled. 
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3.4.5 Effect of proteases on SlpA in vitro and effect on Cwp84 
mutants 
Incubation of CDΔCwp84 SLPs with trypsin cleaves SlpA leaving bands that are 
indistinguishable in size to the WT HMW and LMW S-layer subunits. Moreover, SLPs 
extracted from CDΔCwp84 grown in trypsin supplemented media are also cleaved 
to WT-like bands. This indicates that SlpA in CDΔCwp84 SLPs and immature SlpA 
presented on the surface of CDΔCwp84 are structurally similar and spatially in as 
much as the trypsin cleavage site (TKˇSANDT) is accessible.  
 
Incubation of CDΔCwp84 SLPs with other selected proteases, including papain and 
cathepsin B from the peptidase C1A family (to which Cwp84 is proposed to belong), 
did not cleave SlpA in CDΔCwp84 SLPs to yield WT-like bands. It is unknown as to 
whether this data merely highlights the specificity of the assessed proteases 
cleavage residue(s) (or lack of for papain) or a ‘unique’ spatial orientation/structural 
conformation between trypsin and SlpA. However, full length rCwp84 was found to 
cleave an SlpA fragment (amino acids 1-362, fused to a C-term GST tag) rather than 
full length SlpA (when co-expressed in E. coli) (Dang et al. 2010), suggesting the 
structure of full length SlpA in vitro affects cleavage (even by Cwp84) into the 
respective SLP subunits.  
 
In addition to the cleavage of SlpA in CDΔCwp84 SLPs, there are two other 
interesting points. First, the 120 kDa protein CwpV appears to be resistant to 
degradation by a number of the proteases tested in this chapter, suggesting 
stability to high (digestive) proteolysis potentially key in vivo. Secondly, in vitro, the 
HMW SLP appeared more sensitive to trypsin degradation. Early work on the S-
layer of C. difficile highlighted how a 32 kDa protein, subsequently named as the 
LMW SLP, was resistant to trypsin but not pepsin (Kawata et al. 1984; Takumi et al. 
1987). This may support the proposed orientation of the S-layer in which the HMW 
SLP is the lesser exposed of the two subunits (Fagan et al. 2009), leaving the more 
protease resistant proteins, e.g. LMW SLP subunit and CwpV, to confer a protective 
coat to the bacterium.  
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3.4.6 Ability of CDΔCwp84347 to cause infection 
CDΔCwp84347 was assessed for its ability to cause CDI in the hamster disease model. 
The mutant strain was clearly competent at colonising the hamster gut and caused 
a similar spectrum of symptoms to wildtype C. difficile 630ΔErm with mean of 
fatality of 83.3% in the test groups. Bacterial isolates from the faecal samples taken 
from diseased animals confirmed CDΔCwp84347 as the causative strain and further 
illustrated the stability of the mutation. These data demonstrate firstly, that Cwp84 
does not directly play a critical role in CDI pathogenesis in the animal model and 
secondly, that bacteria expressing immature SlpA are still competent at causing 
disease. With respect to the latter, one possibility is that the SlpA precursor 
polypeptide retains any key biological action(s) of the HMW and LMW SLPs, and 
that the domains mediating this activity are correctly folded within the SlpA 
precursor.  
 
Another possibility is that the SlpA precursor is ‘matured’ via cleavage by the gut 
proteases, as proven by cleavage with trypsin. Thus, it is possible that a proportion 
of CDΔCwp84347 growing in the gut derives a mature S-layer via the action of gut 
proteases. Alignment of 14 SlpA sequences (Eidhin et al. 2006) at their putative 
cleavage sites suggests that the SlpA precursor could potentially be cleaved by gut 
enzymes trypsin or chymotrypsin (Figure 3.4.1). Examination of the gut lumen 
contents after challenge, which would include all bacterial (predominantly C. 
difficile) species and identification of an appropriate size band by western blotting 
with anti-LMW SLP may confirm SlpA cleavage by gut proteases. It remains true 
that C. difficile expressing the SlpA precursor polypeptide are still competent at 
causing disease in the hamster model. The ability of CDΔCwp84347 to cause 
infection may be assisted by changes in toxin production, which may negate the 
deleterious effects of an immature S-layer.  
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Figure 3.4.1 Alignment of predicted cleavage sites for trypsin or chymotrypsin within SlpA 
from fourteen C. difficile ribotypes (Eidhin et al. 2006).  
 
Do changes in toxin production mean the bacterium can forgo an S-layer and still 
cause CDI? Or is immature SlpA still providing the rudimentary structural stability 
provided by an S-layer? To date, knockout of SlpA in C. difficile has been 
unsuccessful, indicating SlpA KO is lethal i.e. the resulting phenotype is unable to 
survive or that the ClosTron KO process does not account for the S-layer-less 
bacterium in its protocols e.g. ability to tolerate antibiotics or a certain nutritional 
requirements, creating the illusion of lethality. It is possible then that an S-layer 
negative strain of C. difficile may be created, perhaps by slpA complementation 
under expression control prior to slpA KO or by conditional KO, but using a different 
or modified KO process. It is possible for normally S-layer encompassed bacteria to 
live without an S-layer, as spontaneous mutant S-layer negative strains of 
Camploybacter fetus have been found (Tummuru & Blaser 1992) (although the 
regulator of S-layer is spontaneously mutated leaving the S-layer genes intact). 
Moreover, S-layer mutants appear to have decreased adherence to cell lines and 
decreased virulence in animal models (Janda et al. 1994; Sakakibara et al. 2007; 
Kern & Schneewind 2009). An S-layer negative strain of C. difficile is therefore likely 
to have impaired virulence, not only from the loss of adherence via its S-layer, or 
lack thereof, but through loss of accessory proteins directly or indirectly integrated 
with the S-layer. 
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3.4.7 Microscopy data 
Despite there being no visible differences in CDΔCwp84 morphology compared to 
WT cells using Gram stain, a range of microscopy techniques were employed to 
determine if the presentation of immature SlpA on the cell surface of CDΔCwp84 
affected cell surface ultra-structure.  
3.4.7.1 Cryo-SEM 
Freeze fracture cryo- SEM did not reveal any morphological differences between 24 
or 48 hr solid phase cultures of WT or CDΔCwp84 respectively, however did find 
that cells of CDΔCwp84 are surrounded by large amounts extracellular material 
consistent with increased cell lysis and inter-cell adhesion.  
 
Two layers were observed on the cell surface of both WT and CDΔCwp84, a smooth 
outer and an intermediate perforated layer. At present there are three known 
‘polymers’ on the C. difficile cell surface: A surface carbohydrate coat (Ganeshapillai 
et al. 2008), the S-layer (Takumi et al. 1992; Cerquetti et al. 2000) and the 
peptidoglycan. The smooth outer layer may be one of two things: a polysaccharide 
capsule as found by Ganeshapillai et al. (2008) or the S-layer. Capsules are found in 
other S-layer containing bacteria e.g. B. anthracis (Mesnage et al. 1998). However, 
any structural relationship between the putative capsule and the S-layer of C. 
difficile requires further investigation. The ability to dissociate the smooth outer 
layer in sheet like fragments, similar to that seen in Figure 3.3.19, and those found 
by Takumi et al. (1991), together with embedded sectioning data suggests that the 
smooth outer layer is the S-layer. Replica freeze fracture TEM of bacterial S-layers 
seldom reveals holes in S-layer arrays (Bahl et al. 1997) suggesting the likely 
identification of the periodically perforated layer as the peptidoglycan. No cryo-
SEM images of the peptidoglycan of Gram positive bacteria are available to confirm 
the predicted identification. The presence of pores in the peptidoglycan have been 
not previously described, casting doubt over this layers presumed identification, 
however these pores could be used to translocate S-layer subunits, for example, to 
and from the cell surface. 
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3.4.7.2 TEM 
TEM analysis of embedded sections suggests that the LMW SLP portion of SlpA 
presented on the cell surface of CDΔCwp84 cannot lock into a regular array, or only 
forms a rudimentary array. This data supports the proposed orientation of the S-
layer with the LMW SLP portion of SlpA outermost exposed to the environment 
linked, via a flexible (conserved cleavage) region, to the HMW SLP portion of SlpA, 
which can interact with the cell wall. However, TEM of CDΔCwp84 whole cells 
revealed that the Cwp84 mutant possesses a similar tetragonal lattice to that 
observed during freeze etching (Cerquetti et al. 2000), suggesting that immature 
SlpA is putatively able to pack on the cell surface. However, this interaction/packing 
may be temporary and easily disrupted or not ‘locked’ thus not affording the 
cellular, e.g. osmotic, protection afforded by an intact S-layer. 
 
The presence of the thick layer underneath the peptidoglycan in CDΔCwp84 (Figure 
3.3.21 B), compared to a very thin layer in WT cells, suggests that CDΔCwp84 is 
producing significantly more of this substance (presumed to be protein(s)) than the 
WT. The identification of this layer is unknown, but is likely to be as a result of 
(surface based) stress. It has been previously shown that environmental or chemical 
stresses change C. difficile surface protein expression (Deneve et al. 2008; Emerson 
et al. 2008) e.g. Cwp66 (Waligora et al. 2001), GroEL (Hennequin et al. 2001), 
putatively CD2767 and CD2797 (Dang et al. 2010). It is possible that the thickened 
layer (layer 3) is made up of surface protein species with N-terminal CWBDs e.g. 
CD2784 or Cwp66, as opposed to surface protein species with C-terminal CWBDS 
e.g. Cwp84 and SlpA. Moreover, an intriguing hypothesis is that this inner layer 
(layer 3) is made up of over-expressed, pre-peptidoglycan translocated SlpA which, 
coupled with an inability to lock SlpA on the cell surface, may be lost to the culture 
supernatant. Immunogold labelling studies using anti-SlpA antibodies may assist in 
testing this hypothesis. 
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3.4.7.3 AFM 
AFM examination of 8 M urea extracted SLPs revealed that both WT and CDΔCwp84 
SLPs formed raised plaque regions, putatively S-layer lattices, similar to those 
described by Chung et al. (2010). The hexagonal array of WT SLPs in AFM was 
significantly larger than the hexagonal array observed by Cerquetti et al. (2000) 
(using negative stained 8 M urea SLPs in TEM). Most significantly, the array formed 
by CDΔCwp84 SLPs displayed a completely different structure to the WT, and 
significantly larger than that observed in vivo on whole CDΔCwp84 cells (~10 nm).  
These data suggest 8 M urea extracts of CDΔCwp84 SLPs form a different array in 
vitro than C. difficile 630ΔErm SLPs. 
 
Due to the limitations of AFM, it is impossible to infer which face of the putative S-
layer array is being imaged. Cerquetti et al. (2000) suggests the in vitro/in vivo 
difference in S-layer arrangement is based on surface location, whereby in vitro, the 
large HMW subunit masks the thinner outer LMW subunit. The hexagonally packed 
intermediate (HPI) layer of Deinococcus radiodurans adsorbs strongly to freshly 
cleaved mica with the hydrophilic outer surface attached to the substrate, while the 
hydrophobic inner surface is exposed to the stylus (Muller et al. 1996). Given the 
proposed end-to-end structure of the HMW/LMW SLP complex (Fagan et al. 2009) 
the HMW may present itself as the uppermost surface, with the LMW attached to 
the substrate. The resulting array cannot be formed by CDΔcwp84 SLPs, suggesting 
that the immaturity of SlpA affects the ability of the S-layer to self-crystallise/self-
assemble in vitro. Moreover, in order for CDΔcwp84 SLPs to form the tetragonal 
array, calcium was required in the wash buffer. The reason for this requirement is 
unknown but may be related to the ability of a mature S-layer array to retain 
chelated calcium required for array formation. Immature SlpA is unable to retain 
the calcium, thus for any array formation to occur calcium must be provided in the 
imaging buffer.  
 
SLPs derived from glycine extracts from either WT or CDΔcwp84 did not appear to 
form an array that could be detected by AFM, which together with data suggesting 
that ultra-purification of the SLP subunits affects their ability to re-crystallise 
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(Takumi et al. 1991; Cerquetti et al. 2000), suggests an element(s) extracted in 8 M 
urea SLPs is necessary for array formation in vitro. However, H/L complex 
formation, a non-covalent interaction between the HMW and LMW SLPs, occurs 
regardless of this unknown (urea extractable) element and is calcium independent 
(Fagan et al. 2009). 
 
3.4.8 Recombinant Cwp84 
Cwp84 has been previously cloned and expressed in E. coli as both a GST-tag fusion 
(full and N-terminal cysteine protease domain) (Savariau-Lacomme et al. 2003; 
Janoir et al. 2004) and a full length His-tagged version (Janoir et al. 2007). 
 
The key features of recombinant Cwp84 expression and purification from previous 
publications are therefore: 
 
 A propensity to aggregate and form inclusion bodies 
 Instability of protein and/or in its degrading abilities 
 Expression of only the N-terminal cysteine protease domain may/may not 
have the same degrading activities as the full length enzyme 
 Mature rCwp84 is approximately 61 kDa after ‘automaturation’ by 
incubation with DTT 
 Cleavage of substrates can be inhibited by 100 µM E64 (cysteine protease 
inhibitor) and only occurs in reducing conditions 
3.4.8.1 Expression of recombinant Cwp84 
Expression of full length rCwp84 with a His6-tag following Janoir et al.’s (2007) 
methodology expressed primarily insoluble. However, upon reducing the 
expression temperature to 16 °C, a soluble 58 kDa protein, presumed to be 
truncated rCwp84, with some enzymatic activity was purified.  
 
The truncation may indicate that the cytoplasm of E. coli provides a sufficient 
reducing environment for rCwp84 to automature or E. coli proteases can cleave 
rCwp84 into a truncated form, which may or may not have been ‘mature’. Prior 
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truncation, either by (auto)maturation or proteolysis, could explain the lack of 
affect of DTT on purified fractions of the 58 kDa rCwp84. Truncation i.e. removal of 
the CWBD(s) during expression in E. coli appeared to significantly decrease inclusion 
body formation and/or ease purification. However, the same 58 kDa species was 
purified regardless of N- or C-terminal His6 tag creating uncertainty as to which end 
rCwp84 was being truncated from. The inclusion of other tags, e.g. NusA or GST, at 
the N-terminus of rCwp84 did not resolve truncation whereas material produced by 
in vitro transcription and translation, to avoid potential E. coli truncation, was found 
as an 84 kDa species.  
 
Removal of the CWBD and expression of just the cysteine protease domain 
(rCwp8433-497) was, as expected, more soluble due to decreased aggregation. N-
terminal tag(s) of rCwp8433-497 were removed indicating a similar auto-maturation 
or E. coli maturation/proteolysis seen for full length rCwp84. However, the size 
difference between putatively mature Cwp8433-497 and immature Cwp8433-497 is 
more consistent with the predicted MW loss upon removal of the cysteine protease 
pro-region (from 52 kDa to ~42 kDa) (Section 3.3.10). Together this data suggests 
that during recombinant expression of Cwp84, the protein may be truncated more 
than is estimated to be removed during (auto)maturation i.e. removal of the pro-
region. 
3.4.8.2 Cleavage of SlpA in CDΔcwp84 SLPs with recombinant Cwp84 
SlpA in CDΔcwp84 SLPs did not appear to be cleaved into LMW and HMW SLPs, as 
seen for trypsin, with recombinant Cwp84. There are a number of explanations for 
this lack of cleavage: 
 
 SlpA in CDΔcwp84 SLPs is presented differently in vitro 
 rCwp84 is presented differently in vitro 
 Combination of the two above. 
 rCwp84 was not correctly folded/matured 
 Trypsin is unique in its ability to access the site of cleavage 
 Combination of all above points 
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It is likely that a combination of the above points explain the lack of SlpA cleavage 
by the rCwp84 produced in this study. It is interesting to note that Dang et al. 
(2010) co-expressed full length Cwp84, rather than just the cysteine protease 
domain, to confirm Cwp84 mediated cleavage of SlpA. This suggests the CWBDs of 
Cwp84 may be required spatial co-ordination between SlpA:Cwp84. Moreover, as 
only the conserved region of SlpA was expressed this may suggest that Cwp84 
mediated cleavage of full length SlpA cannot be replicated in vitro.  
 
The recombinant forms of Cwp84 produced in this chapter were able to cleave SlpA 
but not at the correct cleavage site and with poor efficiency (compared to other 
proteases tested on SlpA) but were inhibited by E64, suggesting cleavage was 
cysteine protease dependant activity. It is unknown which specific conditions in 
vitro e.g. pH, presence of divalent cations, detergents (Krupa & Mort 2000) or the 
presence of reducing environment, affect cleavage (or lack thereof).  
 
Cwp84 is likely to be a highly efficient enzyme as culture medium supplemented 
with 1 mg/ml trypsin shows that 50% of SlpA remained uncleaved. Unfortunately, 
due to the amounts of recombinant Cwp84 produced, cell surface based cleavage 
of SlpA by recombinant Cwp84 was not determined. It is possible that surface 
exposed SlpA, is both accessible and oriented such that rCwp84, or other cysteine 
proteases e.g. papain, can cleave SlpA yielding WT–like SLPs. 
3.4.9 Maturation of Cwp84 
Janoir et al. (2007) suggests that recombinant Cwp84 produced in E. coli should 
‘self-mature’ i.e. remove the proregion activating the cysteine protease, to give a 
61 kDa protein in vitro upon exposure to DTT. However, both full length (putatively 
gylcosylated) 85 kDa and the 61 kDa versions are found on the cell surface.  
 
The active cysteine at 116 aa in Cwp84 leaves only a maximum of 12 kDa (including 
signal peptide) that could be lost from the N-terminus before removal of C116. The 
proregion of papain is 107 aa (approximately 14.5 kDa) (Vernet et al. 1991; Vernet 
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et al. 1995). It is likely then, that the loss of 23 kDa (84 kDa to 62 kDa, as suggested 
by Janoir et al. (2007) means recombinant Cwp84 is not the same as the active form 
of Cwp84 found in vivo. 
 
Intramolecular processing is found in a range of other cysteine proteases for 
example, after removal of the N-terminal pro-protein clostripain requires the 
autolytic removal of an internal nonapeptide to produce a (heavy and light chain) 
heterodimer (Dargatz et al. 1993). Furthermore, gingipains (C25 family cysteine 
protease) undergo a complex scheme resulting in a non-covalent multidomain, 
multifunctional complex anchored into the outer membrane by a glycated, C-
terminal heamaglutanin/adhesin domain (Potempa et al. 2003).  
3.4.10 Cwp84:SlpA hypotheses 
3.4.10.1 SlpA:Cwp84 genetic control  
slpA and cwp84 are upregulated during exposure to sub-MIC levels of antibiotics 
(Deneve et al. 2009a). This co-ordinated upregulation, particularly of cwp84, 
highlights how during stress the bacterium acts to increase the structural 
consistency of the protective S-layer and/or change its surface composition. The 
decreased cell integrity of CDΔCwp84 may also result in upregulation of slpA, 
similar to exposure to oxygen or other detrimental environmental stimulus (Deneve 
et al. 2008; Emerson et al. 2008).  
 
S-layer mRNA stability is thought to be high at around 11-22minutes (Chu et al. 
1993; Bahl et al. 1997; Kahala et al. 1997) (compared to other prokaryotic 
transcripts half-lives of minutes even seconds). It is therefore likely that C. difficile 
slpA mRNA retains this long half-life feature i.e. minimal upregulation required to 
increase protein levels. The higher upregulation of cwp84 may suggest a short half-
life for cwp84 mRNA. In Thermus thermophilus HB, SlpA (100 kDa main S-layer) and 
SlpM (52kDa alternative S-layer like protein) is controlled via a regulated circuit 
involving SlpA which regulates its own expression (and SlpM), together with SlrA 
which acts as a repressor, and SlpM as an activator (Fernandez-Herrero et al. 1997). 
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Does the apparently co-ordinated expression of slpA:cwp84 therefore point to a 
regulatory mechanism? For example cwp84 or Cwp84 directly regulating slpA or 
slpA/SlpA regulating its own expression, deregulated by Cwp84 inhibition.  
 
Control of Cwp84 could occur via the action of its pro-peptide attenuating already 
active Cwp84, or acting on alternative pathways (Maubach et al. 1997; Yamamoto 
et al. 2002; Burden et al. 2008). Control of SlpA cleavage, potentially slpA 
transcription itself, may be performed by up or down regulating cwp84 
transcription and translation (and activation). As Dang et al. (2010) suggests 
expression of slpA is increased in response to chemical inhibition of Cwp84, an 
interesting extension to Dang et al. (2010)’s work could be investigating the 
inhibition of Cwp84 by its own propeptide and its effect on slpA expression.  
3.4.10.2 Cwp84 mediated cleavage of SlpA 
There are two possibilities regarding the maturation of the SlpA by Cwp84 in C. 
difficile : 
 Direct cleavage I- Cwp84 alone matures SlpA 
 Direct cleavage II– Cwp84 cleaves SlpA but requires co-factors 
 Indirect cleavage - Knockout or inhibition of Cwp84 prevents something else 
cleaving SlpA, or prevents SlpA from being cleaved by something else. 
 
The data presented in this chapter, and the work of Dang et al. (2010) provides 
convincing evidence that Cwp84 alone matures SlpA.  
 
However, Dang et al. (2010) demonstrated cleavage of an SlpA fragment but not 
cleavage of the full SlpA precursor. The co-purification of Cwp66, CD2797 and 
CD2767 (Dang et al. 2010) suggests other proteins may be involved in with S-layer 
biogenesis, including its cleavage. Perhaps, SlpA is cleaved by Cwp84 but is then 
bound (non-covalently) to the underlying cell wall e.g. peptidoglycan or SWCP, by 
these ‘accessory’ proteins. S-layers with SLH domains are non-covalently anchored 
to the cell surface via a conserved mechanism involving wall polysaccharide 
pyruvylation (Mesnage et al. 2000). The highly conserved, positively charged N-
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terminal region of the Geobacillus stearothermophilus S-layer protein, SbsC (which 
like the C. difficile S-layer does not have SLH domain(s)) binds to a SCWP of 
negatively charged N-acetyl glucosamine, glucose, and 2,3-dideoxy-diacetamido 
mannosamine uronic acid in the molar ratio of 1:1:2 (Pavkov et al. 2008). 
Furthermore, the N-terminus of the Bacillus stearothermophilus PV72/p2 S-layer 
binds to a SCWP incorporated into the peptidoglycan (Ries et al. 1997). The 
possibility of a SCWP removable by urea, and not glycine (low pH), adds credence to 
the argument that urea SLP extracts contain an element allowing correct/full S-
layer self assembly in vitro as demonstrated by AFM. However, the large amounts 
of SWCP that would be required, up to 20% of the cell surface (Ries et al. 1997), 
have not been found to date in C. difficile. Although, C. difficile has been shown to 
express two highly complex cell-surface teichoic-acid-like polysaccharides (PS-I and 
PS-II), one was composed of a branched pentaglycosyl phosphate repeating unit 
and the other was composed of a hexaglycosyl phosphate repeating units 
(Ganeshapillai et al. 2008).  
 
It is therefore more likely, that Cwp84 cleaves SlpA but correct S-layer lattice 
assembly may be assisted by co-factors. 
3.4.10.3 Other roles for Cwp84 
A direct role for Cwp84 as a colonisation factor through the digestion of 
extracellular matrixes has been proposed. While the findings in this chapter are not 
inconsistent with Cwp84 having additional roles involved in matrix degradation, 
they do demonstrate that the enzyme is not essential for CDI in the animal model 
which could be due to redundancy of function within the surface-associated 
components.  
3.4.10.4 Location of Cwp84 and location of cleavage.  
Convincing evidence suggests that Cwp84 cleaves SlpA, however where on/in the 
cell (envelope) does this cleavage occur? 
 
Immature SlpA found on the surface in CDΔCwp84 lacks its signal peptide, signal 
peptidase cleavage therefore precedes cleavage into SLP subunits i.e. post 
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translocation across the plasma membrane. The S-layer of Haloferax volcanii is also 
post-translationally modified following translocation across the plasma membrane 
(Eichler 2001). Cleavage of the S-layer in C. difficile is likely either underneath, 
amongst or on top of the peptidoglycan (in the S-layer) (or a combination of all 
three).  
 
During early work on the S-layers of C. thermohydrosulfuricum and C. 
thermosaccharolyticum, a surplus of S-layer subunits was observed in the region 
between the cytoplasmic membrane and the cell wall (Sleytr & Glauert 1976). 
Furthermore, Breitwieser et al. (1992) suggests an additional S-layer on the inner 
surface of the peptidoglycan and goes on to suggest that this profile is 
characteristic for cell wall preparations of many S-layer-carrying Gram-positive 
bacteria. It is possible then that the location of the CWBD (at the N- or C-terminus) 
determines the arrangement of proteins beyond the cell membrane, potentially 
either side of the peptidoglycan. The location of the CWBDs in SlpA and Cwp84 
would present both in a similar manner on the cell surface. It is also likely that 
Cwp84 is activated at or near the point of cleavage, as activation before that may 
result in unwanted proteolysis. The insertion sites of new SlpA precursor would be 
the most obvious locus for Cwp84 (and Cwp84 mediated cleavage).  
3.4.11 Conclusion 
Cwp84 is a surface located cysteine protease which matures the S-layer of C. 
difficile. Cleavage of the S-layer is not a pre-requisite for virulence and inhibition of 
S-layer cleavage may induce putative stress responses increasing toxin production. 
Based on the data presented, targeting Cwp84 to decrease S-layer integrity may 
allow other pharmacological treatments. However, the inadvertent changes in cell 
metabolism to counteract surface based changes are unlikely to decrease CDI 
pathology and may cause increased mucosal damage. Therefore, inhibition of S-
layer biosynthesis may not be an immediate route for therapeutic investigation. 
Adhesion to the gut mucosa or prevention of spore formation to prevent spread 
and potentially relapse may be other surface based alternatives. 
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4 CHAPTER 4 – Immunotherapy of C. difficile 
4.1 Introduction 
4.1.1 C. difficile treatment- current options 
The current treatment for C. difficile infection (CDI), beyond removal of the 
offending broad-spectrum antibiotic, is the administration of metronidazole then, if 
unsuccessful, treatment with vancomycin. 
 
Vancomycin is particularly suitable as a gastrointestinal antibiotic as it is completely 
restricted to the colonic lumen i.e. not absorbed, and found at levels more than 100 
times higher than the highest minimum inhibitory concentration reported (Bartlett 
2008a). However, Vancomycin has several problems, the first is the cost 
(approximately £120 for a 10-14 day course, 125 mg given orally four times daily) 
and secondly vancomycin promotes faecal colonisation with vancomycin-resistant 
enterococci (Gerding 1997; Al-Nassir et al. 2008). However, the rates of relapse for 
both vancomycin and metronidazole are approximately 15%–25% (Bartlett 2008a). 
Antibiotics thus cause and treat CDI, however treatment failure means some 
patients suffer repeated rounds of CDI (aka relapses) (McFarland 2005). Relapse (or 
recurrence) is likely to result from either continued exposure to C. difficile spores 
from the environment (healthcare or domestic) or from an endogenous source 
(Pepin et al. 2006).  
 
Therefore, there is a need to develop new therapeutic strategies which both cure 
the initial CDI episode and prevent relapses. A range of ‘new’ antibiotics is being 
evaluated to treat CDI, each with its own set of advantages and disadvantages 
(Bartlett 2009; Gerding & Johnson 2010). Interest in non-antibiotic therapies has 
increased as they are likely to leave the protective gut flora intact (or allow it to 
recover) (Borriello 1990), a facet likely to be key in decreasing relapses. Non-
antibiotic therapies fall into two categories based on preventing or treating 
different parts of the CDI infection cycle:  
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 Competitive inhibition- by re-establishment (or re-insertion) of the normal 
colonic flora (Bakken 2009), insertion of inhibitory species (Tung et al. 2009) 
or insertion of non-toxinogenic C. difficile (Borriello & Barclay 1985).  
 Preventing damage caused by the C. difficile toxins- using chemicals or 
resins to bind the toxin e.g. Tolevamer (Weiss 2009) or by neutralisation of 
the toxicity e.g. using immunoglobulin (O'Horo & Safdar 2009).  
4.1.2 The immune system and C. difficile infection 
A large majority of the population have circulating antibodies to C. difficile toxins 
(Viscidi et al. 1983) making detection and/or discrimination of any CDI induced 
specific antibody responses (serum or mucosal) difficult. Furthermore, the extent of 
and the protective nature of any generated immune responses is debated due to a 
lack of understanding in the pathogenesis of CDI. In particular, which of the C. 
difficile toxins are required for disease (Lyras et al. 2009; Kuehne et al. 2010) and 
thus to which toxin(s) an immune response is generated, what kind of response is 
generated (in terms of antibody type) and whether these responses (or a lack of) 
are protective. Collectively, data appears to suggest that progression of CDI is 
connected with humoral immune deficiencies in response to C. difficile infection 
(Aronsson et al. 1985; Warny et al. 1994; Johnson 1997; Kyne et al. 2000; Kyne et 
al. 2001; Katchar et al. 2007) (Summarised in Figure 4.1.1).  
 
CDI is also characterised by induction of an inflammatory cascade resulting in 
damage from severe inflammation. The extreme inflammatory reaction is thought 
to be derived from C. difficile toxin activation of cell mediated immunity causing 
release of pro-inflammatory cytokines including interleukin-8 (IL-8), IL-1β and TNF-α 
(Pothoulakis et al. 1988; Linevsky et al. 1997; Ng et al. 2010). 
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Figure 4.1.1 Development of C. difficile infection. Figure adapted from Wilcox & Minton 
(2001). *C. difficile may be acquired without flora disruption.  
 
Taken together, if one can increase the systemic humoral immune response- 
protection from direct toxin or inflammatory damage, may be possible i.e. a 
mucosal response may not be necessary. This proposal is supported by Giannasca et 
al. (1999), who found that a protective response in hamsters, afforded by high 
levels of toxin neutralising antibodies in the serum, was only obtained with rectal 
and intramuscular immunisation of C. difficile toxin toxoids and not by other 
mucosal routes. 
4.1.2.1 C. difficile toxin immunotherapy 
C. difficile immunotherapy seeks to increase the immune response via active or 
passive immunisation and given that the toxins alone can replicate many hallmarks 
of CDI (Borriello & Barclay 1985), the toxins represent a key target for vaccine 
development. Active vaccination using toxoids of toxins A or B is attractive and has 
proven to be successful in limited trials (Kotloff et al. 2001; Aboudola et al. 2003; 
Sougioultzis et al. 2005) but the ability of immunocompromised patients to respond 
remains a key unanswered question.  
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Early studies suggested that colostrum was able to neutralise C. difficile toxins, thus 
providing (passive) protection to neonates of which a high proportion are colonised 
with C. difficile (Wada et al. 1980; Kim et al. 1984). Work by Giannasca et al. (1999) 
also found passively administered antibodies, to toxoids of toxins A and B, were 
protective in the hamster model. Since then, a number of studies have assessed the 
protective effects of in vitro administered immunoglobulin (IVIG) in humans, to one 
or both C. difficile toxins (Leung et al. 1991; Lyerly et al. 1991; Salcedo et al. 1997; 
Wilcox 2004; Juang et al. 2007) although limited trial sizes, no set dose ranges and 
mixed results means further research is required (O'Horo & Safdar 2009; Abougergi 
et al. 2010). To date, full protection appears to only be provided with an anti-toxin 
A and B preparation (Kink & Williams 1998; Babcock et al. 2006; Lowy et al. 2010) 
confounding the role of each toxin in CDI.  
 
Antibodies (naturally raised or administered) to toxins do not appear to have any 
effect on colonisation, as C. difficile can be cultured from asymptomatic carriers 
(who have a protective immune response) (Shim et al. 1998; Sanchez-Hurtado et al. 
2008). Moreover, the increased antibody response to C. difficile toxins seen by Kyne 
et al. (2000) in asymptomatic individuals, occurred after colonisation.  
4.1.3 The role of C. difficile surface proteins and their associated 
immune responses in CDI 
The surface proteins of C. difficile are likely to play a key role in colonisation and 
subsequent infection, as a result the surface proteins of C. difficile are potential 
targets for immune attack, in particular the S-layer as the major surface antigen of 
the bacterium. Due to their significant surface coverage and key role in 
adhesion/colonisation, S-layers often undergo antigenic variation via gene 
duplication, switching and recombination events, to try evade the immune 
response e.g. Campylobacter fetus varies the expression of its SLPs via genomic 
rearrangements of S-layer genes in vivo during infection (Sara & Sleytr 2000; 
Thompson 2002). Despite this variation, S-layers induce immune responses, as 
serum from infected patients often reacts with extracted S-layers (Janda et al. 
1994). Moreover, the serum IgG response to Bacteroides forsythus S-layer appears 
to be lower in healthy controls than in cases with adult and early-onset 
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periodontitis (Yoneda et al. 2003), suggesting that an inability to mount a sufficient 
immune response to surface based antigens may be associated with disease 
progression.  
 
Upon blotting surface extracts of C. difficile with CDI patient serum, Pantosti et al. 
(1989) demonstrated that C. difficile non-toxin proteins elicited an immune 
response, specifically the proteins of the S-layer and its constituents. As expected, 
based on surface coverage, the majority of the humoral antibody response appears 
to be directed to the main S-layer (Drudy et al. 2004; Wright et al. 2008). However, 
other ‘minor’ uncharacterised proteins are also capable of generating an immune 
response in the same number of patients as the SLPs, particularly the 
uncharacterised S-layer paralog CD2791 (Cwp2) (Wright et al. 2008). As with many 
proteins certain regions of C. difficile surface proteins appear better epitopes than 
others, for example, the C-terminal region of the putative heat shock adhesin 
Cwp66 raises a greater response than the N-terminal (CWBD) region (Pechine et al. 
2005a; Pechine et al. 2005b). Antibody responses to Cwp66, the flagella core and 
cap (FliC and FliD) and a fibronectin binding protein (Fbp68) also appeared to be 
greater in controls than CDI cases, suggesting an immune response to surface 
proteins, other than the S-layer, could play a role in a host defence mechanism 
(Pechine et al. 2005a). Rectal immunisation using a formalin killed whole-cell 
preparation (which would have contained all the ‘normal’ in vitro vegetative cell 
surface proteins) in conjunction with toxoid culture filtrate appeared to be able to 
induce an, albeit non-protective, immune response (Torres et al. 1995).  
4.1.3.1 Immuno-modulation of S-layer proteins 
C. difficile surface proteins, like its toxins, putatively have the ability to modify the 
immune system beyond creation of an antibody response. Ni Eidhin et al. (2008) 
suggested that the S-layer of C. difficile may divert the immune response in favour 
of a co-administered antigen (a feature utilised in the generation of vaccines by 
genetic fusion of antigens with S-layer proteins e.g. the major birch pollen allergen 
Bet v 1 fused with the S-layer from Geobacillus stearothermophilus ATCC 12980 
(Gerstmayr et al. 2007) or avian flu nucleoprotein on Bacillus thuringiensis S-layer 
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(Liu et al. 2008b)). In support of this hypothesis, Sanchez-Hurtado & Poxton (2008) 
found that C. difficile SLP extracts appeared to increase the toxicity of toxin A when 
administered to Vero and Caco2 cells in vitro, while Brun et al. (2008) found the 
LMW SLP displayed adjuvant-like properties to a co-administered antigen in mice 
immunised via the mucosal intranasal or subcutaneous route.  
 
Another hypothesis is that C. difficile SLPs are able to induce the release of elevated 
amounts of IL-1β and IL-6 pro-inflammatory cytokines by resting monocytes, similar 
to those induced by LPS from E. coli (Ausiello et al. 2006), a result similar to the 
modulation of dendritic cells and T cell function by the S-layer of Lactobacillus 
acidophilus NCFM, as demonstrated by S-layer knockout (Konstantinov et al. 2008). 
Although recent research by Sekot et al. (2011), found that an S-layer negative 
strain of Tannerella forsythia caused significantly higher levels of pro-inflammatory 
IL-1β, TNF-α, and IL-8 compared with wild-type, suggesting the S-layer may even 
provide an immune evasive function. The immune responses of CDI patients to 
surface proteins, yet their apparently non-protective nature, could point to a C. 
difficile (surface based) immune evasion system i.e. generation of high titre but 
non-protective antibodies or that the patients themselves cannot raise an 
adequate, protective (anti-surface protein) immune response.  
4.1.3.2 C. difficile surface protein immunotherapy 
To assess if an immune response to C. difficile surface proteins provides any 
protective effects against CDI, several studies have investigated active and passive 
immunisation of hamsters and the ability of immune response(s) to specific surface 
protein(s) to decrease C. difficile CDI and colonisation. 
 
The ability of an S-layer extract to elicit a protective immune response by active 
immunisation was investigated by Ni Eidhin et al. (2008) using C. difficile R13537 
(Ribotype 001). Purified LMW & HMW SLP were able to elicit a good immune serum 
IgG response particularly when administered at >25 µg with alum intraperitoneally 
(i.p.) in hamsters, although, this response was non-protective. Moreover, SLPs 
administered with Ribi (monophosphoryl lipid A and synthetic trehalose 
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dicorynomycolate), with or without Cholera toxin, did not appear to protect 
challenged hamsters or display any correlation with antibody responses.  
 
Active immunisation with specific surface proteins (rather than a purified S-layer 
extract) appeared to be able to decrease colonisation > 6 days post challenge with 
C. difficile 79–685 in the mouse model (Pechine et al. 2007). In particular, rectal 
administration of encapsulated recombinant flagella cap protein (FliD) in 
combination with a flagella preparation or recombinant Cwp84 (plus cholera toxin), 
although variable, appeared to decrease colonisation statistically significantly more 
than PBS over time. Moreover, a rectally administered cell wall extract (produced 
by vortexing vegetative cells with glass beads) was particularly successful at 
decreasing colonisation from day 13, suggesting a multivalent surface protein 
preparation may be the most successful at CDI prevention. Assessment of 
immunisation route suggested that the rectal administration was deemed to be 
most effective at generating a serum IgG and mucosal IgA (from intestinal lavage), 
while serum IgG was highest from subcutaneous immunisation. Which of the 
immunoglobulin species provided colonisation resistance or the extent of any 
disease progression was not alluded to, but perhaps highlights the differences 
between hamster (time-to-death) and (chronic) mouse models (Chen et al. 2008).  
 
Passively administered anti-SLP antibodies appeared to extend the survival of 
hamsters challenged with C. difficile R13537 (ribotype 001) (clindamycin resistant) 
vegetative cells (pre-incubated with the aforementioned antiserum). Whereby, 
orogastrically anti-SLP antibodies administered 7 hr before challenge then 6, 17 and 
24 hr after challenge, ultimately failed to protect hamsters which still developed 
diarrhoea within 2-5 days post challenge and eventually died (O'Brien et al. 2005). 
Although, O’ Brien et al. (2005) suggested that anti-SLP antibodies exert their 
protective effect by increasing phagocytosis of C. difficile cells, as demonstrated in 
differentiated THP-1 monocytes. 
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The surface proteins of C. difficile are thus able to generate an immune response 
which may decrease colonisation and prevent (or prolong survival) CDI in the 
hamster model.  
 
The aim of this study was therefore to investigate the surface proteins of the C. 
difficile Stoke Mandeville (R20291) ‘hypervirulent’ ribotype 027 strain, in particular 
to examine if passively administered high titre anti-SLP antibodies were able to 
prevent CDI in the hamster model. Presented here are data suggesting that the SLPs 
of the 027 ribotype are largely conserved and while anti-SLP antibodies prevent 
binding to cell lines, they do not prevent CDI when administered systemically and 
thus their usefulness in a clinical setting maybe limited. 
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4.2 Chapter 4 specific methods 
4.2.1 C. difficile SLP extract Toxin A contamination ELISA 
C. difficile R20291 and VPI10463 SLP extracts were assayed by sandwich ELISA as 
described in General Methods section 2.7.1.  
4.2.2 Polyclonal anti-SLP serum production 
4.2.2.1 Small scale in guinea pigs 
C. difficile R20291 and VPI10463 SLP extracts (20 µg diluted in 50 mM HEPES plus 
0.15 M NaCl pH 7.4) were administered, with Titremax Gold™ adjuvant, 
subcutaneously. Initial immunisation was followed by 2 further boosts at 
approximately 6 and 10 weeks. Guinea pigs had test bleeds at 7 weeks and were 
fully bled at 11 weeks.  
4.2.2.2 Large scale production in sheep 
C. difficile R20291 and ARL001 SLP extracts (100 µg diluted in PBS) were 
administered, with Freund's incomplete adjuvant, subcutaneously. Initial 
immunisation was followed by 3 further boosts at approximately 4, 8 and 12 weeks. 
Sheep were bled at week 14.  
4.2.2.3 Anti-SLP serum titre estimation 
Serum titres were estimated by indirect ELISA based on Drudy et al. (2004) except 
using 10 µg/ml C. difficile SLP extract, PBS/T plus 5% foetal calf serum as blocking 
buffer and appropriate anti-species HRP antibody (diluted to 1:2000 with blocking 
buffer). 
4.2.2.4 Large scale purification of anti- R20291 SLP IgG  
Ovine polyclonal anti-SLP antibodies were purified from sheep serum using an 
adapted caprylic acid precipitation method (Steinbuch & Audran 1969) (Abdulla, I., 
personal communication (MicroPharm Ltd.)). Serum was diluted to twice volume 
with 0.9%w/v sodium chloride followed by addition of caprylic acid (octanoic acid) 
to a final concentration of 2% w/w. The mixture was then stirred vigorously for 
30 min, left to stand for further 60 min, then centrifuged at 3488 g for 60 min. The 
supernatant was then collected, filtered through 0.45 µm filter and dialysed against 
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50 mM HEPES plus 0.15 M NaCl pH 7.4. Antibodies were then concentrated to 
~50 mg/ml (A280) using a 10 kDa MWCO Vivapsin 20 spin concentrator and filtered 
through 0.2 µm filter and stored at 2-8 °C (short term) or at -20 °C (long term). 
 
4.2.3 Immunofluorescent binding of anti-SLP antibodies to C. 
difficile  
Purified guinea pig anti-R20291 SLP IgG was labelled with Alexa Fluor® 488 dye 
using the Alexa Fluor® 488 protein labeling kit (Molecular Probes, USA) and was 
then assessed for its binding to C. difficile cells. C. difficile whole cells at OD600 ~0.7, 
were harvested then re-suspended in PBS and 10 µl spread onto a glass slide. The 
cells briefly were stained with ethidium bromide (1:10,000 dilution in PBS) for 10-
15 sec, then rinsed with PBS to aid visualisation. Slides were then incubated with 
10 µg/ml Alexa 488 labelled guinea pig anti-SLP IgG for 30 min, followed by 
washing. 
For competition assay, slides were first blocked with 3% w/v BSA in PBS then 
incubated with unlabelled guinea pig anti-SLP IgG (100 µg/ml) for 1 hr, followed by 
incubation with labelled guinea pig anti-SLP IgG (10 µg/ml) for 30 min with a PBS 
rinse in between. All incubations were at room temperature at 100% relative 
humidity and all specimens were examined with 100x oil-immersion objective using 
a Nikon fluorescent microscope with the FITC filter.  
4.2.4 Bacti-ELISA 
Binding of anti-SLP IgG to C. difficile whole cells was analysed by indirect 
colorimetric ELISA based on Elder et al. (1982) and Prieto et al. (2003). 
Maxisorb microtitre plates (Nunc) were coated for 1 hr at 37 °C with 100 µl of 
washed stationary phase C. difficile cell suspension (approx. OD600 = 1.4) or 
10 µg/ml SLPs (positive control) diluted in PBS. Plates were blocked with 3% BSA in 
PBS/T (blocking buffer) for 1 hr at 37 °C, followed by washing. Plate(s) were then 
incubated for 1 hr at 37 °C with 100 µg/ml guinea pig anti-SLP IgG or 1:100 dilution 
of C. difficile toxin B2 fragment antiserum (to assess C. difficile’s generic IgG binding 
ability). After washing, plates were incubated with goat anti-guinea pig IgG HRP 
conjugate (Sigma) (1:2000) for 1 hr at 37 °C. The plate(s) were washed a final time 
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and developed with TMB substrate and TMB stop solution then read at 450 nm 
using a Tecan™ Sunrise microtitre plate reader. All washes were performed 3 times 
with PBS/T. 
4.2.5 Sequencing of slpA from a range of 027 strains 
slpA was amplified using primers from Qazi et al. (2009) using stationary phase C. 
difficile gDNA extracted (as per General Methods Section 2.1.11) from the following 
C. difficile strains (Table 4.2.1): 
 
Table 4.2.1 C. difficile PCR ribotype 027 strains used in this chapter 
Code Isolation 
location 
Approximate  
Isolation date 
KCH#2 9706 Kings College 
Hosp isolate 
Feb 2006 
918186A Poole 27/9/07 
918692B Southampton 
(1) 
3/11/07 
918341E Medway 6/9/07 
918737F Eastbourne 19/10/07 
918380U Portsmouth 4/10/07 
918443W Crawley 4/7/07 
CDRNE 027 
Reference 
strain 
 from EQA panel 
distributed 
12/07 
R20291 027 Anaerobe 
reference 
laboratory (ARL) 
027 –Stoke 
Mandeville 
isolate. 
All 027 strains were a kind gift from Steve Green (HPA Regional Office, 
Southampton) 
 
4.2.6 Adhesion assay 
The in vitro adhesion assay was developed by L. Blandford. Caco-2 cells were 
seeded into 8 well Lab-TekTM chamber slides at a 1:2 dilution in MEME (approx 5.69 
x 104 cells/well) for 14 days prior to the assay to ensure full differentiation. 18 hr C. 
difficile culture was harvested by centrifugation then washed twice with an equal 
volume of Dulbecco’s phosphate buffered saline (DPBS), before re-suspension in 
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MEME ± ovine anti-R20291 SLP IgG (in 50 mM HEPES 0.15 M NaCl pH 7.4) or ovine 
anti-R20291 crude spore serum. Caco-2 cells in chamber slides were washed twice 
with 0.4 ml per well of DPBS before addition of 0.4 ml of bacterial suspension to 
each well. Slides were incubated for 2 hr 20 min at 37 °C in anaerobic conditions 
followed by washing three times with DPBS. Slides were then fixed with methanol 
at -20 °C for 5-10 minutes and stained with Giemsa stain (Sigma, Poole, UK) diluted 
with Wright-Giemsa stain phosphate buffer pH 6.8 (Park Scientific Ltd, 
Northampton, UK) before microscopic observation at x1000 magnification using an 
oil immersion lens. Enumeration was performed using a single-blind experimental 
design. 
4.2.7 Passive immunisation of hamsters with anti-SLP antibodies 
Syrian hamsters (80-100 g) were housed (2 per cage) in isolator cages, fitted with 
air filters on lids to minimise contamination between groups. Groups of 24 
hamsters were divided into two ‘Test’ subgroups of 10 and a ‘Control’ subgroup of 
4 animals. All 24 hamsters were weighed and administered clindamycin (2 mg in 0.4 
ml sterile H2O) by the orogastric route on Day 0. In the morning of Day 4, hamsters 
in both ‘Test’ subgroups were challenged with 2.0 x 105 colony forming units of C. 
difficile spores in 0.4 ml DMEM, given orogastically. In the afternoon of Day 4, 1 ml 
of purified ovine anti- C. difficile R20291 SLP IgG (approx 500 mg/kg) was 
administered intraperitoneally. On days 7 and 10, 1 ml of purified sheep anti- C. 
difficile R20291 SLP IgG was administered intraperitoneally as before. All animals 
were weighed daily and monitored 6 times/day, up to Day 24, for disease 
symptoms which included: diarrhoea, weight loss, lethargy and tender abdomen 
(Sambol et al. 2001; Babcock et al. 2006). Hamsters were scored on a 0-3 scale for 
disease symptoms, animals in advanced stages of disease or became immobile 
were euthanised. 
 
  
147 
4.3 Results 
4.3.1 Extraction of surface layer proteins from a range of C. difficile 
strains 
It has previously been suggested that the surface of epidemic (hypervirulent) 
strain(s) of C. difficile may differ from that of non-hypervirulent strains resulting in 
increased adherence to human intestinal epithelial cells (Cartman et al. 2010). To 
investigate this, the low pH extracted surface proteins of the putatively 
‘hypervirulent’ ribotype 027 were compared to high toxin producer VPI10463, low 
toxin producer 630 (although using the erythromycin resistant mutant described in 
Hussain et al. (2005)) and the clinically relevant 001 ribotype (Brazier 1998; Cheknis 
et al. 2009). 
 
For all C. difficile strains analysed, there are two main (S-layer) bands which vary 
between strains, except for VPI10463 and ARL001 (See Table 4.3.1). 
 
Table 4.3.1 Variation of the main S-layer bands of various C. difficile strains as measured 
by 1D SDS-PAGE. 
Strain LMW SLP (kDa) HMW SLP (kDa) 
R20291 40 50 
630ΔErm 40 47 
VPI10463 39 49 
ARL001 39 49 
 
Protein bands >50 kDa vary in intensity amongst the strains tested. A consistent 
band at 66 kDa is seen in all strains, while the extract of C. difficile 630ΔErm 
contains a further band at 120 kDa not visible in other extracts (Figure 4.3.1). 
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Figure 4.3.1 Comparison of SLP extracts from 
hypervirulent R20291 with C. difficile 630ΔErm, 
VPI10463 and ARL001 by 1D SDS-PAGE. 
 
 
Bands at 120 kDa, 84 kDa, 66 kDa and 22 kDa in the SLPs of C. difficile 630ΔErm 
were putatively identified in other sections of this thesis as the following: 
 120 kDa band identified as the C-terminal 120 kDa mature fragment of cell 
surface protein (putative haemagglutinin/adhesin) CwpV (CD0514) - 
predicted MW of 160 kDa (Emerson et al. 2009a) (Chapter 3 Section 3.3.4.1) 
 84 kDa band- putatively the band identified as the S-layer precursor protein 
SlpA (slpA (cd2793) - predicted MW of 76.1 kDa (Chapter 3 Section 3.3.4) 
 66 kDa band - identified as the cell surface protein (putative S-layer protein 
precursor) CD2791 a.k.a. Cwp2 (cd2791) - predicted MW of 66.4 kDa 
(Chapter 5 Section 5.3.3.3). 
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 22 kDa band – identified by N-terminal sequencing (MNLKGT) as rubrerythrin 
(energy production and conversion protein) - predicted MW of 20.5 kDa.  
 
Multiple additional bands below the two main S-layer bands are seen and display a 
degree of strain variation (Figure 4.3.1). Interestingly, an SLP extract from 24 hr 
culture C. difficile VPI10463 extracted only the LMW S-layer and not both SLP 
species, supporting the proposed spatial arrangement with the LMW S-layer 
outermost and thus easier to extract. 
 
There may be protein differences in the 027 ribotype SLPs (R20291 reference strain 
in this study) compared to other C. difficile strain surface extracts, however due to 
the insufficient resolving power of 1D SDS-PAGE this study cannot comment on 
such differences. There does, however, appear to be visible differences between 
the high (VPI10463) and low (630) toxin producers, the visible presence of a 
120 kDa (CwpV) species in 630 and low MW (<35 kDa) fragmentation pattern. 
 
4.3.2 Sequencing of slpA from a range of 027 Strains 
The entire S-layer precursor gene slpA (cd2793) was amplified from gDNA extracted 
from a range of regional C. difficile 027 ribotype isolates and sequenced to ascertain 
any sequence variability or conserved domains within the ‘epidemic’ 027 ribotype. 
The slpA gene sequence of the nine isolates was 100% identical. Given the proposal 
of using slpA sequencing as a typing system (Karjalainen et al. 2002; Kato et al. 
2005; Kato et al. 2009), a high degree of similarity is to be expected. This indicates 
that certainly for regional isolates, the largest surface antigen (main S-layer) is 
exactly the same.  
 
BLAST searches of the following published C. difficile 027 ribotype genome 
sequences, revealed that slpA of R20291, 196, 855 and QCD-32g58 are 100% 
identical with each other, and 100% identical with the slpA sequences obtained 
from the 027 ribotype isolates in this study. slpA of C. difficile strain BI1 differs by 
one base pair (GA 1811 bp) resulting in a P156L change. 
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 R20291 a.k.a. SM (Stoke Mandeville) UK, 2006 
 196 - France, 1985 
 BI1 - USA, 1988 
 855 - USA, 2007 
 QCD-32g58 Quebec -Canada, 2005 
 
A highly conserved S-layer amongst the 027 ribotype could suggest that it is a highly 
evolved gene i.e. is more adherent or is less available to immune recognition, and 
therefore worth preserving.  
 
4.3.2.1 In silico analysis of other cell wall binding domain containing 
surface protein genes in 027 ribotype 
In addition to the main S-layer SlpA, the 28 other genes containing the cell wall 
binding domain (CWBD) (Sebaihia et al. 2006) were also assessed for intra 027 
ribotype variation. 
 
The R20291 sequence (used as a 027 ribotype reference sequence) and 196 (and by 
assumption 855, BI1 and QCD-32g58) lack a region of genes between cd2517A - 
cd2520. Thus, the selected 027 ribotype sequences, and by assumption all 027 
ribotype sequences lack the surface protein CD2518, found in this region. Analysis 
upstream of cd2518 in 630 reveals an integrase (cd2519) suggesting that C. difficile 
630 may have acquired cd2518 via an insertion or gene duplication event. 
 
A total of 23 of the 27 remaining CWBD containing gene sequences had >98% 
identity between C. difficile 630 and R20291, four surface proteins did not: 
  
 CD2794 which contains three N-terminal CWBD repeats, a bacterial Ig-like 
domain (Pfam07523) and a SCP-like extracellular protein domain  
o 95.9% identity.  
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 SlpA (CD2793) – main S-layer - which contains three C-terminal CWBD 
repeats  
o 71.7% identity 
 Cwp66 (CD2789) - which contains three N-terminal CWBD repeats  
o 86.2% identity. 
 CwpV (CD0514) – which contains three N-terminal CWBD repeats and a C-
terminal variable tandem repeat region (Emerson et al. 2009b)  
o 74.6% identity. 
  
Comparision of the 27 CWBD containing proteins genes between R20291, 196, BI1 
and QCD-32g58 genomes reveals 25 are 100% identical, while CD3192 and CwpV 
are not.  
 
The cd3192 gene (CDR20291_3048) shares 100% identity between R20291 and 196 
and BI1, however the BLAST result of strain QCD-32g58 found only 1182 bp of the 
full length (1653 bp) CD3192 gene (100% identical up to the truncation). This 
truncation could result in a foreshortened protein of 393 aa rather than 550 aa, 
resulting in the loss of one (or two) of the PepSY (Pfam03413) domains. CD3192 
contains three N-terminal CWBD repeats and two (or three (using InterProScan)) C-
terminal peptidase propeptide (PepSY) domains. PepSY domain(s) show homology 
to the metalloprotease propeptide region and are thought to regulate proteolytic 
activity, including those which are surface associated (Yeats et al. 2004). No gene 
was found to match CD3192 in C. difficile strain 855. 
 
CwpV (CD0514, CDR20291_0440) appears to be truncated by 79 aa (approximately 
one R20291 CwpV repeat unit) in C. difficile BI1 as a result of a stop introduced at 
3274 bp. CwpV in 630 is approximately 495 aa longer than CwpV in R20291, as such 
a large protein (CwpV) may be a target for the immune system, a reduction in size 
could therefore provide an selective advantage. 
 
Taken together these data suggest the surface proteins of the 027 ribotype are 
highly conserved. The conservation of the majority of the CWBD containing proteins 
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suggests a high degree of selective pressure, and may indicated that these ‘minor’ 
CWBD containing species, i.e. not slpA, may play a larger role in cell physiology or 
pathogenesis than previously estimated. 
4.3.3 Polyclonal anti- SLP antibody production and analysis 
(investigational and large scale) 
C. difficile surface proteins, particularly the HMW S-layer subunit, have been 
previously shown to bind to gastrointestinal tissues and to the ECM proteins 
collagen I, thrombospondin, and vitronectin (Calabi et al. 2002). Furthermore, a 
number of other putative surface proteins have been shown to be involved in 
adhesion (Hennequin et al. 2001; Tasteyre et al. 2001a; Hennequin et al. 2003). 
 
These data, together with the conservation of the CWBD containing surface 
proteins, suggest the surface proteins represent a strong vaccine candidate for 
targeting C. difficile colonisation and that adhesion and colonisation is probably 
multifaceted. This study sought to determine if high titre anti-surface protein 
immunotherapy could prevent CDI caused by an epidemic ribotype 027 strain in the 
hamster model. 
 
To develop anti-SLP serum for passive immunisation experiments, crude SLP 
extracts were first used to raise guinea pig, then after characterisation, ovine 
polyclonal hyperimmune serum. By using crude low pH surface protein extracts, the 
multifaceted adhesion of C. difficile is partially addressed. 
 
A total of three C. difficile strains (two ribotypes) were used for antigen production: 
C. difficile R20291 Stoke Mandeville epidemic strain (Ribotype 027) and VPI10463- 
high toxin producer (investigational scale) and ARL001 (large scale) strains 
representing the previous pre-2008 clinically significant 001 ribotype. Prior to 
immunisation, an assessment was made as to the toxicity of SLPs on Vero cells with 
either contaminating biologically active C. difficile toxin(s) or other harmful protein 
components which may have a significant effect on the a) population of antibodies 
generated b) animal wellbeing during immunisation. No toxicity was observed for 
crude SLP extracts permitting antiserum production to commence. 
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4.3.3.1 Characterisation of the guinea pig (investigational scale) anti- 
C. difficile SLP immune response. 
Using solid-phase SLPs in ELISA, both strains anti-SLP antiserum demonstrated that 
a strong immune response was obtained (titre >105 dilution) (individually R20291 1 
x 106, VPI10463 5 x 105) (Figure 4.3.2). 
 
 
Figure 4.3.2 Guinea pig anti-SLP serum titre ELISA. Four guinea pigs were 
immunised with 20µg crude low pH SLP extract from C. difficile VPI10463 or 
R20291 strains. 
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In order to determine which of the specific SLPs the guinea pig antiserum was 
binding to in ELISA, immunoblots were performed using purified antibodies.  
 
Figure 4.3.3 shows anti-R20291 SLP IgG detected the main S-layer bands of the 
originating strain, while cross reaction of 630ΔErm and both VPI10463 and ARL001 
showed a marked preference for detection of the HMW SLP and a lesser response 
to the LMW.  
 
Anti-VPI10463 SLP serum detected both the SLP subunits in the originating strain 
and of ARL001, while cross reacted with R20291 SLPs with similar intensity to the 
cross reactivity of anti-R20291 with VPI10463 SLPs i.e. main HMW, lesser LMW 
response. Only the HMW SLP of 630ΔErm cross reacted with anti-VPI10463 SLP IgG, 
consistent with previous reports and indicating sufficient divergence of SlpA 
(Takeoka et al. 1991; Calabi et al. 2001). Both anti-R20291 and anti-VPI10463 SLP 
IgG detected a 66 kDa band in all SLPs tested and two additional species at 
approximately 84 and 90 kDa in R20291, VPI and ARL001 SLPs.  
 
The reaction of the other species in immunoblots suggests that other protein 
species in SLP extracts are capable of generating an immune response. 
Interestingly, anti-SLP IgG did not react a significant number of protein species 
<35 kDa, suggesting that these proteins are either not immunogenic or are not 
presented to the immune system in native SLPs. 
 
slpA of VPI10463, ARL001 and R20291 was sequenced to examine the cross 
reactivity of guinea pig anti-SLP antibodies. slpA of R20291 and VPI10463 share 
92.0% identity at base pair level and 89.3% at amino acid level, sufficiently high for 
immune cross reactivity. VPI10463 and ARL001 are 100% identical at base pair level. 
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Figure 4.3.3 Immunological cross-reactivity of SLPs from a range of C. difficile strains using guinea pig anti-SLP IgG. Low pH SLPs from strains 
R20291, 630ΔErm, VPI10463 and ARL001 (centre lanes) were blotted with 1 µg/ml guinea pig anti-SLP IgG raised against SLPs from R20291 
(left) or VPI10463 (right). Arrows highlight a 66 kDa species detected using all anti-SLP serum. 
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Binding of anti-SLP antibodies to vegetative cells is key in establishing if anti-SLP 
antibodies can be used immunotherapeutically. Thus, guinea pig anti-R20291 SLP 
antibodies were fluorescently labelled, then their binding to vegetative cells 
examined by fluorescent microscopy. Anti-R20291 SLP antibodies (100 µg/ml) 
bound to vegetative cells; however, their binding did not decrease upon pre-
incubation of cells with 100x concentration of unlabelled antibodies, suggesting 
that the binding sites for the antibodies are present at a high concentration on the 
cell surface.  
 
To quantify antibody binding to vegetative cells, whole cell suspensions and SLP 
extracts (positive control) were assayed by (bacti-) ELISA, whereby bacterial cells 
were immobilised on solid phase followed by normal ELISA protocols.  
 
Anti-VPI10463 SLP IgG bound to VPI10463 and R20291 SLPs to the same extent, but 
to 630ΔErm SLPs and 630ΔErm and R20291 vegetative cells approximately 1-log less 
(Figure 4.3.4A). Anti-VPI10463 SLP IgG appeared to give a poor response to 
VPI10463 vegetative cells. Anti-R20291 SLP IgG bound to R20291 and VPI10463 
SLPs with similar affinity, binding to 630ΔErm SLPs and R20291 vegetative cells was 
approximately 1-log less, while binding to 630ΔErm cells was a further log less. Anti-
R20291 SLP IgG also bound poorly to VPI10463 vegetative cells (Figure 4.3.4B). No 
binding was obtained when using C. difficile toxin B fragment antiserum. 
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Figure 4.3.4 Cross reactivity of guinea pig anti-SLP IgG to SLP and whole cells of different C. difficile strains measured by ELISA. (A) Reaction of anti-R20291 
SLP IgG and (B) Reaction of anti-VPI10463 SLP IgG to low pH SLPs (solid lines) and whole cell preparations (dashed lines). 
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4.3.3.2 Characterisation of ovine (Large scale) anti-SLP antibody 
response 
Taken together, these data suggest that a good high titre antibody response can be 
generated to crude low pH surface protein extracts of C. difficile. The antibodies 
generated appear to be specific to certain SLPs but bound to vegetative cells. 
Responses to vegetative cells were good in the corresponding strain but are 
approximately 1-log less in a differing ribotype, where the predominantly the HMW 
SLP cross-reacts e.g. anti-VPI10463 SLP IgG on 630ΔErm cells. Due to the amount of 
anti-SLP IgG required to assess the efficacy of anti-SLP antibodies in vivo i.e. passive 
immunisation studies (10 hamsters given three 1 ml doses of 50 mg/ml anti-SLP IgG 
(~1.5 g IgG), large scale antiserum production was necessary. 
 
Large scale ovine anti-SLP serum was generated to two C. difficile ribotypes, the 027 
ribotype (strain R20291) and the clinically prevalent 001 ribotype (Cheknis et al. 
2009; Bauer et al. 2011) (using the Aerobe Reference Laboratory reference 001 
ribotype strain, ARL001) rather than the high toxin producing strain VPI10463 
(Merrigan et al. 2010). The slpA gene of C. difficile ARL001 strain is 100% identical 
with VPI10463, thus results from investigational analysis using VPI10463 SLPs 
should be transferable. However, analysis of the SLPs of both strains reveals subtle 
differences (Figure 4.3.1) which may decrease transferable results and/or highlight 
how although slpA is identical, the SLPs of VPI10463 and ARL001 differ.  
 
As previously, using solid-phase SLPs in ELISA, both strains anti-SLP antisera 
demonstrated that a strong immune response was obtained, however only slightly 
better than guinea pigs (titres: R20291 1 x 106, ARL001 1 x 106) possibly indicating a 
limit of immune response had been reached with the crude SLP preparation (Figure 
4.3.5). 
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Figure 4.3.5 Ovine anti-SLP serum titre ELISA. Three sheep were immunised with each 
antigen. 
 
Figure 4.3.6 (α-027) shows that ovine anti-R20291 SLP antiserum detects a pattern 
of proteins in SLPs similar to guinea pig anti-R20291 SLP IgG. The HMW and LMW 
SLPs cross reacted between R20291 and VPI10463, however there was a preference 
for the HMW SLP of ARL001 and, consistent with previous data, only the HMW of C. 
difficile 630ΔErm SLPs was detected. As with guinea pig antibodiesa 66 kDa species 
gave a good immune reaction in all strains tested including C. difficile 630ΔErm. 
Ovine anti-R20291 also appeared to detect an 84 kDa species in all SLP extracts 
examined.  
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Figure 4.3.6 Immunological cross-reactivity of SLPs from a range of C. difficile strains using ovine anti-SLP IgG. Low pH SLPs from strains R20291 (027), 
630ΔErm, VPI10463 and ARL001 (centre lanes) were blotted with 1 µg/ml ovine anti-SLP IgG raised against SLPs from R20291 (left) or ARL001 (right). 
Arrows highlight a 66 kDa species detected using all anti-SLP serum. 
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Ovine anti-ARL001 serum detected both the HMW and LMW SLP in all extracts 
tested, although with a preference for HMW SLP detection of differing ribotype. 
Similar to ovine anti-R20291 SLP, ovine anti-ARL001 reacted with bands at 66 kDa 
and 84 kDa. A 115 kDa species was detected with ovine anti-001 in the C. difficile 
630ΔErm SLP extract, despite this protein not being visible in ARL001 SLP extracts. 
(Figure 4.3.6, α-001) 
 
The above data supports investigational scale antiserum production analysis, that S-
layer extracts can generate a good, high titre, specific immune response. There is 
also compelling evidence which suggests other ‘minor’ species also present in SLP 
extracts are also good at generating an immune response e.g. the 66 kDa species, 
which are capable of cross ribotype reaction where others e.g. LMW SLP, are not. 
4.3.4 Prevention of binding of C. difficile cells in a cell adhesion 
assay  
Antibodies raised to low pH SLP extracts of C. difficile recognise and bind to 
vegetative cells in vitro. In order to determine if anti-SLP antibodies were able to 
prevent the adhesion of C. difficile to gut epithelial cells, an in vitro adhesion assay 
with Caco2 cells was used.  
 
Ovine anti-R20291 (027) SLP IgG significantly inhibited C. difficile R20291 binding at 
all concentrations assessed (Students T-test, p<0.001). However, Anti-R20291 SLP 
IgG, while reducing adhesion of C. difficile 630ΔErm, the difference was not 
significant compared to control (Students T-test, p=0.09) (Figure 4.3.7A) suggesting 
that anti-SLP antibodies preferentially prevent binding of their cognate strain but 
are less effective against a differing strain. 
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Figure 4.3.7 Inhibition of C. difficile binding to Caco-2 cells, by (A) ovine anti-R20291 SLP 
purified IgG and (B) ovine anti-R20291 crude spore prep serum. 
 
a Mean numbers of C. difficile organisms adhering to a cell (± standard error). 
*
Mean from all assays in which anti-R20291 SLP IgG was used against C. difficile 630ΔErm (Mean 
Adhesiona = 0.68±0.18, mean adhesion plus anti-R20291 SLP IgG 0.33±0.06, n=7) 
Measurements made by random field of view counts of a total of >150 Caco-2 cells vs bacterial cells 
at x1000 magnification, each adhesion assay was conducted in duplicate. 
 
 
By comparison, use of an ovine antiserum raised against a C. difficile R20291 crude 
spore preparation, which included spores and vegetative cells, significantly 
inhibited binding of C. difficile R20291 (027), VPI10463 and 630ΔErm to Caco-2 cells 
(Students T-test p<0.05 for R20291, VPI10463 and 630ΔErm) (Table 4.3.2A). Non-
specific antiserum (raised to E. coli OmpA), used at the same concentration, did not 
significantly prevent binding of 630 to Caco-2 (Students T-test p= 0.6411) (Table 
4.3.2B). 
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Table 4.3.2 Inhibition of various C. difficile strains binding to Caco-2 cells by ovine anti-crude spore 
serum.  
A 
Strain Adhesiona Adhesiona + anti- spore 
serum 
% decrease in 
adherence 
R20291 0.66 ± 0.07 0.06 ± 0.02 90.9 ±3% 
VPI10463 1.03 ± 0.11 0.53 ± 0.08 48.5 ±8% 
630ΔErm 0.44 ± 0.06 0.11 ± 0.02 
 
75.0 ±5% 
B 
Strain Adhesiona Adhesiona + anti- 
spore serum 
Adhesiona + anti- 
OmpA serum 
630ΔErm 1.13 ± 0.10 0.29 ± 0.04 1.20 ± 0.11 
 
a
Mean numbers of C. difficile organisms adhering to a cell (± standard error). 
Measurements made by random field of view counts of a total of >150 Caco-2 cells vs 
bacterial cells at x1000 magnification, each adhesion assay was conducted in 
duplicate. 
 
As with anti-SLP antibodies, crude spore serum inhibited binding most when used 
against the corresponding strain (Table 4.3.2 A) and appeared to significantly inhibit 
adhesion at a dilution >1:8 (Figure 4.3.7B).  
 
The numbers of bacteria adhering to cells (approximately 0.5 bacteria/cell) was 
consistent with that found for both the growth medium used (BHI) and cell line 
tested (Karjalainen et al. 1994).  
 
Together, these data suggest that antibodies raised to proteins present in low pH 
SLP extracts can prevent binding in vitro; however antibodies raised to a crude 
spore-vegetative cell preparation containing other antigen(s) further decreases 
adhesion of C. difficile to caco-2 cells. Furthermore, serum raised to SLPs of one C. 
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difficile strain are effective in inhibiting adhesion in another, although is most 
effective upon the strain from which the SLPs were derived. 
4.3.5 Passive immunisation of hamsters challenged with C. difficile  
To date, only one study has been performed assessing the ability of anti-SLP 
antibodies to prevent CDI (caused by a ribotype 001 strain (C. difficile R13537) in 
the hamster model (O'Brien et al. 2005). The study found although hamsters 
succumbed to disease, time-to-death was significantly longer in the antibody group. 
As a result of this study and data presented in this chapter, the ability of passively 
administered systemic anti-SLP antibodies to the epidemic strain R20291 (027 
ribotype) were assessed for their ability to prevent CDI in the hamster model. In an 
initial experiment, where hamsters were challenged with 2 x 102 cfu/ml C. difficile 
R20291 spores, animals did not succumb to CDI. The experiment was therefore 
repeated with 2 x 105 cfu/ml C. difficile R20291 spores, together with an increased 
time from clindamycin to challenge, as R20291 is clindamycin sensitive. 
 
Figure 4.3.8 shows that hamsters immunised intraperitoneally with three doses 
(500 mg/kg) of ovine anti-R20291 SLP IgG, succumbed to CDI at a similar rate to un-
immunised animals. The data suggests that systemically administered anti- C. 
difficile surface protein extract IgG does not protect against CDI caused by the C. 
difficile R20291 (027 ribotype) strain.  
4.3.6 Summary 
In summary, low pH surface protein extracts of C. difficile are capable of inducing an 
immune response. This response is specific to certain protein species in SLP extracts 
but nevertheless recognises whole cells and prevents adhesion to cell lines in vitro. 
The conservation of surface proteins within the 027 ribotype, coupled with the 
identification of a conserved protein in C. difficile SLP extracts recognised by any 
strain’s anti-serum, provides evidence of stable surface based antigens with 
(immuno)therapeutic potential. However, passively administered high titre 
antibodies to surface based antigens were not capable of preventing CDI in the 
hamster model, bringing into question the ability of these antigens to protect 
against CDI. 
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Figure 4.3.8 Ability of passively administered ovine anti-R20291 SLP IgG to prevent CDI in 
hamsters. 2 test groups of 10 animals were challenged with 2 x 105 cfu/ml C. difficile 
R20291 (027 Ribotype). Animals in 1 test group were administered 500 mg/kg of anti-
R20291 SLP IgG on day of challenge and 3 and 6 days later. Data show time from 
challenge to severe disease/death in the hamster model for CDI.  
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4.4 Discussion 
C. difficile infection is primarily a toxin mediated disease. As a result of an inability 
to mount an effective immune response, passive administration of antibodies 
appears to be able to neutralise the cytotoxic activity of the toxins (Babcock et al. 
2006; Demarest et al. 2010; Leav et al. 2010; Lowy et al. 2010) 
 
It appears that certain proteins on the surface of the bacterium can also elicit a 
systemic immune response in patients with CDI (Pantosti et al. 1989; Drudy et al. 
2004; Wright et al. 2008). Moreover, an immune response against selected surface 
proteins may prevent colonisation (Pechine et al. 2007), certainly antibodies against 
surface proteins can prevent their binding to HT-29 cells (Calabi et al. 2002). 
However, it is currently unclear as to whether an inability to respond to surface 
proteins predisposes CDI, or whether this highlights the patient’s own 
immunocompromised state e.g. immunosenescence and the need for a therapy to 
boost such responses. 
 
Once a facility is contaminated with C. difficile, infection occurs more readily 
(Bartlett 2008b). Therefore, there is a putative ‘colonisation window’ in which the 
spores germinate and vegetative cells colonise, then produce toxin. In vitro, toxin 
production only occurs once growth is well underway and cells reach stationary 
phase (Merrigan et al. 2010). Therefore, colonisation represents a key milestone in 
infection. The currently clinically most prevalent 027 ribotype putatively produces 
more spores which are thought to contribute heavily to its increased virulence 
(Akerlund et al. 2008; Merrigan et al. 2010). 
 
To date, there has only been a suggestion that the ‘hypervirulent’ ribotype 027 has 
an altered surface possibly increasing the ability to cause infection (Cartman et al. 
2010). This study sought to understand if there was any evidence of surface based 
differences between C. difficile strains e.g. the 027 ribotype and to assess anti-
surface protein immunotherapy against CDI caused by a 027 ribotype strain 
(R20291). This study suggests that a large majority of the surface proteins in 027 
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ribotype strains appear the same as non-epidemic strains. Furthermore, antibodies 
raised to the surface proteins of one strain can inhibit the adhesion of another, but 
are not protective against the cognate strain in the hamster model. 
4.4.1 Surface proteins of PCR ribotype 027 isolates 
4.4.1.1 Surface layer protein extraction and sequencing of slpA 
There appears to be some inconsistency with the molecular weights of the main 
SLPs observed in this chapter and those reported previously. The 001 ribotype S-
layer bands are expected at 34 kDa and 50 kDa (but found at 39 kDa and 49 kDa in 
this chapter) while 630 (ribotype 012) S-layer bands are expected at 33 kDa and 
47 kDa (but found at 40 and 47 kDa in this chapter) (Calabi & Fairweather 2002; 
Eidhin et al. 2006). Recently, SDS-PAGE analysis of S-layer bands of 027 ribotype 
strains were found to match their predicted MW (34 kDa and 44 kDa) (Spigaglia et 
al. 2011a). However, SLP extracts from C. difficile R20291 in this chapter found the 
LMW and HMW SLP bands at 40 kDa and 50 kDa respectively. Reasons for the 
migration differences are unknown, but likely to be due to differences in the SDS-
PAGE system, e.g. gel type and concentrations used.  
 
Eidhin et al. (2006) suggested that the sequence of slpA from different isolates of 
the same ribotype are all identical. The sequencing of slpA from the regional 027 
isolates in this chapter and work by Spigaglia et al. (2010; 2011a) confirms this. 
Both confirm how slpA sequencing is insufficient in discriminating one 027 isolate 
from another but appears to compliment PCR ribotyping. However, the 027 
ribotype although genetically highly uniform, can be divided into a number of 
different subtypes based on different typing methods e.g. DNA microarray or 
multilocus variable-number tandem-repeat analysis (MLVA) (Stabler et al. 2006; 
Killgore et al. 2008; Stabler et al. 2009; Tanner et al. 2010). However, the 
applicability of these techniques, in a clinical outbreak setting for example, may be 
limited. 
 
The 027 ribotype is reportedly a robust toxin producer (Merrigan et al. 2010), if 
therefore increased toxin production had a surface based determinant, one may 
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observe differential expression of surface proteins between a high and low toxin 
producer. In this chapter, the SLPs of 630ΔErm (low toxin producer) appeared little 
different to R20291 or VPI10463 (high toxin producer). The earlier toxin release of 
selected surface proteins knockout does, however, highlight how the bacterial 
surface and toxin production may be linked, especially in vivo.  
 
Therefore, to date, no specific cell surface based reason for hypervirulence has 
been suggested. The finding that 001 ribotype and 027 ribotype slpA sequences are 
similar (genetically and immunogenically (Spigaglia et al. 2011a; Spigaglia et al. 
2011b) and this work) suggests that these common CDI causing strains may have a 
unique surface particularly well adapted to colonisation. The genes encoding slpA 
and cwp84 are upregulated in response to various stresses (Deneve et al. 2008; 
Emerson et al. 2008; Deneve et al. 2009a) which may suggest a ‘shoring up’ of the 
cell surface in defence. Thus, there may be differences in gene expression, e.g. 
up/down regulation or recombination events with other slpA homologs, which 
occur in vivo, and result in an increase in surface based adhesion or virulence factor 
expression, particularly in hypervirulent strains. For example, the surface layer 
proteins (encoded on a 54 kbp chromosomal DNA locus “sap island”) of 
Campylobacter fetus undergo rearrangement to up‐regulate virulence, for antigenic 
variation and to enter a latent state (Tu et al. 2005).  
4.4.1.2 Other species present in surface protein extracts 
While the HMW and LMW SLPs undoubtedly play key roles in cell physiology and 
pathogenesis, the plethora of ‘minor’ hitherto uncharacterised proteins found on 
the cell surface (Wright et al. 2005) are likely to play key roles in pathogenesis such 
as cell signalling, matrix degradation and adherence.  
 
A 66 kDa protein, identified as CD2791 (aka Cwp2), is found in every surface protein 
extract to date, except in strain 167 (Calabi & Fairweather 2002). This protein is 
highly conserved and reacts with antibodies raised to any strains SLPs. CD2791, 
found during normal growth and discussed further in Chapter 5, is putatively part of 
a polycistronic transcript including the putative 66 kDa heat shock adhesin Cwp66 
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and an unknown ORF (CD2790) (Savariau-Lacomme et al. 2003). CD2791’s role in 
pathogenesis or cell physiology therefore warrants further investigation.  
 
An 84 kDa protein in SLP extracts, particularly in R20291, could be immature SlpA 
similar to that identified in Cwp84 KO SLPs (Kirby et al. 2009). The greater 
prominence of this band in R20291 could suggest slpA upregulation in R20291, a 
known response to bacterial stress (Deneve et al. 2008; Emerson et al. 2008; 
Deneve et al. 2009a). 
 
The extract of C. difficile 630ΔErm has a prominent 120 kDa band, identified as 
CwpV, not visible in the extracts of R20291 or VPI10463. The cwpV gene is under 
phase variable expression (Emerson et al. 2009b), thus a decrease in its expression, 
potentially in R20291, could indicate how it may be detrimental to have large 
amounts of CwpV presented on the cell surface. 
 
In summary, this study found no surface based reason for increased virulence in the 
027 ribotype using low pH SLP extraction. This may be due to no differences being 
present in hypervirulent strains, the severely limited methods used in this study or 
the necessary surface based determinants not being expressed in vitro or under the 
conditions used.  
4.4.1.3 In silico analysis of other cell wall binding domain containing 
surface protein genes in 027 ribotype  
Analysis of C. difficile 027 genomes has mainly centred on comparison of antibiotic 
resistance, genes related to survival and unsurprisingly toxin related genes (Stabler 
et al. 2009). However, little has been discussed regarding differences in the 28 
paralogs of slpA which contain a CWBD found in the genome of C. difficile 630 
(Sebaihia et al. 2006), amongst 027 isolates. 
 
Comparison of R20291 and 630 revealed that only three genes were found to be 
significantly different: slpA, cwp66 and cwpV. It is well documented that slpA is 
variable given its prominence on the cell surface and the need to overcome the 
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host immune response (Karjalainen et al. 2001; Calabi & Fairweather 2002; Eidhin 
et al. 2006). Reasons behind the variability of cwp66 is less well understood, but is 
thought to be as a result of gene clustering with slpA whereby both undergo 
recombinational events and/or strong environmental selective pressure (Lemee et 
al. 2005). Results by Waligora et al. (2001), and particularly results in Chapter 5, are 
in support of cwp66 being under selective pressure because Cwp66 is an adhesin. 
CwpV, as aforementioned, is a large phase variable multi-tandem repeat containing 
protein. Its function and reason for variability are unknown but it may be involved 
in detachment from the host or bacteria-bacteria interactions (Emerson et al. 
2009b). The differing size of cwpV amongst C. difficile strains may suggest it also is 
under selective pressure. 
 
A key question is perhaps, why are there so many CWBD containing proteins with 
no apparent function in the C. difficile genome? The S-layer of Campylobacter fetus 
has one promoter but a number of S-layer genes which undergo genetic 
rearrangement (Thompson 2002; Grogono-Thomas et al. 2003). It is interesting to 
speculate that slpA of C. difficile has undergone an evolutional progression similar 
to the C. fetus sapA gene. In that initially one S-layer gene may have been present, 
however successive tandem duplications and positive selection for SLP antigenic 
variation resulted in a range of S-layer like genes, a pool of SLP genes from which 
rearrangement could occur.  
 
In summary, the most prominent result from 027 slpA paralog analyses is the 100% 
similarity of the majority of the genes in R20291, BI1, QCD34g-58 and 885. The 
conservation of the CWBD genes of C. difficile ribotype 027 strains suggests 
genetically every 027 has the same cell surface, although this hypothesis requires 
further investigation. However, if all strains during an epidemic have the same cell 
surface antigen(s) the prognosis for treatment via surface based, e.g. anti-
colonisation treatment is good.  
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4.4.2 Immunotherapy of C. difficile infection with polyclonal 
antibodies raised to cell surface proteins. 
Antibodies directed to C. difficile toxins are currently under development and 
appear to be able to prevent disease both in the hamster model (Kink & Williams 
1998; Babcock et al. 2006) and in limited clinical cases or clinical trials (Wilcox 2004; 
Koulaouzidis et al. 2008; Leav et al. 2010; Lowy et al. 2010), although much work is 
needed (Abougergi et al. 2010).  
 
Antibodies to the surface proteins of C. difficile are raised during CDI (Drudy et al. 
2004; Pechine et al. 2005b; Wright et al. 2008). However, there are limited studies 
regarding the protective nature of this immune response. Passive administration of 
anti-SLP antibodies prolonged the life of hamsters, while active immunisation using 
SLPs failed to induce a protective response (O'Brien et al. 2005; Ni Eidhin et al. 
2008). In mice, select surface proteins were successful in decreasing colonisation, 
but the protective effects, in terms of CDI development, of this decrease were not 
assessed (Pechine et al. 2007). Therefore, the ability of passively administered anti-
SLP antibodies to protect against CDI, in the hamster model, caused by the 
epidemic 027 ribotype was investigated.  
 
4.4.2.1 Characterisation of investigational scale ant-SLP antiserum 
Small mammals have been used to generate antiserum from both crude surface 
protein extracts and selected SLPs in a number of studies (Cerquetti et al. 1992; 
Calabi et al. 2001; O'Brien et al. 2005; Janoir et al. 2007). In this study, small 
mammals were used to generate investigational scale amounts of antiserum which 
enabled comprehensive analysis of titres, responses and toxicity of the crude SLP 
antigens. 
 
It appears that SLPs are not toxic to Vero cells, although elements of SLPs bind to 
and cleave extracellular matrix (ECM) proteins (Calabi et al. 2002; Janoir et al. 
2007). Therefore, data in this chapter supports Sanchez-Hurtado & Poxton (2008), 
who also found low pH SLPs to be non-toxic to Vero and Caco2 cells.  
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Due to differences in immunisation protocols and antiserum titre estimation 
method variation, comparison of titres obtained in this chapter with previous 
studies is difficult e.g. whole C. difficile cell agglutination (O'Brien et al. 2005) or Log 
OD405 (Ni Eidhin et al. 2008). Although, Ni Eidhin et al. (2008) also found that 
differences in immunisation protocols e.g. SLP dose, appear to do little to affect 
ultimate antibody titres, suggesting that once a maximal response is reached it 
cannot be increased. However, data in this chapter suggest that a high titre 
hyperimmune response to C. difficile SLPs (with an adjuvant) is possible and 
recognises vegetative cells.  
 
Purification of SLPs via HPLC appears to remove their ability to self-assemble 
(Takumi et al. 1991), thus an unknown co-factor (putatively present in urea based 
extracts) is suggested to be required for S-layer array assembly. This would be 
consistent with AFM data (Section 3.3.9.3) which suggested low pH SLPs do not self-
assemble on a Mica surface. It is unknown as to whether this ability to form arrays 
on surfaces in vitro affects the ability to generate (protective) immune responses. It 
is likely then, that it is the structure of the SLPs in solution (in vitro) which controls 
to what extent, to which specific SLP(s) an immune response is generated and 
whether the obtained immune response is protective or not.  
4.4.2.1.1 Cross reactivity of SLPs in investigational scale serum immunoblot 
Previous reports have suggested that only the HMW SLP cross reacts when blotted 
with antiserum generated from a differing strain (Takeoka et al. 1991; Calabi et al. 
2001). However, blots in this chapter revealed weak detection of the LMW SLP from 
a differing ribotype. Sequence analysis of slpA between R20291 and VPI10463 
revealed 92.0% identity, explaining the cross reactivity in western blot in this study. 
Cross reactivity between both HMW and LMW SLPs has been suggested by 
McCoubrey & Poxton (2001), who suggest cross reactivity occurs within the same 
‘serotype’. However, ribotype 001 (VPI10463 & ARL001) belongs to serogroup G 
whereas 027 is unclassified (Karjalainen et al. 2002). The high sequence identity 
(89.0% identity rather than 92.0% identity as found in this chapter) and 
immunological conservancy between 027 and 001 ribotypes has also been reported 
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by Spigaglia et al. (2010; 2011b), who suggest that surface based virulence 
determinants of these ribotypes may be linked.  
 
The 66 kDa CD2791 protein cross reacted with all strains antiserum, consistent with 
its high conservation at gene level (98.1% identity at DNA level between 630 and 
R20291). Analysis of patient serum found the majority of patients raised antibodies 
to CD2791 (aka Cwp2) (Wright et al. 2008). Moreover, ELISA data in Chapter 4 
Section 5.3.3.6 suggests that a significant proportion of the immune response to 
SLPs is to CD2791. CD2791 appears to be highly immunogenic and able to cross all 
strain barriers. The presence of a (hyperimmune) response to other ‘minor’ species 
in SLP extracts confirms that species other than the HMW and LMW SLP are capable 
of generating an immune response.  
 
The majority of the proteins with a molecular weight less than the LMW SLP in low 
pH SLP extracts appear to be fragments of the S-layer subunits (Wright et al. 2005), 
However, despite their prominence in SDS-PAGE, antiserum to SLPs raised in this 
chapter found that no immune response was generated to them, but these proteins 
appear to be immunoreactive against CDI patient sera (Wright et al. 2008). The 
later result would suggest that these fragments only become immunogenic as a 
result of CDI, rather than through the generation of hyperimmune serum with SLP 
extracts.  
4.4.2.1.2 Binding of anti-SLP to vegetative C. difficile cells. 
In order to quantify the binding of guinea pig anti-SLP antibodies to whole cells, 
rather than agglutination, an ELISA with immobilised cells was developed based on 
methods used for Streptococcus sanguis and Moraxella bovis (Elder et al. 1982; 
Prieto et al. 2003). The anti-SLP serum reacted approximately 1-log less with whole 
cells than to corresponding SLPs. The reduced binding to vegetative cells compared 
to SLPs may have several explanations: 
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 Spatial organisation of the SLPs. When using the corresponding strain, the 
LMW SLP could react. When using a different strain, only the underlying 
HMW could react, together with other cross reacting proteins e.g. CD2791. 
 The antiserum was raised to low pH extracted SLPs, which may not have the 
same structure as SLPs presented on the surface of the bacterium. 
 The type of bacterial culture used may have differentially expressed reacting 
SLPs. 
 Antibodies do not adhere to C. difficile cells as well as to protein (SLPs) 
coating the ELISA plate wells. 
 A lack of cells adhering to solid phase.  
 SLPs sloughing off the bacteria and sticking to plate giving the false 
impression of whole cell binding when only SLPs are present.  
 
Given the ability of anti-SLP antibodies to bind whole cells of different strains 
theoretically, with enough antibodies any strain anti-SLP antiserum could be used 
immunotherapeutically against any other strain.  
4.4.2.2 Characterisation of large scale anti-SLP antiserum  
Ovine polyclonal (polyvalent) antibodies are proven to be effective in the 
neutralisation of snake venom and have been widely used (Lavonas et al. 2009). 
Furthermore, sheep antibodies are well tolerated and have good stability in 
humans when administered passively (Landon et al. 1995). Ovine antiserum 
therefore represents a good immunotherapeutic option for the prevention of CDI.  
 
The ability of sheep to develop antibodies to low pH extracted SLPs appeared to be 
very similar to that of guinea pigs, both in terms of titre and specific protein species 
detected in immunoblot. This suggests that the ability of the SLPs to generate an 
immune response is similar in these two mammalian species.  
4.4.2.3 Prevention of binding of C. difficile to Caco-2 cell lines. 
Caco-2 cells have been used previously to determine both putative adhesion 
related proteins (Eveillard et al. 1993; Karjalainen et al. 1994; Cerquetti et al. 2002) 
and to identify specific adhesins in C. difficile e.g. Cwp66 (Waligora et al. 2001) and 
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GroEL (Hennequin et al. 2001). This study sought to identify if antibodies to surface 
protein extracts could prevent binding in vitro, thereby providing support for in vivo 
passive immunisation assessment. Results in this study suggest that anti-SLP 
antibodies prevent adhesion to caco-2 cells, whereby inhibition of C. difficile 
adhesion is best achieved with a corresponding strain antiserum. When a differing 
strain is used, binding inhibition is an order of magnitude less. Adhesion appears to 
be prevented most using antibodies raised to a whole cell and spore preparation 
rather than to just SLPs, indicating that either a) other factors present on the cell 
surface, e.g. carbohydrates, are involved in adhesion, or that b) the presentation of 
proteins (surface or otherwise) on the bacterium is different, resulting in a 
increased ability to prevent adhesion. In humans, IgM responses to EDTA surface 
extracts (which include carbohydrate elements) were more than double responses 
to low pH SLPs, suggesting an factor on the C. difficile surface , removable with 
EDTA, affects immune response (Sanchez-Hurtado et al. 2008).  
 
Any surface protein based immunotherapy should therefore ensure it is 
representative of surface based antigens expressed during CDI in vivo. 
Hyperimmune serum generated, particularly in this chapter, is thus heavily 
dependent on the state of the cells in vitro which may or may not be representative 
of the cells state in vivo during CDI. 
4.4.2.4 Passive immunisation of hamsters with anti-SLP 
As C. difficile surface proteins can induce an immune response and a mucosal 
immune response to toxins does not appear to be necessary for protection, 
passively administered (systemic) anti-SLP antibodies were assessed for their ability 
to protect hamsters against CDI caused by the ‘hypervirulent’ C. difficile R20291 
(027 ribotype) strain. Immunised hamsters developed CDI at the same rate as non 
immunised animals, suggesting passively administered systemic anti-SLP antibodies 
are non protective; explanations for the lack of protection are multi-factorial. 
 
Reports investigating the human serum antibody response to C. difficile surface 
based antigens struggle to find a significant difference between cases, carriers or 
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controls (Drudy et al. 2004; Pechine et al. 2005a; Sanchez-Hurtado et al. 2008), 
suggesting that a serum immune response (or lack of) to surface proteins is not 
connected with CDI progression i.e. CDI occurs regardless of a serum anti-surface 
protein immune response. Circulating IgG (to surface proteins) may therefore not 
be protective due to a lack of access to C. difficile vegetative cells prior to toxin 
mediated damage. Anti- C. difficile colonisation antibodies must therefore reach, 
bind and prevent colonisation before the toxins are produced. A proposed 
mechanism of antibody mediated toxin neutralisation is the leakage hypothesis i.e. 
toxins damage the gut such that circulating antibodies are released, or that the 
toxins cause damage to the mucosa, such that the toxins themselves then become 
exposed to circulating antibodies.  
 
Given that CDI is largely C. difficile toxin mediated, if gut damage has occurred (to 
allow circulating antibodies access to the gut) then anti-colonisation antibodies may 
be too late. However, an intestinal transport system has been proposed and may 
mediate translocation of IgG to the intestinal lumen (Yoshida et al. 2004) which 
would allow binding to C. difficile cells in the absence of epithelial damage. 
Furthermore, although secretory IgA (sIgA) is significantly less sensitive to 
proteolytic degradation by intestinal enzymes than IgG, some bacterial species 
produce anti-immunoglobulin proteases enzymes (Holmgren et al. 1992; Parsons et 
al. 2004). Thus, in this particular case, anti-SLP IgG may be degraded before 
inducing any protective effect. In summary, circulating IgG to C. difficile surface 
proteins may not reach the required location, at the correct time and in sufficient 
amounts to be able to prevent colonisation.  
 
Therefore, an approach to induce/increase the mucosal sIgA response may be more 
applicable to C. difficile surface based antigens and anti-colonisation 
immunotherapy. The importance of mucosal responses, (particularly) secretory IgA, 
has been proven in other gastrointestinal pathogens such as Cholera and E. coli 
(Corthesy & Spertini 1999; Neutra & Kozlowski 2006). Pechine et al. (2007), using 
rectal immunisation, induced a (putatively mucosal) response to a cell surface 
extract antigen which decreased colonisation. However, the ability of this 
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colonisation decrease to prevent CDI or toxin mediated damage was not discussed. 
This raises two key questions: To what percentage must colonisation be decreased 
before CDI is resolved (or prevented)? Can immunotherapy ever reach those levels?  
 
As discussed by Ni Eidhin et al. (2008), the non-protective nature of anti-SLP 
responses may be due to the severity of CDI in the hamster model as opposed to 
the mouse model. Unfortunately, no investigations were made into whether the 
anti-SLP IgG administered in this chapter, exerted an, albeit non-protective, anti- C. 
difficile colonisation effect. The sensitivity of the model may therefore not reflect 
the treatment efficacy, perhaps in mice (Chen et al. 2008) or in humans a lower 
bacterial load may be sufficient to resolve CDI.  
 
The differential presentation of antigens, is likely to affect to which protein(s) a 
response is generated and to what extent that response is protective. There are 
therefore two assumptions in this respect:  
 
Firstly, that low pH SLPs used for hyperimmune serum generation are 
representative of those presented in vivo, during CDI, and to which an immune 
response offers protection. However, Torres et al. (1995) found rectal immunisation 
with a whole cell preparation did not provide hamsters with protection, suggesting 
that even in the native confirmation, surface protein responses are likely to be non-
protective or that anti-surface protein systemic immune response(s) do not reach 
the gut in time, in high enough concentration. It is also possible that during CDI, 
different proteins play different roles but may still generate immune responses, for 
example, the type I pilus system of Aeromonas salmonicida contributes to host 
colonisation but not invasion (Dacanay et al. 2010). C. difficile may therefore divert 
the immune system by having highly reactive surface protein(s) which are not 
involved in CDI or establishing colonisation.  
 
Secondly, the assumption that the mechanism for measuring the immune response 
e.g. ELISA, is predictive of protection. Antibody ELISA titre and antibody quality i.e. 
the ability to prevent CDI, is not necessarily linked as toxin neutralising titres 
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correlate more closely with protection than ELISA titre (Torres et al. 1995; 
Giannasca et al. 1999). Therefore, anti-SLP antibody responses in this chapter 
appear to be ‘high-titre’ (as measured by ELISA), however there may be insufficient 
protective antibodies in the antibody preparation.  
 
Finally, the inability of anti-SLP IgG to protect against CDI in the hamster model may 
be due to the increased virulence of the C. difficile R20291 challenge strain used. 
Although an initial experiment failed to cause disease (suggesting decreased 
virulence), the pathology of CDI in hamsters is reported to be more severe with 
shorter time to death (48 hr) compared to the C. difficile 630 strain (102 hr) (Razaq 
et al. 2007; Goulding et al. 2009).  
 
4.4.3 Immunotherapeutic approaches of CDI using surface proteins 
as antigens- perspectives 
The treatment of C. difficile has sparked a number of different therapeutic regimes 
including toxin binding resins and a range of new antibiotics (Bartlett 2009). 
However, clinical trial failure, high costs and concerns for resistance may limit the 
use of these new treatments, hence immunisation (both passive and active) against 
C. difficile disease could represent viable therapeutic and preventative strategies 
for C. difficile infection (Koo et al. 2010). To date, the most successful immunisation 
(active or passive) strategies appears to be derived from toxoided forms of C. 
difficile toxins (Fernie et al. 1983; Kotloff et al. 2001; Sougioultzis et al. 2005). 
 
Data in support of proteins, other than the toxins, eliciting an immune response 
(Pantosti et al. 1989; Drudy et al. 2004; Wright et al. 2008) creates an opportunity 
to understand whether immunotherapeutic or vaccination strategies using surface 
proteins (individually or together) are feasible. For example, co-administration of 
four surface based antigens of S. aureus afforded high levels of protection against 
invasive disease or lethal challenge with human clinical S. aureus isolates in mice, 
yet only afforded partial protection when the same antigens were administered 
individually (Stranger-Jones et al. 2006). 
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The variability of patient populations has made determination of whether an 
immune response to surface proteins is protective, difficult, particularly given 
possible pre-exposure to C. difficile (Viscidi et al. 1983; Drudy et al. 2004; Sanchez-
Hurtado et al. 2008). Pantosti et al. (1989) suggested that a prolonged presence of 
C. difficile in the gut is required to elicit a strong antibody response to cell surface 
antigens, thus these antibodies are probably non-protective. It is also likely that 
immune sampling i.e. immuno-tolerance (Holmgren & Czerkinsky 2005) may 
prevent excessive reactions to C. difficile (surface proteins) as a transient inhibitor 
of the gut. 
 
Antibodies are protective against antigens derived from colonisation factor antigen 
I (CFA/I), an E. coli fimbriae subunit (Rudin et al. 1996), or against Bordetella 
colonisation factor A (BcfA) an outer membrane immunogenic protein (Sukumar et 
al. 2009), which supports the hypothesis that anti-surface protein vaccines can 
prevent disease. Moreover, a recent study by Jarchum et al. (2011) found that 
administration of a TLR5 agonist (Salmonella-derived flagellin), prevents CDI in the 
mouse model, supporting anti- C. difficile surface protein approaches. 
 
Passively administered antibodies to S-layers have been proven to partially protect 
mice against lethal challenge with Campylobacter fetus (Blaser & Pei 1993). 
Moreover, mice immunised with purified S-layer from Bacteroides forsythus then 
challenged with B. forsythus cells did not develop any abscesses (Sabet et al. 2003), 
which suggests that the immunisation with S-layer proteins can confer protection 
against subsequent infection. Although, both of these organisms do not produce 
toxins which replicate many aspects of the disease, as C. difficile toxins do (Borriello 
et al. 1988).  
 
The key to (passive) anti-colonisation immunisation may be in the treatment of 
relapse/recurrent patients, as patients post-CDI, pre-relapse, are likely to have un-
germinated spores in the GI tract. In vitro immunoglobulin (IVIG) against toxins has 
gained recognition in the treatment against relapse/recurrent CDI (Babcock et al. 
2006; Taylor et al. 2008; Leav et al. 2010). Anti-colonisation therapy would 
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therefore prevent germinated vegetative cell colonisation ‘resolving’ CDI before 
recurrence. However, anti-Spore preparations rather than anti vegetative cell 
preparations may be better suited to prevent relapses in a patient continually 
inhabited by un-germinated spores. Immunisation of rabbits with non-toxigenic 
Bacillus anthracis spores provides protection against toxigenic strains, moreover, 
passively administered anti-spore IgG protected mice from intraperitoneal 
challenge with a lethal dose of fully virulent B. anthracis (Enkhtuya et al. 2006). 
4.4.4 Conclusion 
The vast similarities of the surface proteins within the 027 ribotype suggest that, 
should a protective immune response be generated to one strain within the 
ribotype, protection should be provided against another. If anti- C. difficile 
colonisation immunotherapy is to be successful, a highly protective rather than just 
high-titre ELISA response must be obtained. Careful selection of proteins key to 
adhesion and colonisation, but not necessarily highly immunogenic, will be key in 
this respect, together with methods of antibody administration such that (passively 
administered) antibodies reach the gut at the optimal point in infection and in 
sufficient quantity. Furthermore, understanding how or more specifically when, 
toxins are produced in vivo during infection, will be key to establishing if anti-
colonisation therapy can prevent CDI. Given that inhabitation of C. difficile in the 
gastrointestinal tract does not appear detrimental; certainly when a normal 
microbiota is present, prevention of colonisation may therefore be unnecessary in a 
toxin mediated disease. The commercial application of immunisation against 
surface proteins is probably best suited to the prevention of relapses or used in 
conjunction with anti-toxin therapies.  
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5 Chapter 5 - Selected C. difficile surface protein 
knockout 
5.1 Introduction 
5.1.1 Genetic manipulation of C. difficile 
Effective genetic manipulation tools are required to understand the molecular basis 
of pathogenicity and utilise the amassed knowledge obtained from C. difficile 
genome sequencing. However, genetic modification of C. difficile and Clostridia is 
hampered by difficulties in conducting conjugation and transformation experiments 
as a result of an efficient restriction and modification (RM) system. The RM system 
comprises of a methyltransferase and restriction endonuclease pair. Restriction 
endonucleases cleave foreign, e.g. viral DNA, while methyltransferases protect host 
DNA (by methylating specific bases, which protrude into the major groove of DNA 
at the restriction enzyme binding site and prevents cleavage)(Wilson & Murray 
1991).  
 
Despite the limitations, a number of genetic manipulation reports exist in C. difficile 
including an occurrence of electroporation of the PaLoc from a toxigenic to a non-
toxigenic strain (Ackermann et al. 2001). Progress in C. difficile genetic manipulation 
occurred through development of plasmids able to transfer, usually by conjugation, 
into C. difficile (E. coli–C. difficile shuttle vectors) (Purdy et al. 2002).  
 
The knockout of the glycerol dehydrogenase (GldA) by Liyanage et al. (2001) utilised 
PCR fragments of the gldA gene, cloned into a conjugative vector (pMTL31 
(Williams et al. 1990)) which interrupted gldA by homologous recombination. The 
inactivation of two putative response regulator genes, rgaR and rgbR (O'Connor et 
al. 2006) and a codY mutant (Dineen et al. 2007) were also created by single 
crossover homologous recombination using pJIR1456 developed by O'Connor et al. 
(2006). 
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Most significantly tcdA and tcdB were inactivated using the O'Connor et al. (2006) 
homologous recombination system, leading to the suggestion that toxin B is 
required for virulence (Lyras et al. 2009). 
 
However, as Heap et al. (2009a) points out, the main issue with the O'Connor et al. 
(2006) system is that as it uses single homologous recombination, mutants do not 
appear to be stable and removal of any selection returns the wildtype gene (as 
found by Dineen et al. (2007)). Secondly, that both the pMTL31 (which contains a 
Gram negative ColE 1 -derived replication origin) and the pJIR1456 plasmid (based 
on pIP404 of Clostridium perfringens) were shown to replicate poorly in C. difficile, 
possibly due to the host RM system (Purdy et al. 2002). Purdy et al. (2002) found 
that by utilising the pCD6 plasmid replicon found on the indigenous C. difficile 
plasmid, using a strain cured of the pCD6 plasmid (for erythromycin resistance) and 
using an E. coli strain (CA434) for conjugation, which contains modification 
methylase Sau96I of Staphylococcus aureus (M.Sau96I), it was possible to 
circumvent host RM systems (Purdy et al. 2002). The result was the ability to 
introduce autonomously replicating vectors into C. difficile. 
5.1.1.1 The ClosTron 
The adaptation of a novel stable gene interruption system using retargeted group II 
introns, the ClosTron (Heap et al. 2007; Heap et al. 2010), has enabled the almost 
routine insertional inactivation of C. difficile genes and greatly enhanced the 
molecular tools to study C. difficile pathogenesis. 
 
Group II introns, first described in 1986 (Peebles et al. 1986), are large autocatalytic 
RNAs found in plants, eukaryotes and bacterial genomes (Toro et al. 2007). The 
ClosTron system uses a group II intron from Lactococcus lactis (Ll.ltrB), which after 
identifying its target site by base-pairing (between the excised intron lariat RNA and 
the target site DNA), inserts into the gene via an RNA-mediated ‘retrohoming’ 
mechanism (Lambowitz & Zimmerly 2004) (Figure 5.1.1).  
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Figure 5.1.1 Mechanism of group II intron insertion. Following transcription of the LtrA 
protein (or intron encoded protein IEP) and the ltrB lariat RNA, they assemble to form a 
ribonucleoprotein (RNP). The IEP first recognises a few bases flanking regions of the DNA 
target site and facilitates DNA unwinding enabling the EBS1, EBS2 and δ sequences in the 
intron RNA to base pair with the IBS1, IBS2 and δ sequences in the DNA target site 
(positions -12 to +3). The ltrB then reverse-splices into the sense strand at insertion site 
(IS). The LtrA protein then cleaves the second (antisense) strand downstream of the intron 
insertion site (second strand cleavage site (CS)), providing a template for reverse 
transcription by the LtrA protein. Thereby leaving the target gene interrupted with a stable 
copy of ltrB. Adapted from Zhong et al. (2003), Karberg et al. (2001) and the Sigma 
TargeTron Manual. 
 
As the intron target site is base-pair determined, it is reprogrammable i.e. can be 
mutated, to effectively target any gene (Guo et al. 2000; Karberg et al. 2001). 
Algorithms are used, firstly to find optimal insertion sites for the intron i.e. a best 
match to the positions recognised by the IEP, and secondly, to design primers to 
mutate the intron RNA’s EBS1, 2 and δ sequences, and because the intron is 
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plasmid encoded, the IBS is made complementary to the retargeted EBS sequences 
for efficient precursor RNA splicing (Perutka et al. 2004). 
 
The insertion is permanent as the LtrA (IEP) region of Ll.LtrB which harbours reverse 
transcriptase, maturase and endonuclease activity (Matsuura et al. 1997), is located 
on a plasmid, pMTL007 (Figure 5.1.2). Removal of the plasmid, removes the ability 
of the intron to transpose into another gene. Integrants are selected by use of a 
Retrotransposition-Activated Marker (RAM) (Zhong et al. 2003). The ClosTron RAM 
consists of an erythromycin resistance (ermB) ORF interrupted by a td phage group I 
intron. Upon expression of the group II intron RNA, the group I intron splices out, 
creating coding erythromycin resistance ORF, which together with a erythromycin 
sensitive strain of C. difficile (Hussain et al. 2005) means integrants are easily 
isolated.  
 
To date, a number of C. difficile proteins have been knocked out using the ClosTron 
system including the first C. difficile double, toxin A and B, mutant (Kuehne et al. 
2010).  
 Phase variable surface protein CwpV (Emerson et al. 2009a) 
 Surface located cysteine protease Cwp84 (Kirby et al. 2009) 
 Fibronectin binding protein Fbp68 (Lin et al. 2010) 
 The flagella core subunit FliC (Twine et al. 2009) 
 Sporulation pathway associated protein Spo0A and SleC (Underwood et al. 
2009; Burns et al. 2010b) 
 Transcriptional control CodY (which may have surface based responses) 
(Dineen et al. 2010) 
 FliC and FliD (Baban et al. 2010) 
 
The ClosTron system is therefore a powerful tool to study the pathogenesis of the 
CDI via a negative phenotype approach. 
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Figure 5.1.2 The ClosTron plasmid pMTL007C-E2. The fdx promoter of C.sporogenes drives 
expression of the group II intron, which contains FRT sites flanking the ErmRAM allowing 
marker removal. The lacZ stuffer is replaced during intron retargeting. Vector map taken 
from Heap et al. (2009a). 
 
5.1.2 Surface proteins at targets for gene knockout 
A total of 28 slpA paralogs have been identified in C. difficile genome (Calabi et al. 
2001; Karjalainen et al. 2001; Sebaihia et al. 2006). All of these proteins (including 
slpA) have at their N- or C-terminus, two or three repeat regions with homology to 
the N-acetylmuramoyl-L-alanine amidase CwlB of Bacillus subtilis. This so called cell 
wall binding domain 2 (Pfam 04122) (CWBD) putatively mediates binding of the 
protein to the cell surface by non-covalent interactions. The non-covalent nature of 
this interaction is derived from the fact that the S-layer can be removed from the 
cell surface using EDTA, low pH or chaotroptic agents.  
 
Twelve (inc. slpA) of the CWBD containing proteins exist in a 37 kbp cluster 
surrounding slpA and, as such, this region has been the focus of initial research 
efforts. From this cluster (other than slpA) two proteins have been characterised: 
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Cwp66 (CD2789) (Waligora et al. 2001) a heat shock inducible adhesin (See Chapter 
4 Section 6.1.2.2) and Cwp84 (CD2787) a surface located cysteine protease (Janoir 
et al. 2007) (See Chapter 3). The other CWBD proteins are distributed throughout 
the genome, e.g. cd0514 (cwpV), a phase variable cell surface protein (Emerson et 
al. 2009b). 
 
However, despite the identification of 28 slpA paralogs with 7 of which identified on 
the cell surface (at one point or another), only 3 have been studied in any detail 
(Cwp66, Cwp84 and CwpV (Waligora et al. 1999; Janoir et al. 2007; Emerson et al. 
2009b)), with an in vivo function only identified for one, Cwp84 (Kirby et al. 2009; 
Dang et al. 2010)). The role of the CWBD surface proteins in the physiology and 
pathogenesis of C. difficile has therefore only started to be understood and requires 
much work.  
 
A number of these CWBD paralogs have been proven to be expressed by RT-PCR 
during normal growth, identified proteomically in low pH glycine extracts or 
lysozyme extracts (Table 5.1.1). However, the proteins found on the cell surface do 
not necessarily correspond to those for which a message has been found, e.g. 
CD2782, CD2794. These differences may be due to the type of peptidoglycan-CWBD 
interaction, extraction technique, extraction conditions, e.g. Cwp66’s presence on 
the cell surface is predominantly after heat shock (Waligora et al. 2001), or a non-
direct relationship between gene expression and protein production.  
 
Given the number of surface proteins genes yet to have even basic characterisation, 
efforts were made to knock out a number of surface associated genes using the 
ClosTron system (Table 5.1.2). The chosen targets represent; varied genomic loci, 
characterised and uncharacterised surface proteins, surface proteins with either N- 
or C- terminal CWBDs and proteins with predicted enzymatic function and those 
with none.  
 
The specific approach taken was derived from studies in Chapter 3, whereby intron 
insertion at any site in a gene appeared to result in the same phenotype. As such, 
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only one target site was attempted for each gene. However, using this approach, 
not every gene chosen was successfully knocked out, decreasing both the number 
and range of genes investigated. Only successful mutants and the associated genes 
are discussed further. 
 
Table 5.1.2 Surface associated genes selected for knockout.  
CWBD containing Cell envelope associated Pseudogenes 
slpA cd2791 
(cwp2) 
fliD cd3008 
cd1036 
(cwp17) 
cwp66 cd2797 cd3146 
cd1751 
(cwp13) 
cwp84 
(chapter1) 
 cd2605 
cd2713 
(cwp22) 
cd2767 
(cwp19) 
Only genes in blue were successfully knocked out. Newly 
proposed gene name in brackets (Fagan et al. 2011). 
cd2735 
(cwp14) 
cd2795 
(cwp11) 
cd2784 
(cwp6) 
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Table 5.1.1 All 29 CWBD containing proteins of C. difficile  
CWBD containing 
protein (Alternative 
name)* 
Gene expressed 
during normal 
growth 
Protein found in 
glycine extracts 
Protein found in 
cell wall extracts 
CD0440 (Cwp27)    
CD0514 (CwpV)  X3,6 X3 
CD0844 (Cwp25)  X3 X3 
CD1035 (Cwp16)    
CD1036 (Cwp17)    
CD1047 (Cwp18)    
CD1233 (Cwp26)    
CD1469 (Cwp20)    
CD1751 (Cwp13)    
CD1803 (Cwp23)    
CD1987 (Cwp28)    
CD2193 (Cwp24)  X3  
CD2518 (Cwp29)    
CD2713 (Cwp22)    
CD2735 (Cwp14)    
CD2767 (Cwp19)    
CD2782 (Cwp7) X1   
CD2784 (Cwp6) X1 X3  
CD2786 (Cwp5) X1   
CD2787 (Cwp84, Cwp4) X1 X4 X3 
CD2789 (Cwp66, Cwp3) X1  X5 
CD2791 (Cwp2) X1 X3 X3 
CD2793 (SlpA) X1 X3 X3 
CD2794 (Cwp12) X2   
CD2795 (Cwp11)    
CD2796 (Cwp10)    
CD2798 (Cwp9)    
CD2799 (Cwp8)    
CD3192 (Cwp21)    
1(Calabi et al. 2001) 2(Savariau-Lacomme et al. 2003) 3(Wright et al. 2005) 4(Janoir et al. 
2007) 5(Waligora et al. 2001) 6(Emerson et al. 2009b). *(CwpXX) denote newly proposed 
nomenclature of C. difficile Pfam 04122 containing cell wall proteins (Fagan et al. 2011) 
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5.1.3 Surface proteins knocked out 
5.1.3.1 CD2791 and Cwp66 
 
 
 
Figure 5.1.3 Domain structure of CD2791 (Top) and Cwp66 (bottom). Sig- Signal Peptide, 
CWBD- Cell wall binding domain. 
 
Both CD2791 and Cwp66 are discussed in Chapter 4 Section 6.1.2.1 (CD2791) and 
6.1.2.2 (Cwp66). Briefly, CD2791 is an immunogenic surface protein, its expression 
has been demonstrated, as has its existence on the cell surface. CD2791 is highly 
conserved, as such, antibodies to CD2791 cross react across strains (Calabi & 
Fairweather 2002; Wright et al. 2005; Wright et al. 2008). The role of CD2791 in CDI 
or bacterial physiology is unknown.  
 
Cwp66 is a heat shock inducible adhesin, i.e. it is only found on the cell surface after 
heat shock. Antibodies to Cwp66 inhibit adhesin of C. difficile to Vero cells 
suggesting Cwp66 plays a role in adhesion (Waligora et al. 2001). The C-terminal 
Cwp66 is variable thus Cwp66 is suggested to be an important adhesin requiring 
antigenic variation (Lemee et al. 2005). Moreover, CD2791 and Cwp66 are 
putatively found on the same (polycistronic) transcript (Savariau-Lacomme et al. 
2003). 
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5.1.3.2 CD1036 and CD2784  
 
Table 5.1.3 Comparison of domain structures of CD1036 and CD2784 
CD2784  
675 aa (MW 73024) 
Signal peptide 1-28 
3 x CWBD (170-261,271-364,377-456) 
N-acetylmuramoyl-L-alanine amidase 
(490-671) 
Active residues (H497,E514, H567, E640) 
Metal binding (H497,E514, H567) 
CD1036 
677 aa (MW 74195) 
Signal peptide 1-32 
3 x CWBD (174-265, 275-368, 381-474) 
N-acetylmuramoyl-L-alanine amidase 
(492-673) 
Active residues (H499,E513, H566, E642) 
Metal binding (H499,E513, H566) 
 
 
 
 
Figure 5.1.4 Domain structure of CD1036 (Top) and CD2784 (Bottom). Sig - Signal peptide, 
MurNAc-LAA - N-acetylmuramoyl-L-alanine amidase, CWBD – Cell wall binding domain 
(PFam04122). 
 
RT-PCR revealed that cd2784 (cwp6 aka ORF12) was expressed during normal 
growth and CD2784 has been found on the cell surface in both glycine extracts and 
lysozyme extracts, suggesting that it is surface located and found under normal in 
vitro growth conditions (Calabi et al. 2001; Karjalainen et al. 2001; Wright et al. 
2005). Microarray analysis found at least one reporter of CD2784 was upregulated 
during sub MIC amoxicillin (Emerson et al. 2008). 
 
CD2784 has its CWBDs at the N-terminus and a metal binding N-acetylmuramoyl-L-
alanine amidase (or MurNAc-LAA)(also known as peptidoglycan amidase) at its C-
terminal (Figure 5.1.4). N-Acetylmuramyl-L-alanine amidases hydrolyse the amide 
bond between N-Acetylmuramic acid (MurNAc) and L-alanine (L-Ala), separating 
the glycan strand from the peptide (Figure 5.1.5). These proteins are Zn-dependent 
  
192 
peptidases with highly conserved residues involved in cation co-ordination. They 
are diverse in their roles including sporulation and germination, separation of 
daughter cells, lysis of prey cells, autolysis and peptidoglycan recycling amongst 
others (Vollmer et al. 2008). 
 
 
Figure 5.1.5 Hydrolysis of amide bonds in peptidoglycan. N-acetylmuramyl-L-alanine 
amidases (Ami) hydrolyse the amide bonds between the lactyl group of MurNAc and the L-
alanine of the stem peptide. Adapted from (Vollmer et al. 2008). 
 
C. difficile, in common with E. coli has several peptidoglycan amidases (CD2784, 
CD1035, CD1036, CD2761, CwlD (CD0106), CD2184, CD0784 and several phage 
endolysins (CD0972, CD1898)) located in diverse locations in the genome. Their 
diverse locations, suggests diverse roles in cellular physiology. 
 
CD1036 (and CD1035 which shares 94.3% identity) is located upstream of 23s rRNA 
and downstream of a helicase and ATP- dependant nucleases in the C. difficile 630 
genome. To date, no empirical studies have been performed characterising either 
cd1036 or cd1035, including expression or the cell surface location. It is interesting 
that both CD2784 and CD1036/1035 share similar domain architectures but are in 
completely different genomic locations, this may suggest diversity of roles or gene 
duplication. Indeed the identification of CD2784 on the cell surface and not CD1036 
suggests they are under different regulatory systems.  
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5.1.3.3 CD2735 
 
 
 
Signal peptide ……………………1-27 
3 x CWBD …………………………. 39-125, 134-227, 232-319 
Bacterial SH3 domain ………. 346-398, 418-470 
 
Figure 5.1.6 Domain structure of CD2735. Sig - Signal peptide, CWBD – Cell wall binding 
domain (PFam04122), SH3 – Bacterial Src Homology 3 domain. 
 
 The cd2735 gene is located upstream of mleN (a putative malate-2H(+)/Na(+)-
lactate antiporter, involved in Na+ and alkali resistance (Wei et al. 2000)) and 
downstream of CD2736 (a LysR family transcriptional regulator, involved in 
activation of divergent transcription of linked target genes or unlinked regulons 
encoding extremely diverse functions (Schell 1993)) in the 630 genome. 
 
CD2735 has not been characterised to date but contains two Src Homology 3 (SH3) 
domains (Figure 5.1.6). SH3 domains are involved in protein-protein interactions 
mediating the assembly of large multi-protein complexes (Li 2005). They contain a 
proline-rich (PxxP) core-conserved binding motif, first identified as a conserved 
sequence in the non-catalytic part of several cytoplasmic protein tyrosine kinases, 
e.g. Src. The surface of the SH3-domain bears a flat, hydrophobic ligand-binding 
pocket which consists of three shallow grooves defined by conservative aromatic 
residues in which the ligand adopts an extended left-handed helical arrangement 
(Nguyen et al. 1998). The affinity of SH3 domains for their ligand is relatively low (Kd 
in µM range) and selectivity is marginal at best, but either through multiple 
interactions or tertiary compartmentalised interaction(s), affinity or specificity can 
be increased (Mayer 2001).  
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Figure 5.1.7 The structure of the two classes of SH3 domain (Feng et al. 1994) and surface 
of the SH3 domain with ligand. Figure adapted from Mayer (2001).  
 
Inhibition of the SH3 domain can be accomplished by synthetic proline rich ligands 
(Lee et al. 2002b). Inhibition of the SH3 protein-protein interactions and the 
subsequent inhibition of the commonly associated (kinase) signalling appear to be 
key in controlling tumorigenesis (Lu et al. 2010). 
 
The role of SH3 domains in bacterial pathogenesis is largely unknown but SH3 
domains are present in Listeria monocytogenes invasion protein InlB, mediating 
binding to host ligands (Marino et al. 2002) and iron regulation in Mycobacterium 
sp (Liu et al. 2008a). 
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5.1.3.4 CD2795 cwp11 (Calabi et al. 2001) ORF5 (Karjalainen et al. 2001) 
 
 
 
533 aa (58,743Da predicted)  
Signal peptide  ………………………………………………………..1-28 
3 x CWBD ……………………………………………………………….31-118, 127-213, 217-296) 
Bacterial Ig-like domain (group 3); pfam07523 ………309-361 
SCP_bacterial ………………………………………………………… 398-525 
 
Figure 5.1.8 Domain structure of CD2795 (and CD2794). Sig - Signal peptide, CWBD – Cell 
wall binding domain (PFam04122), Big_3 - Bacterial Ig-like domain (group 3)(PFam07523), 
SCP_bacterial - SCP-like extracellular protein domain 
 
In the C. difficile 630 genome, cd2795 is upstream of cd2794, which is upstream of 
slpA. Both CD2795 and CD2794 share a similar domain arrangement (Figure 5.1.8), 
although CD2794 is 5 aa shorter (528 aa). However, there is only 70.3% identity at 
the DNA level and 63.4% at the amino acid level between cd2794 and cd2795. 
Despite being in the slpA cluster (indeed next to slpA), no characterisation has been 
undertaken with cd2795 nor has CD2795 been identified on the cell surface, 
suggesting that either it is not expressed, or its expression is condition dependant 
(although cd2794 has been proven to be expressed by RT-PCR (Karjalainen et al. 
2001)). 
 
CD2795 contains a bacterial Ig-like domain (group 3) (PF07523) which contains an 
Ig-like fold and is putatively found in a range of bacterial surface proteins. The 
bacterial Ig-like domain has been found in the E. coli adhesion protein intimin, in 
which two Ig-like domains are followed C-terminally by a lectin binding domain 
(Kelly et al. 1999; Luo et al. 2000). An immunoglobulin-like fold consists of a beta-
sandwich of seven or more strands in two sheets with a Greek-key topology (Bork 
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et al. 1994). Ig-like domains often interact with other Ig-like folds, via their beta-
sheets (Potapov et al. 2004).  
 
A     B 
 
Figure 5.1.9 Schematic presentation of the immunoglobulin like fold (A) and the Greek-key 
topology (B). 
 
It is interesting that two proteins (CD2794 and CD2795), containing the Ig-like 
domain, are found next to each other in the C. difficile genome, both with CWBD. It 
is tempting to speculate that they interact possibly forming a protein complex on 
the cell surface, or bind directly to host molecules forming a complex.  
 
At the C-terminal of CD2795 is a SCP bacterial domain. The sperm coat protein 
(SCP) bacterial domain has been found in plants (PR1-like proteins), cysteine-rich 
secretory proteins (CRISPs), reptiles and insects (ion channel blocking venoms) and 
nematodes (Yeats et al. 2003). Certain SCP proteins contain a calcium chelating 
serine protease active site (Fernandez et al. 1997), while others do not, but contain 
conserved residues including histidine and glutamate which may co-ordinate 
ligand(s), for example zinc in Pseudecin snake venom (Suzuki et al. 2008), however 
the role of the SCP domain in bacterial pathogenesis is unknown. 
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5.1.3.5 FliD 
 
 
 
507 aa (55,946Da) 
FliD (Flagella capping protein) ……………………………….. ……………8-506 
FliD_N (Flagellar hook-associated protein 2 C-terminus)........13-117 
FliD_C (Flagellar hook-associated protein 2 C-terminus).........233-496 
 
Figure 5.1.10 Domain structure of FliD - Flagella cap protein. FliD_N - Flagellar hook-
associated protein 2 C-terminus (PFam 02465). FliD_C - Flagellar hook-associated protein 2 
C-terminus (PFam07195). 
 
At its simplest level, flagella are used to move the bacterium from one place to 
another. This locomotion provides the bacterium access to nutrients via chemical 
gradients. The motile flagellum consists of a number of elements, assembled in a 
particular order, topped off with a cap (FliD) (Macnab 2003) (Figure 5.1.11) 
 
The expression of the flagella cap (fliD) gene in C. difficile was found in flagellated 
and non-flagellated strains. However, anti-FliD serum did not react with a ‘flagella 
extract’ of non-flagellated, strains suggesting gene expression and protein 
production are not necessarily correlated. FliD appears to be highly conserved and 
falls into two major forms with 88% identity between them (Tasteyre et al. 2001b). 
However, despite the conservancy, Lemee et al (2005) suggests fliD (and fliC) are 
under selective pressure and demonstrate a number of polymorphisms. Flagellated 
C. difficile strains adhered to Vero cells tenfold greater than non-flagellated strains. 
Furthermore, recombinant FliD binds to mucus and radiolabelled Vero cells bind to 
recombinant FliD respectively (Tasteyre et al. 2001a), supporting a role for the 
flagella in bacterial adhesion.  
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Figure 5.1.11 Schematic representation of the Gram positive flagella. Taken from (Desvaux 
et al. 2006). 
 
Consistent with the role of the flagella in C. difficile pathogenesis, the majority of 
patients appear to raise antibodies to FliD (Pechine et al. 2005b) and responses 
appear to be to the same level as toxin A and B, possibly higher in the control group 
than the CDI case group (Pechine et al. 2005b). Rectally administered encapsulated 
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FliD plus a flagella extract, raised an anti-colonisation protective response in mice 
(Pechine et al. 2007), suggesting FliD plays a role in colonisation of the gut.  
5.1.4 Aim 
The aim of this study was to understand more about selected surface proteins using 
a gene knockout approach, followed by characterisation of mutants to identify 
surface based determinants of virulence worth further investigation. This chapter 
has determined that inactivation of several surface proteins results in changes in 
the bacterium, which both result in a decreased ability to adhere in vitro and 
appears to cause an earlier release of toxin compared to the wildtype. However, 
other aspects of cell physiology e.g. sporulation, morphology and removed surface 
proteins (beyond the species knocked out) are the same as the wildtype. 
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5.2 Chapter 5 Specific Methods 
5.2.1 Knockout of putative surface protein genes 
The ClosTron gene knock-out system was used for insertional inactivation using 
protocols outlined in General Methods Section 2.2.  
 
Intron (re)targeting region using primers designed by the relevant intron 
retargeting site are given in Table 5.2.1. Primers used to screen for intron 
integration are given in Table 5.2.2.  
 
Table 5.2.1 Intron retargeting primers, as designed by ClosTron and Sigma 
TargeTron algorithms 
Gene 
Insertion 
location 
Gene-
intron-gene IBS 
Retargeting 
primers 
 
IBS1d EBS2 
cd1036 1406|1407a 
TTGTGTTTAG
ATAATGATG
ATGCTATAG
AG- intron -
CTCATTACCT
TAGAA 
AAAAAAGCT
TATAATTATC
CTTAGATGCC
ATAGAGGTG
CGCCCAGAT
AGGGTG 
CAGATTGTAC
AAATGTGGT
GATAACAGA
TAAGTCATA
GAGCTTAACT
TACCTTTCTT
TGT 
TGAACGCAA
GTTTCTAATT
TCGATTGCAT
CTCGATAGA
GGAAAGTGT
CT 
cd2735 1113|1114s 
GGATATCTA
AATAATGGT
GATGAAGTA
GAA- intron -
GTTTTAGATG
TGTTA 
AAAAAAGCT
TATAATTATC
CTTAGATGAC
GTAGAAGTG
CGCCCAGAT
AGGGTG 
CAGATTGTAC
AAATGTGGT
GATAACAGA
TAAGTCGTA
GAAGTTAAC
TTACCTTTCT
TTGT 
TGAACGCAA
GTTTCTAATT
TCGATTTCAT
CTCGATAGA
GGAAAGTGT
CT 
cd2784 438|439s 
AATCTTAAG
GATTATGAT
GTTACACAA
GAG- intron -
TTTATAATAA
GTGAT 
AAAAAAGCT
TATAATTATC
CTTAGTTACC
CAAGAGGTG
CGCCCAGAT
AGGGTG 
CAGATTGTAC
AAATGTGGT
GATAACAGA
TAAGTCCAA
GAGTTTAACT
TACCTTTCTT
TGT 
TGAACGCAA
GTTTCTAATT
TCGATTGTAA
CTCGATAGA
GGAAAGTGT
CT 
cd2791   1569|1570s 
GCTGATGTT
GATAAAGAT
AGAAAAGTT
CAA - intron - 
AGAGTTGAA
GGAGAA 
AAAAAAGCT
TATAATTATC
CTTAAGAAA
CGTTCAAGT
GCGCCCAGA
TAGGGTG 
CAGATTGTAC
AAATGTGGT
GATAACAGA
TAAGTCGTTC
AAAGTAACTT
ACCTTTCTTT
GT 
TGAACGCAA
GTTTCTAATT
TCGATTTTTC
TTCGATAGA
GGAAAGTGT
CT 
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cd2795 1320|1321s 
TATATGATG
GATAAAAAA
GTATTTGCAC
AT- intron -
TATATAGATG
GAAAA 
AAAAAAGCT
TATAATTATC
CTTAGTATTC
GCACATGTG
CGCCCAGAT
AGGGTG 
CAGATTGTAC
AAATGTGGT
GATAACAGA
TAAGTCGCA
CATTATAACT
TACCTTTCTT
TGT 
TGAACGCAA
GTTTCTAATT
TCGATTAATA
CTCGATAGA
GGAAAGTGT
CT 
cwp66   519|520s 
AAGGGTCTT
GCTGATGCA
GTGAGTGTT
GGA - intron 
-
GCTATAGCT
GCTCAA 
AAAAAAGCT
TATAATTATC
CTTAGTGAG
CGTTGGAGT
GCGCCCAGA
TAGGGTG 
CAGATTGTAC
AAATGTGGT
GATAACAGA
TAAGTCGTTG
GAGCTAACTT
ACCTTTCTTT
GT 
TGAACGCAA
GTTTCTAATT
TCGATTCTCA
CTCGATAGA
GGAAAGTGT
CT 
cwp84 347|348a   
TCTAAAGTTG
ACATACCTGA
AAAAGACCA
G - intron - 
CATGTATTAA
GACTT 
AAAAAAGCT
TATAATTATC
CTTAGAAAA
CGACCAGGT
GCGCCCAGA
TAGGGTG 
CAGATTGTAC
AAATGTGGT
GATAACAGA
TAAGTCGAC
CAGCATAACT
TACCTTTCTT
TGT 
TGAACGCAA
GTTTCTAATT
TCGATTTTTT
CTCGATAGA
GGAAAGTGT
CT 
fliD   120|121s 
GAAAAAGTT
GATAAAGCA
AAACAAGAA
CAA - intron - 
CAAATCGTTA
AATGG 
AAAAAAGCT
TATAATTATC
CTTAAAACAC
GAACAAGTG
CGCCCAGAT
AGGGTG 
CAGATTGTAC
AAATGTGGT
GATAACAGA
TAAGTCGAA
CAACATAACT
TACCTTTCTT
TGT 
TGAACGCAA
GTTTCTAATT
TCGGTTTGTT
TCCGATAGA
GGAAAGTGT
CT 
cd1751 2024|2025a 
AGATTGTTTG
ATAGGGATG
CTGTTCCTCC
A- intron -
ATAATATAA
GATTTC 
AAAAAAGCT
TATAATTATC
CTTAGCTGTC
CCTCCAGTGC
GCCCAGATA
GGGTG 
CAGATTGTAC
AAATGTGGT
GATAACAGA
TAAGTCCCTC
CAATTAACTT
ACCTTTCTTT
GT 
TGAACGCAA
GTTTCTAATT
TCGATTACAG
CTCGATAGA
GGAAAGTGT
CT 
cd2713 1482|1483a 
TGGTTATTTG
ACCAAGTTCC
TGTAGGTTCA
- intron -
GATGTAATTA
TAGAT 
AAAAAAGCT
TATAATTATC
CTTACCTGTC
GGTTCAGTG
CGCCCAGAT
AGGGTG 
CAGATTGTAC
AAATGTGGT
GATAACAGA
TAAGTCGGTT
CAGATAACTT
ACCTTTCTTT
GT 
TGAACGCAA
GTTTCTAATT
TCGGTTACA
GGTCGATAG
AGGAAAGTG
TCT 
cd2767 1524|1525a 
TACGATATA
GATGGAGTT
CATTTTGATG
AT- intron -
TACTTCTATC
CAGGA 
AAAAAAGCT
TATAATTATC
CTTACATTTC
GATGATGTG
CGCCCAGAT
AGGGTG 
CAGATTGTAC
AAATGTGGT
GATAACAGA
TAAGTCGAT
GATTATAACT
TACCTTTCTT
TGT 
TGAACGCAA
GTTTCTAATT
TCGGTTAAAT
GTCGATAGA
GGAAAGTGT
CT 
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cd2797 2925|2926a 
GGAGTAGCT
GCTAGAGCA
GGAGATGAA
ATC- intron -
ACAGTATAT
GTTGGA 
AAAAAAGCT
TATAATTATC
CTTAGGAGA
CGAAATCGT
GCGCCCAGA
TAGGGTG 
CAGATTGTAC
AAATGTGGT
GATAACAGA
TAAGTCGAA
ATCACTAACT
TACCTTTCTT
TGT 
TGAACGCAA
GTTTCTAATT
TCGATTTCTC
CTCGATAGA
GGAAAGTGT
CT 
cd3008 
(pseudo) 
39|40a 
TTTAATGTGG
CTAGAGGTA
TAATTGAAG
AG- intron -
TATATTAAAG
AATGT 
AAAAAAGCT
TATAATTATC
CTTAATAATC
GAAGAGGTG
CGCCCAGAT
AGGGTG 
CAGATTGTAC
AAATGTGGT
GATAACAGA
TAAGTCGAA
GAGTATAAC
TTACCTTTCT
TTGT 
TGAACGCAA
GTTTCTAATT
TCGGTTATTA
TCCGATAGA
GGAAAGTGT
CT 
cd3146 
(pseudo-
sortase) 
120|121a 
GCTATTATTG
ATAGTGTTTT
CTCTGAGTTC
- intron -
CGTATATACT
TCATC 
AAAAAAGCT
TATAATTATC
CTTATTCTCC
GAGTTCGTG
CGCCCAGAT
AGGGTG 
CAGATTGTAC
AAATGTGGT
GATAACAGA
TAAGTCGAG
TTCCGTAACT
TACCTTTCTT
TGT 
TGAACGCAA
GTTTCTAATT
TCGGTTGAG
AATCGATAG
AGGAAAGTG
TCT 
cdtB 
(CD2605) 
(pseudo) 
645|646s  
ATACCAATA
GATGAAAGT
TGTGTTGAAC
TC- intron -
ATATTTGATG
ATAAT 
AAAAAAGCT
TATAATTATC
CTTATGTGTC
GAACTCGTG
CGCCCAGAT
AGGGTG 
CAGATTGTAC
AAATGTGGT
GATAACAGA
TAAGTCGAA
CTCATTAACT
TACCTTTCTT
TGT 
TGAACGCAA
GTTTCTAATT
TCGGTTACAC
ATCGATAGA
GGAAAGTGT
CT 
slpA 1266|1267s 
GCAATAACT
GATAAAGCA
GTTAATGATA
TA - intron - 
GTATTAGTTG
GATCT 
AAAAAAGCT
TATAATTATC
CTTAGTTAAC
GATATAGTG
CGCCCAGAT
AGGGTG 
CAGATTGTAC
AAATGTGGT
GATAACAGA
TAAGTCGAT
ATAGTTAACT
TACCTTTCTT
TGT 
TGAACGCAA
GTTTCTAATT
TCGATTTTAA
CTCGATAGA
GGAAAGTGT
CT 
slpA 258|259s 
AAGAAAGCG
GACAGAGAT
GCTGCAGCT
GAG - intron 
- 
AAGTTATATA
ATCTT 
AAAAAAGCT
TATAATTATC
CTTAGCTGCC
GCTGAGGTG
CGCCCAGAT
AGGGTG  
CAGATTGTAC
AAATGTGGT
GATAACAGA
TAAGTCGCT
GAGAATAAC
TTACCTTTCT
TTGT  
TGAACGCAA
GTTTCTAATT
TCGATTGCA
GCTCGATAG
AGGAAAGTG
TCT  
slpA 321|322s 
AAATTAGGT
GATGGAGAT
TATGTTGATT
TT - intron - 
TCTGTAGATT
ATAAT 
AAAAAAGCT
TATAATTATC
CTTATATGTC
GATTTTGTGC
GCCCAGATA
GGGTG  
CAGATTGTAC
AAATGTGGT
GATAACAGA
TAAGTCGATT
TTTCTAACTT
ACCTTTCTTT
GT  
TGAACGCAA
GTTTCTAATT
TCGGTTACAT
ATCGATAGA
GGAAAGTGT
CT  
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tcdR 499|500s 
AAATATCTA
GACAAGCT
GTTAATAAG
GCTA- intron 
-
AAAATAGAG
CATTTA 
AAAAAAGCT
TATAATTATC
CTTATTAATC
AGGCTAGTG
CGCCCAGAT
AGGGTG 
CAGATTGTAC
AAATGTGGT
GATAACAGA
TAAGTCAGG
CTAAATAACT
TACCTTTCTT
TGT   
TGAACGCAA
GTTTCTAATT
TCGGTTATTA
ATCGATAGA
GGAAAGTGT
CT     
tcdA 494|495a 
TTAATTGTTG
ATCAAGTTTA
TCAAAGTTTT 
- intron -
CTGATGTATA
ATTAT 
AAAAAAGCT
TATAATTATC
CTTATATCAC
AGTTTTGTGC
GCCCAGATA
GGGTG 
CAGATTGTAC
AAATGTGGT
GATAACAGA
TAAGTCAGTT
TTCTTAACTT
ACCTTTCTTT
GT   
TGAACGCAA
GTTTCTAATT
TCGGTTTGAT
ATCGATAGA
GGAAAGTGT
CT     
Spo0A 178|179a 
ATCCATCTA
GATGTGGC
ATTATTACA
TCTA- intron 
-
GTATTAATA
AGTCCG 
AAAAAAGCT
TATAATTATC
CTTATTATTC
CATCTAGTGC
GCCCAGATA
GGGTG 
CAGATTGTAC
AAATGTGGT
GATAACAGA
TAAGTCCATC
TAGTTAACTT
ACCTTTCTTT
GT   
TGAACGCAA
GTTTCTAATT
TCGGTTAATA
ATCGATAGA
GGAAAGTGT
CT 
 
 
5.2.2 Characterisation of mutants 
Prior to any manipulation or characterisation of mutants, cultures were re-streaked 
onto FAA plate(s) and incubated at 37 °C for 24 hr. Where several characterisations 
were performed simultaneously, the same re-streak was used. 
5.2.2.1 Molecular Methods 
gDNA extraction and RNA extraction was undertaken as per General Methods 
sections 2.1.11 and 2.1.12.2 respectively. 
PCR was undertaken as per General Methods section 2.1.5, while RT-PCR was 
performed using either SuperScript III One-Step RT-PCR System with Platinum® Taq 
DNA (Invitrogen) or QIAGEN OneStep RT-PCR Kit (with Q solution) (Qiagen) using 
primers outlined in Table 5.2.3.  
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Table 5.2.2 Primers used to screen for integration 
Primer Sequence 
CD2791_for  ATG AAT AAA AAA AAT CTT TCT G   
CD2791_rev  TTA CCA ACC TAG TAT TTT AGC 
Cwp66_For  ATG AAA ATA TCA AAA AAG ATA GTG TC 
Cwp66_Rev  TAA AWT CCA TCA TCT GTA 
1036 Up-279_F GGC TAC AGT TAA TTA TCA AGA G 
1036_1703_R CCT TGT TTA TTA GTT GAG CCA T 
CD2735_For(mwg) TCA TCA ATG CTG TGC TTA TCT C 
CD2735_Rev(mwg) CCC ATC CAG TAG CAA ACA TTT C 
CD2784_For TGT TGT CTG TAG CAA TGG TG 
CD2784_Rev CTG TAT CTT CTA TTC CTA TTC C 
CD2795_For ATG AAA ATG AAC AAA AAA ATA 
CD2795_Rev TTA CAA GCT ACC TTC ATT GC 
CD1751_for GTG AAA AAA TTT ACT TC 
CD1751_rev CTA TTT AGC ACT TTT TA 
CD2713_For ATG TTT CTA AAA GAG GGG GA 
CD2713_Rev CTA TTT TGC AAG AAT ATC CA 
CD2767_For ATG AAA AAA ATA AGT ATA TT 
CD2767_Rev TTA CTT AAC TAA GTT TAA GA 
CD2797_For ATG AAA AAG GCA ATA TCT TGT 
CD2797_Rev CTA TTT ATC TCT AAC AAT AT 
FliD_For  ATGTCAAGTATAAGTCC   
FliD_Rev  TTAATTACCCTGTGCTT   
slpAMasSpec_Rev  (Qazi et al. 
2009) 
ATTCTATGTACATAATAAAGAGATGT  
slpAMasSpec_For  (Qazi et al. 
2009) 
ACCTTCACCAGTTTTCAT 
tcdR_For AAGTAAGTCTGTTTTTGAGG 
tcdR_Rev AAGGCTTTATTTCTACCAG 
tcdA_For TTTAGCTGCAGCATCTGACAT 
tcdA_Rev ATGGCTGGGTTAAGGTGTTG 
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Table 5.2.3 Primers used for RT-PCR 
Gene Primer name Primers 
cd1036 1036-1200PreI 
 
1036-1528PostI 
AGA TGA TGA GTT AGA 
GGC TG 
CTC CAG ATG AAT TTC 
CAG GT 
cd2735 2735-1052PreI 
 
2735-1271PostI 
GAA ATG ATG CTA CAA 
TAG AAG C 
TTC CTA ACA TTT AGA 
CCA TC 
cd2791 2791-1000preI 
 
2791-1703PostI 
ACT GCA GTG GCT ATA 
GCA AA 
CCT GCT GCT AAT GCA 
TCT AC 
cd2791 (Post intron) 2791PostIn1576F 
 
2791PostIn1775R 
GAA GGA GAA ACA AGA 
CAC GA 
AGT GCA TTC TTT TGT 
GAG TC 
cwp66 cwp66-200PreI 
 
cwp66-525PostI 
CTT TAT CAG CTA CTC CAT 
TT 
TAT AGC TCC AAC ACT 
CAC TG 
cd2791-cd2790 intergenic  orf8-RT11 
 
orf9-RTR11 
AGT TGA ATT GAC AGT 
AAT AC 
CTG TGC ATA ATA TGA 
CAT GT 
cd2790-cwp66 intergenic orf9-RT12 
 
cwp66-RTR12 
GCT ATA GGA TAT CAT 
TCA G 
GAT AAA GCA TCT GCT 
ATG G 
cd2795 (Primer set 1) 2795-1219PreI F 
 
2795-1446PostIR 
AGA AAA GAA AAA GGC 
AAA GAG C 
TGC CAA GTC TTT TGC 
ATC TT 
cd2795 (Primer set 2) CD2795_for1098  
 
CD2795_rev1478 
CAC TCA TTG CAT CTG 
CTT CTC 
GCA GCA AAG ATA GCT 
GAT AAA C 
1,2  refer to Orf8 RT1 & Orf9 RTR1 and Orf9-RT1 & cwp66 RTR1 respectively from Savariau-
Lacomme et al. (2003). 
5.2.2.2 Growth rate determination  
Triplicate 20 ml sBHI broth was inoculated with 3 streaks of colonies and incubated 
for 16 hr. The overnight culture was inoculated into fresh triplicate 20 ml sBHI broth 
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such that the ~OD600 0.1. At hourly intervals the culture was agitated and samples 
removed and OD600 measured. OD600 vs time was plotted and the linear 
(slope/gradient/exponential) part of the curve used to give a growth rate. 
5.2.2.3 Sporulation 
A stirred 80 ml sBHI culture was inoculated with a streak of colonies and left for 
18 days. After this period samples were taken and plated in dilution, pre and post 
heat shock (62 °C, 40 min), to give viable count (colony forming units/ml). 
5.2.2.4 Toxin ELISA 
Sandwich ELISA for toxins A and B was performed as detailed in General Methods 
(Section 2.7.1). 
5.2.2.5 Motility assay 
The relevant C. difficile strain was inoculated, with a loop, into the top 2 to 5 mm of 
pre-reduced BHI agar (0.05%). Cultures were then incubated for 24 hr in anaerobic 
conditions at 37°C before being photographed.  
5.2.2.6 Surface protein extraction 
Surface proteins were removed by low pH glycine extraction as detailed in General 
Methods (Section 2.7.2). 
5.2.2.7 Adhesion assay 
An in vitro adhesion assay was performed as detailed in Chapter 4 Specific Methods 
(Section 4.2.6). Enumeration was performed using a single-blind experimental 
design. 
5.2.3 Assessment of CD2791 as an adhesin  
5.2.3.1 Expression and purification of rCD279127-322 
Expression and purification of the N-terminal domain of CD2791 was performed as 
detailed in Chapter 4 Specific Methods (Section 6.3.1.1.2). 
5.2.3.2 Labelling of rCD279127-322  
After extensive dialysis into 50 mM HEPES plus 0.15 M NaCl pH 7.4, rCD279127-322 
was labelled with AlexaFluor488 protein labelling kit (Molecular Probes, USA) as per 
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manufacturer’s instructions. The A280 value was used to concentrate the rCD279127-
322 to 2 mg/ml using a Vivaspin 20 10 kDa MWCO spin concentrator. Calculation of 
extinction co-efficient was performed with ProtParam (Gasteiger et al. 2005). 
5.2.3.3 Binding of rCD279127-322 to Caco2 cells or Vero cells 
Caco-2 cells were seeded into 8 well Lab-TekTM chamber slides at a 1:2 dilution in 
MEME for 14 days prior to the assay to ensure full differentiation. Vero cells were 
seeded into chamber slides approximately 18 hr before the assay. 
 
Cells in chamber slides were washed twice with 0.4 ml per well DPBS before 
addition of 200 µl of labelled or unlabelled rCD279127-322 or control solutions (DPBS 
or DMEM). Wells with 1 or 50 µM Alexa488 labelled rCD279127-322 were incubated 
for 1hour. Wells with 10 or 100 µM Unlabelled rCD279127-322 were incubated for 
1hour, washed 3 times with 0.4 ml PBS followed by application of 1 µM Alexa488 
labelled rCD279127-322 and incubated for a further hour. Incubations were 
performed at 37 °C in an atmosphere of 5% CO2. After incubation, solutions in wells 
were removed followed by washing 3 times with 0.4 ml per well of DPBS before 
viewing on a fluorescent microscope with FITC filter. Calculation of rCD279127-322 
µM concentrations was done by adjustment of the A280 using extinction co-efficient 
given by ProtParam (Gasteiger et al. 2005). 
5.2.3.4 ELISA of antibody response to rCD279127-322  
rCD279127-322 was coated onto Nunc Maxisorp 96-well ELISA plates at 10 µg in PBS 
and incubated for 1 hr. The plate was then washed 3 times with PBS/T followed by 
blocking PBS/T with 5% FCS. After washing as before, 1:3 serially diluted ovine anti-
R20291 SLP IgG (1 mg/ml) was applied and the plate incubated for 1 hr. After 
washing as before, donkey anti-sheep HRP conjugate was applied (1:5000 in 
blocking buffer) and incubated for 1 hr. The plate(s) were washed a final time and 
developed with TMB substrate and TMB stop solution, then read at 450 nm using a 
Tecan™ Sunrise microtitre plate reader. All washes were performed 3 times with 
PBS plus 0.1% Tween 20 (Sigma) (PBS/T). All incubations were performed at 37 °C 
with shaking. 
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5.2.3.5 Coupling rCD279127-322 to NHS resin and antibody purification 
5.2.3.5.1 Coupling 
rCD279127-322 was coupled to Pierce NHS-activated agarose slurry (ThermoFisher) as 
per manufacturer’s instructions. Briefly, 10 ml settled resin was washed three times 
H20, followed by two washes with coupling/wash buffer (PBS). Approximately 
17 mg rCD279127-322 in 50 mM HEPES 0.15 M NaCl pH 7.4 was added to the resin 
and incubated for 1.5 hr with end-over-end stirring. The resin was washed twice 
with PBS, followed by blocking with 1 M ethanolamine pH 7.6 for 20 min. Resin was 
again washed once with PBS before loading onto an XK16 column and washed with 
PBS for 100 ml (3 ml/min). The resin was stored in PBS plus 0.05% azide at 4 °C. 
Coupling efficiency was measured by Bradford assay, using BSA as the standard. 
Approximately 60% coupling was achieved. 
5.2.3.5.2 Antibody purification 
The 10 ml NHS.rCD279127-322 resin was extensively washed with tris-buffered saline 
(TBS) followed by application of 40 mg ovine anti-R20291 SLP IgG (1 mg/ml in TBS) 
at 1 ml/min. The column was washed until the OD returned to near baseline. Bound 
material was eluted by 100% gradient to 150 mM glycine pH 2.5, applied at 
1 ml/min (1 ml fractions). Fractions were neutralised by 200 µl 1 M tris pH 9.0. 
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5.3 Results 
5.3.1 Production of C. difficile surface protein knockouts 
Three types of gene were chosen for knockout: 
 Genes which encoded a protein containing a CWBD (Pfam 04122) repeat 
 Associated with cell wall or surface located virulence factor 
 Putative pseudogenes- where no functional protein is produced to assess 
intron insertion at a putatively unimportant site. 
The following genes and insertion site(s) were chosen for investigation based on the 
criteria above (Table 5.3.1).  
 
Table 5.3.1 Genes chosen for knockout (including those used in Chapter 3). 
Gene 
Number of 
predicted intron 
insertion sites 
Site(s) chosen 
for investigation 
Gene size 
(bp) 
Algorithm 
location 
KO? 
cd1036 17 1406|1407a 2034 Clos y 
cd2735 14 1113|1114s 1428 Clos y 
cd2784 16 438|439s 2028 Clos y 
cd2791   15 1569|1570s 1872 TT y 
cd2795 14 1320|1321s 1602 Clos y 
cwp66   24  519|520s 1833 TT y 
cwp84 27 68|69a 2412 TT y 
cwp84 27 347|348a   2412 TT y 
cwp84 27 675|676s 2412 TT y 
cwp84 27 677|678a 2412 TT y 
cwp84 27 2054|2055a 2412 TT y 
fliD   12 120|121s 1524 TT y 
cd1751 26 2024|2025a 2388 Clos n 
cd2713 11 1482|1483a 1962 Clos n 
cd2767 10 1524|1525a 2112 Clos n 
cd2797 51 2925|2926a 5964 Clos n 
cd3008(pseudogene) 7 39|40a 714 Clos n 
cd3146(pseudosortase) 4 120|121a 690 Clos n 
cdtB(CD2605)(pseudo*) 10 645|646s  1536 Clos n 
slpA 18 1266|1267s 2160 TT n 
slpA 18 258|259s 2160 TT n 
slpA 18 321|322s 2160 TT n 
 
Clos- ClosTron free intron retargeting (www.clostron.com), TT- Sigma Targtron Design site 
retargeted.* encodes a truncated non-functional gene, therefore considered a pseudogene. 
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Two methods of intron retargeting were assessed: retargeting via Sigma TargeTron 
algorithm (http://www.sigma-genosys.com/targetron/) which is “an extensively 
validated TargeTron algorithm that predicts optimal intron insertion sites and 
designs primers for mutating the intron to insert into those sites” and the 
implementation of the Perutka et al (2004) algorithm available free at 
www.clostron.com.  
 
The preferred intron insertion sites given by each algorithm, while containing 
similarities, do differ as demonstrated by the top 5 hits of Cwp84 from R20291 
(Table 5.3.2). 
 
Table 5.3.2 Differences between intron retargeting algorithm results for cwp84 of 
C. difficile R20291, using ClosTron.com or Sigma TargeTron. 
 
 
As discussed in Chapter 3 Section 3.3.1, the knockout of cwp84 at multiple sites 
resulted in a negative phenotype being obtained, regardless of the intron insertion 
location. Therefore, the methodology used in this chapter was to only progress one 
intron insertion site in each gene. As a result, not every chosen target was knocked 
out (Table 5.1.2). It is possible that knockout failed for a number of reasons:  
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 Knockout may have failed for technical reasons but the insertion site may 
have been successful. 
 The insertion site was not suitable for intron insertion. 
 Inactivation of that particular gene resulted in a lethal phenotype (as is 
putatively generated by the KO of slpA (discussed in 5.4.1.2)).  
 
5.3.2 Genetic characterisation 
PCR, using primers flanking the chosen genes, was used to confirm intron insertion 
in the Erm resistant C. difficile clone(s) (Figure 5.3.1).  
 
 
Figure 5.3.1 PCR confirmation of intron integration into selected surface protein genes. 
Lower band represents PCR product of WT, upper band represents amplification post 
intron insertion i.e. KO. Numbers refer to kilo base pairs. 
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5.3.2.1 Transcriptional analysis 
Expression of cd2791, cwp66, cd2784 and fliD have been described previously 
(Calabi et al. 2001; Tasteyre et al. 2001b; Savariau-Lacomme et al. 2003). To 
investigate the expression of cd2795, cd1036, cd2735, during normal growth, RT-
PCR was performed on C. difficile 630ΔErm stationary phase RNA (Figure 5.3.2). 
 
 
Figure 5.3.2 RT-PCR of cd1036, cd2735 and cd2795 from stationary phase 
C. difficile 630ΔErm RNA. The size of the reaction products reflects the 
regions chosen for amplification within each sequence. 
 
Data shows that cd1036, cd2735 and cd2795 are all expressed in stationary phase in 
C. difficile 630ΔErm; amplification of cd2795 gave a weak transcript using two 
different primer sets (Table 5.2.3). In silico analysis upstream or downstream of 
cd1036, cd2735 and cd2795 in the C. difficile 630 genome, suggests there are no 
genes within a short intergenic distance (<100 bp), therefore expression of cd1036, 
cd2735 and cd2795 is assumed to be monocistronic.  
 
It is suggested that cd2791-cd2790-cwp66 (cd2789) are encoded on a polycistronic 
message (Savariau-Lacomme et al. 2003). To confirm this, and to investigate 
expression this operon after intron insertion, RT-PCR was performed. Firstly, using 
primers flanking the intron insertion sites (Figure 5.3.4, primer set 1(a) or (b)), no 
products were obtained for the corresponding mutant (Figure 5.3.3 (i) and (ii)), 
confirming truncation of mRNA upon intron insertion  
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To understand how intron insertion, affected the polycistronic message, particularly 
in CDΔcd27911569, RT-PCR was performed amplifying the intergenic regions 
between cd2791-cd2790-cwp66 (cd2789), similar to RT-PCR performed by Savariau-
Lacomme et al. (2003) (Figure 5.3.3 (iii – v)).  
 
 
Figure 5.3.3 RT-PCR using stationary phase RNA from C. difficile 630ΔErm, CDΔcd27911569 
and CDΔcwp66519. Using: (i & ii) Primers amplifying cd2791 or cwp66, flanking the intron 
insertion site (Figure 5.3.4 primers 1(a) or (b)). (iii) Primers amplifying the intergenic region 
between cd2791-cd2790 (Figure 5.3.4 primers 2(a)). (iv) Primers amplifying the intergenic 
region between cd2790-cwp66 (cd2789) (Figure 5.3.4 primers 2(b)). (v) Primers amplifying 
directly after the intron in CDΔcd27911569.The size of the reaction products reflect the 
regions chosen for amplification within each sequence. 
 
Using intergenic primers (Figure 5.3.4, primer set 2(a) or (b)) a transcript is found, 
as expected for a polycistronic message, in C. difficle 630ΔErm and CDΔcwp66519, 
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but also in CDΔcd27911569. A transcript is also found directly after the intron in 
CDΔcd27911569 (Figure 5.3.4, primer set 3). The presence of a post-cd2791 transcript 
in CDΔcd27911569 RNA, suggests a transcript, transcribed from within the intron 
(putatively from the thl promoter of the ermB gene), continues through the 
intergenic regions and putatively encodes a message for CD2790 and Cwp66.  
 
 
 
Figure 5.3.4 Schematic of RT-PCR analyses of cd2791-cd2790-cwp66 cluster. (A) Proposed 
polycistronic message of C. difficile 630ΔErm, CDΔcd2791 and CDΔcwp66. X – termination 
of transcript. • – start of transcript, hashed line - assumed continuation of mRNA (although 
no RT-PCR performed). (B) Location of primers and size of expected products used in 
transcriptional analysis (not to scale). Primers are colour coded with both their respective 
pair and their product. Primer sets - 1(a) & (b) - flanking intron insertion sites, 2 (a) & (b) - 
intergenic primers (same as used in Savariau-Lacomme et al. (2003)), 3 - cd2791 post intron 
insertion site. 
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5.3.3 Characterisation of the knockout mutants 
5.3.3.1 Morphology and growth characteristics 
5.3.3.1.1 Growth 
All surface protein KOs appeared to have normal colony morphology and appeared 
similar to WT cells under Gram stain. The growth rate of the mutants in liquid 
medium was assessed (Figure 5.3.5). All mutants grew at a similar rate to the WT, 
except CDΔcd2784438 (p=0.027, Paired T-test) which appeared to grow significantly 
slower than the WT. The flagella cap (fliD) KO while grew slower, was not 
statistically significantly different to the WT growth rate (p=0.053, Paired T-test). 
5.3.3.1.2 Motility 
The CDΔfliD120 mutant had a tendency to settle in unstirred liquid culture vessels, 
suggesting an inability to maintain in suspension. Results show CDΔfliD120 did not 
appear to demonstrate any motility into soft agar compared to the parental strain 
C. difficile ΔErm or control 001 ribotype strains, suggesting that CDΔfliD120 is non-
motile (Figure 5.3.6). This result is consistent with recently reported data, 
suggesting both the FliD and FliC mutants are non-motile (Baban et al. 2010).  
5.3.3.1.3 Sporulation 
Mutants appeared to retain their ability to sporulate with none of those assessed 
being significantly different to the WT (p>0.05, Students T-Test) (Figure 5.3.7) 
suggesting that the ability to form viable, heat resistant, spores was unaffected. 
5.3.3.2 Toxin production 
Toxins A and B are produced when cultures reach stationary phase (usually after 
15 hr, 24 hr for C. difficile 630 (Merrigan et al. 2010)) and when cultures are 
stressed. The ability of surface protein KO mutants to produce toxin was assessed 
by ELISA and compared to toxin production of the wild-type under similar growth 
conditions.  
 
Figure 5.3.8 shows 24 hr culture supernatants from surface protein mutants had 
higher toxin A concentrations than the wildtype (p>0.05, Students T-test) except 
CDΔcd2784438 (p=0.59, Students T-test) as measured by ELISA. This increase was 
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particularly high in CDΔcwp84347 and CDΔfliD120. CDΔtcdR499 did not appear to 
produce any toxin A above the limit of quantification (5 ng/ml), consistent with its 
role as a positive toxin regulator. Disruption of a gene key for sporulation, but not 
putatively surface located (spo0A), also results in significantly increased toxin 
production after 24 hr (p<0.05, Students T-Test), a result which is contrary to a 
previously reported spo0A KO (Underwood et al. 2009). Toxin B levels of mutant 
24 hr culture supernatants, although demonstrated a slight increase, were not 
significantly different (p>0.05, Students T-test) to the wildtype. 
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Figure 5.3.5 Growth Rates of C. difficile surface protein mutants. (A) Growth rates measured on the linear portion of the growth curve 
(* denotes statistically significant (p<0.05) slower growth rate than the WT) (n=3) (B) Comparison of growth rate of mutants with WT as a 
percentage.  
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Figure 5.3.6 Motility of C. difficile strains in molten agar. C. difficile was inoculated into the first 5 mm of 0.175% sBHI agar and 
grown for 24 hr. 
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Figure 5.3.7 Viable spore count of surface protein mutants.
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Figure 5.3.8 Estimation of Toxin A concentration in culture supernatant from C. difficile strains/mutants by ELISA. Strains grown in 
sBHI culture medium for 24 hr (* denotes statistically significant (p <0.05) higher toxin A concentration than the WT). Limit of 
quantification 5 ng/ml.
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5.3.3.3 Analysis of surface layer proteins of surface protein mutants 
In order to determine if the knockout of various surface proteins had an effect on 
the surface of the bacterium, the surface proteins were removed by low pH 
extraction and examined by SDS-PAGE (Figure 5.3.9). 
 
 
Figure 5.3.9 Coommasie stained SDS-PAGE gel of low pH SLP extracts from 
a range of surface protein mutants. FliC- Flagella core protein, Rr- 
rubrerythrin (Chapter 4 Section 4.3.1). 
 
Mutant SLPs appear largely similar to the WT SLPs. The main S-layer bands appear 
unaffected and are present at 40 kDa and 47 kDa respectively. The lower MW 
fragmentation pattern (<28 kDa) is similar to the WT.  
 
The SLPs of CDΔcd27911569 lack a 66 kDa species, mass spectrometric analysis of this 
protein in the WT identified it as CD2791 (Cwp2), confirming the loss of the CD2791 
from the cell surface corresponds with inactivation of cd2791. In CDΔcd2784438 SLPs 
a 58 kDa band is less dense compared to other mutant and WT SLPs. The SLPs from 
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CDΔfliD120 demonstrate a lack of a 38 kDa species (identified as FliC in CDΔcwp84 
SLPs (Chapter 3 Section 3.3.4.1). The 115 kDa band (identified as CwpV in Chapter 
3) appears unaffected in all mutant SLPs.  
5.3.3.4 Adherence to the Caco-2 colonic cell line 
Under standard culture conditions (after 14-21 days) Caco-2 cells spontaneously 
polarise and display presence both tight junctions, resulting in formation of 
functionally differentiated brush-border microvilli, thereby resembling enterocytes 
lining the small intestine. Caco-2 cells are widely used across the pharmaceutical 
industry as an in vitro model of the human small intestinal mucosa, to predict the 
absorption of orally administered drugs and used to assess adherence of 
gastrointestinal pathogens including C. difficile (Eveillard et al. 1993; Cerquetti et al. 
2002). Therefore, using a cell based adhesion assay, the ability of the created 
surface protein mutants to adhere to Caco-2 cells in vitro was assessed (Figure 
5.3.10).  
 
Results show that mean adhesion of four mutants: CDΔcwp66519, CDΔcd27911569, 
CDΔcd27951320 and CDΔcd27351113 was significantly lower than the WT (p<0.05, 
Students T-test). Two mutants CDΔcd2784438 and CDΔfliD120 displayed increased 
relative adhesion compared to WT. The data suggests that knockout of cd2735, 
cd2795, cd2791 and cwp66 decreases the ability of C. difficile to adhere to Caco-2 
cells in vitro. 
 
Due to the close association of cd2791 and cwp66 genetically, adhesion of 
CDΔcd27911569 and CDΔcwp66519 to Caco-2 cells were assessed in a direct pair-wise 
comparison (Table 5.3.3). The mean adherence of CDΔcd27911569 is statistically 
significantly less compared to CDΔcwp66519 (p=0.003, Students T-Test). Taken 
together, the data suggests that both Cwp66 and CD2791 play a role in adhesion, 
with the inactivation of cd2791 having a profound effect on the ability of bacterial 
cells to adhere in vitro (Figure 5.3.11).  
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Figure 5.3.10 Relative adhesion of C. difficile surface protein mutants in vitro. 
Relative adhesion calculated from mean numbers of mutant C. difficile organisms 
adhering to a cell relative to C. difficile ΔErm in pair wise comparison (± standard 
error). 
Measurements made by random field of view counts of a total of >150 Caco-2 cells vs 
bacterial cells at x1000 magnification, each adhesion assay was conducted in 
duplicate. * denotes statistically significant different adhesion compared to WT.  
 
 
 
Figure 5.3.11 Random field of view comparision of adhesion of C. 
difficileΔErm vs. CDΔcd27911569 to Caco-2 cells in vitro. X1000 
magnification. 
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Table 5.3.3 Adhesion of CDΔcd27911569 vs. CDΔcwp66519 to Caco2 cells 
Mutant Adhesion* % of Δcwp66 adhesion 
Δcwp66 0.15±0.03 100% 
Δcd2791 0.06±0.01 60.0±19.5% 
*Mean numbers of C. difficile organisms adhering to a cell (± standard error). Measurements made 
by random field of view counts of a total of >150 Caco-2 cells vs bacterial cells at x1000 
magnification, each adhesion assay was conducted in duplicate. 
 
5.3.3.5 Binding of rCD279127-322 to cell lines  
Since CDΔcd27911569 displayed decreased adhesion to Caco-2 cells in vitro, the 
ability of a recombinant N-terminal domain of CD2791 (rCD279127-322) to bind to cell 
lines was assessed.  
 
Unfortunately, the apparent auto-fluorescence of Caco2 cells prevented 
qualification of binding of Alexafluor488 labelled rCD279127-322. Using Vero cells 
binding of Alexafluor488 labelled rCD279127-322 was observed at 1 µM and 50 µM 
(Figure 5.3.12). Unfortunately, the Vero cells were significantly more sensitive to 
the washing steps and despite duplicate repeats, Vero cells sloughed from 8-well 
chamber slides preventing confirmation of rCD279127-322 binding or competition 
assay.  
 
On the basis of these preliminary results, the N-terminal domain of CD2791 
(rCD279127-322) appears to have some adhesive properties in vitro. 
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Figure 5.3.12 Adhesion 1 µM or 50 µM of Alexafluor488 labelled rCD279127-322 to Vero cells. 
Slides viewed dry at x4000 magnification. 
5.3.3.6 Purification of anti-CD2791 antibodies from anti-R20291 SLP 
IgG 
As antibodies raised to SLPs react with a 66 kDa species (CD2791) in SLPs of any 
strain (Chapter 4 Section 4.3.3.1or 4.3.3.2), a method utilising an immobilised N-
terminal fragment (rCD279127-322) to purify specific anti-CD2791 was assessed. 
These antibodies would then be used in the caco2 cell adhesion assay for their 
ability to prevent both rCD279127-322 fragment binding and C. difficile adhesion. 
 
In order to quantify the level of the immune response to CD2791 in anti-R20291 SLP 
IgG, ELISA with immobilised rCD279127-322 was performed (Figure 5.3.13).  
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Figure 5.3.13 Binding of ovine anti-R20291 SLP IgG to rCD279127-322 in ELISA 
 
Anti-R20291 SLP IgG reacted with 10 µg/ml rCD279127-322 in ELISA approximately 1 
log less than corresponding SLPs and ½ log less than a differing strain SLPs (C. 
difficile 630ΔErm), suggesting that a significant proportion of the anti-SLP immune 
response is directed to the N-terminus of CD2791. 
 
To purify specific anti-CD2791 antibodies from anti-R20291 SLP IgG, rCD279127-322 
was coupled to N-hydroxysuccinimide (NHS)-agarose, with an approximate 60% 
coupling efficiency. Unfortunately, despite application of 40 mg of anti-R20291 SLP 
IgG (1 mg/ml), only 1 ml of 5 µg/ml specific CD2791 antibodies were eluted, too 
little for use in the adhesion assay. 
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5.4 Discussion 
It is only relatively recently that a stable targeted gene knockout system for the 
genus Clostridium has been developed (Heap et al. 2007; Heap et al. 2010). The 
ClosTron system, derived from the TargeTron system (Sigma-Aldrich), inactivates a 
gene by targeted insertion of a group II intron (Ll.LtrB) from Lactococcus lactis. The 
Ll.LtrB intron is useful, as it has a broad host range (Gram positive and negative 
organisms) (Cousineau et al. 1998; Yao et al. 2005) and because the intron encoded 
protein (IEP) is expressed downstream of the Ll.ltrB intron (on a plasmid), the 
resulting insertion is non-splicing, i.e. is extremely stable. This has been 
demonstrated by Frazier et al. (2003), who found no loss of bacteriophage C2 
resistance of an M1083s-opt::abiD integrant after 80 passages. 
 
To date, there are only four publications reporting the knockout of surface 
associated proteins (CwpV (Emerson et al. 2009a), Cwp84 (Kirby et al. 2009) , FliC 
and FilD (Baban et al. 2010) and Fbp68 (Lin et al. 2010)). There is therefore 
considerable scope for furthering knowledge of C. difficile pathogenesis via a gene 
KO approach. Particularly for surface associated genes which possess a CWBD 
which putatively attaches them (non-covalently) to the cell surface. In this chapter a 
selection of surface associated genes (PFam 04122 containing) and the flagella cap 
were knocked out and the mutant strains characterised. 
5.4.1 Genetic considerations of C. difficile knockouts 
5.4.1.1 Production of C. difficile knockouts 
A total sixteen genes (22 insertion sites) were selected for knockout (Table 5.1.2), 
eleven contained an N- or C- terminal CWBD, two were surface associated (FliD and 
CD2797) and three were putative pseudogenes (annotated as such in the C. difficile 
genome), to assess whether any phenotypes observed were not directly related to 
the ClosTron protocol or intron integration.  
 
The algorithm for selecting insertion sequences and retargeting the region 
responsible for intron specificity was initially only available via the Sigma TargeTron 
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website, but subsequently became available free of charge via www.clostron.com 
(Heap et al. 2010). As revealed in Table 5.3.2, intron insertion sites given by the 
Sigma design site and the those given by the ClosTron.com (Perutka et al. 2004) 
algorithm are different. Out of the 12 sites (8 genes) which were successfully 
knocked out, 8 sites were retargeted via TargeTron and 4 sites were retargeted by 
ClosTron .com (Table 5.1.2). On the basis of these results, KO success is more likely 
with the Sigma TargeTron algorithm than with the ClosTron.com algorithm. 
 
Out of all the sixteen genes selected for knocked, eight were not able to be knocked 
out; these were slpA, cd1751, cd2713, cd2767, cd2797 and three pseudogenes. 
There are several reasons to explain failure to KO selected genes in this chapter.  
 
The first of these, is the approach taken in this chapter (as opposed to that used in 
Chapter 3), whereby choosing only one target site in each gene severely restricts 
the likelihood of success. If a chosen target site is not amenable to intron insertion 
then the gene will not be knocked out, however many times the site is tried, i.e. 
independent of protocol repetition or optimisation. The second reason for KO 
failure may be technical problems with specific parts of the ClosTron protocol, e.g. 
conjugation, or reversion of C. difficile 630ΔErm to erythromycin resistant (as 
reported by (Hussain et al. 2005)), making integrant screening difficult. A third 
reason for failure may simply be the screening of an insufficient number of clones 
for correct integration. Heap et al. (2009a) recommends that if screening 4 clones 
does not result in successful integrant identification, to flood the plate and/or 
screen large amounts of colonies. The third reason is not failure to KO, but failure to 
isolate KO clones. Finally, and particularly applicable to slpA (discussed in 5.4.1.2 
below) is the possibility that insertional inactivation of the chosen genes results in a 
lethal phenotype.  
 
A trial of a double KO using CDΔcd27911569 and CDΔcwp66519 or vice versa was 
unsuccessful, however, to date, only one double KO mutant has been reported 
(Kuehne et al. 2010) and utilised a slightly modified knockout procedure. It is also 
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possible that the double cd2791/cwp66 mutant failed due to alterations on the cell 
surface prevented successful conjugation. 
5.4.1.2 Knockout of slpA 
Knockout of the main S-layer gene was repeatedly attempted; however, no mutant 
clones were isolated. It is suspected that KO of slpA creates a lethal phenotype, in 
which the cell can no longer retain any structural integrity, as provided by a 
rudimentary S-layer (such as that found in the cwp84 mutant (Kirby et al. 2009)). 
However, S-layer negative strains of Aeromonas sp. (Janda et al. 1994), B. anthracis 
(Kern & Schneewind 2009), Tannerella forsythensis (Sakakibara et al. 2007) or 
Campylobacter fetus subsp. Fetus (Grogono-Thomas et al. 2000) exist, suggesting 
that an S-layer negative C. difficile mutant may be possible, as normally S-layer 
positive bacteria can survive without their S-layers.  
 
As the KO of certain surface protein KOs resulted in earlier release of toxin A and B, 
it was hypothesised that tcdE (a holin of C. difficile that lyses E. coli (Tan et al. 
2001)) may also be upregulated. Therefore, a double slpA:tcdD(R) knockout was 
tried, tcdD(R) is a positive (alternative sigma factor) regulator of toxin production 
(Karlsson et al. 2003). By using a tcdD(R) mutant, putative upregulation tcdE or 
other self harming proteins under tcdD(R)’s regulation should not be induced. This 
technique created pin prick transconjugants previously unattainable using the 
normal C. difficile 630ΔErm; however, subsequent plating dramatically decreased 
colonies, indicating that while conjugation could occur upon intron integration a 
lethal phenotype resulted. The type of colonies obtained may be similar to those 
obtained by knockout of glycerol dehydrogenase (gldA) by Liyanage et al. (2001). 
Dang et al. (2010) also highlights how, to date, despite widespread efforts it has not 
proven possible to generate a slpA knockout strain. 
 
Preventing the lethal phenotype produced from KO of essential genes is therefore a 
challenge. Creation of conditional mutants or complementation prior to KO may 
provide a way to circumvent the effects of inactivation. If the latter technique is 
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used, particularly with the ClosTron technique, one must prevent the intron 
inserting into the plasmid rather than the desired location in the host genome.  
5.4.1.3 Transcriptional analysis of cd2791-cd2790-cwp66 cluster 
RT-PCR in this chapter has confirmed the existence of a polycistronic transcript 
between cd2791-cd2790-cwp66, as suggested by Savariau-Lacomme et al. (2003). 
Transcription of the polycistronic message is assumed to proceed through cd2791-
cd2790-cwp66 in C. difficile 630ΔErm and up until the intron in CDΔcwp66519 (Figure 
5.4.1, WT and Δcwp66). Due to the polar insertion of the intron in CDΔcd27911569, a 
transcript, originating from the thlA promoter (used to drive the introns ErmB 
expression), is found past the intron insertion site putatively encoding CD2790 and 
Cwp66 (Figure 5.4.1, Δcd2791).  
 
 
 
 
Figure 5.4.1 Proposed transcription of the cd2791-cd2790-cwp66 operon 
before and after knockout of cd2791 and cwp66. All three genes are encoded 
as a polycistronic message (light blue) in the wildtype C. difficile 630ΔErm 
(WT). Messenger RNA is truncated at cwp66 in CDΔcwp66519 (Δcwp66) and 
cd2791 in CDΔcd27911569 (Δcd2791); however in CDΔcd27911569, an intron 
derived transcript continues along the operon and putatively encoding a 
message for CD2790 and Cwp66 (grey). 
 
It is likely that unless CD2790 and Cwp66 are post-transcriptionally controlled, polar 
intron insertion in CDΔcd27911569 results in non-wildtype transcription of cd2790 
and cwp66 and may subsequently alter CD2790 and Cwp66 levels. This polar effect 
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could be resolved by removal of the ermB gene using FRT sites, leaving only the 
940 bp group II intron region, which is normally efficiently transcribed and should 
not cause premature termination of transcripts (Heap et al. 2009a), or by using a 
unique gene deletion technique recently developed using the ClosTron system (Jia 
et al. 2011).  
 
It is unknown as to whether the genes downstream of cd2791 are still translated 
from the resultant (intron-derived) message. However, it is likely that the regulation 
of 2790-cwp66 and putatively the resulting protein(s) is altered from the WT (unless 
they are post-transcriptionally regulated). The identification/presence of Cwp66 on 
the cell surface of CDΔcd27911569 and/or proof that its regulation is unaffected by 
cd2791 KO would be required to confirm phenotypic changes were not due to 
decreased expression of cwp66 (or cd2790). Although, inactivation of cd2791 
decreases adhesion more than cwp66 KO alone. This suggests that CD2791 plays a 
role in adhesion different to that of Cwp66, or CD2790 plays a larger role than 
previously thought in mediating adhesion. 
 
CD2790 is labelled a hypothetical protein in the C. difficile 630 genome but shares 
amino acid homology with N-acetylglucosaminyl phosphatidylinositol deacetylases, 
which participate in the second step of glycosylphosphatidylinositol (GPI) 
biosynthesis. GPI is used to anchor surface proteins in membranes in eukaryotic 
cells (Kinoshita & Inoue 2000). However, HMM-HMM structure modelling reveals 
that CD2790 shares strong homology to the zinc-dependent metalloenzyme 
deacetylases. Deactelyation of peptidoglycan protects the bacterial cell wall from 
host lysozymes (Blair et al. 2005; Wang et al. 2010). The role of a deacteylase in 
conjunction with CD2791 or Cwp66 in C. difficile is currently unknown, but may be 
connected with a surface based response to stress. 
 
Clusters of genes modifying cell surface proteins have been found in Shigella 
flexneria, where a cluster of three genes (gtrA,B,X), in a series of steps, glucosylate 
the O antigen (Guan et al. 1999). Hence, given the polycistronic message, it is 
possible cd2791-cd2790-cwp66 form a part of the bacterial surface operon. 
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However, as discussed in Chapter 4, as cd2791-cd2790-cwp66 are encoded on the 
same transcript, the lack of identification of Cwp66 during normal growth (Wright 
et al. 2005) and the constitutive presence of CD2791 on the cell surface, suggests 
these two proteins are differently (possibly post-transcriptionally) regulated. 
5.4.2 Characterisation of the knockout mutants  
5.4.2.1 Colony morphology, growth, motility and sporulation. 
The colony morphology of all mutants produced in this chapter appeared WT-like, 
suggesting that inactivation of the chosen surface proteins do not affect the ability 
of the bacterium to form ‘normal’ spreading grey glass-like colonies. C. difficile 
colony morphology has been reported to change in response to Cwp84 or CwpV KO 
(Kirby et al. 2009; Reynolds et al. 2010). In CDΔCwp84, this is due to an increase in 
extracellular debris changing cellular migration and optical diffraction. 
The growth rate of the mutants, were largely the same as the WT. The growth rate 
of the CD2784 mutant was significantly slower than the WT, suggesting that the 
ability of the bacterium to grow was affected.  
 
It has been reported that inactivation of the peptidoglycan hydrolase, Acp, affects 
cell separation in Clostridium perfringens (Camiade et al. 2010). Therefore, it was 
expected that mutants deficient in CD2784 and CD1036, which contain a 
peptidoglycan aminohydrolase domain, would show altered cell morphology. 
However no difference was seen, suggesting that these proteins do not play a role 
in cell morphology or daughter cell separation. 
 
As aforementioned C. difficile, in common with E. coli, has several peptidoglycan 
hydrolases. Therefore, inactivation of one such protein, e.g. CD2784, may not have 
an effect, as another can fulfil its role e.g. CD1036. In 1976, Fein & Rogers (1976) 
reported B. subtilis N-acetylmuramoyl-L-alanine amidase and endo-beta-N-
acetylglucosaminidase mutants appeared to grow at normal rates, but as very long 
chains of un-separated cells. The mutants readily reverted, suggesting that the 
mutation was in a regulatory gene rather than the autolytic enzymes themselves. 
Therefore, it is possible that inactivation of an, as yet undiscovered, autolytic 
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regulatory protein(s) will have more of a marked effect on C. difficile than individual 
peptidoglycan hydrolase mutants. Work by Johann Peltier and colleagues is 
investigating this hypothesis by inactivation of sigD, a putative regulator of 
autolysins (Peltier et al. 2010). Indeed, all the twelve E. coli periplasmic 
peptidoglycan hydrolases have the potential to degrade the cell wall, however why 
they do not under normal growth conditions still remains to be answered (Vollmer 
et al. 2008). 
 
All mutants produced in this chapter appeared to sporulate with sporulation level 
similar to that of the WT. Cell wall hydrolase mutants of Streptomyces coelicolor 
have heat sensitive spores (Haiser et al. 2009), however, all mutants produced heat 
resistant spores in this chapter.  
 
Consistent with both the FliD KO in Pseudomonas aeruginosa (Arora et al. 2000) 
and the FliD mutant produced by Baban et al. (2010), the FliD mutant produced in 
this study was non-motile. The non-motile nature of the flagella cap (FliD) mutant 
caused it to appear to grow slower in un-agitated liquid cultures (as measured by 
A600), as cells settled rather than producing normal suspension.  
5.4.2.2 Toxin production of mutants 
Toxin production in C. difficile is initiated in times of nutritional stress, typically 
occurring in stationary phase (Karlsson et al. 2008; Merrigan et al. 2010). Toxin 
production also appears to be increased upon exposure to sub-MIC concentrations 
of certain antibiotics (Onderdonk et al. 1979; Gerber et al. 2008). However, to date, 
there is only one reported occurrence of increased toxin production after knockout 
of surface associated genes (Baban et al. 2010).  
 
Culture supernatants of CD2735, Cwp66, CD2791, Cwp84, CD2795, FliD and Spo0A 
mutants contained more toxin A than the wildtype, C. difficile 630ΔErm, after 24 hr. 
As discussed in Chapter 3, the increased toxin production found for the cwp84 
mutant is likely to be a result of the altered S-layer and the upregulation of stress 
pathways due to decreased cell integrity, or that decreased cell integrity means 
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toxin is able to ‘leak’ from the cell (a mechanism similar to the role putatively 
performed by TcdE (Tan et al. 2001)) 
 
As CD2791 is surface located, it is possible that removal of CD2791 from the cell 
envelope results in decreased cell integrity or results in changes to membrane/cell 
wall genetic regulation of toxin genes, resulting in earlier release of toxin. The 
current lack of identification of CD2735, CD2795 on the cell surface and the 
conditional expression of Cwp66 draws the cell integrity hypothesis into question. 
One presumes that the cell wall of the spo0A mutant is not affected, yet the spo0A 
mutant in this chapter produces increased toxin similar to CD2735, Cwp66, CD2791 
and CD2795 mutants. Although, caution is to be exercised regarding C. difficile 
Spo0A mutants and toxin production, as there is conflicting evidence regarding links 
between sporulation and toxin production, as results in this chapter contradict 
Underwood et al. (2009). A Bacillus subtilis spo0A mutant was prone to cell lysis 
(though a lack of autolysin degradation via extracellular proteases) (Kodama et al. 
2007), therefore, although Spo0A is not directly surface based, it may still play a 
role in cell integrity and as a result, on toxin production.  
 
The non-motile nature of the FliD KO (or the FliC KO in (Baban et al. 2010)) means 
the bacterium is limited to utilising the nutrients in the local area, once these are 
spent, i.e. nutrient limitation conditions, toxin production begins. Baban et al. 
(2010) also suggests that the increased toxin may help the bacterium cause disease 
in the animal model, as postulated for the Cwp84 KO. 
 
Together these results suggest that certain surface proteins have an intimate link 
with toxin production, exemplified by the CD2784 mutant not producing any more 
toxin A than the WT after 24 hr. Therefore, it appears CD2784 is not involved in any 
pathways which result in the release of toxin, particularly if they become non-
functional. 
 
It is interesting that C. difficile 630 (and its ΔErm variant) are low toxin producers, 
whereas ribotype 027/B1 strains have increased toxin production, as does VPI10463 
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(Merrigan et al. 2010). Do these high toxin producing strains have an altered 
surface that results in increased toxin production, increasing their virulence? Are 
toxin production, cell metabolism and cell surface integrity connected via a 
regulatory network e.g. a change in CodY expression (Dineen et al. 2010)? If so, the 
integration of these two systems may be key to infection progression in vivo. 
Moreover, co-administration of crude C. difficile toxin preparations, with a non-
toxigenic strain, resulted in a significantly greater adherence to small bowel mucosa 
comparable to that of the toxigenic strain, suggesting the ability to produce toxin 
may confer some ecological, colonisation, advantage (Borriello & Barclay 1985; 
Borriello et al. 1988; Feltis et al. 1999).  
5.4.2.3 Surface proteins of mutants 
The SLPs of mutants produced in this chapter are largely similar to the SLPs of the 
WT. The differences that do occur are the loss of the 66 kDa CD2791 protein 
(CD2791 KO), loss of the 36 kDa FliC (FliD KO) and changes in a 58 kDa band 
intensity (CD2784 KO). The loss of the FliC band from the SLPs of FliD indicates that 
the flagella are no longer correctly assembled, confirmed by a lack of motility in the 
FliD KO. 
 
Confirmation of KO i.e. the loss of a knocked out protein from the cell surface or 
identifying if the original KO affects other surface proteins, is largely dependent on 
the use of a method (growth and extraction) which reliably removes that protein(s) 
from the WT. Therefore, particularly applicable to CD2795 and CD2735 KO, 
confirming protein loss after KO is hampered by the apparent lack of these proteins 
on the cell surface. Therefore, cell surface based changes may have occurred in the 
mutants produced in this study, but using low pH glycine extraction they have not 
been revealed. The lack of observed major effect on the SLPs upon loss of Cwp66, 
CD2795, CD2735 and CD1036, could suggest how their presence and expression is 
conditional. 
 
Antibodies to the surface proteins knocked out in this chapter may have helped 
their identification (and their subsequent loss). Interestingly, Abcam plc (Cambridge 
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UK) sell two antibodies (catalogue numbers 93756 and 93728), one to the N-
terminal and another to the C-terminal end of a protein “highly similar to 1035”, if 
these are CD1036, they could have been used for immunological studies.  
 
Confirming the loss of a knocked out protein (on the cell surface) is, however, only 
one part of the story. More complex methods such as microarray, proteomics or 
transcriptome sequencing are likely to be required to reveal, or start to reveal, the 
complex interactions between surface proteins and the bacterium. 
 
The ClosTron system is, therefore, best suited to where there is a prior idea of the 
likely outcome of KO or at least a way of measuring the KO outcome, rather than 
randomly targeting individual genes and hoping for a negative phenotype, as 
attempted in this chapter. A random mutagenesis approach, such as the use of a 
transposon (Cartman & Minton 2010; Hussain et al. 2010) may be more applicable 
to identification of genes required in key pathways.  
5.4.2.4 Adherence to cell lines 
Surface protein extraction techniques only reveal proteins found on the cell surface 
in vitro and do not demonstrate those which are only necessary for infection in 
vivo.  
 
In the absence of in vivo animal models, an in vitro adhesion assay using Caco-2 
cells was used to determine if any of the mutants produced in this chapter had 
altered cell binding abilities. It was discovered that using post confluent fully 
differentiated Caco-2 cells, four surface protein mutants (CD2735, CD2795, CD2791 
and Cwp66) adhered lower than C. difficile 630ΔErm, indicating that inactivation of 
either one of these four proteins, results in a decreased ability to adhere to Caco-2 
cells in vitro.  
5.4.2.4.1 CD2735 
CD2735 contains two SH3 domains which participate in protein-protein 
interactions, mediating assembly of specific protein complexes via binding to a 
proline-rich (PXXP) core-conserved binding motif in their respective binding partner 
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(Mayer 2001). The KO of CD2735 containing these domains and the subsequent 
decrease in adhesion suggests that the SH3 domains in CD2735 partially mediate 
binding in C. difficile. However, SH3 domains bind their ligand with low affinity, thus 
are enhanced by multiple interactions, suggesting that CD2735 is prevalent on the 
cell surface; however, it has not been found to date.  
 
Putative roles for CD2735 include: 
 Assisting in the formation of multi-meric protein complexes on the surface 
of C. difficile.  
 Binding directly to host protein(s) sufficiently to anchor C. difficile to the 
host cell. 
 CD2735 upon binding to a host protein(s) affects the host in such a way that 
adhesion is increased, but is not involved directly in adhering bacterial cells. 
 CD2735 upon binding to a host protein affects C. difficile surface proteins 
such that other stronger adhesins (perhaps forming a complex) are brought 
into play. 
 CD2735 is a signal molecule for C. difficile and its KO prevents a signal 
reaching an adhesin that would normally be upregulated in the presence of 
a binding environment. 
 
It has been shown that invasive pathogens, such as Salmonella typhimurium, 
promote assembly of focal adhesion complexes, which contain SH3 domains, in 
response to bacterial attachment (Ireton & Cossart 1998; Shi & Casanova 2006). 
Moreover, modified SH3 domains are found on the surface of the Listeria 
monocytogenes invasion protein InlB and mediate binding to host ligands (Marino 
et al. 2002). While C. difficile is putatively not invasive, it is possible one or more of 
its surface proteins promote adhesion by modification of host cell physiology. The 
subversion of host cell physiology is found in the enteropathogenic Escherichia coli 
(EPEC) secreted protein, EspF. The EspF protein contains three proline-rich repeats 
and six putative SH3 binding domains and disrupts intestinal barrier function 
through mitochondrial targeting, specifically by binding to sorting nexin 9 (Marches 
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et al. 2006). Further work examining CD2735 and binding to host cell receptors is 
therefore required.  
5.4.2.4.2 CD2795 
The proposed ability of the bacterial Ig-like domains to interact (Potapov et al. 
2004), suggests that loss of CD2795 from the cell surface may decrease adhesion 
through an inability to form CD2795-CD2795 and/or CD2795-CD2794 (adhesin) 
complexes, which may or may not directly impact interactions with host cell 
proteins. In Leptospira spp. three bacterial Ig-like domain containing proteins (LigA, 
B, C containing thirteen and twelve Ig-like domains respectively) have been found 
to bind fibronectin, and when administered to hamsters prevent mortality (Silva et 
al. 2007; Lin et al. 2008). However, given that these (Lig) proteins contain far more 
Ig-like domains than CD2795 (and CD2794), inferences about CD2795 (or CD2794) 
are limited, but serves to highlight how these domains may play a role in bacterial 
adhesion.  
 
The role of the SCP domain in bacterial pathogenesis or adhesion is not well 
understood. The SCP family includes plant pathogenesis-related protein 1 (PR-1), 
mammalian cysteine-rich secretory proteins (CRISPs) and allergen 5 from vespid 
venom (Yeats et al. 2003). One protein, human GAPR-1 protein (PR-1 member), is 
suggested to form a serine protease active site upon dimerisation (Serrano et al. 
2004). It is interesting that CD2795 is next to CD2794 which shares domain 
structure, if not particularly high amino acid identity (70.4%). It is possible CD2795 
and CD2794 form a dimeric adhesin/protease complex key to binding to host cell 
receptors.  
 
The apparent absence of CD2795 (or CD2794) on the cell surface, yet their loss from 
the cell decreases the ability of the bacterium to adhere in vitro, suggests how 
these and other proteins, not yet characterised, play a role in adhesion and possibly 
a role in adherence in vivo. Further research into both bacterial SCP domains and 
CD2795 (and CD2794) of C. difficile is therefore needed. 
5.4.2.4.3 Cwp66 
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The Cwp66 protein has been proven to be an adhesin (Waligora et al. 2001). The 
results in this chapter confirm this, as knockout of this protein resulted in a 
decreased ability to bind to Caco2 cells. Waligora et al. (2001) suggests that Cwp66 
is a heat shock inducible adhesin and found that anti-Cwp66 N- or C-terminal 
antibodies did not inhibit adherence if bacteria were not heat shocked. If Cwp66 
was therefore a heat shock only inducible adhesin, knockout of Cwp66 should, 
theoretically, only affect the bacterium after heat shock and not under normal 
conditions. However, adhesion of the Cwp66 KO was less than 50% that of the WT 
under normal conditions, suggesting that Cwp66 plays a role in adhesion in normal 
growth conditions and that its expression is not associated with heat shock.  
5.4.2.4.4 CD2791 
The highest decrease in adhesion to Caco2 cell in vitro was that of the CD2791 
mutant. The results obtained with the CD2791 mutant are difficult to interpret due 
to two factors. Firstly, the effects of knocking out a protein at the start of a 
polycistronic message (encoding cd2791-cd2790-cwp66). Secondly, applicable to 
CDΔcd27911569, is presence of a powerful thlA promoter which can lead to 
increased expression of downstream genes or lead to increased expression of 
upstream genes via anti-sense and transcriptional interference effects (Heap et al. 
2009a) i.e. non-wildtype levels of protein or message, due to non-wildtype 
regulation. As discussed in Section 5.3.2.1, a solution to this problem is the removal 
of the ermB gene, flanked by FRT sites, leaving only the 940 bp group II intron which 
putatively has no effect on downstream genes. This technique requires plasmids 
encoding the flippase recombination enzyme (FLP) to insert into ClosTron mutants. 
Unfortunately, these plasmid(s) were not available for this study. Further studies 
with the cd2791 mutant, any mutants involved in operons, or indeed any KO should 
include this ermB removal step to prevent any misinterpretation of phenotypes.  
 
However, the polar effects of the insertion in CDΔcd27911569 on cd2790 and cwp66 
transcription may not necessarily affect protein levels. CD2791 is constitutively 
present on the cell surface, indeed the cd2791 (cwp2) promoter has been used in 
complementation studies of a CwpV mutant (Emerson et al. 2009b). Yet, Cwp66 is 
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not always found on the cell surface (Wright et al. 2005). If, as evidence suggests, 
cd2791 and cwp66 are on the same transcript, finding one and not the other 
suggests post-transcriptional control mechanism(s). Therefore, regulation of Cwp66 
may be performed, not by upregulation of cd2791-cd2790-cwp66, but through 
translational control. Thus, as a transcript is found for cwp66 in CDΔcd27911569, it is 
possible that Cwp66 is still translated and (post-transcriptionally) regulated in a 
wildtype fashion. 
 
The ~50% adhesion of CDΔcd27911569 compared to CDΔcwp66519 suggests that even 
if Cwp66 has been affected, loss of CD2791 also markedly decreases the ability of C. 
difficile to adhere to Caco2 cells. CD2791 is, therefore, putatively an adhesin of C. 
difficile. CD2791 specific inhibitors may putatively further demonstrate the role of 
CD2791 in adhesion. 
5.4.2.4.5 FliD  
The adhesion of two mutants appears to be greater than the WT (CD2784 and FliD). 
The increased adhesion of a FliC mutant has been reported (Baban et al. 2010), 
suggesting that knockout of flagella genes increases adhesion. It is possible that a 
non-motile, normally motile, bacterium may be in a stressed state and as such, 
increases stress related (adherence) proteins, e.g. Cwp66. Although, why the other 
surface protein mutants produced in this chapter, which are also presumably 
stressed, do not show increased adhesion is unknown. Tasteyre et al. (2001) 
reported that non-flagellated strains did not bind to mouse ceca as well as 
flagellated strains; one would expect therefore, that flagella mutants should not 
adhere as well as the flagellated wildtype. In B. subtilis, N-acetylmuramoyl-L-alanine 
amidase (peptidoglycan hydrolase) synthesis is controlled by a regulatory network 
involving SigD, co-regulated with flagella motility (Lazarevic et al. 1992). If a similar 
network exists in C. difficile, where flagella and surface proteins are co-regulated, 
inhibition of one may change expression of the other. Recently, Jarchum et al. 
(2011) reported that administration of Salmonella typhimurium derived flagellin, a 
TLR5 agonist, protects mice from C. difficile. TL5 activation not only decreased 
colonisation but also prevented epithelia damage. The increased virulence of the 
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FliC mutant (Baban et al. 2010) may result from decreased activation of TLR5 
cascades, consistent with TLR5 negative mice being more susceptible to disease 
(Lawley et al. 2009a).  
5.4.2.4.6  CD2784 and CD1036 
The reasons for increased adhesion of the CD2784 mutant is unknown, especially as 
this protein displays slower growth than the WT but does not produce any more 
toxin. It is possible that inactivation of CD2784, results in unnoticed changes to the 
cell surface resulting in increased intercell adhesion. Increased intercell adhesion 
would appear to reduce the growth rate as measured by A600 and may explain 
higher adhesion to Caco2 cells (through more bacteria sticking together or sticking 
to the cells). Further work is needed to confirm the increased adhesion of the 
CD2784 mutant. The mean adhesion of the CD1036 mutant was not significantly 
different to the WT, suggesting that CD1036 is not involved in the same pathways 
as CD2784, although their different genomic locations hint at this. 
 
Peptidoglycan hydrolase mutants typically have normal growth rates but 
attenuated virulence and may form chains in vitro (Sanchez-Puelles et al. 1986; 
Mani et al. 1994; Mercier et al. 2002). A Listeria monocytogenes peptidoglycan 
hydrolase (IspC) mutant displayed no defects in in vitro growth, colony and 
microscopic morphologies or biochemical characteristics but displayed attenuated 
in virulence in cell culture models. The attenuated virulence was attributed to the 
finding that the IspC knockout had altered expression of other surface based 
adhesins. IspC, CD1036 and CD2784 are similar in that one end is the catalytic 
domain, while the other is a CWBD. It was proposed that the catalytic domain of 
IspC alters the peptidoglycan, providing the necessary cell wall architecture for 
display of other virulence factors (Wang & Lin 2008). The knockout of CD2784 may, 
therefore, alter the presentation of other surface based adhesins, increasing 
adhesion. However, the redundancy of peptidoglycan hydrolases (autolysins) makes 
it difficult to study their interactions.  
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The absence of a completely non-adherent C. difficile mutant highlights how 
adhesion is likely to be multifaceted process. Moreover, direct relationships to 
adherence are difficult to infer as the KO of one protein may have dramatic effects 
on other proteins, and it may be these proteins which affect adhesion. C. difficile 
bacterial adhesion is severely decreased if the surface proteins are removed with 
4 M GnHCl or 8 M urea (Takumi et al. 1991), suggesting that a relatively limited 
number of proteins result in bacterial adhesion and subsequent colonisation. If the 
actions of 4 M GnHCl or 8 M urea could be replicated therapeutically, it may form 
an effective any anti-colonisation treatment. 
5.4.2.5 Adhesion studies of rCD279127-322 
The adhesion assay suggested that the CD2791 mutant had a marked reduction in 
adherence compared to the WT. To investigate if the CD2791 protein acted as an 
adhesin directly, fluorescently labelled purified N-terminal domain of CD2791 was 
incubated with Caco2 and Vero cells. 
 
The binding of rCD279127-322 to Vero cells at 1 µM suggests that CD2791 is an 
adhesin. Unfortunately, Vero cells did not adhere well to the glass chamber slides, 
thus preventing competition studies with unlabelled rCD279127-322 or further 
determination of binding affinities. Further work is necessary to confirm the binding 
of rCD279127-322 including the instrumentation of confocal laser scanning 
microscopy (CLSM), which has been widely used to identify bacterial adhesion 
(including C. difficile) to Caco-2 cells, (Miller et al. 2000; Cerquetti et al. 2002).  
 
Autofluorescence of Caco2 cells has not been reported, therefore it is possible that 
rCD279127-322 did not bind to Caco2 cells, and the high exposure gains used, created 
an artificial impression of autofluorescence. Further work is required to assess 
binding of rCD279127-322 to Caco2 cells in vitro, including inhibition of C. difficile 
adhesion to cell lines using rCD279127-322 or anti- rCD279127-322 antibodies.  
 
Efforts to obtain anti-CD2791 antibodies from anti-R20291 SLP IgG, using 
rCD279127-322 coupled to an NHS ester resin, largely failed as only tens of 
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micrograms of antibodies were purified, too low for use in adhesion studies. 
Reasons for the low yield include: coupling shielding binding epitopes, CD2791 
antibodies being out-competed by S-layer antibodies or that the antibody:antigen 
interaction is weaker than expected despite, reasonable ELISA titres using sheep 
anti-R20291 SLP IgG. To further a CD2791 adhesin hypothesis, e.g. prevention of C. 
difficile binding by anti-CD2791, it is necessary for antiserum to be raised in 
animals. 
5.4.3 Summary 
In this chapter, a number of genes coding proteins putatively associated with the 
cell envelope of C. difficile have been knocked out using the ClosTron system. 
Characterisation of the mutants revealed growth rates were largely similar to the 
WT, apart from the CD2784 mutant. All mutants sporulate, suggesting none of the 
proteins knocked out are key in forming viable spores. Four mutants demonstrated 
increased culture supernatant toxin A levels after 24 hr and but demonstrated 
decreased adherence in vitro. The surface protein CD2791 was identified as a 
putative adhesin, but further work is required to test this hypothesis. Challenge of 
an animal model with surface protein mutants, may help to determine if in vitro 
results are replicated in vivo.  
5.4.4 Conclusions 
To date, of the 29 proteins in the C. difficile genome that contain a PFam04122 
binding domain, only 11 have been proven to be expressed and/or surface located. 
Using a knockout approach, work in this chapter confirms that some of those 
surface proteins already identified are likely adhesins, e.g. Cwp66, but other, as yet 
uncharacterised surface proteins may also play a role in adhesion. Therapeutically 
targeting surface proteins must be approached with caution, as inactivation of 
several of the surface proteins in this chapter resulted in increased toxin production 
in vitro. The key to progressing knowledge into C. difficile adhesion and colonisation 
remains the identification of specific surface protein(s) with key roles in vivo during 
CDI. 
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CHAPTER 6 – 
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6 CHAPTER 6 – Crystallisation of selected C. difficile 
surface proteins 
6.1  Introduction 
6.1.1 Introduction to protein crystallography 
In order to fully understand protein function, specifically the physical recognition of 
substrates and any conformational changes induced during action, it is necessary to 
observe protein structure(s) at atomic resolution. The 3D structural knowledge 
obtained then provides a basis by which rational drug design and structure based 
functional studies can develop therapeutics. 
 
To observe protein structure(s) at atomic resolution, two methods are typically 
used; Nuclear Magnetic Resonance (NMR) (9% known structures) and X-ray 
crystallography (90% known structures). X-rays are suited to structure 
determination as X-rays have wavelength in the range of 100 to 0.1 Å (typically 
1.5 Å), about the same as the C-C bond length. Crystals of proteins increase 
diffraction intensities due to their periodicity, i.e. repeated unit cells. Structural 
determination of proteins using X-ray crystallography ultimately obtains structures 
of proteins by back calculation of the physical locations of the atoms from the 
resulting protein crystal X-ray diffraction pattern (electron density). The typical 
process is outlined in Figure 6.1.1. 
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Figure 6.1.1 Outline of steps involved in protein crystallography 
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6.1.1.1 Expression and purification 
The goal of this step is to obtain pure (>90%) protein, as any contamination of the 
protein sample could affect the way that the protein crystallises, if the sample 
crystallises at all. The ideal source of protein would be the native source, for 
example, a C. difficile surface protein extract. Commonly, to increase yield, the 
chosen protein is over-expressed recombinantly. The benefits of recombinant 
expression are many fold, e.g. inclusion of tags, modification/expression of 
domains, with an aim to produce soluble protein, although the expression system 
often asserts its own restrictions on that aim. In most cases, however, these 
restrictions can be overcome. 
 
Once protein is obtained it is often necessary to remove any contaminating 
proteins. These may be natively derived or as a result of the recombinant 
expression system. Several different purification systems exist and are detailed in 
several texts (particularly those by GE Healthcare). Protein purification relies on 
interactions of the protein with various chromatographic media. This interaction 
can be based on size (gel filtration), charge (ion exchange), specific protein 
interaction (affinity), or hydrophobicity (hydrophobic interaction or reverse phase). 
One or more of these may be employed in order to obtain pure protein, or, at least, 
as pure as possible to attempt crystallisation.  
6.1.1.2 Crystallisation 
While the process of crystallisation is well understood, the determination of 
conditions necessary for protein crystallisation is largely empirical (verging on luck), 
often requiring screening of hundreds of crystallisation conditions. Crystallisation 
occurs when the protein concentration in solution is greater than its limit of 
solubility, thus the protein enters a supersaturated state (Figure 6.1.2).  
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Figure 6.1.2 Phase diagram for vapour diffusion. Adapted from McCoy (2005) 
 
Once the protein is in a suitable state, nucleation and subsequent crystal growth 
occurs in three dimensions. As proteins are irregularly shaped, this results in the 
formation of large, solvent filled, channels in the crystals. Protein crystals are 
therefore crystalline solids, an intermediate between a fluid and a solid held 
together by non-covalent interactions. These solvent channels can be used to the 
crystallographer’s advantage, where crystals can be soaked with a solution to study 
ligand interactions or with heavy metals to solve the phase problem (discussed later 
in 6.1.1.5). 
 
Physically crystallising a protein can be accomplished by several methods including 
dialysis, batch and vapour diffusion. The most common method of crystallisation is 
vapour diffusion (sitting drop or hanging drop), in which solvent in a protein drop 
(plus a small amount of reservoir solution) and reservoir solution equilibrate by 
vaporisation, resulting in an increase of the precipitant concentration in the drop to 
a level optimal for crystallisation of the protein.  
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6.1.1.3 X-ray data collection 
The obtained crystals are placed in a beam of X-rays; the resulting diffraction of the 
X-ray beam produces (Laue) spots (reflections) on a detector, Figure 6.1.3.  
 
 
Figure 6.1.3 X-ray diffraction set-up. Taken from 
http://pruffle.mit.edu/atomiccontrol/education/xray/xray_diff.php. 
 
The crystal is then rotated to collect a full data set. The amount of rotation need 
not be 360°, but is largely determined by the mathematical concept of Ewalds 
sphere (Ewald 1969) and the crystal symmetry (space group) (higher symmetries 
need less rotation due to the likelihood of seeing the same plane). Crystals are 
made up of several families of planes (called lattice planes or Bragg’s planes), thus 
using simple wave mechanics: if reflections from a crystal are in phase (constructive 
interference) a spot is observed, if they are not, they cancel out (destructive 
interference). The angle and distance between lattice planes can be derived from 
Braggs Law: 
 
nλ = 2dsinθ 
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Where n is an integer (in constructive interference), λ is the wavelength of a beam 
of incident x-rays on a crystal with lattice planes separated by distance d, and θ is 
the Bragg or scattering angle (illustrated in Figure 6.1.4). 
 
 
Figure 6.1.4 Diagrammatic representation of Braggs Law. Taken from 
http://serc.carleton.edu/research_education/geochemsheets/BraggsLaw.html 
 
Protein crystals deconstructed to their simplest form are made up of asymmetric 
units (Figure 6.1.5). By definition, this is the smallest portion of a crystal structure to 
which crystallographic symmetry can be applied to generate one unit cell. There 
may be several protein molecules per asymmetric unit, or just one. A unit cell is the 
element repeating that makes up the crystal in three dimensions. The unit cell can 
be described by the lengths of three edges (a, b, c) and the angles between them 
(α, β, γ) (Figure 6.1.6). 
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Figure 6.1.5 Fundamental parts of crystal structures. The asymmetric unit (green upward 
arrow) is rotated 180 degrees about a two-fold crystallographic symmetry axis (black oval) 
to produce a second copy (purple downward arrow). The asymmetric unit may contain 
several protein molecules or just one. Together the two arrows comprise the unit cell. The 
unit cell is then translationally repeated in three directions to make a 3-dimensional crystal. 
Taken from http://www1.rcsb.org/pdb/static.do?p=education_discussion/Looking-at-
Structures/bioassembly_tutorial.html 
 
 
 
 
Figure 6.1.6 Measurable parameters of crystals 
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As all six of these dimensions can be varied, it gives rise to seven lattice systems 
with an increasing order of symmetry based on the number of parameters set 
(Cubic) to no parameters set (Triclinic) (Table 6.1.1). In addition to these seven 
primitive lattices, Bravais discovered another seven non-primitive lattices with 
additional lattice points at the centre of the cell (I), on the centre of each face (F), or 
on only one face (A, B or C) (a total of 14 Bravais lattices are thus possible).  
 
Table 6.1.1 Types of Bravais lattices 
Crystal system  Number of Lattices Lattice symbols Parameters 
Triclinic 1 P a≠b≠c  
α≠β≠γ 
Monoclinic 2 P, C a≠b≠c  
α=β=90° ≠ γ 
Orthorhombic 4 P, C, I, F a≠b≠c  
α=β=γ=90° 
Tetragonal 2 P, I a=b≠c  
α=β=γ=90° 
(Rhombohedral) 
Trigonal 
1 P a=b=c  
α=β=γ≠90° 
Hexagonal 1 P a=b≠c  
α=β=90° γ= 120° 
Cubic 3 P, I, F a=b=c  
α=β=γ=90° 
 
6.1.1.4 Data analysis and model building 
The two dimensional diffraction images must then be converted to a 3D 
representation of the electrons which diffracted the X-rays. To do this, firstly, the 
images are indexed, i.e. identifying the dimensions of the unit cell and which image 
peak corresponds to which position in reciprocal space. The term ‘reciprocal space’ 
is used as there is a reciprocal relationship between the distances between lattice 
planes (d) and the scattering angle (θ). Smaller distances cause wider diffraction 
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patterns in ‘real’ space, whereas lattices with a larger d result in a closer diffraction 
pattern. 
 
The intensity of the spots from the images is then integrated and the complete data 
merged and scaled into one data file. This process resolves which peaks appear in 
two or more images (merging) and scales the relative images so that they have a 
consistent intensity scale.  
 
Using an inverse Fourier transform (as crystals are periodic), the electron density 
can be derived from the structure factor equation. To fulfil this equation and 
calculate the electron density, there is one piece of information missing, the phase 
(lost through the physical act of measuring the diffracted waves). To put it another 
way, the obtained x-ray data contains the structure factor magnitudes in the form 
of intensities/amplitudes but not their positions. 
6.1.1.5 The phase problem 
There are several methods in which to obtain the phase or at least estimate the 
phase: 
 
 The Direct Method 
Typically applied to molecules with <1000 atoms per asymmetric unit or if the 
resolution is <1.2 Å. Individual atoms can be fitted and the problem is join-the-dots. 
 Molecular replacement (MR) 
When the protein being studied shares >20% identity with a known structure in the 
PDB, over a reasonable portion of the protein, the known molecular model is used 
to solve the unknown crystal structure. The known model is orientated and 
positioned such that the predicted diffraction (as if the known model had 
crystallised) best matches the observed diffraction (Evans and Coy, 2008). MR 
assumes that proteins with similar amino acid sequences share tertiary structure; 
this is not always the case. Homology models used as templates may work in MR 
but on the same basis as primary sequence identity, i.e. are good matches without 
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large sequence deletions/additions. Using a known model can however bias the 
model of the unknown protein.  
 
 Multiple Isomorphous Replacement (MIR) 
Crystals are soaked in heavy metal solutions, such that the heavy metals diffuse 
into spaces originally occupied by the solvent. The heavy metal should be 
introduced such that the crystal lattice is unaltered, i.e. isomorphous. By comparing 
the reflections generated by several different isomorphous crystals, the positions of 
the heavy atoms can be worked out and this allows the phase diffraction in the un-
substituted crystal to be deduced.  
 
 Multiple Wavelength and Single Wavelength Anomalous dispersion (MAD 
and SAD) 
Similar to MIR, heavy atoms are incorporated into proteins, usually by substituting 
sulphur for selenium, in methionine (selenomethionine) (or sulphur for cysteine in 
selenocysteine (Strub et al. 2003)). This method is applicable for native metallo-
proteins or for recombinant proteins, and requires approximately one 
selenomethionine residue for every ∼75–100 amino acids (Hendrickson et al. 1997; 
Strub et al. 2003). By changing the X-ray wavelength from where the metal does 
not absorb (normal diffraction, obeying Friedels law Fhkl = Fhk), to where the metal 
does absorb (anomalous diffraction, disobeying Friedels law Fhkl ≠ Fhk) and 
comparing the intensities of Friedel’s pairs, the position of heavy atoms in the unit 
cell are determined.  
Combinations of the two heavy metal methods can be applied, utilising the benefits 
of both e.g. Single wavelength Isomorphous Replacement with Anomalous 
Scattering (SIRAS) and Multiple wavelength Isomorphous Replacement with 
Anomalous Scattering (MIRAS).  
6.1.1.6 Refinement, Validation and Submission 
When a model has been built, it is refined, i.e. adjusted to improve the agreement 
with the measured diffraction data. Refinement modifies bond length, bond angle, 
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torsion (dihedral) angle, and planarity of the peptide bond together (Figure 6.1.7) 
with the thermal vibration ‘temperature’ (B-factor), to give a better fit for each 
atom. 
 
From this, a number called the 
reliability factor (R-Factor, or Rwork) 
is calculated which is simply a 
measure of the agreement between 
the crystallographic model and the 
experimental X-ray diffraction data 
(the lower the better with typically 
0.2 for well refined protein model). 
However, it is possible to over fit or 
'misfit' the diffraction data. By using 
a randomly selected (typically 
~10%) set of reflections that are 
omitted in the modelling and 
refinement process, it is possible to 
measure the agreement between 
observed and computed structure 
factor amplitudes (Rfree) (Brunger 
1992). 
 
After refinement, one can assess, 
i.e. validate, how successful the 
model is by the use of a number of 
statistical or graphical figures. A 
common assessment is the 
Ramachandran plot which assesses the phi and psi torsion angles to identify amino 
acids of the polypeptide backbone in sterically disallowed conformations. Once the 
structure has been validated it is submitted to the Research Collaboratory for 
Structural Bioinformatics (RCSB) protein data bank (PDB) (www.pdb.org). 
Figure 6.1.7 Diagrammatic representation of 
polypeptide chain and the degrees of 
freedom. Rotation can occur along the Cα- C’ 
bond (psi ψ) or N-Cα bond (phi φ). Taken from 
Branden & Tooze (1999). 
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6.1.2 Proteins selected for crystallisation 
The bacterial cell surface serves two central purposes: protection from and 
interaction with, the environment. Infections by microbes follow a similar pattern: 
adhesion to host cells followed by complex interactions that often involve secretion 
of effector proteins, e.g. toxins and induction of signalling processes by the host 
cells. The proteins of the cell surface are of considerable interest both academically 
and industrially as they represent a novel interaction site between host and 
pathogen. The interruption of such interactions may result in the cessation of a 
potentially harmful infection. 
 
The sequence of amino acids which make up (surface) proteins can provide a great 
deal of information about the likely roles of the protein, primarily in relation to (and 
as a result of) other already characterised proteins. It is the tertiary or 3D structure 
of the protein that reveals the true interactions between proteins and their 
ligand/receptor interactions. Understanding this complex interaction requires data 
at the molecular or even atomic level obtained by X-ray crystallography and/or 
Nuclear Magnetic Resonance spectroscopy (NMR).  
 
C. difficile proteins, for which structural information has been obtained, has 
understandably been directed towards the main virulence factors: the toxins (Ho et 
al. 2005; Pruitt et al. 2009; Sundriyal et al. 2009; Albesa-Jove et al. 2010; Pruitt et 
al. 2010; Puri et al. 2010). 
 
To date, there is only one report of high-resolution structural information for a C. 
difficile surface protein, a fragment of the LMW SLP (3CVZ) (Fagan et al. 2009) (see 
General Introduction 1.2.2) and a structure submitted, but no published literature, 
for a putative membrane protein (CD3042)(3KMI) (Chang et al. 2009). Moreover, 
given the large number of the 28 slpA paralogs which have yet to be assigned even 
a hypothetical function, there are considerable gaps in the understanding how the 
surface proteins of C. difficile interact with both themselves and the environment. 
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Structural data is likely to be key in furthering our understanding of S-layer 
biogenesis, the interactions of the CWBD with the underlying cell surface and how 
surface proteins interact with themselves or host cell proteins. 
 
To begin to address this issue a number of surface proteins containing the CWBD 
(PFam04122) were selected for obtaining x-ray crystallographic information. The 
determination of function from structure was the primary goal in this chapter, 
particularly trying to obtain structural information on full length surface proteins, 
including their CWBDs. It was discovered that the lack of homology to known 
proteins prevents all but speculative function prediction and it is likely that only x-
ray crystallographic structural information will reveal the folds (novel or not) to 
help identify functions for these important proteins. 
6.1.2.1 CD2791 (Cwp2/ORF2, ORF8) 
 
623 aa, (66,445Da predicted) 
Signal peptide      1-26 
N-terminus  Unknown function 
2x CWBD  326-417, 426-512 
 
Figure 6.1.8 Domain structure of CD2791. Sig- Signal Peptide, CWBD- Cell wall binding 
domain. Putative domain location(s) obtained from C. difficile 630 genome annotations, 
available at ncbi.nlm.nih.gov. 
 
The cd2791 gene was first identified in 2001 together with the identification of the 
cluster of genes surrounding slpA (Calabi et al. 2001; Karjalainen et al. 2001).  
 
The cd2791 gene is highly conserved in all strains and appears to be transcribed 
during normal growth (Calabi et al. 2001) and is suggested to be at the start of a 
polycistronic message also encoding CD2790 and Cwp66, putatively part of an 
adhesin complex (Savariau-Lacomme et al. 2003). However, this complex has not 
been found on the cell surface to date. Microarray analysis found one of duplicate 
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reporters for cwp2(cd2791), cwp84, cwp6(cd2784) and cwp7(cd2782) was 
upregulated during exposure to sub-MIC amoxicillin (Emerson et al. 2008).  
 
The protein encoded by cd2791 was initially described as an approximately 70 kDa 
protein, identified on the cell surface in guanidine SLP extracts of all isolates by 
McCoubrey & Poxton (2001). The authors also reported that this protein cross-
reacted with all antisera tested, consistent with data in Chapter 4. A 66 kDa protein 
on the cell surface was also reported by Calabi & Fairweather (2002), who 
demonstrated that it had lost its signal peptide and did not appear to undergo post-
translational modification as the predicted MW matched the observed. Moreover, 
N-terminal sequencing of the 66 kDa protein matched the N-terminus of Cwp2 
(ORF2) (CD2791) in the unfinished C. difficile 630 genome. BLASTP of CD2791 
revealed homologies to both the S-layer of Bacillus sphaericus and the transducer 
of rhodopsin (Htr) II from the archaebacterium Natronobacterium pharaonis (Calabi 
& Fairweather 2002). Proteomic analysis of low pH or lysozyme cell wall extracts 
confirmed that the 66 kDa protein found in surface extracts was CD2791 (Wright et 
al. 2005) and perhaps unsurprisingly, given its apparent constitutive expression, 
CD2791 is also found in the spore coat (Lawley et al. 2009b). However, despite 
being surface located, an N-terminal 38-41 kDa protein fragment of CD2791 
appears to be present in the culture supernatant, particularly during conditions 
promoting high toxin production (Mukherjee et al. 2002). 
 
Secondary structure analysis suggested that the N-terminal, predicted ‘functional’ 
domain of CD2791, consisted of a largely alpha-helical conformation (71%) with a 
putative trans-membrane segment, which shared no significant homology with 
known proteins (Savariau-Lacomme et al. 2003).  
 
As discussed in Chapter 4, CD2791 appears to be highly immunogenic as virtually all 
patients raise antibodies to CD2791 (Wright et al. 2008). This, coupled with a lack of 
CD2791 in strain 167 (a clinical isolate) (Calabi & Fairweather 2002), highlights how 
antibodies to CD2791 are likely to be non-protective and that CD2791 does not 
appear to be necessary per se for CDI. However, the altered S-layer and lack of 
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CD2791 in strain 167, may be negated by changes in other virulence associated 
factors e.g. increased adhesion or increased toxin production, particularly as the 
Cwp84 mutant (with an immature S-layer) is still able to cause CDI in the hamster 
model (Kirby et al. 2009). 
 
Therefore, CD2791 represents a good protein for which to undertake structural 
studies, as CD2791’s constitutive expression, immunogenicity and presence on the 
cell surface suggest it is a key protein to C. difficile either physiologically or 
pathogenically. Data in Chapter 5 also suggest CD2791 may play a role in adhesion, 
further supporting the precedent to obtain structural information about this 
protein. 
6.1.2.2 Cwp66 (cwp3 (Calabi et al. 2001) 
 
610 aa (66,779Da predicted) 
Signal peptide      1-29 
3x CWBD   33-121, 130-221, 228- 322 
C-terminus  Unknown function 
 
 
Figure 6.1.9 Domain structure of Cwp66. Sig- Signal Peptide, CWBD- Cell wall binding 
domain. Putative domain location(s) obtained from C. difficile 630 genome annotations, 
available at ncbi.nlm.nih.gov. 
 
A putative heat shock associated cell wall protein of 66 kDa was first characterised 
in 2001 (Waligora et al. 2001), after initial data suggested that heat shock increased 
adherence in C. difficile (Eveillard et al. 1993). Analysis of cwp66 expression by RT-
PCR confirms that cwp66 expression occurs during stress conditions, e.g. heat 
shock, as cwp66 was upregulated during high osmolarity and showed a slight 
increase in the presence of sub-MIC concentrations of ampicillin, but not  iron 
limiting conditions (Deneve et al. 2008).  
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Waligora et al. (2001) also suggested that cwp66 was unlikely to have its own 
promoter since no prominent promoter structure could be identified in the short 
intergenic region between cd2790 (orfA) and cwp66 (orfB). Savariau-Lacomme et 
al.(2003) suggests cwp66 is encoded on a polycistronic message with cd2790 and 
cd2791, despite cd2791 (ORF8) (and cd2790 (ORF9)) being preceded by promoter 
consensus sequences at -10 and -35. Savariau-Lacomme et al.(2003) also suggests 
that expression of the polycistronic message was found at only the beginning of 
exponential phase. However, given the constitutive presence of CD2791 on the cell 
surface, this may suggest how transcription may be linked but translation is not. 
The ability of cwp66 to be inhibited by its own antisense mRNA was assessed, but 
no significant effect on Cwp66 protein levels or adhesion in vitro was observed 
(Roberts et al. 2003). 
 
Cwp66 contains three N-terminal CWBDs and a C-terminal domain which is 
predicted to have a secondary structure of an extended beta strand formation. 
Using immunogold labelling anti-cwp66 N- or C- terminal antibodies did not detect 
cwp66 on the surface of C. difficile grown in normal conditions, however, after cells 
were heat shocked, anti-cwp66 C-terminal antibodies reacted strongly suggesting 
that the C-terminal domain was surface most, at least after heat shock. Adhesion to 
Vero cells was prevented by recombinant cwp66 N- or C-term at 50 µg/ml and anti-
cwp66 antibodies prevented adhesion to ~50%, however, only when heat shocked 
bacteria were used (Waligora et al. 2001).  
 
There appears to be some debate as to the existence of Cwp66 on the cell surface 
during normal conditions, as Cwp66 (aka paralog 3) was not found on the cell 
surface during proteomic analysis of cell wall extracts (using low pH or lysozyme 
extraction of un-heat shocked cells (Wright et al. 2005)). Whereas Cwp66 was used 
in two studies as a cell wall (peptidoglycan and SLP fraction) protein marker, 
specifically detected by anti-Cwp66 C-terminal antiserum (Hennequin et al. 2001; 
Hennequin et al. 2003). Cwp66 has also been found to co-purify with ABP labelled 
Cwp84 (together with CD2767 and CD2797), suggesting that it may form part of a 
complex on the cell surface (Dang et al. 2010). 
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As discussed in Chapter 4, the large majority of the surface proteins are highly 
conserved whereas the C-terminal domain of Cwp66 is highly variable and three 
different ‘typing’ groups have been suggested (Waligora et al. 2001; Calabi & 
Fairweather 2002).It is suggested that cwp66, like slpA, may be under strong 
environmental selective pressure (Lemee et al. 2005). Karjalainen et al. (2001) also 
suggests that the variable domain of Cwp66 is up to 40% homologous with the 
‘variable’ domains of Orf10(cd2786), Orf5(cd2795), Orf6(cd2794) and Orf2(cd2798), 
and that the third CWB repeat is less conserved than the first two.  
 
During CDI, the C-terminal domain of Cwp66 appears to generate a greater 
antibody response in a greater number of patients (14/17), than the N-terminal 
domain (02/17) (Pechine et al. 2005b), supporting Waligora et al. (2001) suggesting 
that the C-terminal is surface exposed. Although, analysis of CDI case patient serum 
by Pechine et al. (2005a) found the anti-Cwp66 C-terminal response was not 
statistically different from controls, whereas the lower anti-Cwp66 N- terminal 
response appeared to be statistically significantly higher in cases than in controls. 
However, the control serum used by Pechine et al. (2005a) was from maternity 
wards, which may have skewed due to the high culture rates of C. difficile from 
infants and the likely presence (and possible pre-exposure) of C. difficile in the 
environment. Identification of immunoreactive proteins in SLP extracts using CDI 
patient serum did not detect Cwp66 (Wright et al. 2008) although this may have 
been due to a lack of this protein in the SLP extract used (Wright et al. 2005). 
 
Therefore, Cwp66 marks one of the first identified adhesins of C. difficile 
particularly after heat shock. How transferable heat shock results are to in vivo 
conditions, during CDI, is unknown but a change in surface presentation, e.g. 
adhesins, as a result of stress/environmental conditions, is feasible. Similar to 
CD2791, Cwp66 also lacks homology or similarity with known proteins, structural 
determination may therefore aid understanding of this C. difficile adhesin. The 
adhesive nature of Cwp66 may lend itself to ligand docking experiments and/or 
determination of host receptors. 
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6.1.2.3 CD2767 
 
703 aa (77,829Da predicted) 
Sig peptide       1-26 
N-terminus   27-371 DUF187 (Uncharacterised BCR, COG1649; 
pfam026387) 
3x CWBD   402-493, 505-596, 609-684 
 
 
Figure 6.1.10 Domain structure of CD2767. Sig- Signal Peptide, DUF187- PFam02638, 
CWBD- Cell wall binding domain. Putative domain location(s) obtained from C. difficile 630 
genome annotations, available at ncbi.nlm.nih.gov. 
 
The cd2767 gene is downstream of a large cluster of capsular polysaccharide 
synthesis proteins and polysaccharide glycosyl transferases (cd2778 - cd2764). To 
date, CD2767 has been identified as cell wall protein recognised by human antisera 
to surface proteins (Wright et al. 2008) and during a pull down assay of ABP 
labelled Cwp84 (Dang et al. 2010). Publications examining the cell surface and cell 
surface extracts proteomically (Wright et al. 2005) have not found CD2767, 
implying that either it is compartmentalised such that existing cell wall extraction 
techniques cannot removed it, its surface based location only occurs in specific 
conditions, e.g. in vivo or upon the inhibition of Cwp84, or the protein is extremely 
labile and thus not easily recovered.  
 
CD2767 has (like SlpA and Cwp84) three C-terminal CWBD and a ‘functional’ 
DUF187 N-terminal domain. Although DUF187 specifically refers to a protein 
domain of unknown function, protein signature searches suggest the DUF187 family 
is a member of TIM barrel glycosyl hydrolase clan, which contains members such as 
alpha-amylase, cellulase and a variety of glycosyl hydrolase families which in total 
contains 56,730 proteins.  
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DUF187 is found in diverse species including the YngK protein of Bacillus subtilis and 
Bacillus amyloliquefaciens FZB42 and the FenI protein of Streptosporangium 
roseum DSM 43021. In B. subtilis, YngK is suggested to be involved in the synthesis 
of an antifungal lipopeptide antibiotic, pliplastin (Tsuge et al. 1999). Inactivation of 
YngK, results in upregulated sigma X (Turner & Helmann 2000), an extracytoplasmic 
sigma factor that functions in regulating cell envelope modification as a defence 
against cationic antimicrobial peptides (Cao & Helmann 2004). A gene in C. difficile 
strains NAP8 and NAP7 has been labelled as YngK, in both strains the gene is 99% 
similar to CD2767 of C. difficile 630. This gene of C. difficile strains NAP8 and NAP7 
genes are annotated in Uniprot as possessing putative carbohydrate metabolic 
activity, but also having cation binding activity, i.e. interacting selectively and non-
covalently with cations (charged atoms or groups of atoms with a net positive 
charge) suggesting that cations may be required by CD2767 in some way.  
 
The TIM barrel is a characteristic protein fold named after triose phosphate 
isomerase (TIM) which contains eight α-helices and eight parallel β-strands 
arranged such that a central ‘barrel’ is formed (Wierenga 2001) (Figure 6.1.11).  
 
 
Figure 6.1.11 The structure of the TIM barrel. Top (left) and side (right) views of 
triosephosphateisomerase (TIM) (8TIM). Prepared using PyMOL (www.pymol.org). 
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The loops at the C-terminal end of the ‘barrel’ sheets tend to contain the active site. 
The α/β barrel (TIM barrel) is by far the most common tertiary fold observed in high 
resolution protein crystal structures and it is estimated that 10% of all known 
enzymes have this domain (Farber & Petsko 1990). 
 
Glycosyl hydrolases (glycosidases or glycoside hydrolases) hydrolyse the glycosidic 
bond between two or more carbohydrates or between a carbohydrate and a non-
carbohydrate moiety. The fold is more conserved than the sequence; as such 
nomenclature is now based on sequence homology and structural comparisons, 
complied in the Carbohydrate-Active Enzymes database (CAZy) (Cantarel et al. 
2009).  
 
Hydrolysis of the glycosidic bond requires two critical residues: a proton donor and 
a nucleophile/base (commonly glutamic acid (E) or aspartic acid (D)). Hydrolysis 
occurs via two major mechanisms, depending on spatial location of the nucleophilic 
catalytic base, as the position of the proton donor is identical in both.  
 
The catalytic base is in close vicinity of the sugar (5.5 Å) in retaining enzymes, 
whereas the accommodation of a water molecule results in a greater (10 Å) 
distance in inverting enzymes. Retaining glycosidases operate through a two-step 
mechanism, with each step resulting in inversion, for a net retention of 
stereochemistry (Figure 6.1.12A). Inverting glycosidases result in inversion of 
anomeric configuration, this is generally achieved via a one step, single-
displacement mechanism involving oxocarbenium ion-like transition states (Figure 
6.1.12B). Active site surface topology determines substrate specificity, as pocket-
like active sites are found in exoenzymes, which cleave monosaccharide units from 
chain ends, whereas endoenzymes have active sites situated in clefts on enzyme 
surfaces, allowing cleavage to occur in the middle of the chain (Davies & Henrissat 
1995). Known inhibitors are sugar shaped molecules e.g. swainsonine, 
castanospermine and the antiviral Tamiflu (oseltamivir). 
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Therefore, CD2767 represents one of the few C. difficile proteins whereby a 
function can be postulated. Structural determination of CD2767 may therefore 
confirm this function i.e. glycosidase and allow further investigations into its role in 
C. difficile.  
6.1.2.4 Aim 
In summary, the genes chosen for recombinant expression and crystallisation 
consist of: 
 An immunogenic conserved cell surface protein (CD2791) 
 A variable cell surface based heat shock inducible adhesin (Cwp66) 
 A putative cell surface based TIM barrel glycosidase (CD2767) 
 
Both Cwp66 and CD2791 contain a domain (C-term in Cwp66 or N-term in CD2791) 
which appears to have little similarity to known proteins using protein signature 
searches, thus an opportunity exists to gain a structural insight into these proteins 
which may reveal function from structure. Similarly for CD2767, structural 
determination will hopefully provide information as to specific positioning of active 
site residue(s), which often determines glycosidase substrate/ligand binding and 
specificity.  
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Figure 6.1.12 The two mechanisms of glycoside hydrolases (A) Retaining – In the first step, 
the glycosidic oxygen is protonated by the acid catalyst (A-H) and nucleophilic assistance to 
aglycon departure is provided by the base B-. The resulting glycosyl enzyme intermediate is 
hydrolysed by a water molecule and this second nucleophilic substitution at the anomeric 
carbon generates a product with the same stereochemistry as the substrate. (B) Inverting – 
involves a single-displacement mechanism involving oxocarbenium ion-like transition states 
where protonation of the glycosidic oxygen and aglycon departure are accompanied by a 
concomitant attack of a water molecule that is activated by the base residue (B-) yielding a 
product with opposite stereochemistry to the substrate. Figure taken from Davies & 
Henrissat (1995). 
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6.2 Chapter Specific methods 
6.2.1 Genetic methods 
6.2.1.1 Synthetic synthesis of full length C. difficile 027 (R20291) strain 
cwp66, cd2791 and cd2767 genes 
C. difficile 630 gene sequences were BLAST searched against the Sanger Institute’s 
C. difficile strain R20291 (Stoke Mandeville, UK) assembly (cwp66) or Pathema’s 
QCD32g58 (Quebec, Canada) complete genome (cd2791 and cd2767) (March, 
2008). The BLAST result match was translated in silico, and the resulting the amino 
acid sequence (minus predicted signal sequences), flanked by BamHI and XhoI 
restriction sites followed by two N-terminal stop codons, was submitted to 
GENEART for E. coli optimised gene synthesis and direct insertion into pET28(a) 
using the same two restriction sites.  
6.2.1.2 Insertion of optimised surface protein genes into a range of 
expression vectors 
The synthetically synthesised genes were cloned into a number of expression 
vectors, assessed to investigate different fusion tags (Table 6.2.1). 
 
Table 6.2.1 Expression vectors used in this chapter 
        Vector Details 
 
 
Gene 
pET28a  
(Novagen) 
N-term His.T7  
kanR 
pET43.1a  
(Novagen) 
N-term NusA.His 
ampR 
pGEX-6P-1  
(GE Lifescience) 
N-term GST 
ampR 
cd2791 ✓ N/D N/D 
cwp66 ✓ N/D ✓ 
cd2767 ✓ ✓ ✓ 
N/D not determined 
6.2.2 Expression of full length selected surface proteins 
6.2.2.1 General expression protocol 
Constructs were expressed in E. coli BL21 (DE3) Star™ as per the large scale 
expression protocol, General Methods (Section 2.3.3) 
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6.2.2.2 IMAC Purification  
IMAC was performed as detailed in General Methods (Section 2.4.1.3) 
6.2.2.3 IEX and HIC purification  
IEX was performed as detailed in General Methods (2.4.2). IEX (Q sepharose) was 
performed as described at pH 7.5 or pH 8.0, whereas IEX (S sepharose) was 
performed at only pH 5.5. HIC was performed using 5 ml HiTrap phenyl HP (Section 
2.4.3) using start/binding buffer- 50 mM sodium phosphate, 1 M NaCl pH 7.0 final 
buffer 50 mM sodium phosphate pH 7.0, elution of pure (>90%) His.T7.CD2791 was 
performed using H2O. Fractions were stored at 4 °C, then pooled and frozen -80 °C. 
6.2.3 Cell wall hydrolase assay for CD2791-Lysoplate method 
To assess if purified His.T7.CD2791 was correctly folded, an assay was developed 
based on the homology of the cell wall binding domain (found in both CD2791 and 
all the 28 SlpA paralogs) to N-acetylmuramoyl-L-alanine amidase. This assay is 
broadly the same as Osserman & Lawlor (1966) and uses the lysis of Micrococcus 
lysodeikticus cells walls immobilised in agarose.  
 
Briefly, 50 mg Micrococcus lysodeikticus ATCC No. 4698 (Sigma) was re-suspended 
in a small volume of TK buffer (0.1 M tris-HCl, 0.1 M KCl pH 7.0). Resuspended cells 
were added to molten 1% (w/v) agarose in TK buffer, poured into Petri dishes, 
allowed to set, then 2 mm (dia.) wells were made. Each well held approximately 
30 µl. Samples and controls: lysozyme (10 µg), amidase from Pseudomonas 
aeruginosa (Sigma) control (30 µg), TK buffer only control (diluted in where 
necessary in TK buffer) were added to the wells. Plates were incubated at room 
temperature for 24 hr, after which zones of α (incomplete) or β (complete) lysis 
(transparency) were measured. 
6.2.4 Crystallisation of His.T7.rCD2791 
His.T7.CD2791 was first dialysed into 50 mM HEPES pH 7.4 then concentrated to 
approximately 5 mg/ml, then using a nano-dispensing robot (Art Robins 
Instruments), sitting drop vapour diffusion crystallisation trials were set up in 
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96 well Intelli-Plate(s) (Art Robins Instruments). 0.15 µl (150 nl, 300 nl for 2:1 ratio) 
CD2791 protein solution was dispensed into each of the three wells along with an 
appropriate amount of reservoir solution giving 2:1, 1:1 and 1:2 protein:reservoir 
ratios. The following screens were initially assessed 
 
 PACT premier™ (PEG/ion screen) 
 JCSG-plus™ (sparse matrix)  
 Structure Screen 1 (sparse matrix) 
 Structure Screen 2 (extension of SS1 but with novel precipitants and 
combinations) 
All of which are available from Molecular Dimensions™.  
 
Conditions with potential results (herein referred to as hits), i.e. crystallisation 
conditions were close but needing to be optimised, were manually set up as 
hanging drop vapour diffusion crystallisations in 24-well plates. Conditions and 
original screen along with optimisations in x- and y- axes are given in Table 6.2.2.  
6.2.5 Expression, purification and crystallisation of domains of 
selected surface proteins 
The synthetically synthesised genes of selected surface proteins were 
mutated/truncated such that the predicted CWBDs were removed (CD2791 and 
CD2767 C-term, Cwp66- N-term) leaving only the ‘functional domain’.  
 
This was accomplished by two methods: 
 
1. Amino acid sequences corresponding to the functional domains, flanked by 
NdeI and EcoRI and two stop codons, were submitted to GENEART for 
synthetic synthesis. The resulting gene(s) were cloned into pET28(a) using 
the same two restriction sites thus, providing an N-terminal His6 tag only. 
 
2. The same domain(s) as submitted to GENEART above were cloned from the 
original GENEART optimised gene(s) (Section 6.2.1.1) using primers found in 
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Table 6.2.3. The resulting PCR product was cloned into the pET SUMO 
(Invitrogen) vector via TA cloning. The resulting protein product was fused at 
the N-terminus to His6 and SUMO tags. 
 
Table 6.2.2 Manually set-up hanging drop vapour diffusion crystallisation of 
His.T7.rCD2791 
Screen  
(if 
appropriate) 
Original condition Optimisation 
x-axis 
Optimisation 
y-axis 
 Salt Buffer Precipitant   
PACT 
premier™ 
 
- 0.1 M SPG 
buffer pH 
7.0 
 
25% w/v 
PEG 1500 
pH  
6.0, 7.0, 8.0 
% PEG 1500 
30, 25, 20, 
15 
Manual 1 - 0.1 M SPG 
buffer pH 
6.0 
20% w/v 
PEG 1500 
- - 
JCSG-plus™ - 0.1 M 
sodium 
cacodylate 
pH 6.5 
40% v/v 
MPD, 5% 
w/v PEG 
8000 
pH 
5.5, 6.5, 7.5 
% MPD 
40, 30, 20, 
10 
0.2 M 
NaCl 
0.1 M 
HEPES 
pH 7.5 
10% v/v 2-
propanol 
pH 
6.5, 7.5, 8.5 
% 2-
propanol 
20, 15, 10, 5 
- 0.1 M tris 
pH 8.5 
20% v/v 
ethanol 
pH 
7.5, 8.5, 9.5 
% ethanol 
40, 30, 20, 
10 
Structure 
Screen 1 
- - 0.2 M 
magnesium 
Formate 
- Molarity  
0.4, 0.3, 0.2, 
0.1 
 Manual 2 - - 0.2 M 
sodium 
formate  
- Molarity  
0.4, 0.3, 0.2, 
0.1 
 Manual 3 - - 0.2 M 
magnesium 
sulphate 
- Molarity  
0.4, 0.3, 0.2, 
0.1 
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Table 6.2.3 Primers used to remove selected surface proteins CWBD and for 
insertion into pET SUMO expression vector 
Gene Predicted 
CWBDsa 
Region 
Cloned 
Primers for pET SUMO TA 
cloningb 
Approx 
MW 
[amino 
acids] 
cd2791 326-417 
426-512 
27-322 2791_SUMO_F 
AGC ACC ACC CAG GTG AAA 
AAA GAA A  
 
2791_SUMO_R TTA TTT GCT 
GTT GCC TTC CAG CG 
32.0 kDa 
[298] 
cwp66 33-121 
130-221 
228- 322 
324-585 cwp66_SUMO_F 
AGC ATT GAT ATG CAG GAA 
GA 
 
cwp66_SUMO_R 
TTA GAT GTG ATC CAT TTT 
CGG 
29.9 kDa 
[264] 
cd2767 402-493 
505-596 
609-684 
27-401 2767_SUMO_F 
AGC AAC GAT AAA GAA ATG 
CG 
 
2767_SUMO_R 
TTA CAC TTT CAC GTT GCT CG 
42.5 kDa 
[376] 
a as given by C. difficile 630 genome sequence (NCBI) 
b with addition of N-terminal Serine (AGC) to improve SUMO protease cleavage 
6.2.5.1 Expression of Purification of domains of selected surface 
proteins 
6.2.5.1.1 His tagged only (pET28a) constructs 
Expression was as described in General Expression protocol (Section 6.2.2.1). IMAC 
purification of functional domains was performed as described in General Methods 
Section 2.4.1.3. His.rCD276727-401 was also purified as described (Section 2.4.1.3) 
but using 50 mM sodium phosphate (monobasic) pH 7.5 in place of 50 mM tris 
pH 8.0, as tris is a known inhibitor of alpha amylase activity. 
6.2.5.1.2 pET SUMO (His.SUMO) constructs 
Expression was as described in General Expression protocol (Section 6.2.2.1) except 
using E. coli BL21 (DE3). His.SUMO tagged proteins were first purified by IMAC as 
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per General Methods Section 2.4.1.3. Collected eluted fractions were then dialysed 
into SUMO protease cleavage buffer (50 mM tris-HCl, 150 mM NaCl pH 8.0, 0.2% 
igepal, 1 mM DTT). A second round of IMAC was performed using 50 mM tris-HCl, 
150 mM NaCl pH 8.0 as binding/wash buffer to ensure any uncleaved material 
and/or contaminants bound, with cleaved untagged protein not binding. To remove 
residual detergent from the cleavage buffer, the flow through was dialysed into IEX 
(Q pH 8.0) start buffer and purification undertaken as per General Methods (Section 
2.4.2).  
6.2.5.2 Crystallisation of domains of selected surface proteins  
6.2.5.2.1 Concentration 
6.2.5.2.1.1 rCD279127-322  
Post Q purification, His.SUMO derived rCD279127-322 was concentrated in a Vivaspin 
20 10k MWCO spin concentrator then dialysed into 20 mM tris pH 8.0 (final 
concentration 12.04 mg/ml (A280) (or ~5mg/ml using ProtParam (Gasteiger et al. 
2005) calculated extinction co-efficient 0.419) before sitting drop vapour diffusion 
crystallisation as detailed in Section 6.2.5.3. 
6.2.5.2.1.2 His.rCD276727-401 
Post IMAC, His.rCD276727-401 was dialysed into 50 mM tris 150 mM NaCl pH 8.0 (or 
50 mM MES 150 mM NaCl pH 6.0) 0.2 µm filtered then concentrated in a 
Vivaspin 20 10 kDa MWCO spin concentrator (Table 6.2.4) 
 
Table 6.2.4 Assessment of concentration of His.rCD276727-401  
Pre concentration 
Dilution A280 Approx mg/ml*  Volume Total protein 
(mg) 
1:10 0.857  3.87  20 ml 171.4 mg  
Post concentration  
1:100  1.678 75.7 750 µl 125 mg  
1:200  1.060 95.76 750 µl 159 mg 
1:500  0.533 120.2 750 µl 199 mg  
* using ProtParam (Gasteiger et al. 2005) extinction co-efficient of 2.216 
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6.2.5.3 Crystallisation set-up 
Using a nano-dispensing robot (Art Robins Instruments), sitting drop vapour 
diffusion crystallisation trials were set up in 96 well Intelli-Plate(s) (Art Robins 
Instruments). 0.15 µl (150 nl, 300 nl for 2:1 ratio) protein solution was dispensed 
into each of the three wells along with an appropriate amount of reservoir solution 
giving 2:1, 1:1 and 1:2 protein:reservoir ratios. The following screens were 
assessed: 
 PACT premier™ (PEG/ion screen) 
 JCSG-plus™ (sparse matrix)  
 Structure Screen 1 (sparse matrix) 
 Structure Screen 2 (extension of SS1 but with novel precipitants and 
combinations) 
 Memgold (sparse matrix membrane protein specific screen covering a range 
of pH, PEGs and salt additives) 
 Morpheus™ (3D grid design covering a range of pH, PEGs and salt additives) 
All of which are available from Molecular Dimensions™.  
 
Conditions with potential results (hits) i.e. crystallisation conditions were close but 
needing to be optimised, were set up as hanging drop vapour diffusion 
crystallisations manually in 24-well plates (Table 6.2.5).  
6.2.5.4 His.rCD276727-401 single crystal data collection and processing 
A total of 250 images from a single crystal of His.rCD276727-401 (in 50 mM tris 
150 mM NaCl pH 8.0 from well D10 (Structure Screen 1 & 2, 0.05 M potassium 
dihydrogen phosphate, 20 % w/v PEG 8000)) were recorded to a resolution of 
approximately 2 Å, with an oscillation angle of 1  per image on the φ axis 
(perpendicular to the x-ray beam), with a crystal to detector distance of 300.51 mm 
and exposure time of 2.6 sec, at 100K on beamline IO4-1 at the Diamond Light 
Source (Didcot, Oxon).  
 
Diffraction images were processed (indexing, cell-refinement and integration) with 
iMOSFLM v1.0.4 (Leslie 2006) in each of the proposed space groups (Table 6.3.5). 
  
274 
Data were scaled in all possible space groups using SCALA (CCP4 1994) and taken 
for further analysis including molecular replacement and cell content analysis. 
Preliminary molecular replacement trials were performed using the PHENIX 
package of crystallography programs (Adams et al. 2010). 
 
 
Table 6.2.5 Manually set up vapour diffusion crystallisation of rCD279127-322  
Original 
Screen 
well 
Buffer/Salt 
 
Buffer/Salt 
 
pH 
 
Precipitant Protein:Reservior 
PACT 
Premier 
B3 
0.1 M MIB* 
buffer   
None 6.0 25-10% w/v 
PEG1500 
1:2 
PACT 
Premier 
C3 
0.1 M 
PCTP* 
buffer  
None 6.0 25-10% w/v 
PEG1500 
1:2, 1:3 
PACT 
Premier 
D3 
0.1 M 
MMT* 
buffer 
None 6.0 25-10% w/v 
PEG1500 
1:2, 1:3 
Manual 
1 
None None - 25-10% w/v 
PEG1500 
1:2 
 
*MIB - malonic acid, imidazole, boric acid, PCTP - sodium proponate, sodium cacodylate, 
bis-tris propane, MMT- malic acid, MES, tris. 
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6.3 Results 
The following CWBD containing surface proteins were chosen for crystallisation, 
based on their likelihood to be implicated in adherence or pathogenesis and/or 
immuno-stimulatory ability: 
 
 CD2791 (66 kDa)- an uncharacterised immunogenic surface protein  
 Cwp66 (66 kDa)- a heat shock inducible adhesin 
 CD2767 (77 kDa)- an uncharacterised putative glycoside hydrolase  
 
Two tracks were used to express and purify protein(s) for crystallisation: Expression 
of the full length protein (minus signal peptide) containing CWBDs, which may 
potentially yield structural information about both the functional domain and vital 
data regarding the CWBD(s) and expression of only the ‘functional’ domain (without 
the CWBD (and signal peptide)).  
6.3.1 CD2791 
6.3.1.1 Expression and purification of rCD2791 (full length) 
rCD2791 expressed as a clear band at 66 kDa when fused to N-terminal His6 and T7 
tags (His.T7.rCD2791). IMAC purified His.T7.rCD2791 plus truncated material 
between 28 kDa - 66 kDa which are detected with anti-His, anti-T7®Tag and anti-
R20291 SLP IgG in western blot (Figure 6.3.1). To remove degraded/truncated 
species two IEX chromatography (Q-sepharose or SP-Sepharose) resins were tested, 
however neither satisfactorily isolated pure His.T7.rCD2791, in both cases 
His.T7.rCD2791 eluted as a single peak with contaminating material.  
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Figure 6.3.1 His.T7.rCD2791 purification. Lane 1 Western blot 
with anti-R20291 SLP IgG of Lane 2. Lane 2 IMAC elute showing 
extensive N-terminal degradation/truncation, Lane 3 and 4 
material not bound to or eluted during HIC purification, Lane 4 
Water eluted 66 kDa (His.T7.rCD2791) material from the same 
phenyl sepharose HP (HIC) column. 
 
Using hydrophobic interaction chromatography a fraction of His.T7.rCD2791 
appeared to bind so strongly it could only be eluted with water, this lead to >90% 
His.T7.rCD2791 purity by SDS-PAGE (Figure 6.3.1). Contaminating material either 
did not bind or eluted during the desalting gradient. 
6.3.1.1.1.1 Assay for N-acetylmuramoyl-L-alanine amidase activity 
It has been shown previously that the HMW SLP (which consists of three CWBDs) 
exhibits N-acetylmuramoyl-L-alanine amidase (amidase) activity in zymogram assay 
against Micrococcus luteus cells (Calabi et al. 2001). The amidase activity of the two 
C-terminal CWBDs of CD2791 were therefore available to help determine if the 
His.T7.rCD2791 purified was correctly folded.  
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A method using immobilised Micrococcus lysodeikticus (also known as Micrococcus 
luteus) was ‘the lysoplate’ developed, based on serum and urinary lysozyme 
(muramidase) activity (Osserman & Lawlor 1966), where cell lysis/amidase activity 
results in transparent area(s) in a solid phase agarose- Micrococcus cell gel matrix 
(Table 6.3.1).  
 
Table 6.3.1 Lysoplate results for rCD2791 fractions 
Well number α-lysis (incomplete) (mm 
diameter) 
β-lysis (complete) (mm 
diameter) 
1- 10 µg Lysozyme control 39 22 
2- 30 µg Amidase* control  39 1 
3- 11.19 µg water eluted 
CD2791 
13 0 
4- 31.08 µg water eluted 
CD2791 
14 0 
5- 10.75 µg flow-through 
material 
0 0 
6- Buffer only 0 0 
* Amidase from Pseudomonas aeruginosa (Sigma- A6691). TK buffer 0.1 M tris-HCl, 0.1 M KCl pH 7.0 
(Fan & Beckman 1973). 
 
After 24 hr, water eluted 66 kDa (His.T7.rCD2791) gave a zone of lysis 
approximately one third that of the amidase control (at both concentrations 
tested). The HIC non-binding or ‘normally’ eluted material did not show any lytic 
activity. Varying pH (6, 7 or 8) and/or including 1 mM ZnCl2 in the reaction buffers 
did not alter lysis zones for His.T7.rCD2791 (zinc or other divalent cations are a 
known requirement of N-acetylmuramoyl-L-alanine amidases (Shida et al. 2001; 
Kerff et al. 2010)). This data suggests that the two C-terminal CWBDs, of HIC water 
eluted His.T7. CD2791, were at least partially correctly folded and able to lyse 
Micrococcus cell walls in a manner analogous to the HMW SLP. Consequently, 
His.T7.rCD2791 was dialysed into 10 mM HEPES pH 7.4, concentrated to 
approximately 6 mg/ml and put forward into crystallisation. 
6.3.1.1.1.2 Crystallisation of rCD2791 
Robotic assisted sitting drop crystallisation trials (570 conditions in total over 5 
commercially available crystallisation screens) revealed a range of buffer conditions 
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(~20) where crystallisation may occur. Hits were primarily sea urchin like or fine tiny 
needles (Table 6.3.2). 
 
There did not appear to be a consistent feature of the hits, e.g. buffer or 
precipitant, other than a pH requirement between pH 6.5 - 8.5. Although, 
approximately one third of the hits included magnesium chloride and/or tris based 
buffers. Manually set up hanging drop crystallisation, optimising buffer 
composition, pH and precipitant concentration did not change crystal quality or size 
and yielded small needles (See Figure 6.3.2). 
 
 
Figure 6.3.2 His.T7.rCD2791 needle crystals. Obtained from manually 
set-up hanging drop crystallisation trial with His.T7.rCD2791 (6.02 mg/ml 
in 10 mM HEPES pH 7.0) in 0.2 M NaCl, 0.1 M HEPES, 10% isopropanol 
pH 7.5 (derived from JCSG-plus™ sparse matrix screen). 
 
6.3.1.1.1.3 Optimisation of rCD2791 for crystallisation 
Due to the limited crystallisation displayed in sitting drop crystallisation screens it 
was suspected that crystallisation was being hindered by impurities in the protein 
sample or intra/inter protein or a combination of both. Therefore, methods were 
used to assess the native state of the protein and to improve the purity. 
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Table 6.3.2 Sitting drop crystallisation conditions which demonstrated varying degrees of 
crystallisation of His.T7.rCD2791 
 
 
  Reservoir conditions  
Screen Well Salt Buffer pH Precipitant Result 
Structure 
Screen 1 
& 2 
D12 - -  0.2 M 
magnesium 
formate 
Needles 
 E4 0.2 M 
magnesium 
chloride 
0.1 M tris 8.4 3.4 M 1,6-
hexanediol 
Clusters 
 E9 - 0.1 M tris 8.5 20% ethanol Clusters 
 F7 - 0.1 M 
HEPES 
7.5 10% PEG 8000, 
8% ethylene 
glycol 
One lone 
needle 
JCSG-
plus™ 
B10 0.2 M 
magnesium 
chloride 
0.1 M 
sodium 
cacodylate 
6.5 50% PEG200 Needles 
 B8 0.2 M 
magnesium 
chloride 
0.1 M tris 7  10% PEG8000 Needles 
 C8 - 0.1 M tris 8.5 20% v/v ethanol small 
cluster of 
needles 
 E3 0.2 M NaCl 0.1 M 
HEPES 
7.5 10% v/v 2-
propanol 
Needle 
clusters 
 E9 - 0.1 M 
MES 
pH 6.5 
6.5 1.6 M 
magnesium 
sulphate 
Needles 
 F6 - 0.1 M 
bicine pH 
9.0 
9 
 10% MPD 
sea 
urchins 
 F5 0.2 M 
magnesium 
chloride 
0.1 M tris 
pH 8.5 
8.5 
 50% ethylene 
glycol 
crystaloids 
PACT 
premier™ 
G12 -  0.1 M 
SPG buffer 
7 25 % w/v PEG 
1500, 25 % w/v 
PEG 1500 
Sea 
Urchins  
 A4 
0.2 M sodium 
malonate 
 0.1 M bis 
tris 
propane 
7.5 20 % w/v PEG 
3350 
Tiny rods 
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6.3.1.1.1.3.1 Size exclusion chromatography (SEC) 
To assess if the protein sample was aggregated, SEC was used. SEC of ‘pure’ HIC 
water eluted His.T7.rCD2791 revealed that the protein was predominantly 
aggregated and came out in the void volume. The second largest species (50% peak 
size) correlated with a size of a dimeric species 163 kDa (132 kDa predicted) 
followed by a small amount of monomeric species (74.8 kDa, 66 kDa predicted) and 
smaller impurities (Figure 6.3.3). 
 
 
Figure 6.3.3 Size exclusion chromatography (SEC) of His.T7.rCD2791. His.T7.rCD2791 in 
10 mM HEPES pH 7.4 (6 mg/ml) using a Superdex 200 10/300 GL column equilibrated with 
PBS. Numbers in brackets represent elution volume (ml). 
 
Therefore, the presence of aggregated material was likely to have affected both the 
ability of His.T7.rCD2791 to crystallise, i.e. pack into a regular periodic structure, 
and possibly affected the amidase activity, due to a lack of free-unaggregated 
material to cleave Micrococcus cell walls. 
6.3.1.1.1.3.2 IMAC optimisation 
The hydrophobic nature of His.T7.rCD2791 observed during HIC purification and the 
aggregation seen in SEC, was suspected to be due to the CWBDs aggregating with 
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themselves or other proteins. Certain surface proteins containing CWBDs, e.g. SlpA, 
CD2791 or CD2784, can be removed from the C. difficile cell surface using low pH or 
chaotropic agents, i.e. disrupt CWBD interactions, a range of protease inhibitors, 
sugars, detergents, kosmotropic and chaotropic additives (as suggested by Bondos 
& Bicknell (2003)), were added to cell lysis and IMAC buffers to potentially decrease 
aggregation and degradation. A single 66 kDa species was obtainable, using all 
additives, as a secondary and tertiary IMAC peak(s) when using gradient elution on 
small (50 ml) culture volumes, with 1% CHAPS giving the largest (mAU) yield (Figure 
6.3.4A). 
 
Upon scale up (1litre), the addition of 1% CHAPS did not appear to result in the 
same triphasic elution and His.T7.rCD2791 eluted impurely (Figure 6.3.4B). Further 
purification with high resolution MonoQ, with buffers also supplemented with 
1% CHAPS, did not purify His.T7.rCD2791 away from contaminants.  
 
Denaturing purification and on-column refolding were assessed twice. The first run 
eluted microgram amounts of pure His.T7.rCD2791, not enough for crystallisation. 
During the second run, after removing denaturant, His.T7.rCD2791 and 
contaminants eluted from the column before elution with imidazole.  
 
Full length, C-terminally His6 tagged rCD2791, may have expressed and purified 
without the N-terminal truncates seen for His.T7.rCD2791, interactions of the 
CWBDs were still likely to have impeded obtaining pure (un-aggregated) protein. 
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Figure 6.3.4 IMAC purification of His.T7.rCD2791 with buffers 
supplemented with 1% CHAPS. (A) Chromatograph showing elution peaks 
(B) SDS-PAGE analysis of fractions from small scale test (50 ml culture, 1 ml 
HisTrap HP) (Lane 1-3) large scale purification (1 litre culture, 5 ml HisTrap) 
(Lane 4). 
6.3.1.1.2 Expression and purification of the N-terminal domain of CD2791 
(rCD279127-322) 
Due to the difficulties in obtaining pure non-aggregated full length rCD2791, 
expression of only the ‘functional’ domain was assessed, i.e. minus the CWBDs, 
from residue T27-K322 (rCD279127-322). T27 represents the predicted start of 
CD2791 after the signal peptide, although A25 has been shown to be the actual 
starting N-terminal residue (Calabi & Fairweather 2002).  
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A His6 tagged version (His.rCD279127-322) expressed and purified as a 45 kDa species 
(~33 kDa predicted) in IMAC with a large amount of truncated (<30 kDa) species. 
Dialysis into an IEX (MonoQ pH 8.0) buffer appeared to precipitate both 
contaminating species and a significant proportion of His.rCD279127-322. The 
remaining His.rCD279127-322 eluted as a single peak with a 1 M NaCl gradient giving 
a prominent band at 45 kDa with contaminating species at 35, 30, 25 and 20 kDa in 
SDS-PAGE (Figure 6.3.5). 
 
Figure 6.3.5 Purification of His.rCD279127-322. Lane 1- Material eluted from 
IMAC. Lane 2- Unprecipitated material eluted from Mono Q. 
 
To prevent the precipitation seen post IMAC and to try to decrease N-terminal 
truncation, fusion to a small ubiquitin-like modifier (SUMO) tag was assessed, as 
this protein has been shown to aid purification of difficult proteins (Butt et al. 2005; 
Marblestone et al. 2006). His.SUMO.rCD279127-322 expressed well and purified as a 
52 kDa species in IMAC. Subsequent removal of the His.SUMO tag with SUMO 
protease and a second round of IMAC (cleavage removes the His6 tag so rCD279127-
322 flows through) left a 40 kDa species (predicted 32 kDa) with 84, 30, 28, 25 and 
20 kDa impurities. IEX purification to remove SUMO protease buffer, eluted a single 
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peak containing a main 40 kDa band (rCD279127-322) plus other minor species at 
approximately 29 and 31 kDa (Figure 6.3.6). The ratio of 40 kDa rCD279127-322 to 
other species decreased across the eluted peak. After dialysis into 10 mM tris 
pH 8.0 and concentration to 12.04 mg/ml, the eluted rCD279127-322 material was 
used in crystallisation trials. Interestingly, the final His.SUMO version of rCD279127-
322 demonstrates a similar SDS-PAGE profile to the MonoQ purified (un-
precipitated) His.rCD279127-322 purified in Figure 6.3.5. 
 
SEC of His.SUMO.rCD279127-322 and the native (post tag removal) rCD279127-322 gave 
monomeric species of approximately 74 kDa and 44 kDa respectively, putatively 
supporting SDS-PAGE results suggesting that rCD279127-322 runs larger than the 
predicted molecular weight (32 kDa). 
 
Figure 6.3.6 Purification of His.SUMO tagged rCD279127-322. Lane 
1- IMAC elute, Lane 2- rCD279127-322 Post His.SUMO cleavage 
IMAC flow through, Lane 3- Post His.SUMO cleavage IMAC elute 
showing uncleaved full length and liberated His.SUMO. Lane 4(i & 
ii)- IEX (Q, pH 8.0) purification of rCD279127-322 IMAC flow through. 
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6.3.1.1.2.1 Crystallisation of rCD279127-322 
Robot setup sitting drop crystallisation screens of rCD279127-322 appeared to have a 
number of hits (Table 6.3.3), particularly in proprietary buffers from the PACT 
premier screen (Figure 6.3.7). However, manual setup and optimisation of these 
conditions all resulted in protein precipitation. 
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Table 6.3.3 Sitting drop crystallisation conditions which demonstrated varying degrees of 
crystallisation rCD279127-322  
 
*MIB - malonic acid, imidazole, boric acid, PCTP - sodium proponate, sodium cacodylate, 
bis-tris propane, MMT- malic acid, MES, tris. 
a For details of the composition of the buffers in the Morpheus screen please see Molecular 
dimensions screen datasheet. 
 
  Reservoir conditions  
Screen Well Salt Buffer pH Precipitant Result 
JCSG+ F9 None 
 
None 
 
7.0 
 
2.4 M sodium 
malonate 
Needles 
 H9 0.2 M lithium 
sulphate 
0.1 M 
bis tris 
5.5 
 
25 % w/v PEG 
3350 
Needles 
 H10 0.2 M 
ammonium 
acetate 
0.1 M 
bis tris 
 
5.5 
 
25 % w/v PEG 
3350 
Needles 
Memgold A3 None 
 
0.015 M 
tricine 
8.5 
 
24 % w/v PEG 
4000 
Needles 
 C7 None 
 
0.02 M 
bis tris 
7.0 
 
15 % w/v PEG 
2000 
‘Sea 
Urchins’ 
 D3 None 
 
0.05 M 
HEPES 
7.5 
 
22 % v/v PEG 
4000 
Needles 
 F8 0.1 M sodium 
chloride/ 
0.005 M 
magnesium 
chloride 
0.1 M 
tris 
 
8.5 
 
30 % w/v PEG 
2000 MME 
Needles 
PACT 
premier 
B3-5 0.1 M MIB* 
buffer   
None 7.0-
9.0 
25% w/v 
PEG1500 
Figure 
3.3.4 
 C3-5 0.1 M PCTP* 
buffer  
None 7.0-
9.0 
25% w/v 
PEG1500 
Figure 
3.3.4 
 D3-5 0.1 M MMT* 
buffer  
None 7.0-
9.0 
25% w/v 
PEG1500 
Figure 
3.3.4 
Screen Well Ligand stock Buffer 
stock 
pH Precipitant 
stock 
Result 
Morpheusa H5 0.1 M amino 
acids 
0.1 M 
Buffer 2 
7.5 30% 
P550MME_P20K 
Needles 
with 
spheroids 
 G1 0.1 M 
carboxylic 
acids 
0.1 M 
Buffer 1 
6.5 30% 
P550MME_P20K 
Spheroids 
 H9 0.1 M amino 
acids  
Buffer 3 8.5 30% 
P550MME_P20K 
Needles 
  
2
8
7
 
 
Figure 6.3.7 Sitting drop crystallisation of rCD279127-322 using the PACT premier™ PEG/Ion screen. Protein (P) : Reservoir solution (R) ratio. 
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6.3.1.1.3 Modelling of CD279127-322  
Previous BLASTP analysis of the CD2791 N-terminal region revealed homology 
(39% amino acid similarity) to both the 125 kDa SLP of Bacillus sphaericus and the 
transducer of rhodopsin (Htr) II from the archaebacterium Natronobacterium 
pharaonis (Calabi & Fairweather 2002). 
 
BLASTP, in this chapter, suggests that the C-terminal region of CD279127-322 (Y124-
E318) shares approximately 30% identity with the S-layer (Pfam 04122 containing) 
proteins of Clostridium hiranonis DSM 13275 and a ~50 aa region (between V221-
S270) shares approximately 40% identity with the cytotoxin associated protein 
CagA of Helicobacter pylori (Backert et al. 2010). CD279127-322 shares approximately 
17% identity to the LMW SLP. The full length (minus signal peptide) CD2791 and 
SlpA share 29.4% identity, although this is largely through the CWBDs. 
 
Performing a BLAST search of the sequences derived from structural domains in 
CATH (Protein structure classification database, www.cathdb.info) reveals that 
CD279127-322 has a 41 amino acid region with 36.59% identity with both 1KIX 
(Peersen et al. 2002) and 1JB7 (Horvath & Schultz 2001), both of which are 
telomere binding proteins from the ciliate protozoa Oxytricha nova. 
 
Therefore, BLAST analysis suggests that CD279127-322 shares little homology with 
known proteins at sequence level. Using tertiary structure homology modelling 
programs to try to reveal protein similarities confounds the lack of similar proteins 
as SWISS-MODEL (Bordoli et al. 2009) and ESyPred3D (Lambert et al. 2002) could 
not identify useful template structures. CPHmodels (Nielsen et al. 2010), using 
remote homology modelling, suggests a poor quality model (Z-score 5.6, Z-score 
10+ indicates a high reliability model) based on Listeria invasion protein InlB (2UZX) 
(Figure 6.3.8). 
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Figure 6.3.8 Predicted structure of CD279127-322, homology 
modelled on Listeria invasion protein InlB (2UZX) (by CPHmodels-
3.0)(Nielsen et al. 2010). Prepared using PyMOL (www.pymol.org) 
(N- blue C- red). 
 
Threading (fold recognition) servers also found little to no similarity to known folds, 
as found with homology searches. Both Phyre (Kelley & Sternberg 2009) and 
HHPred (Soding 2005) found small regions with limited fold similarity to known 
proteins. However, mGenThreader (Lobley et al. 2009) which uses fold recognition 
and identification of distant homologues using profile-profile alignments and 
predicted secondary structure (using PSIPRED (Jones 1999)), suggests that the 
secondary structure of CD279127-322 is similar to the S-layer protein SbsC of 
Geobacillus stearothermophilus (2RA1), sufficiently that the fold match is rated 
‘High’ (p value <0.001) (while sharing 10.5% identity) (Figure 6.3.10). Entering the 
alignment into MODELLER (Eswar et al. 2007) and aligning it with SbsC (Pavkov et 
al. 2008), reveals CD279127-322 aligns with domains II and III of rSbsC(31–443), although 
the N-terminus of CD279127-322 (see secondary structure prediction Figure 6.3.11) 
aligns with the alpha-helical SCWP binding domain I of SbsC (Figure 6.3.9).   
 
Analysis of just the secondary structure prediction (Figure 6.3.11) (PSIPRED (Jones 
1999)) suggests CD279127-322 has two sheet-helix-sheet repeats at the N-terminus 
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then a predominantly β -sheet region ending with a helix, which putatively marks 
the start of the largely α-helical CWBDs. Secondary structure prediction suggests, 
that after the signal peptide has been removed, the N-terminus of CD2791 contains 
a helix and loop ‘head’ domain followed by a stem β sheet domain, then the two 
CWBD. It is interesting to that the both the predicted secondary structure of 
CD279127-322  and the LMW SLP (Fagan et al. 2009) are both two domain proteins, 
suggesting that this type of arrangement may be involved in S-layer array packing. 
 
 
Figure 6.3.9 Superposition of pGENThreader (Lobley et al. 2009) secondary 
structure fold alignment of CD279127-322 (Blue N- Red C-term, modelled 
with MODELLER (Eswar et al. 2007)) with S-layer protein SbsC of 
Geobacillus stearothermophilus (2RA1) (Grey). Prepared using PyMOL 
(www.pymol.org) (N- blue C- red). 
 
The lack of reference structures upon which CD2791 can be modelled (by either 
homology or fold modelling), highlights the need for a crystal structure to enable 
novel fold identification or allow understanding of function based on conserved 
folds not identifiable by current predictive modelling servers.  
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                 10        20        30        40        50        60 
         CCHHHHHHHHHHHHHHHHHHHHHHHHHHCCCCCHHHHHHHHHHHHHHHHHHHHHHHHHCH 
2ra1A0   TDVATVVSQAKAQMKEAYYTYSHTVTETGQFPDIKDVYAAYNKAKQAYANAVAVVNKAGG 
2791     ------------------------------------------------------------ 
         ------------------------------------------------------------ 
                                                                    
 
                 70        80        90       100       110       120 
         HHHHHHHHHHHHHHHHHCCCCCCCCCCCHHHHHHHHHHHHHHHHHHHHHHHHHHHCCCHH 
2ra1A0   AKKDAYLADLQAIYETYVFKANPKSGEARVATYIDAYNYATKLDKMRQELKAAVDAKDLK 
2791     ------------------------------------------------------------ 
         ------------------------------------------------------------ 
                                                                    
 
                130       140       150       160       170       180 
         HHHHHHHHHHHHHHHCCHHHHCCCCHHHHHHHHHHHHHHHHHHHHHCHHHHHHHHHHHHH 
2ra1A0   KAEELYHKISYELKTRTVILDRVYGQSTRELLRSTFKADAQALRDRLIYDITVAMKAREA 
2791     ------------------------------------------------------------ 
         ------------------------------------------------------------ 
                                                                    
 
                  190       200       210                        220 
         HHHHHCC--CHHHHHHHHHHHHHHHHHCCCCC-----------------HHHHHHHHHHH 
2ra1A0   QDAVKAG--NLDKAKAALDQVNQYVSKVTDAF-----------------KAELQKAAQDA 
2791     TTQVKKETITKKEATELVSKVRDLMSQKYTGGSQVGQPIYEIKVGETLSKLKIITNIDEL 
         CCEEEEEEEEHHHHHHHHHHHHHHHHCCCCCCCCCCCCEEEEEECCEECCCCEECCHHHH 
                 10        20        30        40        50        60 
 
               230       240              250        260       270  
         HHHHHHHCCCCEEEEEEEEC-------CEEEEEECCCCCCCC-CCCCCEEEEECCCCC-- 
2ra1A0   KAAYEAALTPKVESVSAIDS-------TSFKVTFTKPVDKAT-AIPKNFSITLKGTET-- 
2791     EKLVNALGENKELIVTITDKGHITNSANEVVAEATEKYENSADLSAEANSITEKAKTETN 
         HHHHHHCCCCCEEEEEEECCCEEEECCCEEEEECCCCCCCCCHHHHHHCHHHHHCCCCCC 
                 70        80        90       100       110       120 
 
                  280       290       300                       310 
         ---EECEEEEEECCCCCEEEEEECCCCCCCCEEEEEEC----------------CCCCCC 
2ra1A0   ---KLYPKSVEVSESGLTATVTLYDTLVDGKTYTVVTS----------------GLKDTA 
2791     GIYKVADVKASYDSAKDKLVITLRDKTDTVTSKTIEIGIGDEKIDLTANPVDSTGTNLDP 
         CEEEEEEEEEEEECCCCEEEEEECCCCCCCCEEEEEEECCCEEEECCCCCCCCCCCCCCC 
                130       140       150       160       170       180 
 
              320           330       340       350       360       
         CCCCCCEEEEEEC----CCCCCCEEEECCCEECCCCCEEHHHHEEEECCCCCCCCCCC-- 
2ra1A0   GKEFETSTNEFTY----NKPVPASITFNFNKLPEDSAVDLTKYVTVKDAAGNVIKSGF-- 
2791     STEGFRVNKIVKLGVAGAKNIDDVQLAE---------------ITIKNSDLNTVSPQDLY 
         CCCCEEEEEEEEEEECCCCCCCCCEEEE---------------EEEECCCCCCCCCCCCC 
                190       200                      210       220    
 
           370               380       390       400       410      
         -EEEEEEC--------CCCCCCCEECCCCCCEEEEEEEEECCCCCCCCEEEEECC----- 
2ra1A0   -ELEFTSS--------EKLTQGKFINTTGKKSVIVNATVKGTNVTTGNVILAVED----- 
2791     DGYRLTVKGNMVANGTSKSISDISSKDSETGKYKFTIKYTDASGKA--IELTVESTNEKD 
         CCEEEEECCCEECCCCCCCEECCCCCCCCCCEEEEEEEEECCCCCE--EEEEEECCCHHH 
           230       240       250       260       270         280  
 
                     
         ------------- 
2ra1A0   ------------- 
2791     LKDAKAALEGNSK 
         HHHHHHHHCCCCC  
Figure 6.3.10 pGENThreader (Lobley et al. 2009) alignment of CD279127-322 with the S-layer 
protein SbsC of Geobacillus stearothermophilus (2RA1) (Pavkov et al. 2008). 
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Figure 6.3.11 Secondary structure prediction of the N-terminal domain of 
CD2791 (CD279127-322). Prediction using PSIPRED (Jones 1999). 
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6.3.2 Cwp66 
As mentioned in Chapter 5 specific methods (Section 6.2.1.1), the putative C. 
difficile R20291 cwp66 gene was obtained by BLAST searching the C. difficile Stoke 
Mandeville 027 (R20291) assembly (Sanger, March 2008) with the published C. 
difficile 630 cwp66 gene. However, the subsequent completion of the C. difficile 
R20291 genome (and publishing onto NCBI) revealed that the R20291 cwp66 gene 
was in fact 25 residues longer than the Sanger Stoke Mandeville BLAST result 
suggested (Figure 6.3.12).  
 
 
Figure 6.3.12 Alignment of transcribed putative cwp66 from Stoke Mandeville 
(Sanger) BLAST (March, 2008) (labelled BLAST027) against published C. difficile 
R20291 sequence (September 2010) (Labelled R20291). 
 
It is unknown what effect either the change or extension of residues had on the 
structure of Cwp66 expressed in this study. However, comparison of the C-terminal 
secondary structure of Cwp66 from R20291 (completed) and the putative Cwp66 
R20291 sequences, reveals that the end 25 amino acids of the putative BLAST 
Cwp66 form a helix whereas the completed Cwp66 R20291 do not (Figure 6.3.13). 
The species expressed in this chapter was based on the BLAST result and as such are 
numbered up to I585 to represent the end of the putative gene. 
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Figure 6.3.13 Secondary structure prediction of Cwp66 C-terminal regions from: putative 
Cwp66 (Sanger, Stoke Mandeville BLAST result) (I324-I585) and completed R20291 Cwp66 
sequence (V323-I611). Arrows highlight regions different between two Cwp66 variants. 
Secondary structure prediction made with PSIPRED v3.0 (Jones 1999). 
 
6.3.2.1 Expression and purification of full length rCwp66 
Full length rCwp66 with His6 and T7 tags (His.T7.rCwp66) expressed poorly and 
predominantly formed inclusion bodies. IMAC purification of the soluble fraction 
yielded a fragmented species, although purification using a Co2+ charged IMAC 
column purified a larger proportion of 66 kDa His.T7.rCwp66 than Ni2+ (Figure 
6.3.14). The Co2+ IMAC eluted His.T7.rCwp66 precipitated upon dialysis into 1 M 
NaCl 50 mM sodium phosphate pH 7.0 for HIC purification.  
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Figure 6.3.14 IMAC purification of His.T7.rCwp66. Lane 1 & 2- 5 ml HisTrap 
HP (nickel charged) anti-His6 blot and IMAC elute respectively, Lane 3- 5 ml 
BD TALON™ (cobalt charged) media IMAC elute. 
 
To increase solubility and ease purification of rCwp66, a GST tagged construct was 
assessed. Expression of this construct was largely insoluble despite optimisation of 
expression conditions. The limited amount of soluble GST.rCwp66 displayed 
progressive aggregation and precipitation during manipulation, e.g. dialysis or 
purification step(s), such that little to no protein could be purified. 
 
6.3.2.2 Expression and purification of the C-terminal domain of Cwp66 
(rCwp66324-585) 
The position of the N-terminal CWBDs and a propensity to form N-terminal 
truncates (as found in other pET vectors in this chapter) was suspected to be 
hindering purification. Therefore, a strategy to express only the C-terminal domain 
was investigated. 
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The ‘functional’ C-terminal domain of Cwp66 was expressed with only a His6 tag 
(His. rCwp66324-585). This construct expressed poorly as a 38 kDa species (~32 kDa 
predicted). Western blotting after IMAC revealed that the 38 kDa His.rCwp66324-585 
species only weakly bound to the IMAC column and mostly flowed through. A broad 
shallow elution ‘peak’ contained small amounts of the 38 kDa species, together 
with 63 and 98 kDa species, all detectable with anti-His6 (Figure 6.3.15), suggesting 
His.rCwp66324-585 may form dimers (even trimers).  
 
 
Figure 6.3.15 IMAC purification of His.rCwp66324-585. (A) SDS-PAGE (B) 
Western blot with anti-His6. L- Load E. coli lysate, FT- unbound flow 
through, E1-4 Eluted fractions.  
 
In case the His6 tag was occluded and to improve solubility, rCwp66324-585 was 
expressed as a SUMO fusion (Figure 6.3.16). His.SUMO.rCwp66324-585 appeared to 
be in the soluble fraction after cell lysis, but prior to IMAC a large amount of 
insoluble precipitate formed. Removal of the precipitate and application until the 
IMAC column became blocked or using a batch purification procedure, resulted in a 
small amount of His.SUMO.rCwp66324-585 being purified. Incubation of this material 
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with SUMO protease cleaved the His.SUMO moiety; however, the majority of the 
protein was precipitated during dialysis into the cleavage buffer.  
 
 
Figure 6.3.16 SUMO tagged rCwp66324-585 purification. Lane 1- IMAC 
purified His.SUMO.rCwp66324-585, Lane 2- Incubation of 20 µg 
His.SUMO.rCwp66324-585 with 10 units SUMO protease in SUMO cleavage 
buffer (50 mM tris, 150 mM NaCl, 0.2% igepal, 1 mM DTT pH 8.0) for 1 hr at 
30 °C 
 
The majority of the protein also precipitated upon dialysis into MonoQ IEX buffer 
(50 mM tris pH 8.0) after IMAC.  
 
These results suggest that rCwp66324-585 is a protein prone to aggregation and that 
this feature may be involved in its putative adhesive function in vivo. 
 
6.3.2.3 Modelling of the C-terminal domain of Cwp66 from R20291 
(Cwp66323-611) 
Due to the issues between the cwp66 BLAST result from the unfinished R20291 
(March 2008) and the completed R20291 cwp66 sequence (Section 6.3.2.1), 
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bioinformatics’ searches in this section were performed on the C-terminal 289 
amino acids (Cwp66323-611) of the finalised R20291 Cwp66 sequence, as found on 
NCBI.  
 
There are currently no predicted conserved domains (CDD search (Marchler-Bauer 
et al. 2009)) or predicted protein signatures (Interpro) (Hunter et al. 2009) for 
Cwp66323-611. BLASTP reveals limited (approx 27% identity) homology with the S-
layer proteins of Clostridium hiranonis DSM 13275 but also finds 32% identity 
(K397-I475) and 26% identity (I353-L445) with cell division protein FtsQ of 
Bacteroides sp. and probable cell surface glycoprotein of Haloarchaeon 
respectively. Interestingly, the 96 amino acid region, similar to the cell surface 
glycoprotein of Haloarchaeon, corresponds to a PapD-like region, PapD is a 
periplasmic chaperone necessary for the assembly of pili. Performing a BLAST of the 
CATH database only finds matches for a 52 amino acid region with a very low E-
value of 1.1 indicating an extremely limited match.  
 
Homology modelling with SWISSMODEL (Arnold et al. 2006) and EsyPred3D 
(Lambert et al. 2002) confirms limited sequence similarity with known proteins, as 
neither could find any suitable templates. However, CPHmodels (Nielsen et al. 
2010), using remote homology modelling, suggests T333-D609 of Cwp66323-611 
shares homology to chondroitinase B from Pedobacter heparinus (1OFL) (Z-score 
6.9, >10 indicates a high reliability model) (Figure 6.3.17). Homology modelling 
therefore suggests that Cwp66323-611 may have a parallel β sheet structure. 
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Figure 6.3.17 T333- D609 of Cwp66323-611 modelled on chondroitinase B 
from Pedobacter heparinus (1OFL) by CPHmodels (Nielsen et al. 2010). (A) 
rotated approximately 90° to show ‘hollow’ core of right-handed, parallel 
β-helix (B). Prepared using PyMOL (www.pymol.org) (N- blue C- red). 
 
Secondary structure prediction (PSIPRED (Jones 1999)) also suggests the C-terminal 
domain of Cwp66 is largely β-sheet structure (Figure 6.3.20). Given that the cwp66 
gene is variable, it is therefore likely that the variation occurs such that the 
structure of the protein is maintained or occurs in the loop regions. Comparison of 
the C-terminus of Cwp66 between 630 and R20291 reveals that the secondary 
structure is conserved while the amino acid sequence has 61.5% identity (Figure 
6.3.20). Moreover, differing residues are found as predicted in the coil (loop) 
regions of the structure. This suggests that while Cwp66 is one of the few surface 
proteins to be genetically variable, the structure is conserved, highlighting the 
importance of that particular structure for Cwp66 and for role(s) that Cwp66 
performs in C. difficile. 
 
Threading (fold recognition) servers confirm the likely β-sheet structure; however, 
they suggest several methods by which the β-sheets can be arranged. 
 
pGENThreader (Lobley et al. 2009) suggests a parallel β-sheet formation by 
alignment with the parallel β-sheet region of heme binding protease from 
pathogenic E. coli (1WXR) or alignment with the collagen adhesin (2F68) arranged 
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the β-sheets in sub-domains, each adopting a variant IgG-fold. Both the 
pGENThreader (Lobley et al. 2009) results are both rated high, suggesting that 
either arrangement is possible. 
 
However, Phyre (Kelley & Sternberg 2009) suggests fold homology with Invasin, a 
bacterial integrin-binding protein (1CWV) (Hamburger et al. 1999) and Intimin, 
which together with translocated intimin receptor (Tir), mediates adhesion 
between mammalian cells and pathogens (1F02) (Luo et al. 2000). The arrangement 
of β-sheets in these two models is into separate domains connected by variable 
loop regions (Figure 6.3.18). The fact that these matches are with bacterial adhesins 
may suggest that if Cwp66 is an adhesin, it may adopt a fold more like these.  
 
 
Figure 6.3.18 Phyre (Kelley & Sternberg 2009) models of Cwp66323-611 A349-S599 on invasin 
(1CWV) (A) and A349-S491 on intimin (1F02) (B). Prepared using PyMOL (www.pymol.org) 
(N- blue C- red)(or green in (B)). 
 
HMM-HMM homology (HHPred) (Soding et al. 2005) suggests that the β-sheets are 
arranged in a parallel β sheet structure, with homology to rhamnogalacturonase A 
from Aspergillus aculeatus (1RMG) (Petersen et al. 1997) or chondroitinase B from 
Flavobacterium heparinum (IDGB) (Huang et al. 1999) (Figure 6.3.19). Similar to 
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CPHmodels (Nielsen et al. 2010), the TM-score of HHPred for both the 
aforementioned alignments are approximately 0.32 and 0.29, and a TM-Score ≥ 0.4 
corresponds to meaningful predictions, thus caution is applied when speculating 
putative structures. 
 
 
 
Figure 6.3.19 Cwp66323-611 homology modelled on (A) Rhamnogalacturonase A (1RMG) (B) 
Chondroitinase B (1DBG). Models produced by alignment with HHPRED (Soding et al. 2005) 
then modelled in MODELLER (Eswar et al. 2007). Prepared using PyMOL (www.pymol.org) 
(N- blue C- red). 
 
  
3
0
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Figure 6.3.20 Comparison of secondary structure of Cwp66 C-terminal regions (residue 323+) from C. difficile 630 and R20291. Secondary structure 
predicted with PSIPRED v3.0 (Jones 1999).
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6.3.3 CD2767 
6.3.3.1 Expression and purification of full length rCD2767 
Recombinant expression of CD2767 has not been reported to date, thus the full 
length protein was assessed for expression and purification. Full length 
His.T7.rCD2767 expressed in the soluble fraction and purified, using IMAC, as a 
fragmented species between 76-49 kDa (Figure 6.3.21 Lane 1), detectable with anti-
His6, suggesting N-terminal truncation to a stable 49 kDa intermediate.  
 
 
Figure 6.3.21 Purification of His.T7.rCD2767. Lane 1- Elution fraction from 
His.T7.rCD2767 IMAC. Lane 2- Lane1 blotted with anti-His. Lane 3 & 4- flow 
through and eluted material from phenyl sepharose HIC purification. Lane 
5 & 6- flow through and eluted material from Q Sepharose (pH 8.0) IEX 
purification. 
 
IMAC purified His.T7.rCD2767 appeared to bind irreversibly to phenyl sepharose 
during HIC purification with only a very small proportion being eluted (Figure 6.3.21 
Lane 4), while IEX (Q, pH 8.0) purification appeared to cause triple bands (76, 66, 
62 kDa) to elute (Figure 6.3.21 Lane 6), both methods appeared to somewhat 
remove contaminating species. A His.NusA fusion rCD2767 exhibited the same C-
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terminal fragmentation and purified easily in IMAC. However, after cleavage of the 
His.NusA moiety with enterokinase no free rCD2767 was observed in SDS-PAGE. A 
GST fusion was assessed, but expressed predominantly insoluble and was not 
progressed further. 
6.3.3.2 Expression and purification of rCD276727-401  
Due to the extensive N-terminal truncation/degradation and problems obtaining 
pure protein with full length rCD2767, the expression and purification of the N-
terminal ‘functional’ domain (corresponding to residues 27-401 of the full length 
CD2767) containing the predicted glycosidase catalytic core, was assessed. 
 
 
Figure 6.3.22 IMAC purification of His tagged rCD276727-401. 
Lanes 1-7 - tris based IMAC buffers (L – E. coli lysate, FT- unbound 
material, E1-5 eluted fractions from early (E1) and late (E5) in 
eluted peak) Lane 8 - sodium phosphate (monobasic) based IMAC 
buffers. Arrow denotes approximate dimer MW.  
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Using only an N-terminal His6 tag (His.rCD276727-401), IMAC purification yielded a 
highly pure 47 kDa species in SDS-PAGE in one step, particularly early in the elution 
peak (Figure 6.3.22). Only this species was detected by western blot with anti-His6, 
confirming both its identity and that other eluted bands were not N-terminal 
truncates. 
 
SEC of this material gave a single peak corresponding to a monomeric protein of 
approximately 28 kDa (~42 kDa predicted). When purifying His.rCD276727-401 with 
tris based IMAC buffers, a single species was predominant with some lower MW 
contaminants (as seen in Figure 6.3.22). However, IMAC purification using 
phosphate based IMAC buffers; an 87 kDa species was present, which blotted with 
anti-His6 suggesting dimerisation of His.rCD276727-401. 
 
Fractions from early in the tris based IMAC elution peak, >90% SDS-PAGE ‘pure’ 
His.rCD276727-401 (as measured by densitometry) was pooled, concentrated then 
dialysed into 50 mM tris 150 mM NaCl pH 8.0 prior to crystallisation. His.rCD276727-
401 could be concentrated (by centrifugal spin column) to 120.2 mg/ml (by A280) or 
167 mg/ml (by Bradford Assay using BSA as the standard) (both quantifications 
used a 1:500 dilution), suggesting a very soluble protein. During crystallisation set-
up the nanodispensing robot ball-bearing valve system remained open, suggesting 
an increased viscosity corresponding to high protein concentrations. Fusion of 
rCD276727-401 to a C-terminal toxin B fragment appeared to increase the toxin 
fragments solubility to the same extent as commercial thioredoxin and NusA fusion 
tags, confirming rCD276727-401 had soluble properties. 
 
Mass spectrometric analysis suggested, that despite the loss of the N-terminal 
methionine, that the observed molecular weight (44644 Da + 131 Da (Met) = 
44775 Da) matched the predicted molecular weight (44775 kDa). Storage of the 
putatively highly concentrated His.rCD276727-401 for 3 months at 4 °C resulted in a 
decrease in quantified protein concentration. Both the A280 and Bradford assay 
concentrations were approximately 50% figures obtained from freshly purified 
His.rCD276727-401. Analysis of the stored material by SDS-PAGE did not reveal 
  
306 
additional bands, suggesting precipitation was lowering the overall protein quantity 
rather than degradation.  
 
6.3.3.3 Identification of functional enzymatic activity for rCD276727-401 
As CD2767 has not been characterised to date, in order to determine if 
His.rCD276727-401 was correctly folded, an activity assay was required. To develop 
an assay, a substrate/ligand for the putatively glycosidase catalytic core of 
CD276727-401 needed to be identified. 
 
A protein signature domain search with InterProScan (Hunter et al. 2009) suggests 
CD276727-401 is a TIM beta/alpha barrel O-glycoside hydrolase. An O-glycoside is a 
sugar linked to a non-carbohydrate via an O-glycosidic bond (in reference to the 
glycosidic oxygen that links the glycoside to the aglycone or reducing end sugar). 
Using a NCBI Conserved domain search (Marchler-Bauer et al. 2009), CD276727-401 
had homology to alpha amylase (Family 13), melibase or the glycosyl hydrolase 
Family 31 (GH31) including alpha-glucosidase (glucoamylase and sucrase-
isomaltase), alpha-xylosidase, 6-alpha-glucosyltransferase, 3-alpha-
isomaltosyltransferase and alpha-1,4-glucan lyase.  
 
BLASTP revealed that CD276727-401 shares high identity (≥96%) with surface proteins 
of Clostridium hiranonis DSM 13275 (EEA85382.1), Peptostreptococcus stomatis 
DSM 17678 (EFM64818.1) and P. anaerobius 653-L (EFD05798.1), and shares 91% 
identity with the FenI protein of Streptosporangium roseum DSM 43021 
(ACZ88859.1), suggesting the role CD2767 may performs is conserved across 
several bacterial species. However, BLASTP using the Protein Data Bank (PDB), only 
finds a small region of CD276727-401 (L37 – D169) that shares 25% identity with a 
glycosyltrehalose trehalohydrolase from Sulfolobus Solfataricus (alpha-amylase 
(Family 13)) (1EHA) (Feese et al. 2000; Yoneda et al. 2003) or a 83 aa region (Y137-
V220) which shares 27% identity with a glycogen branching enzyme 1,4-alpha-D-
glucan 6-glucosyl-transferase from Mycobacterium tuberculosis H37rv (3K1D).  
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As a result of these findings, the following assays were assessed with rCD276727-401 
to identify any enzymatic activity/substrate for CD2767: 
 Alpha amylase activity (starch hydrolysis – Phaedebas© test) 
o From conserved domain search 
 Trehalase assay (based on detection of liberated glucose) 
o Based on the limited amino acid sequence identity to 
glycosyltrehalose trehalohydrolase from Sulfolobus Solfataricus 
 O-glycosidase assay (hydrolysis of p-nitrophenyl galacto-N-bioside) 
o from InterProScan results 
 β- glucosidase assay (hydrolysis of p-nitrophenyl-β-D-glucopyranoside) 
o A common TIM barrel glycosidase 
 
Where necessary rCD276727-401 was re-purified using buffers, or in the absence of 
buffers may have affected results, e.g. chloride ions activate, while tris ions inhibit 
alpha amylase activity (Aghajari et al. 1998) yet chloride ions inhibit O-glycosidase 
activity (Umemoto et al. 1977). 
 
No activity was observed in the assays tested. These data suggest that the substrate 
of CD2767 is not one of those assessed in this chapter, as glycosidases can be 
specific for their substrate, or that rCD276727-401 was not correctly folded or 
requires a metal co-factor for activity. The lack of activity observed by rCD276727-401 
may reveal that, putatively like recombinant Cwp84, the CWBDs are required for 
spatial positioning for enzymatic activity.  
6.3.3.4 Modelling CD2767 domain 
Protein signature searches suggested that CD276727-401 had sequence homology 
with TIM barrel structures which have β-sheets forming a central core around 
which α-helices are arranged (Figure 6.1.10). To further identify any putative 
substrate, the putative glycosidase domain of CD2767 (CD276727-401) was entered 
into a number of tertiary structure prediction servers. 
 
  
308 
Using homology modelling (the assumption that two homologous amino acid 
sequences will share very similar structures) appears to provide little more 
information about CD276727-401 than BLASTP results (Section 6.3.3.3). Performing a 
BLAST of the CATH database identifies the 133 aa region of CD276727-401 is similar to 
the glycosyltrehalose trehalohydrolase (1EH9 and 1EHA) (whose structure was 
solved by multiple isomorphous replacement) (Feese et al. 2000). 
 
SWISSMODEL (Arnold et al. 2006) found six templates upon which CD276727-401 
could be aligned and while all had low sequence identity, with decreasing identity 
the models produced were increasingly TIM barrel-like (Figure 6.3.24). 
 
Geno3D (Combet et al. 2002) modelled the 132 aa region of limited identity 
between CD276727-401 (L37 – D169) and the glycosyltrehalose trehalohydrolase 
from Sulfolobus Solfataricus (1EHA or 1EH9). The model produced appears to 
correspond to some of the α-helices surrounding the barrel core (Figure 6.3.23). 
 
 
 
Figure 6.3.23 Geno3D (Combet et al. 2002) homology model of CD276727-401 (L37 – D169) 
(Blue) aligned to glycosyltrehalose trehalohydrolase from Sulfolobus Solfataricus (1EHA) 
(Feese et al. 2000)(Grey). Models superposed in Coot (Emsley et al. 2010) and prepared 
using PyMOL (www.pymol.org). 
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Figure 6.3.24 SWISS-MODEL (Arnold et al. 2006) alignments of CD276727-401 and 
corresponding models of those regions. The lower the E-value, or the closer it is to zero, 
the more "significant" the match is. 
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Similar to the BLAST result (Section 6.3.3.3), ESyPred3D (Lambert et al. 2002) finds 
CD276727-401 S38-V318 has limited identity with the 1,4-alpha-glucan-branching 
enzyme from Mycobacterium tuberculosis H37RV (3K1D) sufficiently high to 
produce a model. The region aligned by ESyPred3D (Lambert et al. 2002) 
corresponds to an outer region of the protein away from the barrel core (Figure 
6.3.25). 
 
 
Figure 6.3.25 ESyPred3D (Lambert et al. 2002) tertiary model of CD276727-401 on 3K1D. 
CD276727-401 (blue), 3K1D surface (white) with TIM barrel highlighted (grey). Prepared using 
PyMOL (www.pymol.org). 
 
The TIM barrel nature of CD276727-401 appears to be confirmed upon tertiary 
structure prediction by threading methods (fold recognition). This method is 
particularly applicable for glycosidases, as the TIM barrel fold is often more 
conserved than the sequence. 
 
The Phyre server (Kelley & Sternberg 2009) suggests CD276727-401 folds belong to 
the amylase catalytic domain family. Proteins with similar folds are E. coli 1,4-alpha-
glucan branching enzyme (1M7X) (Abad et al. 2002) (E-value 3.1e-17), isomaltulose 
synthase (PalI) of Klebsiella sp. LX3 (1M53) (Zhang et al. 2003) (E-value 4.9e-17) and 
B. cereus oligo-1,6-glucosidase (1UOK)(Watanabe et al. 1997) (E-value 7.4e-17). 
  
311 
 
HHPred (Soding et al. 2005) also finds a 213 aa region has folds common to the 
glycosyl transferase E. coli 1,4-alpha-glucan branching enzyme (1M7X), alpha-
galactosidase (3MI6) and cyclomaltodextrinase (1EA9). Models produced using the 
HHPred alignments with MODELLER (Eswar et al. 2007) suggest a conserved 
Aspartic acid (D195) at the bottom of the core at the end of a β-sheet in each of the 
models of the above enzymes (Figure 6.3.26 marked in pink). Homology models are 
only models and are biased on the template used and cannot define the nature of 
arrangement or conformation of the protein molecules, as defined by experimental 
methods. 
 
pGENThreader (Lobley et al. 2009), suggests matches ranked ‘certain’ with endo-
beta-1,4-galactanases (involved in pectin degradation) from Bacillus licheniformis 
(1UR4), the fungi Humicola insolens (1HJQ) and Aspergillus aculeatus (1FOB), as 
expected, all are TIM barrels and two of which (1UR4 and 1FOB) require calcium for 
activity.  
 
In summary, the N-terminal domain of CD2767 shows no significant sequence 
similarity to any known glycoside hydrolase. Fold prediction aligns CD2767 with 
other glycosidases, all with a TIM barrel, suggesting that this particular fold family 
be assessed during data processing or model building. However, given the substrate 
specificity (despite structural similarities as pointed out by Lee et al. (2002a)) 
specific ligand determination, as attempted in section 6.3.3.3, was unsuccessful. 
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Figure 6.3.26 Predicted structures of CD276727-401. Homology modelled on (i) alpha-galactosidase (melibase) from Lactobacillus brevis (3MI6) (ii) 
Cyclomaltodextrinase (1EA9) (iii) E. coli glycogen branching enzyme (1M7X). Conserved aspartic acid shown in pink. Models produced by MODELLER (Eswar 
et al. 2007) after alignment with HHPred (Soding et al. 2005). Prepared using PyMOL (www.pymol.org) (N- blue C- red).
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6.3.3.5 Crystallisation of rCD276727-401  
6.3.3.5.1 Crystallisation set-up 
Sitting drop vapour diffusion crystallisation screens were setup with the highly 
concentrated His.rCD276727-401, after 3 months no observed hits could be seen, nor could 
any precipitation in any condition. However, after 4 months there were visible hits in 
several conditions (Table 6.3.4). Most notably a large crystal in one condition in the 
Structure Screen 1 & 2 screen (Figure 6.3.27). A preparation of His.rCD276727-401 
concentrated to 6 mg/ml (A280) and dialysed into 50 mM MES 150 mM NaCl pH 6.0 had 
small crystals in a well at 2:1 protein:reservoir concentration in the same D10 screen 
condition after a similar timescale. This suggests that 0.05 M potassium dihydrogen 
phosphate, 20 % w/v PEG 8000 is the likely condition by which one can crystallise 
His.rCD276727-401. 
 
 
Figure 6.3.27 His.rCD276727-401 crystal. Crystal formed in sitting drop 
vapour diffusion crystallisation of His.CD276727-401 in 0.05 M potassium 
dihydrogen phosphate, 20 % w/v PEG 8000 with 1:1 protein: reservoir 
ratio. 
 
This crystal was delicate when probed; however, a portion could be picked up with a loop 
and loaded onto the goniometer, this portion diffracted to approximately 2 Å using the 
Diamond synchrotron X-ray source (Figure 6.3.28). 
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Table 6.3.4 Sitting drop crystallisation conditions which demonstrated varying degrees 
of crystallisation His.rCD276727-401. 
 
 
  Reservoir conditions  
Screen Well Buffer/Salt Buffer/Salt pH Precipitant Result 
SS 1 & 2 D10 0.05 M 
potassium 
dihydrogen 
phosphate 
None None 
 
20 % w/v PEG 
8000 
Figure 
6.3.27 
PACT 
premier 
A5-6 0.1 M SPG 
buffer 
None 
 
8.0-
9.0 
25 % w/v PEG 
1500 
Tiny Sea 
Urchins 
 B5-6 0.1 M MIB 
buffer 
None 
 
8.0-
9.0 
25 % w/v PEG 
1500 
As above 
 C6 0.1 M PCTP 
buffer 
None 
 
9.0 25 % w/v PEG 
1500 
As above 
 D6 0.1 M 
MMT 
buffer 
None 
 
9.0 25 % w/v PEG 
1500 
As above 
 C10 0.2 M 
magnesium 
chloride 
0.1 M 
HEPES 
7.0 
 
20 % w/v PEG 
6000 
As above 
 D10 0.2 M 
magnesium 
chloride 
0.1 M tris 8.0 
 
20 % w/v PEG 
6000 
As above 
Screen Well Ligand 
stock 
Buffer 
stock 
pH Precipitant 
stock 
Result 
Morpheus C9 0.09M 
nitrate 
phosphate 
sulphate 
(NPS) 
0.1M 
Buffer 3 
8.5 
 
30.0% 
P550MME_P20K 
 
Tiny Sea 
Urchins 
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Figure 6.3.28 X-ray diffraction pattern of His.CD276727-401 crystal from Figure 6.3.27. 
 
6.3.3.5.2 Crystal data processing 
X-ray diffraction patterns of the His.CD276727-401 crystal were initially processed with 
iMOSFLM (Leslie 2006) and scaled using SCALA (CCP4 1994) (as per section 6.2.5.4). Initial 
indexing resulted in a space group ambiguity between: C-centered orthorhombic (C222 & 
C2221), primitive monoclinic (P2 & P21), C-centered monoclinic (C2) and primitive triclinic 
(P1) (Table 6.3.5).  
 
Matthew’s coefficient (Matthews 1968) was calculated to estimate both the number of 
molecules per asymmetric unit and resulting % volume occupied by solvent. This is 
derived from the unit cell dimensions (and angles), the molecular weight of CD276727-401 
and number asymmetric of units in the unit cell (i.e. the number of symmetry operators in 
the space group). Due to the high solvent content (which is typically between 27-65% 
(Matthews 1968)), and the high Rmerge value, C-centered orthorhombic (C222 & C2221) 
space groups were unlikely. While, Rmerge was lower in P21 (P2) and P1 space groups, 6 
molecules per asymmetric unit were estimated for the P1 space group whereas a more 
likely 3 molecules per asymmetric unit for P2 and P21, making the P1 space group 
unlikely. POINTLESS in iMOSFLM (Leslie 2006), which scores all the possible Laue groups 
consistent with the crystal class by matching potential symmetry equivalent reflections, 
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also  suggested the P21 space group. Preliminary molecular replacement trials were 
attempted using primitive monoclinic P21 space group. 
6.3.3.5.2.1 Molecular replacement (MR) trials 
Due to the problems outlined in Section 6.3.3.3 and 6.3.3.4, i.e. a lack of proteins with 
sufficient sequence identity to CD276727-401, finding a model to use in molecular 
replacement was difficult. Various models from homology modelling servers, e.g. Phyre 
(Kelley & Sternberg 2009) and SWISS-MODEL (Arnold et al. 2006), were tried with 
molecular replacement program PHENIX (Adams et al. 2010) to assess the feasibly of 
solving the structure. All models were taken through an initial round of refinement, 
despite low translation function Z-score (TF Z-scores) (typically <6 in the “unlikely” 
category (TF-Z >8 = definitely solved)), yielding phase error (lower numbers suggest 
accurate structures) and figure of merit (FOM) statistics (higher numbers suggest accurate 
structures) (Table 6.3.6).  
 
A model from Phyre (Kelley & Sternberg 2009) and i-Tasser (Zhang 2008) was assessed, 
but both phase error and the FoM were too high and low respectively, probably due to 
complexity of the tertiary structure prediction models, e.g. incorrect loops. Therefore, 
models produced by homology modelling server SWISSMODEL (Arnold et al. 2006), which 
contained only regions of higher homology (identity or similarity), were progressed 
further. 
 
Initially, searching for 1 molecule in the asymmetric unit, model 5 of SWISSMODEL 
(Arnold et al. 2006) (based on a portion of 2GSJ See Figure 6.3.24) gave the lowest phase 
error and highest figure of merit (0.39). A polyalanine model (to remove side chain 
interference) did not give satisfactory statistics. Molecular replacement was assessed 
using SWISSMODEL model 5 but with 2 molecules per asymmetric unit, but was not 
successful (PHENIX (Adams et al. 2010) gave an error of “asymmetric unit too full” with 
the suggested solution being to search for 1 molecule).  
 
In summary, due to the low sequence similarity of the CD276727-401 with known proteins 
(in the protein databand), it is unlikely that the structure will be solved by molecular 
  
317 
replacement. Given that the glycosidases often have conserved structure but not 
sequence, this is not surprising. Further work crystallising the CD2767 N-terminal domain 
with heavy metal derivatives should result in the solution of the structure. 
6.3.4 Summary 
Selected C. difficile surface proteins that represented characterised (Cwp66), partially 
characterised (CD2791) and uncharacterised (CD2767) proteins were trialled for their 
ability to be expressed and purified for X-ray crystallographic studies. It was found that 
the CWBD hindered purification and upon removal, both CD2791 and CD2767 were 
purified to sufficient purity. The N-terminal domain of CD2767 appeared to be very 
soluble and the identification of crystallisation conditions and an initial data set to 2.0 Å, 
means its structure should be solvable (although not by molecular replacement).
  3
1
8
 
Table 6.3.5 Potential space groups for the His.CD276727-401 crystal data. 
 
 C2221 C222 C2 C2(penalty 3) P2 P21 P1 (penalty 1) 
 Overall Outershell Overall Outershell Overall Outershell Overall Outershell Overall Outershell Overall Outershell Overall Outershell 
Low Resolution Limit (Å) 54.16 2.11 54.15 2.11 54.06 2.11 54.07 2.11 54.06 2.11 54.06 2.11 54.13 2.11 
High Resolution limit (Å) 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 
Rmerge 0.513 0.720 0.502 0.656 0.489 0.666 0.468 0.609 0.135 0.538 0.135 0.538 0.100 0.439 
Completeness 99.1 98.1 98.3 97.8 97.9 95.9 94.6 93.1 91.4 82.9 91.4 82.9 84.3 75.6 
a (Å)     /     α (°) 122.41 90 122.39 90 122.32 90 180.84 90 109.13 90 109.13 90 61.23 111.84 
b (Å)     /     β (°) 181.18 90 181.16 90 180.8 89.98 122.34 90.08 61.2 111.85 61.2 111.85 109.23 90.08 
c(Å)       /     γ (°) 61.26 90 61.25 90 61.2 90 61.22 90 109.15 90 109.15 90 109.29 89.93 
Volume of Unit cell (Å
3
)  1358639.2  1358045.6  1353465.9  1354429.2  728986.2  728986.2  730948.2 
Divided by number of asymmetric 
units in the unit cell  
(Z) 
 169829.9  
 
(8) 
 169755.7  
 
(8) 
 338366.5  
 
(4) 
 338607.3 
 
(4) 
 364493.1 
 
(2) 
 364493.1 
 
(2) 
 730948.2 
 
(1) 
Divided by MW (44,775 Da)  3.79  3.79  7.56  7.56  8.14  8.14  16.32 
Molecules/asymmetric unit*  1  1  1  3  3  3  6 
Vm  3.79  3.79  7.56  2.52  2.71  2.71  2.72 
V'p (≈1.23/Vm)  0.32  0.32  0.16  0.49  0.45  0.45  0.45 
Vsolv (1-V'p)  68%  68%  84%  51%  55%  55%  55% 
 
Penalty figures in brackets refer to a spacegroup solution but with a higher penalty.  
a, b, c refer to cell dimensions whereas α, β, γ refer to cell angles.  
Rmerge - A statistical measure of how well the X-ray diffraction data scale together (good-quality structures have low values).  
* Most likely number of molecules/asymmetric unit. 
Vm - Matthews coefficient (typically between 1.68 - 3.53). 
V’p – Fraction of the total crystal volume occupied by protein. 
 Vsolv - Putative percentage solvent in the unit cell. 
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Table 6.3.6 Molecular replacement statistics from PHENIX (Adams et al. 2010) using various tertiary CD2767 structure prediction models 
with P21 space group. 
 SWISSMODEL 
Model 5 
SWISSMODEL 
Model 6 
Phyre  
d1m7xa3 model 
PolyAla  
Model 5 2gsj 
2gsj I-TASSER 
(Model 2) 
 initial final initial final initial final initial final initial final initial final 
Rwork 0.817 0.495 0.828 0.493 0.577 0.490 0.575 0.515 0.572 0.486 0.577 0.483 
Rfree 0.763 0.526 0.768 0.522 0.574 0.525 0.571 0.537 0.551 0.521 0.582 0.540 
Figure of Merit (FOM)  0.390  0.210  0.140  0.250  0.330  0.250 
Phase Error  61.640  74.960  80.550  72.400  66.750  73.020 
 
 
Definitions: 
Rwork- a measure of the agreement between the crystallographic model and the experimental X-ray diffraction data (typically between 15% to 
25% for accurate structures). 
Rfree (Brunger 1992)- measures the agreement between observed and computed structure factor amplitudes for a 'test' set of reflections 
(typically 10% (5% in this data)) that is omitted in the modelling and refinement process.  
Figure of merit (FOM) - Accurate structures have higher figures of merit (>0.9) 
Phase error- is the difference of the calculated phase from the true phase; lower figures represent more accurate structures. 
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6.4 Discussion 
A total of 29 putatively surface located proteins in C. difficile have been identified as 
having a domain with homology to the N-acetylmuramoyl-L-alanine amidase (CwlB) 
of Bacillus subtilis. This PFam 04122 domain (cell wall binding 2 domain (CWBD)) is 
found in multiple repeats at either the N or C-terminus with the other end, often 
but not always, having a functional activity.  
 
To date, only a fragment of the LMW S-layer subunit of C. difficile has been 
crystallised and its structure determined by X-ray crystallography (3CVZ) (Fagan et 
al. 2009). Although this structure is not the first S-layer to be crystallised (Evrard et 
al. 1999), nor the first S-layer structure to be reported (Pavkov et al. 2008), it is 
nevertheless a significant step in understanding the most important surface protein 
of C. difficile. 
 
Given that there are only 40 structures deposited in the protein databank for C. 
difficile at the time of writing (some of which are with multiple ligands) and only 
one of those is a proven surface protein (3CVZ, (Fagan et al. 2009)), there is 
considerable scope to supplement the structural knowledge for C. difficile surface 
based proteins. In this chapter, selected surface proteins were expressed 
recombinantly, whole or as domains, in order to obtain structural information using 
X-ray crystallography. The three proteins chosen were: 
 
 CD2791 an immunogenic surface located protein 
 Cwp66 (Waligora et al. 2001) a heat shock inducible adhesin 
 CD2767 a protein of unknown function but putatively containing glycosidase 
activity. 
6.4.1 CD2791 aka Cwp2 
The protein encoded by the cd2791 gene (630 genome numbering, cwp2 Calabi et 
al.(2001) numbering) appears to be consistently expressed and found on the cell 
surface of C. difficile during normal growth (Calabi & Fairweather 2002; Wright et 
al. 2005). Given its existence on the cell surface it is perhaps unsurprising that 
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CD2791 is also found in the C. difficile 630 spore coat (Lawley et al. 2009b). 
However, two facts bring into question the role of the CD2791 protein in C. difficile 
pathogenesis. Firstly, CD2791 (expression and protein) is absent in C. difficile strain 
167 (a clinical isolate) indicating its non-essential nature for both cell growth and/or 
pathogenesis (although this strain’s S-layer is also altered). Secondly, a significant 
number of CDI patients raise antibodies to CD2791, suggesting that antibodies 
raised to CD2791 are not protective (Wright et al. 2008), i.e. targeting this protein 
does not prevent disease. However, if CD2791 was non-essential, why should it be 
expressed so constitutively? Indeed, data in Chapter 5 suggests that knockout of 
CD2791 results in decreased adhesion to Caco-2 cells suggesting CD2791 is an 
adhesin.  
6.4.1.1 Full length rCD2791 
To date, recombinant expression of CD2791 has not been reported, although its 
promoter has been for complementation of mutants (Emerson et al. 2009b) (see 
constitutive expression above). Full length rCD2791 was expressed for two reasons; 
firstly any structural data obtained from crystals of rCD2791 would include key 
information about the CWBDs. Secondly, as there is no predicted functional activity 
of the N-terminus, determination of correct protein folding relied upon N-
acetylmuramoyl-L-alanine amidase (amidase) activity of the two CWBDs.  
 
The HMW SLP (which consists of three CWBDs) exhibits (amidase) activity in 
zymogram assay against Micrococcus luteus cells (Calabi et al. 2001). Using a similar 
assay it was determined that full length rCD2791 also exhibited amidase activity, 
confirming that other proteins CWBD also exhibit this amidase activity. The 
relatively low activity may have been due only to two CWBDs present at the C-
terminus CD2791 (rather than 3 of the HMW SLP) or that a large proportion of the 
protein sample was aggregated. 
 
Full length rCD2791 expressed well in E. coli, however it was apparent during 
purification that removal of contaminating E. coli protein(s) or rCD2791 truncates 
and aggregates was difficult. Hydrophobic interaction chromatography purified 
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seemingly pure rCD2791, although size exclusion chromatography revealed it was a 
largely aggregated mass. This data suggests that the hydrophobicity of proteins 
increases when there are CWBDs present. This hydrophobicity would fit well with 
the embedding/lower positioning in the cell wall/S-layer array.  
 
The ability of rCD2791 to crystallise was clearly hampered by the inability to form a 
crystalline lattice due to the presence of this aggregated mass. Additives, e.g. 
detergents, chaotropes included in purification buffers, derived from their ability to 
remove the SLPs from the C. difficile cell surface, did appear to reduce aggregation, 
but were not successful upon scale up. Interestingly, purification of an 8 M urea SLP 
extract (to purify CD2791 from its native source) did not appear to purify CD2791 
away from the HMW and LMW SLPs, suggesting an intimate interaction not 
interruptible by urea. 
 
Together, the data suggests that it is possible to obtain soluble full length 
recombinant CD2791 in E. coli. However, the presence of two CWBDs putatively 
causes aggregation throughout each step of recombinant protein production. It is 
likely that the presence of two CWBDs of CD2791 are ‘tolerated’ during E. coli 
recombinant production, such that aggregation is manageable, as opposed to the 
HMW SLP which contains three CWBD, which required refolding (Fagan et al. 2009). 
Interestingly, expression of the 48.9 kDa conserved N-terminal of CwpV, which 
includes three CWBDs, was purified using a GST tag followed by SEC, did not require 
refolded (Emerson et al. 2009b). This may suggest that the CWBD, although 
conserved, may be sufficiently different in some surface proteins to behave 
differently during purification. This difference may be reflected in the attachment 
of the surface protein to the C. difficile cell wall.  
6.4.1.2 N-terminal domain expression 
Expression of the N-terminal region of CD2791 (rCD279127-322) was more successful 
than full length expression, whereby protein could be purified which was not 
aggregated. When fused to just a His6 tag, rCD279127-322 still appeared to purify 
with a large amount of truncates, suggesting the rCD279127-322 message had 
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elements causing ribosomal dissociation or that rCD2791 is easily cleaved by E. coli 
proteases. The former is unlikely as the gene had putatively undergone 
optimisation for expression in E. coli. However, a C-terminal His6 tag may have 
resolved these truncate purification issues. SEC analysis revealed that rCD279127-322 
existed in solution in a monomeric form; suggesting removal of the CWBD removed 
the preference of CD2791 to form soluble yet aggregated masses (with itself or 
other E. coli proteins). The predicted molecular weight of rCD279127-322 appeared to 
be ~32 kDa in SDS-PAGE, however rCD279127-322 (post SUMO cleavage or with just a 
His6 tag) migrated as a ~45 kDa species with a small percentage (a presumed 
truncated version) running at 32 kDa, although it is not uncommon for proteins to 
migrate at a different size to their predicted MW in SDS-PAGE, primarily through 
differences in SDS loading (Rath et al. 2009). 
 
6.4.1.3 Crystallisation and modelling 
Crystallisation of rCD279127-322 in this study started to reveal some promising hits 
and suggests that the N-terminal region of CD2791 maybe crystallisable given the 
right conditions. 
 
There appears to be a lack of deposited structures in the PDB which have either 
sufficient sequence similarity or fold homology to the N-terminal domain of CD2791 
for tertiary structure prediction. The proportion of β-sheets in the predicted 
secondary structure for CD279127-322 could suggest a structure similar to the heavily 
β-sheeted secondary structure of the Cwp66 C-terminal domain. However, it is 
particularly interesting that the secondary structure prediction aligns with the S-
layer (SbsC) of Geobacillus stearothermophilus (2RA1) (Pavkov et al. 2008). The 
putative alpha-helical structure of the C. difficile CWBDs and the highly alpha helical 
cell wall binding region of SbsC may suggest a common S-layer attachment 
mechanism. From the data in this study, CD2791 requires crystallising for any novel 
fold(s) to be elucidated. 
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6.4.1.4 CD2791 – hypotheses 
The reasons behind CD2791 having two predicted CWBDs remains elusive, but 
could the result of a bioinformatical error, as CD2791 may actually have three 
CWBD (N. Fairweather, personal communication). If CD2791 does have two CWBDs, 
it is possible CD2791 is not bound tightly to the cell surface, i.e. it is shed or that it 
can be shed if necessary, or that very C-terminal end of CD2791 (past the last 
CWBD) is required for another cell surface process/mechanism. There is one report 
of CD2791 being found in the supernatant of high toxin producing cells (Mukherjee 
et al. 2002), however, it is likely that this is from cell lysis rather than 
export/shedding. 
 
The presence of CD2791 on the cell surface during normal growth suggests that it is 
required for some cellular process(s). As CD2791 is highly immunogenic, this 
suggests that the antibody responses to CD2791 are probably non-protective. 
Therefore, CD2791 may be a permanent decoy for the immune system and 
antibody responses to CD2791 do not prevent CDI. The conservation of the cd2791 
gene across strains suggests there is pressure to maintain conservation.  
 
Given that CD2791 is putatively on the same polycistronic message as cwp66 
(Savariau-Lacomme et al. 2003), it would be interesting to understand how the 
expression of the genes on the ‘operon’ vary, for example, one reporter for cd2791 
(cwp2) was upregulated by amoxicillin, while cwp66 is upregulated during 
environmental and chemical stresses (Deneve et al. 2008; Emerson et al. 2008). 
Increased amounts of Cwp66 would require upregulation of the entire polycistronic 
message, which also results in increased cd2791 (and cd2790) message, unless 
cd2791, cd2790 or cwp66 are post-transcriptionally regulated.  
6.4.2 Cwp66 
Cwp66 was shown to be surface located particularly after heat shock with the C-
terminus being presented outermost (Waligora et al. 2001). Consistent with this, 
individuals (cases or controls) appear to raise antibodies to primarily the C-terminal 
domain (Pechine et al. 2005a; Pechine et al. 2005b). Antibodies to Cwp66 and 
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recombinant Cwp66 appear to be able to prevent adhesion to Caco-2 cell, 
suggesting Cwp66 as an adhesin (Waligora et al. 2001). It is suggested that Cwp66 
may be attached to the cell surface differently to the main SLPs, which can be 
removed with low pH treatment, as degradation of the peptidoglycan is often 
needed to reveal Cwp66 (Hennequin et al. 2001; Hennequin et al. 2003), even then 
identification of Cwp66 is not always possible (Wright et al. 2005). 
 
6.4.2.1 Full length and C-terminal domain expression of Cwp66 
Previous studies have determined that recombinant Cwp66 expression is when the 
protein is expressed as separate N- and C-terminal domains (Waligora et al. 2001; 
Pechine et al. 2005a). This was confirmed in this chapter, where expression of full 
length rCwp66 (± fusion tag) resulted in insoluble aggregates (as appears common 
for recombinant CWBD containing proteins).Interestingly despite Waligora et al. 
(2001) being unable to express length Cwp66, western blots of cell wall extracts 
detected bands at similar molecular weights (80 kDa, 50kDa and 30 kDa) to those 
detected by anti-His6 during recombinant full length Cwp66 (Section 6.3.2.1, Figure 
6.3.14) suggesting Cwp66 is susceptible to proteolytic cleavage. It is currently 
unknown if Cwp66 is post-translationally processed or is cleaved by endogenous 
proteases during either cell wall extraction or recombinant production.  
 
Expression of only the C-terminal region did result in soluble protein; however, the 
propensity to aggregate remained, preventing successful purification. Taken 
together these results suggest that Cwp66 is a protein with adhesive properties, a 
characteristic which appears not limited to the N-terminal CWBDs.  
6.4.2.2 Crystallisation and modelling 
Secondary structure analysis in this chapter is consistent with data found by 
Waligora et al. (2001) whereby the predicted secondary structure of the Cwp66 C-
terminal is largely β-Sheets. The arrangement of the beta sheets and the resulting 
function remains unknown. However, tertiary structure prediction suggested 
Cwp66 may utilise proteoglycans such as chondroitin sulfate (dermatan sulphate) 
and/or heparin, as used by Chlamydia trachomatis or the CS protein of Plasmodium 
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falciparum to bind host cells (Rostand & Esko 1997). Alternative tertiary structure 
predictions, which suggested homology to the C-terminal domain with invasin, a 
bacterial integrin-binding protein (1CWV) (Hamburger et al. 1999) and intimin, a 
surface bound adhesin of attachment-and-effacement bacteria (Luo et al. 2000) 
may suggest Cwp66 plays a role in bacterial adhesion, similar to type III secreted 
adhesins of certain Gram-negative species. 
6.4.2.3 Cwp66 – hypotheses 
Cwp66 has been identified as a heat shock inducible adhesin, however the co-
purification of Cwp66 (and CD2767 and CD2797) with ABP labelled Cwp84 (Dang et 
al. 2010), suggests that Cwp66 may also be upregulated during surface related 
stress, i.e. SlpA maturation inhibition. 
 
Antibodies to the C-terminal of Cwp66 only detected Cwp66 at the cell surface after 
heat shock and not in normal physiological conditions (Waligora et al. 2001), 
underlining how surface protein expression changes in response to in vitro 
conditions. It is therefore likely that surface protein expression is altered in vivo 
during CDI or during the initial colonisation stage.  
 
The putatively tighter association of Cwp66 with the peptidoglycan and the location 
of the CWBD at the N-terminal of Cwp66 (rather than the C-terminal for CD2791, 
SlpA and Cwp84), may suggest that the presentation of the CWBDs at the N- or C- 
terminus dictates to what extent and how the protein interacts with a SCWP or the 
peptidoglycan.  
 
Both the variability of the C-terminus of Cwp66, i.e. through selective pressure 
(Lemee et al. 2005), and that patient serum is predominantly raised to the C-
terminal of Cwp66, suggest that (the C-terminal of) Cwp66 is both expressed and 
accessible to the immune system during infection, regardless of how putatively 
integrated into the cell envelope Cwp66 is.  
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6.4.3 CD2767 
The protein encoded by the cd2767 gene has not been investigated to date. The 
presence of 28 SlpA paralogs has been known about since 2001 (Calabi et al. 2001; 
Karjalainen et al. 2001), thus attention has largely centred on the proteins 
surrounding slpA (cd2793), whereas the cd2767 gene is found downstream with a 
range of capsular polysaccharide biosynthesis proteins. CD2767 has not been found 
using any surface protein extraction techniques, however one patient was found to 
have antibodies to CD2767 (Wright et al. 2008) and upon inhibition of Cwp84, 
CD2767 co-purified during a pull down assay of ABP labelled Cwp84 (Dang et al. 
2010). 
6.4.3.1 Full length and C-terminal domain expression 
Recombinant full length CD2767 suffered in the same way as full length expression 
of other surface proteins forming primarily insoluble aggregates. The addition of 
fusion tags partially resolved this; however purification was hampered until all the 
CWBDs were removed. The N-terminal domain of CD2767 (rCD276727-401) was 
extremely soluble and purified in a monomeric form in one step. It was also 
apparent that rCD276727-401 could be concentrated to very high (>100 mg/ml) 
concentrations. SEC analysis suggested rCD276727-401 was appearing as a smaller 
MW species than predicted (despite known % errors in SEC size estimation). This 
suggests that rCD276727-401 may be surrounded by a hydration shell masking 
hydrophobic residues and thus allowing increased protein concentrations (and 
decreased SEC MW estimation). Proteins can be preferentially hydrated (and 
stabilised as more compact conformations) by certain salts, amino acids and sugars, 
leading to their altered solubility (Jenkins 1998). Furthermore, the binding of 
proteins to specific salts influences solubility, through changes in protein 
conformation, or masking of certain amino acids involved in self-interaction 
(Arakawa & Timasheff 1985; Shire et al. 2004). Although rCD276727-401 exhibited 
increased solubility, it was apparent that stability at higher concentrations was 
compromised and degraded when stored at 4 °C. This process of degradation to a 
stable intermediate enabled the crystallisation of the LMW SLP (Fagan et al. 2009). 
Expression of stable intermediates of rCD276727-401 may have assisted crystal 
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formation, particularly if the putatively hydrated compact conformation of 
rCD276727-401 prevented the formation of a supersaturated thermodynamically 
meta-stable state and subsequent crystal growth.  
6.4.3.2 Crystallisation and modelling 
BLASTP revealed that a number of other bacteria have a proteins with very high 
identity (>90%) to the N-terminal domain of CD2767, suggesting that the protein 
domain found in the N-terminus of CD2767 (DUF187) is conserved in several 
species. This conservation either suggests the DUF domain is conserved for 
functional reasons or that it has been acquired by horizontal transfer. The 
identification of CD2767 on the cell surface and the reaction of patient sera to 
CD2767 (Wright et al. 2008; Dang et al. 2010) suggests C. difficile expresses CD2767 
under certain conditions. 
 
From pattern and profile searches the N-terminal domain of CD2767 matches with 
(trans)glycosidases of the alpha amylase superfamily. In the structural classification 
of proteins database (SCOP) the first seven of the TIM beta/alpha-barrel 
superfamilies contain a phosphate binding motif ((trans)glycosidases are number 
9), thought to be of evolutionary origin (Murzin et al. 1995; Nagano et al. 2002). It is 
therefore interesting that IMAC purification of rCD276727-401 in the presence of 
phosphate increased the propensity of rCD276727-401 to form dimers and that 
crystals formed in the presence of phosphate (0.05 M potassium dihydrogen 
phosphate).  
 
Tertiary structure predictions using EsyPred (Lambert et al. 2002), Phyre (Kelley & 
Sternberg 2009) and HHPred (Soding et al. 2005) largely matched with proteins in 
the alpha amylase superfamily (TIM barrel), while pGENThreader (Lobley et al. 
2009) suggested CD276727-401 had folds similar to the beta-glycanase superfamily 
(TIM barrel), although some of the predicted CD276727-401 structures did not always 
correspond to the barrel region (see Figure 6.3.25). Kleiger et al. (2004) criticises 
tertiary structure servers, as a large proportion of them use a form of PSI-BLAST 
(pattern specific iterative BLAST). Kleiger et al. (2004) suggest that other methods 
  
329 
such as prediction of function through tertiary interactions (PFIT) or prediction of 
function through residues at tertiary interactions (PFRIT), may perform better at 
determination of glycosidase activity particularly of α/β barrel fold containing (or 
predicted to contain) proteins. In that, glycosidase activity can be wrongly 
attributed, in a larger number of cases, using PSI-BLAST than PFIT or PFRIT. 
However, the widespread availability of PSI-BLAST facilities makes them a simple 
step in determination of putative protein function. Moreover, low sequence 
identity is characteristic of glycosidases, which have a conserved structure rather 
than sequence (Nagano et al. 2002) and also adopt folds other than the TIM barrel 
(Davies & Henrissat 1995; Henrissat & Davies 1997).  
 
Taken together, if the bioinformatic searches are correct, this suggest the N-
terminal domain of CD2767 is likely to be a (trans)glycosidase, within the alpha 
amylase superfamily, containing a TIM (α/β barrel). 
 
Table 6.4.1 Members of the alpha amylase superfamily from SCOP 
Bacterial alpha-
amylase 
Maltogenic amylase, 
central domain 
1,4-alpha-glucan 
branching enzyme, 
central domain 
Oligo-1,6, 
glucosidase   
Amylomaltase 
MalQ   
Maltosyltransferase Neopullulanase, central 
domain 
Isoamylase, central 
domain   
Isomaltulose 
synthase PalI   
A4 beta-
galactosidase   
Cyclodextrin 
glycosyltransferase 
Cyclomaltodextrinase, 
central domain 
G4-amylase (1,4-
alpha-D-glucan 
maltotetrahydrolase)   
Amylosucrase Bacterial beta-
amylase   
Animal alpha-
amylase 
Maltooligosyl trehalose 
synthase 
Plant alpha-amylase   Sucrose 
phosphorylase   
beta-Amylase   
Fungal alpha-
amylases 
glycosyltrehalose 
trehalohydrolase, 
central domain   
4-alpha-
glucanotransferase   
Melibiase   Pullulanase 
PulA   
 
The alpha amylase superfamily belongs to the glycoside hydrolase Family 13 and 
contains diverse members including glycosyl transferases (Table 6.4.1). Members 
are retaining enzymes which act on α-glucoside containing substrates (Koshland 
1953; MacGregor et al. 2001). Sub-specificities are defined by structural 
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requirements for preferred substrates or the structure of the predominant 
product(s).  
 
The conserved catalytic residues of GH13 are found at the C-terminal end of the β 
strands with aspartic acid acting as catalytic nucleophile and glutamic acid as 
general acid/base, another Asp also participates in stabilising the transition state 
(Matsuura 2002; Nagano et al. 2002). These conserved residues are putatively 
found at the C-terminal end of strand β4 (Asp), strand β5 (glu), strand β7 (Asp) 
(Janecek et al. 2007).  
 
Unfortunately, the structure of His.CD276727-401 has not been solved by molecular 
replacement, not unexpectedly, given the conserved structure rather than 
sequence of glycosidases (Nagano et al. 2002). Therefore, extra information is 
required to solve the phase problem, as an accurate enough model is not available 
for molecular replacement. Although, in certain cases, homology modelling can be 
used for molecular replacement successfully, e.g. the CaspR server (Claude et al. 
2004). However, the identification of conditions in which crystals of His.CD276727-
401 form, makes multiple isomorphous replacement (MIR) viable. Based on the 
amino acid composition of His.CD276727-401 Class A compounds (which non-
covalently bind to the negatively charged carboxylate groups of Asp and Glu (26 x 
Asp and 17 x Glu) would give higher incorporation rates than Class B compounds 
(which bind covalently to His, Met and Cys) (Agniswamy et al. 2008). Heavy atom 
screening is considered a lengthy process both physically, e.g. crystal soaking 
requires upto 30 days for ethyl mercurithiosalicylate, and production of multiple 
heavy atom incorporated crystals requires empirical determination to ensure 
isomorphous incorporation. Rational approaches to heavy atom incorporation have 
been proposed, simplifying the process (Agniswamy et al. 2008). Crystals 
production from His.CD276727-401 (in MES pH 6.0) would make ideal candidates for 
MIR further study based on the findings of Agniswamy et al. (2008).  
 
Given that there are 6 methionines in His.CD276727-401 (at 1, 21, 27, 117, 130, 360), 
it is possible that sufficient selenomethionine (SeMet) would be incorporated into 
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the structure, evenly spaced, for multi-wavelength anomalous dispersion (MAD) 
phase determination, as approximately one selenomethionine residue is required 
for every ∼75–100 amino acids (Hendrickson et al. 1997; Strub et al. 2003). SeMet 
substitution is considered easier due to the ease of incorporation of recombinant 
proteins and may be worth pursuing with His.CD276727-401 given the ease of 
purification. Moreover, the structure of the LMW SLP (3CVZ (Fagan et al. 2009)) was 
solved by SeMet substitution and MAD, yet only has two methionines.  
 
Due to time limitations, only preliminary crystallisation and X-ray diffraction data 
processing was undertaken. In terms of future prospects, it seems possible that the 
structure of CD276727-401 can be solved using MIR and/or MAD. 
 
6.4.3.3 CD2767 – hypotheses 
Why is there a protein, with homology to alpha amylase superfamily of 
glycosidases, presented on the cell surface only in certain conditions i.e. upon 
inhibition of Cwp84 (Dang et al. 2010) or potentially in vivo (Wright et al. 2008)?  
 
The identification of CD2767 on the cell surface, only during certain conditions, e.g. 
Cwp84 inhibition or during CDI, may suggest that either: a) cd2767’s expression is 
conditional b) CD2767 is a highly labile protein or c) CD2767 is located in a different 
region of the cell during normal (in vitro) growth such that surface protein 
extraction techniques cannot remove it.  
 
There are two factors that suggest that CD2767 may be involved in surface capsular 
biosynthesis or be involved in a coordinated surface response to stress (nutritional 
or otherwise). Firstly, the location of the cd2767 gene in the C. difficile 630 genome 
next to a set of capsular polysaccharide synthesis genes, suggesting that it may be 
controlled with these genes rather than with other surface protein genes. Secondly, 
the predicted function(s) from tertiary structure prediction. 
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The ‘highest’ sequence identity of CD2767 was with the glycosyltrehalose 
trehalohydrolase from Sulfolobus Solfataricus (1EHA or 1EH9)(Feese et al. 2000). 
Glycosyltrehalose trehalohydrolase, with the aid of an intramolecular glycosyl 
transferase, turns soluble starch into trehalose, a non-reducing α-1,1 linked 
disaccharide (Feese et al. 2000). Trehalose is efficacious in the maintenance of cell 
integrity and protects against a variety of environmental injuries and nutritional 
limitations (Arguelles 2000). For example, during stress increasing cellular 
concentrations or cell surface trehalose may well protect the bacterium from 
damage, i.e. increase cell integrity. Tertiary structure prediction, by HHPred (Soding 
et al. 2005), also found homology to isomaltulose synthase, which isomerises 
sucrose to isomaltulose or trehalose (Zhang et al. 2003). 
 
Three of the tertiary structure prediction servers found matches with 1,4-alpha-
glucan-branching enzymes of E. coli and M. tuberculosis. In M. tuberculosis a 
glycogen branching enzyme (whose structure was recently reported 3K1D (Pal et al. 
2010)) synthesises an α-glucan capsule which mediates non-opsonic binding to CR3 
(complement receptor3 - an integrin, involved in cell-cell adhesion), blocks CD1 
expression and also displays antiphagocytic properties (Pal et al. 2010). Therefore, 
CD2767 may produce (or help to produce) a capsule in C. difficile a) under normal 
conditions- however it is not found in cell surface extracts, b) in response to stress. 
The putative carbohydrate branching enzyme activity may be linked to secondary 
cell wall polymer (SCWP) construction (role during S-layer biogenesis). SCWPs are 
known to anchor the S-layer (non-covalently) to the cell wall (Schaffer & Messner 
2005), for example, the S-layer homology domain (SLH-domain) of the Bacillus 
anthracis S-layer has been recently found to bind to a pyruvylated SCWP (Kern et al. 
2010). Moreover, the CWBDs of Lactobacillus acidophilus ATCC 4356 S-layer protein 
shows homology to carbohydrate binding regions of C. difficile toxins, suggesting 
the involvement of carbohydrates in the cell wall binding mechanism (Smit et al. 
2001). 
 
Other possible roles for CD2767 include a role in the synthesis of the highly complex 
cell-surface teichoic-acid-like polysaccharides (PS-I and PS-II), identified by 
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Ganeshapillai et al. (2008) similar in composition to the surface carbohydrates 
discovered by Poxton & Cartmill (1982), composed of glucose, mannose, 
galactosamine and phosphate in the approximate molar proportions of 
2:0.65:1:0.63 (PS-II) and glucose, glucosamine, phosphate and fatty acid (PS-I). 
 
Surface located glycosidases have been found to play key roles in adhesion in 
Streptococcus pneumonia and Streptococcus pyogenes. In S. Pneumonia, knockout 
of a sortase attached surface-associated O-glycosidase decreased adhesion to 
human airway epithelial cells and significantly decreased its ability to colonise the 
upper respiratory tract (Marion et al. 2009). In S. pyogenes, a sortase bound, 
glycoprotein-binding and carbohydrate-degrading, pullulanase (PulA) mutant 
showed decreased binding to thyroglobulin (Hytonen et al. 2003). To date, CD2767 
has not been knocked out, thus its role in C. difficile is still to be determined. 
 
An intriguing concept for the surface of C. difficile is the possibility of cellulosomes 
or a modified version of cellulosomes. Cellulosomes are large extracellular enzyme 
complexes that break down plant cell wall polysaccharides, such as cellulose, 
hemicellulose and pectin into sugars (first identified in Clostridium cellulolyticum 
(Bayer & Lamed 1986; Felix & Ljungdahl 1993). The cellulosome complex consists of 
various kinds of enzymes (glycoside hydrolases inc. amylases, polysaccharide lyases, 
and carboxyl esterases) arranged around a scaffolding protein that does not exhibit 
catalytic activity but enables the complex to adhere to cellulose. It is postulated 
that the SLH domains help to bind the cellulosome to the cell surface (Doi & Kosugi 
2004), for example, OlpA, OlpB and SdbA of the C. cellulolyticum cellulosome all 
contain SLH domains. The SLH domain equivalent in C. difficile is the CWBD and 
CD2767 contains three CWBDs. Furthermore, CD2797, a surface protein without 
CWBDs but found in the slpA cluster, putatively contains a dockerin type I domain 
which functions with a cohesion domain for complex formation in the cellulosome 
(Bayer et al. 2008). It is therefore possible that CD2767 is part of an, as yet 
uncharacterised cellulosome of C. difficile. 
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It is possible that when the structure of CD2767 is solved, speculation over the 
enzymatic mechanism/function will end. However, highly selective and specific 
ligand-binding sites or novel protein fold(s), may mean that a high-throughput 
putative ligand searching approach, similar to that used by Hermann et al. (2007), 
may be necessary to identify any substrate(s). Caution must be excercised when 
speculating about the structure and function of CD2767, particularly when using 
tertiary structure prediction. However, CD2767’s co-purification with ABP-labelled 
Cwp84 in vitro by Dang et al. (2010) and its immunogenticity in humans (Wright et 
al. 2008), suggests CD2767 is expressed and accessible to the immune system 
during CDI, highlighting the need for further research to understand the role of 
CD2767 in C. difficile. 
6.4.4 Summary 
Recombinant expression of select surface proteins was undertaken with a view to 
obtaining structural information by X-ray crystallography. Three proteins were 
chosen, Cwp66, CD2791 (Cwp2) and CD2767. As has been found previously, 
removal of the CWBD repeats of C. difficile surface proteins, greatly aids purification 
to obtain pure protein. However, only one protein, CD2767, formed crystals and 
gave an initial data set to approximately 2 Å, although its structure was not solved 
by molecular replacement. However, tertiary structure prediction provided clues as 
to functions of some of the selected surface proteins. Overall this chapter has 
highlighted the need for structural data, particularly about the CWBD, to help 
determine how the CWBD(s) are attached to the cell surface. In conclusion, the 
surface of C. difficile is likely to be littered with proteins which play distinct roles in 
infection and cellular metabolism (or both), which desperately require further 
study.  
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7 General Discussion 
Over the past 30 years, infection with Clostridium difficile has become a worldwide 
problem, contributing to many thousands of deaths within the developed world 
(Bartlett 2008b; Brazier 2008). The increased incidence throughout Europe and the 
US is of considerable cost, not only in terms of human suffering, but also a 
significant economic burden (Ghantoji et al. 2010).  
 
Efforts to produce vaccines against C. difficile are hampered by the many aspects of 
CDI that remain unclear, in particular, the mechanisms by which the bacterium 
establishes and maintain its niche within the gut. The study of this aspect of the 
disease process is of paramount importance for the development of new 
therapeutics and prophylactics. Therefore, the proteins on the bacterial surface are 
at the forefront of this research need, as adherence and subsequent colonisation 
represents a key milestone in infection.  
 
In this thesis, efforts to understand more about the role of surface proteins and 
their possible role in CDI have centred on proteins containing the putatively cell 
wall binding repeat domain (CWBD) at the N- or C- terminus, which displays 
homology to the N-acetylmuramoyl-L-alanine amidase, CwlB, of Bacillus subtilis 
(PFam04122). Some of these proteins have been implicated as playing a role in 
adhesion and colonisation processes, and therefore represent potential targets for 
therapeutic and structural research. 
7.1  Entry into the Host 
In order to cause disease, C. difficile must enter a host. The primary means for this 
to occur is via spores. The integrity of the spore is key to its survival and 
transmission, as such it can survive extremely harsh purification procedures (Lawley 
et al. 2009b) and exists on surfaces for up to 5 months (Kim et al. 1981). Proteomic 
analysis of C. difficile 630 spores, amongst other proteins, identified three CWBD 
containing proteins, SlpA, CwpV and CD2791, in the spore coat (Lawley et al. 
2009b). However, firstly, the Cwp84 mutant produced viable spores (Kirby et al. 
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2009), suggesting SlpA maturation, or lack thereof, does not alter spore stability. 
Secondly, the CD2791 mutant produced viable spores, at a similar concentration to 
the wildtype, suggesting CD2791 does not play a role in spore viability. Thirdly, 
sporulation level of the CwpV mutant, although not reported to date (Emerson et 
al. 2009b; Reynolds et al. 2010), has been proven in our laboratory (V. Kumar, 
unpublished data) suggesting CwpV does not play a role in sporulation. In fact, none 
of the mutants produced in this thesis had altered spore viability; this suggests that 
the proteins investigated in this thesis do not affect spore viability or the ability to 
make viable spores. These results suggest, that absence of any one of the CWBD 
containing proteins, either on the cell surface or those found in the spore coat, do 
not affect C. difficile’s ability to produce viable spores.  
 
As the primary transmission vehicle spores, and spore specific proteins, represent a 
lucrative drug and vaccine target. Structural information about putative spore 
germination receptors (Ramirez et al. 2010) may enable the design inhibitors 
preventing germination, and preventing disease, for example, work by Howerton et 
al. (2011) has begun to identify amino acid derivates which preventing spore 
germination. If spore specific proteins are conserved across all C. difficile ribotypes, 
vaccination against C. difficile spores may largely prevent CDI in all mammalian 
species.  
7.2  Adherence and colonisation 
Given the ability of C. difficile surface proteins to illicit an immune response (Drudy 
et al. 2004; Pechine et al. 2005a; Wright et al. 2008), it has been suggested that 
increasing an immune response to these proteins, may prevent adherence and 
subsequently prevent CDI. Furthermore, as a large number of the C. difficile surface 
proteins can be removed using low pH or urea, they represent an easily obtainable 
surface antigen, for vaccine and/or immunotherapeutic investigation. Results in this 
thesis confirm a previous study by O'Brien et al. (2005), that passively administered 
systemic antibodies to C. difficile surface proteins are ultimately non-protective in 
the animal model, as eluted to by Pantosti et al. (1989). However, the decrease in  
colonisation observed by Pechine et al. (2007), suggests that inducing a more 
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complete mucosal protection may provide some form of colonisation resistance. 
Preventing colonisation before toxin production remains a key aspect to this 
approach.  
 
To understand more about how C. difficile adheres in the gut, the identification of 
proteins on the bacterial surface are an obvious first line of investigation. Results in 
this thesis have identified four putative adhesins of C. difficile: Cwp66, CD2791, 
CD2735 and CD2795. The surface protein Cwp66 is suggested to be a heat shock 
inducible adhesin (Waligora et al. 1999), but results presented here suggest it is 
also plays a role in adhesion under normal conditions in vitro. Structural studies on 
CD2735, CD2795, Cwp66 and CD2791, the knock of which caused a dramatic 
decrease in adherence in vitro, may enable the design of inhibitors to prevent C. 
difficile adhesion, without requiring or needing to resort to the variable immune 
system.  
 
The CWBD containing surface proteins of the C. difficile 027 ribotype appear 
conserved, a result confirmed by another group (Spigaglia et al. 2011a), and a result 
which supports the ribotyping system.  The surface proteins that are not conserved 
(between ribotypes), e.g. SlpA, Cwp66 and CwpV, are putatively under selective 
pressure for immune evasion, while other, conserved, CWBD containing surface 
proteins, e.g. Cwp84, CD2791, are conserved to retain function, i.e. do not display 
genetic drift. Together with results from the knockout of cwp66, data suggests that 
Cwp66 is under strong selective pressure (as suggested by (Lemee et al. 2005)), 
because it plays a key role in adhesion. Moreover, secondary structure prediction 
maps variations in protein sequence, as a result of genetic variability, to loop 
regions, unlikely to affect the overall structure of the protein. Therefore, it is 
imperative that further work into a structural basis for Cwp66 ligands is performed.  
 
In order to hasten structural studies, it appears necessary to express only the 
‘functional’ domain(s) of surface proteins, without the accompanying CWBD. 
However, using this practice, one cannot obtain vital information on how the CWBD 
interacts with the peptidoglycan, any SCWP or other structures in the cell envelope. 
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The lack of sequence and particularly fold homology with deposited proteins, for 
example with Cwp66 and CD2971, may suggest novel folds and highlights a need for 
structure determination, which may or may not assist in ligand determination. The 
limiting factor in S-layer crystallography is the unique propensity of S-layers to form 
2D arrays, rather than 3D crystalline structures. In order to obtain crystals of the 
CWBD (which is also likely to exhibit a propensity to form 2D arrays), it is possible 
some of the techniques used for membrane proteins may be employed (Wiener 
2004), e.g. detergent use or any of the other methods suggested by Engelhardt & 
Peters (1998).  
7.3  Damage to Host 
A number of the mutants produced in this study had altered toxin release 
compared to the wildtype C. difficile 630ΔErm, particularly the Cwp84 and FliD 
mutants. However, toxin production of a Cwp84 inhibited culture (using E64 for 
example (Dang et al. 2010)) has not been reported, but if it too produced higher 
extracellular toxin titres (after 24 hr), care must be taken in targeting surface 
proteins for therapeutic interventions. It is possible, upon (chemical) inhibition of 
Cwp66 or CD2791, despite potentially decreasing adherence, extracellular toxin 
levels may increase resulting in increased mucosa damage.  
 
The apparent link between increased toxin and decreased adhesion requires further 
study. Further work is also required to understand how knockout of the flagella 
increases adhesion but also severely increases toxin production, potentially causing 
a more virulent strain (Baban et al. 2010). Recent work suggesting that activation of 
TLR5 with Salmonella typhimurium flagellin appears to protect mice from CDI 
(Jarchum et al. 2011), further complicates the role of flagella and flagellins in both 
colonisation and CDI. 
 
This apparent inverse relationship between toxin and adherence has been 
described in a histone-like nucleoid structuring regulatory gene (hns) mutant of E. 
coli 091:H21 strain B2F1 (Scott et al. 2003). This mutant showed decreased 
adherence to T84 human colonic epithelial cells and an increase in the production 
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of hemolysin. H-NS proteins putatively play a role regulating gene expression, 
including regulation of adhesins (Beltrametti et al. 1999), although they have not 
been found in Gram-positive bacteria (Tendeng & Bertin 2003). 
 
It is possible that knockout of certain surface proteins, alters cell integrity resulting 
in increased bacterial stress (similar to nutrient limiting conditions) causing changes 
in toxin levels, or that the physical loss of that surface protein results in a decrease 
in cellular integrity and results in the release of intracellular toxin, i.e. toxin leakage 
hypothesis. Under this latter hypothesis, any surface protein mutant with toxin 
levels comparable to the wild-type may not have sufficiently altered cell integrity, 
detectable by toxin changes, however, confirms that the regulation of virulence 
factors is complex and requires further work.  
7.4  Release and spread 
The ability of C. difficile to transmit relies on the ability to produce viable spores 
and, as aforementioned, all of the surface proteins mutants created in this thesis 
produced viable spores. Although, it has been found that a mutation in a protein 
synthesised during sporulation and incorporated into the spores, affects 
morphology but not viability (Mallozzi et al. 2008). Therefore, it would be 
interesting to determine if surface protein mutant spores are affected 
morphologically, particularly for C. difficile Cwp84, CD2791 or CwpV mutants given 
their connection with the spore coat.  
7.5  Therapeutics 
The goal of a C. difficile therapy, particularly a vaccine, is to prevent CDI occurring, 
although, as suggested by computer modelling, targeting C. difficile recurrence may 
also be lucrative (Lee et al. 2010a). However, there is understandably caution over 
whom to vaccinate and even if vaccination is effective, whether it is likely to fail in 
those whose immune system becomes compromised.  
 
There are several approaches to the treatment of CDI, including a plethora of ‘new’ 
antibiotics, some of which are likely to be more successful at treating CDI than 
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others (Bartlett 2009). Use of an in vitro gut model has been shown to be 
remarkably successful in identifying therapeutics which have gone on to fail in 
clinical trial (Baines et al. 2009) and may therefore represent a ‘simple’ test for 
appropriate forthcoming anti-C. difficile agents. There are also other ‘out of the 
box’ therapies, briefly discussed in Chapter 4, including chemical toxin 
neutralisation, restoration of the protective gut flora and immunotherapy (active 
and passive) (Gerding & Johnson 2010). Gerding and Johnson (2010) point out how 
several of these ‘non-traditional’ therapeutics appear promising, which together 
with the rapidly growing number of bacterial species resistant to multiple 
antibiotics, e.g. Mycobacterium tuberculosis (Caminero et al. 2010), puts real 
impetus on finding new ways to treat infection. 
 
Techniques to target virulence, i.e. the ability of the bacterium to cause disease, 
rather than simply the targeting of bacterial existence (as antibiotics currently do), 
has the putative advantage that it may not impart as high selective pressure for 
resistance than current antibiotics (Clatworthy et al. 2007; Cegelski et al. 2008).  
 
In light of the results of this thesis, what is the future, or what is required for a 
future into a surface, i.e. anti-adhesion/colonisation, therapy for C. difficile? 
 
Presentation of an immature C. difficile S-layer at the cell surface results in 
decreased cell integrity (Kirby et al. 2009; Dang et al. 2010), therefore targeting S-
layer biogenesis to prevent CDI, as suggested by Dang et al. (2010), may provide a 
novel way to prevent CDI via a mechanism not dissimilar to β-lactam antibiotics. 
Therefore, there may be an opportunity to develop new therapies based on the 
aberration of cell surface (S-layer) construction. As the SLPs of C. difficile can be 
removed via chemical methods, e.g. low pH, LiCl, EDTA or denaturing agents, and as 
demonstrated by Takumi et al. (1991), the loss of the SLPs results in an inability to 
adhere to the gut, development of a chemical therapy to dissociate the SLPs, i.e. 
prevent adherence, is feasible (although the author would not suggest an 8 M urea 
enema to ‘resolve’ CDI). However, in order to even contemplate development of a 
novel CWBD neutralising compound, research is required into understanding how 
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the CWBD interacts with the peptidoglycan, a SCWP or other structure(s) in the cell 
envelope, structural research would be key in this respect.  
 
The apparent inability of passively administered anti-SLP IgG to prevent CDI in the 
animal model (Chapter 4 and O'Brien et al. (2005)), may point to differences in the 
presentation of surface proteins in vitro to in vivo, or an inability of the antibodies 
to access the gut when they are required to prevent adhesion. Development of 
anti-surface protein (immuno)therapeutics must therefore ensure that the in vitro 
antigen, matches the in vivo form. Having said that, patients who have CDI are 
presented with C. difficile surface antigens in their ‘correct’ form, but whether 
(humoral) responses to the surface proteins are protective requires further study 
(Drudy et al. 2004; Pechine et al. 2007; Sanchez-Hurtado et al. 2008; Wright et al. 
2008). Therefore, the key to anti-colonisation immunotherapy may be in generating 
the correct type of protective immune response. Lessons learnt from C. difficile 
toxin therapy research, has revealed that the native toxins raise a large immune 
response, but it is not protective, i.e. not cytotoxin neutralising. Anti-SLP antibodies, 
may, therefore cause a similar non-protective response, except only act on one part 
of the infection cycle e.g. adhesion. To resolve the toxin antibody paradox, toxins 
are toxoided, i.e. chemically modified with formaldehyde (Salnikova et al. 2008). 
Therefore, to increase the ability of the SLPs to raise a protective immune response, 
it is possible they require ‘fixing’, possibly preventing the presentation of highly 
immunoreactive, but non-protecting antibodies. The protein CD2791 may be 
particularly good at this at raising non-protecting antibodies, as all CDI patients 
were found to raise antibodies to CD2791 (Wright et al. 2008). 
 
The conservation of the large majority of the SLPs, and the variability of relatively 
few, suggests that different surface proteins have different selective pressures put 
upon them, e.g. variation for immune evasion (SlpA and Cwp66 (Lemee et al. 2005)) 
or conservation of action (Cwp84). Therefore, developing on results in this thesis, 
knockout of all 28 slpA paralogs, and assessment of their virulence in vivo, may be 
necessary to understand if any of the paralogs have roles in C. difficile 
pathogenesis.  
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7.6  Identification of factors necessary for infection 
C. difficile in vitro gene expression is modified by environmental factors (Waligora 
et al. 1999; Karlsson et al. 2003; Deneve et al. 2008; Emerson et al. 2008; Karlsson 
et al. 2008; Deneve et al. 2009a). However, it is almost impossible to account for, in 
vitro, the complex milieu of the gut, host-cell interactions and the dynamic 
environmental stimuli associated with the infection process in vivo (Acheson & 
Luccioli 2004; O'Hara & Shanahan 2006; Kim et al. 2010).  
 
However, there are a number of genetic techniques which have yet to be applied to 
C. difficile pathogenesis studies, that may help elucidate key genes/proteins 
associated with infection in vivo. These are: differential fluorescence induction 
(DFI), in vivo expression technology (IVET), signature tagged mutagenesis (STM) and 
in vivo-induced antigen technology (IVIAT) (reviewed in Hautefort et al. (2002)). 
7.6.1 Differential Fluorescence Induction (DFI) (Bumann & Valdivia 
2007) 
DFI involves the creation of a library of random genomic fragments, fused to a 
promotorless gfp gene. The fragments are cloned into a plasmid and entered into 
the organism of interest. If a fragment contains a promoter, active during certain 
stimuli, e.g. in vivo or infecting mammalian cells, GFP will be expressed and 
fluorescent cells can be isolated by FACS. Comparison of the fragment with the 
genome sequence, allows the identification of genes whose products may be 
associated with the response of the organism to the condition assessed. Therefore, 
application of DFI to C. difficile requires a plasmid stable in C. difficile, the 
pMTL80000 series of vectors (Heap et al. 2009b), could fulfil this need. However, 
DFI is subject to criticism, such as, use of a fluorophore and an inability to measure 
post-transcriptionally regulated genes (Rediers et al. 2005). 
7.6.2 In vivo expression technology (IVET) (Angelichio & Camilli 
2002) 
IVET, similar to DFI, uses ‘promoter trapping’ and positive selection in that it selects 
for genes that are expressed in vivo. Classical IVET requires an essential growth 
factor (egf) mutant, and a plasmid containing a promotorless copy of the egf gene 
and a reporter gene. Random bacterial DNA is cloned into the plasmid which is then 
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integrated in the chromosome of the egf mutant strain. The Δegf mutants, with 
insertions, are then infected into the appropriate animal model. When the 
promoter is expressed, the EGF is returned, i.e. the mutant is complemented, thus 
the strain causes disease and can be isolated from the target organ(s). Recovered 
bacteria are plated and reporter negative clones are analysed. There have been 
modifications to IVET over time including use of antibiotic selection rather than an 
auxotroph, dual reporter system or inheritable antibiotic-sensitive phenotype. Use 
of IVET in C. difficile would require an auxotroph, presumably created with the 
ClosTron system and a plasmid able to homologously recombine in C. difficile, 
potentially as used in Lyras et al. (2009), as stability is not required. IVET, if used 
with antibiotic selection, amongst other limitations, is likely to result in 
transcription of genes associated with exposure of the organism to that antibiotic, 
e.g. C. difficile to clindamycin (Deneve et al. 2009a), rather than as a result of the 
infection process (Rediers et al. 2005).  
7.6.3 Signature tagged mutagenesis (STM) (Hensel et al. 1995; 
Autret & Charbit 2005) 
As opposed to IVET or DFI, STM uses negative selection to identify genes required 
for infection in vivo. A library of random mutants is created with individually tagged 
transposons. The viable mutants are pooled then assessed for their ability to cause 
disease in the appropriate animal model. If a mutant cannot cause infection, then 
that mutant's tag will not be detected among the recovered bacteria. Therefore, 
STM identifies genes important for virulence and survival in vivo, rather than just 
genes that are switched on (as IVET or DFI does). Therefore, for STM there is a 
requirement for random insertional mutagenesis, the recently reported transposon 
systems by Hussain et al. (2010) and Cartman & Minton (2010) are prime 
candidates for the development of STM in C. difficile. Many of the limitations of 
STM revolve around the use of a mutant pool, true randomness of the transposon 
and hybridisation issues. 
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7.6.4 In vivo induced antigen technology (IVIAT) (Handfield et al. 
2000) 
Perhaps the ‘easiest’ of the techniques to identify factors expressed during 
infection, in terms of applicability to C. difficile, i.e. without genetic modification, is 
that of IVIAT. IVIAT uses convalescent sera which are exhaustively absorbed against 
bacteria grown in vitro, leaving only antibodies against antigens that are expressed 
in vivo. The adsorbed serum is then used to probe an E. coli inducible protein 
expression library, reacting clones are then sequenced and the protein(s) identified. 
Additional confirmation of the expression in vivo can be performed by, for example, 
immunohistochemistry, using fluorescent-labelled antibodies to screen biological 
specimens. IVIAT has obvious advantages in that it does not require animal models, 
or any genetic manipulation of the disease causing organism. However, one of the 
major flaws of IVIAT is that it can identify proteins that are good immunogens in 
vivo, but not necessarily required for virulence. As demonstrated for C. difficile 
toxins, a good immune response does not necessarily equal a good neutralising titre 
(Giannasca et al. 1999). IVIAT could be considered an extension of work by Wright 
et al. (2008), where rather than proteomic analysis of defined surface antigens 
using patient serum, a genomic library would be screened. IVIAT has been 
successfully used to identify several surface proteins of B. anthracis involved in 
infection (Rollins et al. 2008), highlighting IVIATs applicability in identification of 
(surface based) factors associated with in vivo infection. 
 
7.7  Summary 
C. difficile is a serious problem, not only in the healthcare setting but increasingly in 
the community. The results presented in this thesis have implications in different 
steps of C. difficile pathogenesis, and in furthering C. difficile knowledge into the 
role of surface proteins in CDI. In particular, only the C. difficile Cwp84 surface 
protein mutant had altered sporulation ability but not viability, suggesting 
vegetative cell surface proteins are not involved in spore stability and viability. It is 
also apparent that C. difficile has a highly integrated metabolism and regulatory 
system, as surface proteins and toxin production are connected in some way. New 
treatments for C. difficile infection are required that both prevent and treat CDI, but 
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also prevent relapses. Immunotherapy targeting bacterial surface proteins, from 
the circulation to prevent colonisation, did not prevent CDI in the hamsters model, 
suggesting other (potentially immunotherapeutic) anti-colonisation approaches be 
sought. One of the key aims of C. difficile research will be in the identification of 
(surface) proteins involved in infection. In this respect, newly developed genetic 
tools make identification of these key virulence factors a real possibility. 
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8 Conclusions 
In order to understand more about how C. difficile colonises the gut, research was 
undertaken into the surface proteins of C. difficile, in particular, proteins which 
contain a PFam04122 domain, which putatively mediates their attachment to the 
cell surface. 
 
Using a recently developed knockout system, a number of novel surface protein 
knockouts were made. A total of eight surface protein encoding genes were 
knocked out (cd1036, cd2735, cd2784, cd2791, cwp66, cwp84, cd2795 and fliD) and 
several of these were found to be key in bacterial surface physiology and adhesion. 
Of key importance was the knockout of Cwp84, which results in the presentation of 
immature SlpA (S-layer precursor) on the cell surface. Efforts to obtain structural 
information about the surface proteins CD2791, Cwp66 and CD2767, by X-ray 
crystallography were hampered by the PFam04122 repeats, as their removal 
significantly aided purification. However, an initial dataset to 2 Å was obtained from 
a crystal of the N-terminal domain of CD2767. Efforts to understand any surface 
based reason for increased virulence of the ‘epidemic’ 027 ribotype, revealed that 
that Pfam04122 containing surface proteins are largely similar genetically and that 
passively administered antibodies, raised to low pH extracted 027 ribotype surface 
proteins, are not protective in hamsters. 
 
8.1 Summary of contributions 
Using a knockout approach, it was discovered that the surface-located cysteine 
protease Cwp84 cleaves SlpA and presentation of an immature S-layer on the 
bacterial cell surface severely affects bacterial physiology. CD2735, Cwp66, CD2791, 
and CD2795 mutants had decreased adhesion in vitro and, particularly for FliD and 
Cwp84 mutants, displayed higher toxin A production after 24 hr. Inactivation of 
peptidoglycan hydrolase domain containing surface protein CD2784 slows bacterial 
growth and potentially increases adhesion, while knockout of CD1036, which has a 
similar domain structure to CD2784, has no observable affect on C. difficile function 
in vitro. All surface protein mutants produced viable spores.  
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Genetically the Pfam04122 containing surface proteins of C. difficile are largely 
conserved, apart from slpA, cwp66 and cwpV. Moreover, passively administered 
(systemic) antibodies to an epidemic 027 ribotype strain (R20291) do not protect 
hamsters from CDI.  
 
To readily obtain pure protein for crystallisation, the PFam04122 repeats needed to 
be removed, i.e. the protein expressed without these repeats. Once this was 
accomplished, crystals of the N-terminal DUF187 domain of CD2767 were grown 
and diffracted to 2 Å, although the structure was not solved by molecular 
replacement due to a lack of similar structures in the protein databank. 
 
8.2 Future work 
As outlined throughout this thesis, there is still much work to be done regarding 
understanding the mechanisms by which C. difficile adheres to the gut.  
 
While Cwp84 mediated cleavage of SlpA has been conclusively proven, further work 
is required to fully understand S-layer biogenesis, particularly as post-translational 
cleavage of the S-layer is unique to C. difficile. Understanding specifics of the 
cleavage mechanism would be significantly aided by structural information for both 
Cwp84 and full length SlpA, for example, in identifying the likely conformational 
change of SlpA after cleavage. Identification of the location of cleavage, i.e. where 
on or in the cell wall cleavage occurs, and the point of Cwp84 (auto)maturation also 
requires further work. Underlying this research is the requirement to understand 
how the cell wall binding domain (Pfam 04122) (CWBD), present in 28 other 
putative C. difficile surface proteins, is connected to the cell envelope, secondary 
cell wall polymers (SWCPs) or peptidoglycan via a non-covalent mechanism. Many 
other bacterial S-layers cell wall binding domains have been found to use SWCPs, 
although such a polymer has yet to be identified in C. difficile.  
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To date, not all of the 28 SlpA paralogs have been found on the cell surface or even 
their expression proven. It is apparent that further work is required to understand 
if, when, and why these proteins are or are not expressed and their role in C. 
difficile physiology and pathogenesis. Investigations into the connection (or 
apparent connection) between surface proteins and other systems, e.g. toxin 
production, are required, particularly as toxins are the major virulence factor of C. 
difficile. 
 
Structural studies, X-ray, NMR or electron based, are key in furthering knowledge 
into S-layer biogenesis and the myriad of proteins found on the cell surface, 
particularly those found to be important in vivo. In this respect, the development of 
anti-colonisation inhibitors or vaccines would be significantly aided by structural 
data. Moreover, structural information may provide physical links to functionality, 
particularly for those surface proteins for which no function can be assigned at 
present. 
 
The role of the immune system in C. difficile infection is one area only touched on in 
this thesis. However, recent data suggests that both colonisation and development 
of CDI can be controlled by management of the immune system (Jarchum et al. 
2011). Research into anti-colonisation therapy may need to look beyond serum 
based responses to a mucosal disease. Research also needs to clarify at what point 
during infection adhesion, colonisation and toxin production occur, and where the 
immune system plays a role in those processes.  
 
The ubiquitous nature of C. difficile spores in the environment means acquisition is 
highly probable, for humans or animals. Research into the C. difficile spore structure 
and spore germination is required to fully understand the C. difficile delivery 
vehicle. A therapy aimed at resolving CDI by preventing the sporulation pathway 
may decrease a) the chances of patient relapse, b) transmission and contamination 
of the environment.  
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The role of genetic manipulation of C. difficile will provide much needed 
information about all aspects of C. difficile pathogenesis and physiology. However, a 
limitation of the ClosTron system is that only one gene is knocked out at a time and 
theoretically requires each mutant to be assessed for its ability to cause CDI, in vivo, 
to identify factors key for infection. Approaches outlined for the identification of 
multiple genes expressed in vivo, e.g. STM, IVET, may be key in this respect and 
require investigation.  
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